Consolidated_NNP cash_NN flow_NN statement_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002 2002 2001_CD Notes_NNP 000_CD 000_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 28a_JJ 302,321_CD 202,876_CD Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN :_: Interest_NN and_CC other_JJ income_NN received_VBD 15,434_CD 13,077_CD Interest_NN paid_VBN 8,458_CD 8,122_CD Interest_NN element_NN of_IN finance_NN lease_NN rentals_NNS 45_CD Net_JJ cash_NN inflow_NN from_IN returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN 6,931_CD 4,955_CD Taxation_NNP :_: Overseas_NNP corporation_NN tax_NN paid_VBN 73,145_CD 44,982_CD Capital_NN expenditure_NN and_CC financial_JJ investments_NNS :_: Purchase_NN of_IN long-term_JJ investment_NN 2,957_CD Purchase_NN of_IN intangible_JJ fixed_JJ assets_NNS 15,470_CD 20,159_CD Purchase_NN of_IN tangible_JJ fixed_JJ assets_NNS 15,014_CD 9,593_CD Proceeds_NNS from_IN sale_NN of_IN a_DT business_NN 44,103_CD Proceeds_NNS from_IN sale_NN of_IN intangible_JJ fixed_JJ assets_NNS 3,200_CD Proceeds_NNS from_IN sale_NN of_IN tangible_JJ fixed_JJ assets_NNS 542_CD 4,974_CD Net_JJ cash_NN inflow_NN outflow_NN for_IN capital_NN expenditure_NN and_CC financial_JJ investments_NNS 11,204_CD 21,578_CD Acquisitions_NNPS and_CC disposals_NNS :_: Purchase_NN of_IN subsidiary_NN undertaking_NN 11,647_CD Expenses_NNS of_IN acquisitions_NNS 235_CD 16,450_CD Net_JJ cash_NN acquired_VBN with_IN subsidiary_NN undertakings_NNS 33_CD 44,452_CD Net_JJ cash_NN outflow_NN inflow_NN from_IN acquisitions_NNS 11,849_CD 28,002_CD Cash_NN inflow_NN before_IN management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN 235,462_CD 169,273_CD Management_NN of_IN liquid_JJ resources_NNS :_: Decrease_NN increase_NN in_IN cash_NN placed_VBN on_IN short-term_JJ deposit_NN 28b_JJ 254,561_CD 325,479_CD Financing_NN :_: Issue_NN of_IN ordinary_JJ share_NN capital_NN 1,050_CD Exercise_NN of_IN share_NN options_NNS 3,985_CD 46,961_CD Expenses_NNS of_IN share_NN issues_NNS 23,584_CD Capital_NNP element_NN of_IN finance_NN leases_NNS 28b_JJ 74_CD Net_JJ decrease_NN increase_NN in_IN debt_NN during_IN the_DT year_NN 28b_JJ 832_CD 182,808_CD Net_JJ cash_NN inflow_NN from_IN financing_VBG 3,079_CD 207,235_CD Increase_VBP in_IN cash_NN in_IN the_DT year_NN 28b_JJ 493,102_CD 51,029_CD The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN this_DT consolidated_JJ cash_NN flow_NN statement_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 25_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 1_CD Accounting_NN policies_NNS The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN applicable_JJ accounting_NN standards_NNS and_CC under_IN United_NNP Kingdom_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNPS UK_NNP GAAP_NNP ._.
The_DT particular_JJ accounting_NN policies_NNS adopted_VBN by_IN the_DT directors_NNS ,_, all_DT of_IN which_WDT have_VBP been_VBN applied_VBN consistently_RB throughout_IN the_DT year_NN and_CC the_DT preceding_JJ year_NN ,_, are_VBP described_VBN below_IN ._.
a_DT Accounting_NN convention_NN The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN the_DT historical_JJ cost_NN convention_NN ._.
b_NN Basis_NN of_IN consolidation_NN The_DT consolidated_JJ financial_JJ statements_NNS incorporate_VBP the_DT financial_JJ statements_NNS of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN and_CC all_DT its_PRP$ subsidiary_NN undertakings_NNS drawn_VBN up_RP to_TO 31_CD December_NNP each_DT year_NN ._.
c_NN Acquisitions_NNS and_CC disposals_NNS On_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, including_VBG an_DT interest_NN in_IN an_DT associated_VBN undertaking_NN ,_, fair_JJ values_NNS are_VBP attributed_VBN to_TO the_DT Groups_NNS share_NN of_IN net_JJ separable_JJ assets_NNS ._.
Where_WRB the_DT cost_NN of_IN the_DT acquisition_NN exceeds_VBZ the_DT fair_JJ values_NNS attributable_JJ to_TO such_JJ net_JJ assets_NNS ,_, the_DT diference_NN is_VBZ treated_VBN as_IN purchased_VBN goodwill_NN and_CC capitalized_VBN in_IN the_DT balance_NN sheet_NN in_IN the_DT year_NN of_IN acquisition_NN ._.
Prior_RB to_TO the_DT implementation_NN of_IN FRS_NNP 10_CD in_IN the_DT year_NN ended_VBD 31_CD December_NNP 1998_CD ,_, purchased_VBD goodwill_NN was_VBD written_VBN off_RP directly_RB to_TO reserves_NNS and_CC has_VBZ not_RB been_VBN reinstated_VBN ._.
The_DT profit_NN or_CC loss_NN on_IN the_DT disposal_NN of_IN a_DT previously_RB acquired_VBN business_NN includes_VBZ the_DT attributable_JJ amount_NN of_IN any_DT purchased_VBN goodwill_NN relating_VBG to_TO that_DT business_NN not_RB previously_RB charged_VBN through_IN the_DT profit_NN and_CC loss_NN account_NN ._.
The_DT results_NNS and_CC cash_NN flows_NNS relating_VBG to_TO a_DT business_NN are_VBP included_VBN in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN and_CC the_DT consolidated_JJ cash_NN flow_NN statement_NN from_IN the_DT date_NN of_IN acquisition_NN up_IN to_TO the_DT date_NN of_IN disposal_NN ._.
d_LS Intangible_JJ assets_NNS goodwill_NN For_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, including_VBG an_DT interest_NN in_IN an_DT associated_VBN undertaking_NN ,_, purchased_VBD goodwill_NN is_VBZ capitalized_VBN in_IN the_DT year_NN in_IN which_WDT it_PRP arises_VBZ and_CC amortised_VBN over_IN its_PRP$ estimated_VBN useful_JJ economic_JJ life_NN up_IN to_TO a_DT maximum_NN of_IN 20_CD years_NNS ._.
The_DT directors_NNS regard_VBP 20_CD years_NNS as_IN a_DT reasonable_JJ maximum_NN for_IN the_DT estimated_VBN useful_JJ economic_JJ life_NN of_IN goodwill_NN since_IN it_PRP is_VBZ difficult_JJ to_TO make_VB projections_NNS exceeding_VBG this_DT period_NN ._.
Provision_NNP is_VBZ made_VBN for_IN any_DT impairment_NN ._.
The_DT asset_NN is_VBZ deemed_VBN to_TO be_VB impaired_VBN to_TO the_DT extent_NN that_IN the_DT carrying_VBG amount_NN exceeds_VBZ the_DT recoverable_JJ amount_NN ._.
The_DT impairment_NN loss_NN is_VBZ recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Capitalised_VBN purchased_VBN goodwill_NN in_IN respect_NN of_IN subsidiaries_NNS is_VBZ included_VBN within_IN intangible_JJ assets_NNS ._.
Capitalised_NNP purchased_VBD goodwill_NN relating_VBG to_TO associates_NNS is_VBZ included_VBN within_IN the_DT carrying_VBG value_NN of_IN the_DT associate_NN ._.
Goodwill_NN which_WDT arose_VBD on_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, prior_RB to_TO the_DT implementation_NN of_IN FRS_NNP 10_CD which_WDT was_VBD written_VBN off_RP to_TO the_DT profit_NN and_CC loss_NN reserve_NN as_IN a_DT matter_NN of_IN accounting_NN policy_NN ,_, remains_VBZ eliminated_VBN in_IN that_DT reserve_NN and_CC will_MD be_VB charged_VBN or_CC credited_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN as_IN appropriate_JJ on_IN the_DT subsequent_JJ disposal_NN of_IN the_DT business_NN to_TO which_WDT it_PRP relates_VBZ ._.
e_LS Intangible_JJ assets_NNS intellectual_JJ property_NN Intellectual_NNP property_NN ,_, including_VBG trademarks_NNS ,_, for_IN products_NNS with_IN an_DT immediate_JJ defined_VBN revenue_NN stream_NN and_CC acquired_VBN for_IN valuable_JJ consideration_NN ,_, are_VBP capitalized_VBN and_CC amortised_VBN in_IN equal_JJ annual_JJ instalments_NNS over_IN the_DT estimated_VBN useful_JJ life_NN of_IN the_DT product_NN generally_RB not_RB exceeding_VBG 20_CD years_NNS ._.
Intellectual_NNP property_NN with_IN no_DT defined_VBN revenue_NN stream_NN is_VBZ written_VBN off_RP on_IN acquisition_NN ._.
f_LS Tangible_JJ assets_NNS Depreciation_NN is_VBZ not_RB provided_VBN on_IN freehold_JJ land_NN ._.
All_DT other_JJ tangible_JJ fixed_JJ assets_NNS are_VBP shown_VBN at_IN cost_NN less_JJR accumulated_VBN depreciation_NN and_CC any_DT provision_NN for_IN impairment_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN a_DT straight_JJ line_NN basis_NN at_IN rates_NNS calculated_VBN to_TO write_VB off_RP the_DT cost_NN less_JJR estimated_VBN residual_JJ value_NN of_IN each_DT asset_NN over_IN its_PRP$ estimated_VBN useful_JJ life_NN at_IN the_DT following_JJ annual_JJ rates_NNS :_: Freehold_NNP buildings_NNS 2-5_CD %_NN per_IN annum_NN Office_NNP furniture_NN and_CC fittings_NNS 10-25_CD %_NN per_IN annum_NN Equipment_NNP and_CC other_JJ 10-25_CD %_NN per_IN annum_NN g_NN Investments_NNP Except_IN as_IN stated_VBN below_IN ,_, investments_NNS held_VBD as_IN fixed_JJ assets_NNS are_VBP stated_VBN at_IN cost_NN less_JJR provision_NN for_IN any_DT impairment_NN ._.
In_IN the_DT consolidated_JJ accounts_NNS ,_, shares_NNS in_IN joint_JJ ventures_NNS are_VBP accounted_VBN for_IN using_VBG the_DT equity_NN method_NN ._.
The_DT consolidated_JJ profit_NN and_CC loss_NN account_NN includes_VBZ the_DT Groups_NNS share_NN of_IN pre-tax_JJ profits_NNS and_CC attributable_JJ taxation_NN of_IN the_DT joint_JJ ventures_NNS based_VBN on_IN audited_JJ financial_JJ statements_NNS for_IN the_DT financial_JJ year_NN ._.
In_IN the_DT consolidated_JJ balance_NN sheet_NN ,_, the_DT investment_NN in_IN joint_JJ ventures_NNS is_VBZ shown_VBN at_IN the_DT Groups_NNS share_NN of_IN the_DT net_JJ assets_NNS of_IN the_DT joint_JJ ventures_NNS ._.
In_IN the_DT Company_NN balance_NN sheet_NN ,_, for_IN investments_NNS in_IN subsidiaries_NNS acquired_VBN for_IN consideration_NN including_VBG the_DT issue_NN of_IN shares_NNS qualifying_VBG for_IN merger_NN relief_NN ,_, advantage_NN has_VBZ not_RB been_VBN taken_VBN of_IN this_DT relief_NN and_CC the_DT share_NN premium_NN of_IN the_DT shares_NNS issued_VBN has_VBZ been_VBN included_VBN in_IN the_DT cost_NN ._.
Current_JJ asset_NN investments_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
h_NN Stocks_NNS Stocks_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Cost_NN incurred_VBN in_IN bringing_VBG each_DT product_NN to_TO its_PRP$ present_JJ location_NN and_CC condition_NN is_VBZ based_VBN on_IN purchase_NN costs_NNS calculated_VBN on_IN a_DT first-in_NN ,_, first-out_JJ basis_NN ,_, including_VBG transport_NN ._.
Net_JJ realisable_JJ value_NN is_VBZ based_VBN on_IN estimated_VBN normal_JJ selling_NN price_NN less_RBR further_JJ costs_NNS expected_VBN to_TO be_VB incurred_VBN to_TO completion_NN and_CC disposal_NN ._.
Provision_NNP is_VBZ made_VBN for_IN obsolete_JJ ,_, slow_JJ moving_VBG or_CC defective_JJ items_NNS where_WRB appropriate_JJ ._.
26_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 1_CD Accounting_NN policies_NNS continued_VBD i_FW Deferred_JJ taxation_NN Deferred_VBN tax_NN is_VBZ provided_VBN in_IN full_JJ on_IN timing_NN differences_NNS which_WDT result_VBP in_IN an_DT obligation_NN at_IN the_DT balance_NN sheet_NN date_NN to_TO pay_VB more_JJR tax_NN ,_, or_CC a_DT right_NN to_TO pay_VB less_JJR tax_NN ,_, at_IN a_DT future_JJ date_NN ,_, at_IN rates_NNS expected_VBN to_TO apply_VB when_WRB they_PRP crystallise_VBP based_VBN on_IN current_JJ tax_NN rates_NNS and_CC law_NN ._.
Timing_NN differences_NNS arise_VBP from_IN the_DT inclusion_NN of_IN items_NNS of_IN income_NN and_CC expenditure_NN in_IN taxation_NN computations_NNS in_IN periods_NNS different_JJ from_IN those_DT in_IN which_WDT they_PRP are_VBP included_VBN in_IN the_DT financial_JJ statements_NNS ._.
Deferred_JJ tax_NN is_VBZ not_RB provided_VBN on_IN timing_NN differences_NNS arising_VBG on_IN unremitted_JJ earnings_NNS of_IN subsidiaries_NNS and_CC associates_NNS where_WRB there_EX is_VBZ no_DT commitment_NN to_TO remit_VB these_DT earnings_NNS ._.
Deferred_JJ tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ regarded_VBN as_IN more_RBR likely_JJ than_IN not_RB that_IN they_PRP will_MD be_VB recovered_VBN ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP not_RB discounted_VBN ._.
j_NN Turnover_NN The_DT Group_NNP recognizes_VBZ turnover_NN when_WRB :_: there_EX is_VBZ persuasive_JJ evidence_NN of_IN an_DT arrangement_NN :_: delivery_NN of_IN products_NNS has_VBZ occurred_VBN or_CC services_NNS have_VBP been_VBN rendered_VBN :_: the_DT sellers_NNS price_NN to_TO the_DT buyer_NN is_VBZ fixed_VBN or_CC determinable_JJ :_: and_CC collectibility_NN is_VBZ reasonably_RB assured_VBN ._.
Revenues_NNS are_VBP stated_VBN net_NN of_IN VAT_NNP and_CC similar_JJ taxes_NNS ,_, trade_NN discounts_NNS and_CC intra-Group_JJ transactions_NNS ._.
The_DT principal_JJ components_NNS of_IN the_DT Groups_NNS turnover_NN and_CC their_PRP$ respective_JJ accounting_NN treatments_NNS are_VBP set_VBN out_RP below_IN ._.
Product_NN sales_NNS are_VBP recognized_VBN net_JJ upon_IN shipment_NN to_TO customers_NNS ._.
Provisions_NNS for_IN certain_JJ rebates_NNS ,_, product_NN returns_NNS and_CC discounts_NNS to_TO customers_NNS are_VBP provided_VBN for_IN as_IN reductions_NNS to_TO net_JJ turnover_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
Licensing_NN and_CC development_NN fees_NNS represent_VBP revenues_NNS derived_VBN from_IN licence_NN agreements_NNS and_CC from_IN collaborative_JJ research_NN and_CC development_NN arrangements_NNS ._.
Initial_JJ licence_NN fees_NNS are_VBP not_RB considered_VBN to_TO be_VB separable_JJ from_IN the_DT associated_VBN research_NN and_CC development_NN activities_NNS ,_, even_RB where_WRB such_JJ fees_NNS are_VBP nonrefundable_JJ and_CC not_RB creditable_JJ against_IN research_NN and_CC development_NN services_NNS to_TO be_VB rendered_VBN ._.
Initial_JJ licence_NN fees_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN of_IN the_DT licence_NN term_NN or_CC the_DT period_NN of_IN the_DT associated_VBN research_NN and_CC development_NN agreement_NN ._.
In_IN circumstances_NNS where_WRB initial_JJ licence_NN fees_NNS are_VBP not_RB for_IN a_DT defined_VBN period_NN ,_, revenues_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN to_TO the_DT expiration_NN of_IN the_DT relevant_JJ patent_NN to_TO which_WDT the_DT licence_NN relates_VBZ ._.
During_IN the_DT term_NN of_IN certain_JJ research_NN and_CC development_NN agreements_NNS ,_, the_DT Group_NNP receives_VBZ non-refundable_JJ milestones_NNS as_IN certain_JJ technical_JJ targets_NNS are_VBP achieved_VBN ._.
Revenue_NN is_VBZ recognized_VBN on_IN achievement_NN of_IN milestones_NNS ._.
The_DT Group_NNP also_RB receives_VBZ non-refundable_JJ clinical_JJ milestones_NNS when_WRB certain_JJ targets_NNS are_VBP achieved_VBN during_IN the_DT clinical_JJ phases_NNS of_IN development_NN ,_, such_JJ as_IN the_DT submission_NN of_IN clinical_JJ data_NNS to_TO a_DT regulatory_JJ authority_NN ._.
These_DT clinical_JJ milestones_NNS are_VBP recognized_VBN when_WRB receivable_NN ._.
If_IN milestone_NN payments_NNS are_VBP creditable_JJ against_IN future_JJ royalty_NN payments_NNS ,_, the_DT milestones_NNS are_VBP deferred_VBN and_CC released_VBN over_IN the_DT period_NN in_IN which_WDT the_DT royalties_NNS are_VBP anticipated_VBN to_TO be_VB paid_VBN ._.
Royalty_NN income_NN relating_VBG to_TO licensed_JJ technology_NN is_VBZ recognized_VBN when_WRB earned_VBN ._.
No_DT revenue_NN is_VBZ recognized_VBN for_IN consideration_NN ,_, the_DT value_NN or_CC receipt_NN of_IN which_WDT is_VBZ dependent_JJ on_IN future_JJ events_NNS ,_, future_JJ performance_NN ,_, or_CC refund_NN obligations_NNS ._.
k_NN Research_NN and_CC development_NN Research_NN and_CC development_NN expenditure_NN includes_VBZ funded_VBN and_CC unfunded_JJ expenditure_NN and_CC is_VBZ written_VBN off_RP in_IN the_DT period_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN ._.
l_NN Pensions_NNS The_DT Group_NNP contributes_VBZ to_TO personal_JJ defined_VBN contribution_NN pension_NN plans_NNS of_IN employees_NNS ._.
Contributions_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP become_VBP payable_JJ ._.
Differences_NNS between_IN contributions_NNS payable_JJ and_CC contributions_NNS actually_RB paid_VBN are_VBP shown_VBN as_IN either_DT accruals_NNS or_CC prepayments_NNS in_IN the_DT balance_NN sheet_NN ._.
m_NNP Foreign_NNP currency_NN Transactions_NNS denominated_VBN in_IN foreign_JJ currencies_NNS are_VBP translated_VBN into_IN the_DT functional_JJ currency_NN at_IN the_DT rates_NNS ruling_VBG at_IN the_DT dates_NNS of_IN the_DT transactions_NNS ._.
Monetary_NNP assets_NNS and_CC liabilities_NNS denominated_VBN in_IN foreign_JJ currencies_NNS at_IN the_DT balance_NN sheet_NN date_NN are_VBP retranslated_VBN at_IN the_DT rates_NNS ruling_VBG at_IN that_DT date_NN ._.
With_IN the_DT exception_NN of_IN US_NNP dollar_NN balances_NNS ,_, which_WDT are_VBP taken_VBN directly_RB to_TO reserves_NNS ,_, these_DT translation_NN differences_NNS are_VBP dealt_VBN with_IN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
The_DT results_NNS of_IN overseas_JJ operations_NNS are_VBP translated_VBN at_IN the_DT average_JJ rates_NNS of_IN exchange_NN during_IN the_DT period_NN and_CC their_PRP$ balance_NN sheets_NNS at_IN the_DT rates_NNS ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
Exchange_NNP differences_NNS arising_VBG from_IN the_DT translation_NN of_IN the_DT opening_NN net_JJ assets_NNS and_CC on_IN foreign_JJ currency_NN borrowings_NNS ,_, to_TO the_DT extent_NN that_IN they_PRP hedge_VBP the_DT Groups_NNS investments_NNS in_IN such_JJ operations_NNS ,_, are_VBP taken_VBN directly_RB to_TO reserves_NNS ._.
All_DT other_JJ exchange_NN differences_NNS are_VBP included_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
n_JJ Leases_NNP Assets_NNPS acquired_VBD under_IN finance_NN leases_NNS are_VBP capitalized_VBN at_IN their_PRP$ fair_JJ value_NN on_IN the_DT inception_NN of_IN the_DT leases_NNS and_CC depreciated_VBN over_IN the_DT shorter_JJR of_IN the_DT period_NN of_IN lease_NN and_CC the_DT useful_JJ economic_JJ lives_NNS of_IN the_DT assets_NNS ._.
The_DT finance_NN charges_NNS are_VBP allocated_VBN over_IN the_DT period_NN of_IN the_DT lease_NN in_IN proportion_NN to_TO the_DT capital_NN amount_NN outstanding_JJ and_CC are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Operating_VBG lease_NN rentals_NNS are_VBP charged_VBN to_TO profit_VB and_CC loss_NN in_IN equal_JJ amounts_NNS over_IN the_DT lease_NN term_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 27_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 1_CD Accounting_NN policies_NNS continued_VBD o_JJ Finance_NNP costs_NNS Finance_NNP costs_NNS of_IN debt_NN are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT term_NN of_IN the_DT debt_NN at_IN a_DT constant_JJ rate_NN on_IN the_DT carrying_VBG amount_NN ._.
p_NN Debt_NNP Debt_NNP is_VBZ initially_RB stated_VBN at_IN the_DT amount_NN of_IN the_DT net_JJ proceeds_NNS after_IN deduction_NN of_IN issue_NN costs_NNS ._.
The_DT carrying_VBG amount_NN is_VBZ increased_VBN by_IN the_DT finance_NN cost_NN in_IN respect_NN of_IN the_DT accounting_NN period_NN and_CC reduced_VBN by_IN payments_NNS made_VBN in_IN the_DT period_NN ._.
Convertible_JJ debt_NN is_VBZ treated_VBN as_IN a_DT liability_NN as_RB long_RB as_IN there_EX is_VBZ no_DT genuine_JJ commercial_JJ possibility_NN that_IN the_DT option_NN to_TO issue_VB ordinary_JJ shares_NNS or_CC American_JJ Depository_NNP Shares_NNP will_MD be_VB exercised_VBN ._.
No_DT gain_NN or_CC loss_NN is_VBZ recognized_VBN on_IN conversion_NN ._.
q_NNP Government_NNP grants_NNS Government_NNP grants_NNS in_IN respect_NN of_IN funded_JJ research_NN and_CC development_NN expenditure_NN are_VBP credited_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN the_DT related_JJ expenditure_NN is_VBZ incurred_VBN ._.
r_NN Derivative_JJ financial_JJ instruments_NNS The_DT Group_NNP uses_VBZ derivative_JJ financial_JJ instruments_NNS to_TO reduce_VB exposure_NN to_TO foreign_JJ exchange_NN risk_NN and_CC interest_NN rate_NN movements_NNS ._.
The_DT Group_NNP does_VBZ not_RB hold_VB or_CC issue_VB derivative_JJ financial_JJ instruments_NNS for_IN speculative_JJ purposes_NNS ._.
For_IN a_DT forward_RB foreign_JJ exchange_NN contract_NN to_TO be_VB treated_VBN as_IN a_DT hedge_NN the_DT instrument_NN must_MD be_VB related_VBN to_TO actual_JJ foreign_JJ currency_NN assets_NNS or_CC liabilities_NNS or_CC to_TO a_DT probable_JJ commitment_NN ._.
It_PRP must_MD involve_VB the_DT same_JJ currency_NN or_CC similar_JJ currencies_NNS as_IN the_DT hedged_VBN item_NN and_CC must_MD also_RB reduce_VB the_DT risk_NN of_IN foreign_JJ currency_NN exchange_NN movements_NNS on_IN the_DT Groups_NNS operations_NNS ._.
Gains_NNS and_CC losses_NNS arising_VBG on_IN these_DT contracts_NNS are_VBP deferred_VBN and_CC recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ,_, or_CC as_IN adjustments_NNS to_TO the_DT carrying_VBG amount_NN of_IN fixed_JJ assets_NNS ,_, only_RB when_WRB the_DT hedged_VBN transaction_NN has_VBZ itself_PRP been_VBN reflected_VBN in_IN the_DT Groups_NNS accounts_NNS ._.
For_IN an_DT interest_NN rate_NN swap_NN to_TO be_VB treated_VBN as_IN a_DT hedge_NN the_DT instrument_NN must_MD be_VB related_VBN to_TO actual_JJ assets_NNS or_CC liabilities_NNS or_CC a_DT probable_JJ commitment_NN and_CC must_MD change_VB the_DT nature_NN of_IN the_DT interest_NN rate_NN by_IN converting_VBG a_DT fixed_JJ rate_NN to_TO a_DT variable_JJ rate_NN or_CC vice_NN versa_RB ._.
Interest_NN differentials_NNS under_IN these_DT swaps_NNS are_VBP recognized_VBN by_IN adjusting_VBG net_JJ interest_NN payable_JJ over_IN the_DT periods_NNS of_IN the_DT contracts_NNS ._.
If_IN an_DT instrument_NN ceases_VBZ to_TO be_VB accounted_VBN for_IN as_IN a_DT hedge_NN ,_, for_IN example_NN because_IN the_DT underlying_VBG hedged_JJ position_NN is_VBZ eliminated_VBN ,_, the_DT instrument_NN is_VBZ marked_VBN to_TO market_NN and_CC any_DT resulting_JJ profit_NN or_CC loss_NN recognized_VBN at_IN that_DT time_NN ._.
s_PRP Employee_NNP share_NN schemes_NNS In_IN accordance_NN with_IN UITF_NNP Abstract_NNP 17_CD Employee_NN share_NN schemes_NNS ,_, the_DT cost_NN of_IN awards_NNS to_TO employees_NNS that_WDT take_VBP the_DT form_NN of_IN shares_NNS or_CC rights_NNS to_TO shares_NNS is_VBZ recognized_VBN as_IN a_DT charge_NN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
The_DT amount_NN recognized_VBN ,_, which_WDT is_VBZ the_DT difference_NN between_IN the_DT market_NN value_NN at_IN date_NN of_IN grant_NN and_CC the_DT underlying_JJ share_NN and_CC any_DT exercise_NN price_NN ,_, is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT period_NN the_DT shares_NNS are_VBP vested_VBN ,_, with_IN a_DT corresponding_JJ credit_NN to_TO reserves_NNS ._.
t_NN Related_VBN party_NN transactions_NNS In_IN accordance_NN with_IN the_DT exemptions_NNS in_IN FRS_NNP 8_CD Related_VBN party_NN disclosures_NNS ,_, transactions_NNS between_IN Group_NNP companies_NNS have_VBP not_RB been_VBN disclosed_VBN since_IN Group_NNP accounts_NNS are_VBP prepared_JJ and_CC include_VBP the_DT results_NNS of_IN all_DT subsidiary_NN undertakings_NNS ._.
u_NNP Significant_NNP accounting_NN estimates_VBZ Sales_NNS deductions_NNS primarily_RB consist_VBP of_IN statutory_JJ rebates_NNS to_TO state_NN Medicaid_NNP agencies_NNS ,_, contractual_JJ rebates_NNS with_IN health-maintenance_NN organizations_NNS ,_, product_NN returns_NNS ,_, and_CC trade_NN discounts_NNS ._.
Provisions_NNS for_IN rebates_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS with_IN estimates_NNS of_IN future_JJ utilisation_NN derived_VBN from_IN historical_JJ trends_NNS ._.
Provisions_NNS for_IN product_NN returns_NNS and_CC trade_NN discounts_NNS to_TO customers_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS with_IN estimates_NNS based_VBN upon_IN past_JJ activity_NN levels_NNS and_CC duration_NN of_IN time_NN in_IN the_DT processing_NN of_IN deductions_NNS ._.
28_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 2_CD Turnover_NN and_CC segment_NN information_NN a_DT Turnover_NN and_CC loss_NN profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN The_DT directors_NNS believe_VBP that_IN there_EX is_VBZ one_CD business_NN segment_NN ._.
Licensing_VBG Product_NNP and_CC Other_JJ sales_NNS development_NN Royalties_NNS revenues_NNS Total_JJ Year_NN to_TO 31_CD December_NNP 2002 000 000 000_CD 000_CD 000_CD Turnover_NN 596,313_CD 2,041_CD 114,146_CD 27_CD 712,527_CD Cost_NN of_IN product_NN sales_NNS 95,042_CD 95,042_CD Distribution_NN costs_NNS 167,095_CD 167,095_CD Funded_VBN research_NN and_CC development_NN costs_NNS 5,041_CD 5,041_CD 334,176_CD 3,000_CD 114,146_CD 27_CD 445,349_CD Unfunded_JJ research_NN and_CC development_NN costs_NNS 121,105_CD Depreciation_NN and_CC amortisation_NN 794,499_CD Expenses_NNS not_RB allocated_VBN general_JJ overheads_NNS 62,890_CD Operating_NN loss_NN 533,145_CD Share_NN of_IN joint_JJ ventures_NNS operating_VBG loss_NN 559_CD Finance_NNP charges_NNS ,_, net_JJ 6,931_CD Loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 526,773_CD General_NNP overheads_NNS have_VBP not_RB been_VBN allocated_VBN by_IN business_NN activity_NN as_IN management_NN does_VBZ not_RB run_VB the_DT business_NN in_IN this_DT way_NN ._.
Licensing_VBG Product_NNP and_CC Other_JJ sales_NNS development_NN Royalties_NNS revenues_NNS Total_JJ Year_NN to_TO 31_CD December_NNP 2001 000 000 000_CD 000_CD 000_CD Turnover_NN 508,626_CD 3,810_CD 66,132_CD 1,801_CD 580,369_CD Cost_NN of_IN product_NN sales_NNS 83,149_CD 83,149_CD Distribution_NN costs_NNS 147,400_CD 147,400_CD Funded_VBN research_NN and_CC development_NN costs_NNS 4,358_CD 4,358_CD 278,077_CD 548_CD 66,132_CD 1,801_CD 345,462_CD Unfunded_JJ research_NN and_CC development_NN costs_NNS 99,468_CD Depreciation_NN and_CC amortisation_NN 121,438_CD Expenses_NNS not_RB allocated_VBN general_JJ overheads_NNS 48,134_CD Operating_NN profit_NN 76,422_CD Finance_NNP charges_NNS ,_, net_JJ 4,955_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 81,377_CD General_NNP overheads_NNS have_VBP not_RB been_VBN allocated_VBN by_IN business_NN activity_NN as_IN management_NN does_VBZ not_RB run_VB the_DT business_NN in_IN this_DT way_NN ._.
c_NN An_DT analysis_NN of_IN net_JJ operating_NN expenses_NNS 2002 2001 000 000_CD Distribution_NN costs_NNS 167,095_CD 147,400_CD Research_NNP and_CC development_NN 126,146_CD 103,826_CD Administrative_JJ expenses_NNS 857,389_CD 169,572_CD 1,150,630_CD 420,798_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 29_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 2_CD Turnover_NN and_CC segment_NN information_NN continued_VBD d_SYM Analysis_NN of_IN continuing_VBG and_CC discontinuing_VBG operations_NNS Continuing_VBG Discontinued_NNP Total_NNP Continuing_NNP Discontinued_NNP Total_NNP 2002 2002 2002 2001_CD 2001_CD 2001_CD Turnover_NN 696,552_CD 15,975_CD 712,527_CD 563,249_CD 17,120_CD 580,369_CD Cost_NN of_IN sales_NNS 91,208_CD 3,834_CD 95,042_CD 78,781_CD 4,368_CD 83,149_CD Gross_NNP profit_NN 605,344_CD 12,141_CD 617,485_CD 484,468_CD 12,752_CD 497,220_CD Net_JJ operating_NN expenses_NNS 1,146,947_CD 3,683_CD 1,150,630_CD 415,496_CD 5,302_CD 420,798_CD Operating_NN loss_NN profit_NN 541,603_CD 8,458_CD 533,145_CD 68,972_CD 7,450_CD 76,422_CD The_DT total_JJ figures_NNS for_IN continuing_VBG operations_NNS in_IN 2002_CD include_VBP the_DT following_JJ amounts_NNS relating_VBG to_TO acquisitions_NNS :_: turnover_NN 653,000_CD ,_, cost_NN of_IN sales_NNS 1,637,000_CD ,_, gross_JJ loss_NN 984,000_CD ,_, net_JJ operating_NN expenses_NNS 847,000_CD and_CC operating_VBG loss_NN 1,831,000_CD ._.
3_CD Operating_NN loss_NN profit_NN Operating_NN loss_NN profit_NN is_VBZ stated_VBN after_IN crediting_VBG charging_VBG :_: 2002 2001 000 000_CD Government_NN grant_NN 1,855_CD 1,824_CD Research_NNP and_CC development_NN 126,146_CD 103,826_CD Auditors_NNS remuneration_JJ audit_NN fees_NNS Group_NNP 600_CD 515_CD Company_NN 20_CD 20_CD non-audit_JJ fees_NNS Group_NNP 933_CD 1,245_CD Company_NN 48_CD 48_CD Operating_NN lease_NN rentals_NNS plant_NN and_CC machinery_NN 2,332_CD 2,101_CD other_JJ 2,264_CD 1,891_CD Impairment_NN of_IN goodwill_NN and_CC other_JJ intangible_JJ fixed_JJ assets_NNS 631,447_CD 3,092_CD Depreciation_NN of_IN tangible_JJ fixed_JJ assets_NNS owned_VBN 8,995_CD 7,092_CD held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS 78_CD Amortisation_NNP of_IN goodwill_NN 138,513_CD 96,710_CD Amortisation_NNP of_IN intangible_JJ fixed_JJ assets_NNS 15,466_CD 14,544_CD Profit_NN on_IN sale_NN of_IN discontinued_VBN operations_NNS 2,006_CD Loss_NN on_IN sales_NNS of_IN fixed_JJ assets_NNS 854_CD 7,646_CD 4_CD Directors_NNS remuneration_NN ,_, interests_NNS and_CC transactions_NNS Aggregate_JJ remuneration_NN The_DT total_JJ amounts_NNS for_IN directors_NNS remuneration_NN and_CC other_JJ benefits_NNS were_VBD as_IN follows_VBZ :_: 2002 2001 000 000_CD Emoluments_NNP 2,300_CD 2,019_CD Compensation_NNP for_IN loss_NN of_IN office_NN 2,754_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 2,962_CD 22,005_CD Money_NN purchase_NN pension_NN contributions_NNS 383_CD 103_CD 5,645_CD 26,881_CD No_DT fees_NNS were_VBD payable_JJ to_TO third_JJ parties_NNS in_IN respect_NN of_IN directors_NNS services_NNS for_IN either_DT year_NN ._.
30_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 4_CD Directors_NNS remuneration_NN ,_, interests_NNS and_CC transactions_NNS The_DT number_NN of_IN directors_NNS who_WP were_VBD members_NNS of_IN a_DT Company_NN pension_NN scheme_NN was_VBD as_IN follows_VBZ :_: 2002_CD 2001_CD Number_NNP Number_NNP Money_NNP purchase_NN schemes_NNS 4_CD 3_CD Contributions_NNS paid_VBN by_IN the_DT Group_NNP in_IN respect_NN of_IN these_DT directors_NNS can_MD be_VB found_VBN in_IN the_DT remuneration_NN report_NN on_IN page_NN 20_CD ._.
The_DT above_JJ amounts_NNS for_IN remuneration_NN include_VBP the_DT following_VBG in_IN respect_NN of_IN the_DT highest_JJS paid_VBN director_NN :_: 2002 2001 000 000_CD Aggregate_NNP emoluments_NNS 1,144_CD 258_CD Compensation_NNP for_IN loss_NN of_IN office_NN 2,754_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 2,836_CD 21,437_CD 3,980_CD 24,449_CD Further_JJ disclosures_NNS relating_VBG to_TO directors_NNS remuneration_NN and_CC interests_NNS in_IN transactions_NNS can_MD be_VB found_VBN in_IN the_DT remuneration_NN report_NN ._.
5_CD Staff_NN costs_NNS Particulars_NNPS of_IN employee_NN costs_NNS including_VBG executive_JJ directors_NNS remuneration_NN are_VBP shown_VBN below_IN :_: 2002 2001 000 000_CD Wages_NNS and_CC salaries_NNS 79,383_CD 78,888_CD Social_NNP security_NN costs_NNS 7,761_CD 7,608_CD Pension_NN contributions_NNS 4,702_CD 3,123_CD 91,846_CD 89,619_CD The_DT Group_NNP operates_VBZ an_DT Inland_NNP Revenue_NN approved_VBD employee_NN share_NN option_NN scheme_NN and_CC has_VBZ taken_VBN advantage_NN of_IN the_DT exemption_NN given_VBN in_IN UITF_NNP Abstract_NNP 17_CD Employee_NN share_NN schemes_NNS from_IN recognizing_VBG a_DT charge_NN in_IN the_DT profit_NN and_CC loss_NN account_NN for_IN the_DT discount_NN on_IN the_DT options_NNS ._.
The_DT average_JJ monthly_JJ number_NN of_IN people_NNS employed_VBN by_IN the_DT Group_NNP during_IN the_DT year_NN was_VBD as_IN follows_VBZ :_: 2002_CD 2001_CD Number_NNP Number_NNP Manufacturing_NNP and_CC distribution_NN 292_CD 236_CD Sales_NNS and_CC marketing_NN 791_CD 704_CD General_NNP and_CC administrative_JJ 298_CD 220_CD Research_NNP and_CC development_NN 424_CD 315_CD 1,805_CD 1,475_CD 6_CD Finance_NNP charges_NNS ,_, net_JJ 2002 2001 000 000_CD Investment_NN income_NN 15,434_CD 13,077_CD Interest_NN payable_JJ and_CC similar_JJ charges_NNS 8,458_CD 8,122_CD Finance_NNP leases_NNS and_CC hire_VB purchase_NN contracts_NNS 45_CD 8,503_CD 8,122_CD Finance_NNP charges_NNS ,_, net_JJ Investment_NN income_NN 15,434_CD 13,077_CD Interest_NN payable_JJ and_CC similar_JJ charges_NNS 8,503_CD 8,122_CD 6,931_CD 4,955_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 31_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 7_CD Tax_NNP on_IN loss_NN profit_NN on_IN ordinary_JJ activities_NNS The_DT tax_NN charge_NN comprises_VBZ :_: 2002 2001 000 000_CD Current_JJ tax_NN UK_NNP corporation_NN tax_NN 76_CD Overseas_NNP corporation_NN tax_NN 66,461_CD 46,879_CD Adjustment_NNP to_TO prior_JJ year_NN tax_NN charge_NN UK_NNP corporation_NN tax_NN 1,190_CD Overseas_NNP corporation_NN tax_NN 196_CD 2,049_CD 67,455_CD 44,906_CD Deferred_JJ tax_NN Origination_NNP and_CC reversal_NN of_IN timing_NN differences_NNS 5,829_CD 762_CD Total_JJ deferred_JJ tax_NN 5,829_CD 762_CD Total_JJ tax_NN on_IN loss_NN profit_NN on_IN ordinary_JJ activities_NNS 61,626_CD 45,668_CD The_DT differences_NNS between_IN the_DT total_JJ current_JJ tax_NN shown_VBN above_IN and_CC the_DT amount_NN calculated_VBN by_IN applying_VBG the_DT standard_JJ rate_NN of_IN UK_NNP corporation_NN tax_NN to_TO the_DT profit_NN before_IN tax_NN is_VBZ as_IN follows_VBZ :_: 2002 2001 000 000_CD Group_NNP loss_NN profit_NN on_IN ordinary_JJ activities_NNS before_IN tax_NN 526,773_CD 81,377_CD Tax_NNP on_IN loss_NN profit_NN on_IN ordinary_JJ activities_NNS at_IN standard_JJ UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN 2001_CD :_: 30_CD %_NN 158,032_CD 24,413_CD Effects_NNPS of_IN :_: Expenses_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 9,247_CD 782_CD Non_NNP deductible_JJ goodwill_NN 225,749_CD 29,090_CD Additional_JJ tax_NN benefits_NNS non_VBP taxable_JJ income_NN 1,796_CD 4,090_CD Utilisation_NNP of_IN tax_NN losses_NNS 9,255_CD 256_CD Capital_NN taxes_NNS and_CC withholding_NN taxes_NNS 550_CD 4,360_CD Different_JJ tax_NN rates_NNS on_IN overseas_JJ earnings_NNS 24,341_CD 6,582_CD Deferred_JJ tax_NN liability_NN 5,829_CD 762_CD Adjustments_NNS to_TO tax_NN charge_NN in_IN respect_NN of_IN previous_JJ periods_NNS 994_CD 2,049_CD Group_NNP current_JJ tax_NN charge_NN for_IN period_NN 67,455_CD 44,906_CD The_DT Group_NNP earns_VBZ a_DT significant_JJ proportion_NN of_IN its_PRP$ profits_NNS in_IN the_DT US_NNP ._.
The_DT US_NNP statutory_JJ federal_JJ tax_NN rate_NN is_VBZ higher_JJR than_IN that_DT of_IN the_DT UK_NNP :_: profits_NNS being_VBG taxed_VBN at_IN 35_CD %_NN ._.
In_IN the_DT future_NN ,_, changes_NNS in_IN US_NNP tax_NN law_NN may_MD affect_VB the_DT Group_NNP tax_NN charge_NN ._.
No_DT current_JJ tax_NN deduction_NN is_VBZ available_JJ on_IN the_DT write-down_NN of_IN goodwill_NN that_WDT was_VBD created_VBN on_IN the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP 8_CD Loss_NN profit_NN attributable_JJ to_TO Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN The_DT loss_NN for_IN the_DT financial_JJ year_NN dealt_VBD with_IN in_IN the_DT accounts_NNS of_IN the_DT Company_NN was_VBD 7,038,000_CD 2001_CD :_: profit_NN of_IN 1,643,000_CD ._.
As_IN provided_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, no_DT profit_NN and_CC loss_NN account_NN is_VBZ presented_VBN in_IN respect_NN of_IN the_DT Company_NN ._.
32_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 9_CD Loss_NN earnings_NNS per_IN share_NN Loss_NN earnings_NNS per_IN share_NN EPS_NNP has_VBZ been_VBN calculated_VBN by_IN dividing_VBG the_DT loss_NN profit_NN on_IN ordinary_JJ activities_NNS after_IN taxation_NN for_IN each_DT period_NN by_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN during_IN those_DT periods_NNS ._.
The_DT weighted_JJ average_JJ number_NN of_IN shares_NNS used_VBN in_IN calculating_VBG diluted_JJ earnings_NNS per_IN share_NN has_VBZ been_VBN adjusted_VBN for_IN the_DT effects_NNS of_IN all_DT dilutive_JJ potential_JJ ordinary_JJ shares_NNS ._.
No_DT such_JJ amounts_NNS were_VBD included_VBN in_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN 2002_CD as_IN their_PRP$ inclusion_NN would_MD be_VB anti-dilutive_JJ in_IN a_DT loss_NN making_VBG period_NN ._.
The_DT $_$ 400_CD million_CD convertible_JJ loan_NN note_NN is_VBZ excluded_VBN from_IN the_DT calculation_NN of_IN weighted_JJ average_JJ number_NN of_IN shares_NNS for_IN diluted_JJ earnings_NNS per_IN share_NN in_IN 2002_CD and_CC 2001_CD as_IN it_PRP was_VBD not_RB dilutive_JJ ._.
The_DT zero_CD coupon_NN convertible_JJ loan_NN note_NN included_VBD in_IN 2001_CD has_VBZ no_DT impact_NN on_IN the_DT numerator_NN for_IN diluted_JJ earnings_NNS per_IN share_NN ._.
Basic_JJ and_CC diluted_JJ 2002 2001 000 000_CD Loss_NN profit_NN for_IN the_DT financial_JJ year_NN 588,399_CD 35,709_CD The_DT weighted_JJ average_JJ number_NN of_IN shares_NNS used_VBN in_IN each_DT year_NN are_VBP as_IN follows_VBZ :_: 2002_CD 2001_CD Number_NNP Number_NNP Total_NNP for_IN basic_JJ EPS_NNP 500,687,594_CD 412,183,058_CD Conversion_NNP of_IN convertible_JJ debt_NN 289,101_CD Exercise_NN of_IN share_NN options_NNS 6,270,923_CD Exercise_NN of_IN warrants_NNS 919,029_CD Total_JJ for_IN diluted_VBN EPS_NNP 500,687,594_CD 419,662,111_CD 10_CD Intangible_JJ assets_NNS intellectual_JJ property_NN Group_NNP Company_NNP 000_CD 000_CD Cost_NN As_IN at_IN 1_CD January_NNP 2002_CD 321,756_CD 10,068_CD Additions_NNPS 15,470_CD 13,600_CD Transfer_NNP to_TO goodwill_NN note_NN 11_CD 2,755_CD Disposals_NNS 49,115_CD Foreign_JJ exchange_NN 24,408_CD As_IN at_IN 31_CD December_NNP 2002_CD 260,948_CD 23,668_CD Amortisation_NNP As_IN at_IN 1_CD January_NNP 2002_CD 61,906_CD 933_CD Charge_NNP for_IN the_DT year_NN 15,466_CD 1,345_CD Impairment_NN 17,464_CD Disposals_NNPS 11,442_CD Foreign_JJ exchange_NN 5,850_CD As_IN at_IN 31_CD December_NNP 2002_CD 77,544_CD 2,278_CD Net_JJ book_NN value_NN As_IN at_IN 31_CD December_NNP 2001_CD 259,850_CD 9,135_CD As_IN at_IN 31_CD December_NNP 2002_CD 183,404_CD 21,390_CD During_IN the_DT second_JJ quarter_NN of_IN 2002_CD ,_, and_CC included_VBD within_IN additions_NNS for_IN the_DT year_NN ,_, the_DT Group_NNP purchased_VBD SOLARAZE_NNP for_IN 13.6_CD million_CD ._.
The_DT impairment_NN was_VBD in_IN respect_NN of_IN write-downs_NNS made_VBN to_TO non-strategic_JJ products_NNS that_WDT are_VBP no_RB longer_RB marketed_VBN by_IN the_DT Group_NNP ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 33_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 11_CD Intangible_JJ assets_NNS goodwill_NN Group_NNP Company_NNP 000_CD 000_CD Cost_NN As_IN at_IN 1_CD January_NNP 2002_CD 2,764,478_CD Transfer_NNP in_IN from_IN intellectual_JJ property_NN note_NN 10_CD 2,755_CD Acquisition_NNP of_IN subsidiary_NN undertaking_NN note_NN 14_CD 7,066_CD Foreign_JJ exchange_NN 7_CD As_IN at_IN 31_CD December_NNP 2002_CD 2,774,292_CD Amortisation_NNP As_IN at_IN 1_CD January_NNP 2002_CD 120,900_CD Charge_NNP for_IN the_DT year_NN 138,513_CD Impairment_NNP 613,983_CD As_IN at_IN 31_CD December_NNP 2002_CD 873,396_CD Net_JJ book_NN value_NN As_IN at_IN 31_CD December_NNP 2001_CD 2,643,578_CD As_IN at_IN 31_CD December_NNP 2002_CD 1,900,896_CD At_IN 31_CD December_NNP 2002_CD ,_, an_DT impairment_NN charge_NN was_VBD booked_VBN in_IN relation_NN to_TO goodwill_NN which_WDT was_VBD created_VBN on_IN the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP ._.
A_DT discounted_JJ cash_NN flow_NN model_NN was_VBD used_VBN to_TO estimate_VB the_DT recoverable_JJ value_NN of_IN the_DT business_NN and_CC the_DT impairment_NN charge_NN is_VBZ included_VBN within_IN net_JJ operating_NN expenses_NNS in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN ._.
A_DT range_NN of_IN discount_NN rates_NNS between_IN 8-10_CD %_NN were_VBD applied_VBN to_TO probability_NN adjusted_VBN forecasts_NNS ._.
34_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 12_CD Tangible_JJ assets_NNS continued_VBD The_DT net_JJ book_NN value_NN of_IN the_DT Groups_NNS assets_NNS held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN agreements_NNS is_VBZ shown_VBN below_IN :_: 2002 2001 000 000_CD Buildings_NNS 3,848_CD Equipment_NNP and_CC other_JJ 61_CD 3,909_CD All_DT finance_NN leases_NNS and_CC hire_VB purchase_NN arrangements_NNS are_VBP short_JJ leases_NNS with_IN a_DT life_NN of_IN less_JJR than_IN 50_CD years_NNS ._.
b_NN Company_NN Office_NNP furniture_NN Equipment_NNP and_CC and_CC fittings_NNS other_JJ Total_JJ 000 000 000_CD Cost_NN As_IN at_IN 1_CD January_NNP 2002_CD 1,459_CD 3,591_CD 5,050_CD Additions_NNS 149_CD 2,389_CD 2,538_CD As_IN at_IN 31_CD December_NNP 2002_CD 1,608_CD 5,980_CD 7,588_CD Depreciation_NN As_IN at_IN 1_CD January_NNP 2002_CD 645_CD 1,964_CD 2,609_CD Charge_NNP 304_CD 1,034_CD 1,338_CD As_IN at_IN 31_CD December_NNP 2002_CD 949_CD 2,998_CD 3,947_CD Net_JJ book_NN value_NN As_IN at_IN 31_CD December_NNP 2001_CD 814_CD 1,627_CD 2,441_CD As_IN at_IN 31_CD December_NNP 2002_CD 659_CD 2,982_CD 3,641_CD The_DT net_JJ book_NN value_NN of_IN the_DT Companys_NNP equipment_NN includes_VBZ 61,000_CD 2001_CD :_: nil_NN in_IN respect_NN of_IN assets_NNS held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 35_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 13_CD Fixed_VBN asset_NN investments_NNS Group_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Subsidiary_NNP undertakings_NNS 3,435,332_CD 3,400,281_CD Other_JJ investments_NNS 37,345_CD 45,045_CD 559_CD 1,898_CD 37,345_CD 45,045_CD 3,435,891_CD 3,402,179_CD Principal_NN Group_NNP investments_NNS The_DT parent_NN company_NN and_CC the_DT Group_NNP have_VBP investments_NNS in_IN the_DT following_JJ subsidiary_NN undertakings_NNS and_CC other_JJ investments_NNS which_WDT principally_RB affected_VBD the_DT profits_NNS or_CC net_JJ assets_NNS of_IN the_DT Group_NNP ._.
To_TO avoid_VB a_DT statement_NN of_IN excessive_JJ length_NN ,_, details_NNS of_IN investments_NNS which_WDT are_VBP not_RB significant_JJ have_VBP been_VBN omitted_VBN ._.
Country_NN of_IN incorporation_NN or_CC principal_NN business_NN Holding_VBG address_NN Principal_NN activity_NN %_NN Subsidiary_NNP undertakings_NNS Roberts_NNP Pharmaceutical_NNP Corporation_NNP US_NNP Intermediate_NNP holding_VBG company_NN 100_CD Shire_NNP Pharmaceuticals_NNP Limited_NNP UK_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD Shire_NNP Pharmaceutical_NNP Development_NNP Limited_NNP UK_NNP Development_NNP of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD Shire_NNP International_NNP Licensing_NNP BV_NNP Netherlands_NNP Licensing_NNP and_CC development_NN of_IN pharmaceuticals_NNS 100_CD Shire_NNP Laboratories_NNPS Inc_NNP US_NNP Development_NNP and_CC licensing_NN of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD Shire_NNP Supplies_NNPS US_NNP ,_, LLC_NNP US_NNP Holder_NNP of_IN intellectual_JJ property_NN 100_CD Shire_NNP France_NNP SA_NNP France_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD Shire_NNP Deutschland_NNP GmbH_NNP &_CC Co_NNP K_NNP G_NNP Germany_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD Shire_NNP US_NNP Inc_NNP US_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD Shire_NNP Pharmaceuticals_NNP Ireland_NNP Limited_NNP Ireland_NNP Marketing_NNP and_CC distribution_NN of_IN pharmaceuticals_NNS 100_CD Shire_NNP Italia_NNP SpA_NNP Italy_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD Shire_NNP Pharmaceuticals_NNP Iberica_NNP SL_NNP Spain_NNP Marketing_NNP and_CC distribution_NN of_IN pharmaceuticals_NNS 100_CD Shire_NNP Pharmaceuticals_NNP Development_NNP US_NNP Inc_NNP US_NNP Development_NNP of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD Shire_NNP BioChem_NNP Inc_NNP Canada_NNP Research_NNP and_CC development_NN of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD Shire_NNP Finance_NNP Limited_NNP Cayman_NNP Islands_NNP Issuer_NNP of_IN convertible_JJ notes_NNS 100_CD Shire_NNP Biologics_NNPS Inc_NNP US_NNP Research_NNP and_CC development_NN of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD Shire_NNP Pharmaceutical_NNP Contracts_NNPS Limited_NNP UK_NNP Marketing_NNP of_IN phamaceuticals_NNS 100_CD Shire_NNP US_NNP Manufacturing_NNP Inc_NNP US_NNP Manufacturer_NNP of_IN phamaceuticals_NNS 100_CD Held_VBN directly_RB by_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc._NN ._.
All_DT subsidiary_NN undertakings_NNS have_VBP been_VBN included_VBN in_IN the_DT consolidated_JJ financial_JJ statements_NNS ._.
Subsidiary_NNP undertakings_NNS Company_NN Amount_NNP Shares_NNP in_IN due_JJ from_IN subsidiary_NN subsidiary_NN undertakings_NNS undertakings_NNS Total_JJ Cost_NN 000 000 000_CD At_IN 1_CD January_NNP 2002_CD 3,200,583_CD 199,698_CD 3,400,281_CD Additions_NNS 10,165_CD 10,165_CD Net_JJ drawdown_NN of_IN loans_NNS 24,886_CD 24,886_CD Interest_NN on_IN intra-Group_JJ loan_NN 4,412_CD 4,412_CD Write_VB down_IN of_IN investment_NN in_IN subsidiary_NN undertaking_NN 4,412_CD 4,412_CD At_IN 31_CD December_NNP 2002_CD 3,206,336_CD 228,996_CD 3,435,332_CD Included_VBN in_IN the_DT amounts_NNS due_RB from_IN subsidiary_NN undertakings_NNS is_VBZ an_DT amount_NN of_IN 96.6_CD million_CD due_JJ from_IN Shire_NNP Holdings_NNP Europe_NNP Limited_NNP ,_, a_DT Group_NNP company_NN ._.
This_DT relates_VBZ to_TO Unsecured_NNP Convertible_NNP Redeemable_NNP Loan_NNP Stock_NNP 1997-2002_CD ._.
With_IN effect_NN from_IN 30_CD June_NNP 2002_CD the_DT terms_NNS of_IN the_DT loan_NN were_VBD amended_VBN such_JJ that_IN it_PRP now_RB bears_VBZ interest_NN at_IN 1_CD %_NN above_IN LIBOR_NNP ._.
36_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 13_CD Fixed_VBN asset_NN investments_NNS continued_VBD Other_JJ investments_NNS Group_NNP Company_NNP Other_JJ Other_JJ investments_NNS Total_JJ investments_NNS Total_JJ 000 000 000 000_CD At_IN 1_CD January_NNP 2002_CD 45,045_CD 45,045_CD 1,898_CD 1,898_CD Additions_NNS 7,697_CD 7,697_CD Disposals_NNS 5,282_CD 5,282_CD 1,339_CD 1,339_CD Foreign_JJ exchange_NN 4,306_CD 4,306_CD At_IN 31_CD December_NNP 2002_CD 43,154_CD 43,154_CD 559_CD 559_CD Provisions_NNS for_IN impairment_NN At_IN 1_CD January_NNP 2002_CD Written_VBN off_RP 5,809_CD 5,809_CD At_IN 31_CD December_NNP 2002_CD 5,809_CD 5,809_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 2001_CD 45,045_CD 45,045_CD 1,898_CD 1,898_CD At_IN 31_CD December_NNP 2002_CD 37,345_CD 37,345_CD 559_CD 559_CD a_DT Investments_NNP in_IN private_JJ companies_NNS i_FW GeneChem_NNP funds_NNS The_DT Group_NNP has_VBZ made_VBN investments_NNS in_IN two_CD venture_NN capital_NN funds_NNS ._.
The_DT fund_NN managers_NNS distribute_VBP income_NN to_TO the_DT partners_NNS of_IN the_DT funds_NNS in_IN respect_NN of_IN dividends_NNS or_CC realized_VBN gains_NNS made_VBN on_IN sale_NN of_IN investments_NNS ._.
In_IN March_NNP 1997_CD ,_, the_DT Group_NNP entered_VBD into_IN an_DT agreement_NN to_TO make_VB an_DT investment_NN of_IN 11.8_CD million_CD CAN$_NNP 30.0_CD million_CD in_IN the_DT GeneChem_NNP Technologies_NNPS Venture_NNP Fund_NNP L._NNP P._NNP a_DT venture_NN capital_NN fund_NN sponsored_VBN by_IN a_DT Group_NNP subsidiary_NN ,_, GeneChem_NNP Financial_NNP Corporation_NNP ._.
This_DT CAN$_NNP 100.0_CD million_CD Fund_NNP invests_VBZ in_IN advanced_JJ academic_JJ research_NN projects_NNS and_CC early_JJ stage_NN private_JJ or_CC public_JJ companies_NNS in_IN the_DT area_NN of_IN genomics_NNS and_CC related_VBN technologies_NNS for_IN human_JJ application_NN ._.
Our_PRP$ partners_NNS in_IN this_DT fund_NN are_VBP a_DT select_JJ group_NN of_IN financial_JJ investors_NNS ._.
As_IN of_IN 31_CD December_NNP 2002_CD ,_, the_DT Group_NNP has_VBZ invested_VBN 10.6_CD million_CD CAN$_NNP 27.0_CD million_CD in_IN the_DT GeneChem_NNP Technologies_NNPS Venture_NNP Fund_NNP L._NNP P._NNP and_CC is_VBZ ,_, therefore_RB ,_, committed_VBN to_TO investing_VBG a_DT further_JJ 1.2_CD million_CD CAN$_NNP 3.0_CD million_CD into_IN this_DT Fund_NN ._.
In_IN September_NNP 2000_CD ,_, the_DT Group_NNP entered_VBD into_IN an_DT agreement_NN to_TO invest_VB 5.9_CD million_CD CAN$_NNP 15.0_CD million_CD in_IN the_DT GeneChem_NNP Therapeutics_NNPS Venture_NNP Fund_NNP L._NNP P._NNP This_DT CAN$_NNP 135.0_CD million_CD fund_NN invests_VBZ in_IN genomics_NNS companies_NNS focusing_VBG on_IN cancer_NN and_CC infectious_JJ diseases_NNS ._.
As_IN of_IN 31_CD December_NNP 2002_CD ,_, the_DT Group_NNP had_VBD invested_VBN 2.7_CD million_CD CAN$_NNP 6.8_CD million_CD and_CC the_DT Group_NNP has_VBZ committed_VBN to_TO invest_VB a_DT further_JJ 3.2_CD million_CD CAN$_NNP 8.2_CD million_CD in_IN the_DT GeneChem_NNP Therapeutics_NNPS Venture_NNP Fund_NNP L._NNP P._NNP The_NNP manager_NN and_CC general_JJ partners_NNS of_IN these_DT funds_NNS are_VBP wholly_RB owned_VBN subsidiaries_NNS of_IN the_DT Group_NNP ._.
The_DT underlying_JJ funds_NNS have_VBP not_RB been_VBN consolidated_JJ because_IN the_DT operational_JJ substance_NN of_IN the_DT funds_NNS are_VBP such_JJ that_IN the_DT other_JJ partners_NNS have_VBP the_DT ability_NN to_TO veto_VB investment_NN decisions_NNS ._.
ii_FW EGS_NNP Healthcare_NNP fund_NN In_IN November_NNP 2000_CD ,_, the_DT Group_NNP entered_VBD into_IN an_DT agreement_NN to_TO invest_VB up_RP to_TO 6.2_CD million_CD $_$ 10.0_CD million_CD in_IN various_JJ EGS_NNP healthcare_NN funds_NNS ._.
EGS_NNP is_VBZ a_DT private_JJ equity_NN company_NN that_WDT makes_VBZ investments_NNS in_IN healthcare_NN companies_NNS that_WDT focus_VBP mainly_RB on_IN biotechnology_NN and_CC specialty_NN pharmaceuticals_NNS ._.
As_IN of_IN 31_CD December_NNP 2002_CD ,_, the_DT Group_NNP has_VBZ invested_VBN 3.2_CD million_CD $_$ 5.1_CD million_CD in_IN EGS_NNP healthcare_NN funds_NNS and_CC the_DT Group_NNP is_VBZ ,_, therefore_RB ,_, committed_VBN to_TO invest_VB a_DT further_JJ 3.0_CD million_CD $_$ 4.9_CD million_CD into_IN these_DT funds_NNS ._.
b_NN Investments_NNP in_IN public_JJ companies_NNS As_IN at_IN 31_CD December_NNP 2002_CD ,_, the_DT Group_NNP held_VBD 8.8_CD million_CD of_IN investments_NNS in_IN public_JJ companies_NNS 2001_CD :_: 9.5_CD million_CD ._.
During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, there_EX were_VBD no_DT new_JJ investments_NNS made_VBN in_IN public_JJ companies_NNS ._.
On_IN 29_CD July_NNP 2002_CD ,_, the_DT Groups_NNS 7.1_CD million_CD $_$ 11.1_CD million_CD preference_NN share_NN investment_NN in_IN Immunogen_NNP Inc._NNP was_VBD converted_VBN into_IN a_DT common_JJ stock_NN holding_NN ._.
In_IN addition_NN ,_, the_DT Group_NNP impaired_VBD the_DT cost_NN of_IN investments_NNS in_IN public_JJ companies_NNS by_IN 0.9_CD million_CD ._.
Current_JJ asset_NN investments_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN and_CC as_IN a_DT result_NN ,_, any_DT market_NN gains_NNS or_CC losses_NNS have_VBP not_RB been_VBN recognized_VBN ._.
As_IN at_IN 31_CD December_NNP 2002_CD ,_, the_DT market_NN value_NN of_IN listed_VBN investments_NNS was_VBD 0.8_CD million_CD above_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN 2001_CD :_: nil_NN ._.
There_EX are_VBP no_DT other_JJ differences_NNS between_IN cost_NN and_CC market_NN value_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 37_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 14_CD Acquisitions_NNS and_CC disposals_NNS Acquisitions_NNS On_IN 27_CD September_NNP 2002_CD ,_, the_DT Group_NNP acquired_VBD 100_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN of_IN Atlantic_NNP Pharmaceutical_NNP Services_NNPS Inc._NNP ._.
APS_NNP for_IN a_DT cash_NN consideration_NN of_IN 11.9_CD million_CD including_VBG 0.2_CD million_CD acquisition_NN costs_NNS ._.
The_DT fair_JJ value_NN of_IN the_DT net_JJ assets_NNS acquired_VBN was_VBD 4.8_CD million_CD ,_, resulting_VBG in_IN 7.1_CD million_CD of_IN goodwill_NN being_VBG capitalized_VBN on_IN the_DT balance_NN sheet_NN ._.
The_DT transaction_NN was_VBD accounted_VBN for_IN using_VBG acquisition_NN accounting_NN ._.
The_DT loss_NN profit_NN after_IN taxation_NN of_IN APS_NNP was_VBD as_IN follows_VBZ :_: Loss_NN profit_NN after_IN tax_NN Results_NNS prior_RB to_TO acquisition_NN 000_CD 1_CD January_NNP 2002_CD to_TO the_DT date_NN of_IN acquisition_NN 1,071_CD Preceding_VBG financial_JJ year_NN ended_VBD 31_CD December_NNP 2001_CD 45_CD The_DT following_JJ table_NN summarises_VBZ the_DT adjustments_NNS made_VBD to_TO book_NN value_NN of_IN the_DT major_JJ category_NN of_IN assets_NNS and_CC liabilities_NNS acquired_VBN to_TO arrive_VB at_IN the_DT fair_JJ values_NNS included_VBN in_IN the_DT financial_JJ statements_NNS at_IN the_DT date_NN of_IN acquisition_NN ._.
The_DT cash_NN flow_NN effects_NNS of_IN the_DT acquisition_NN are_VBP given_VBN in_IN note_NN 28b_CD ._.
Accounting_NNP Fair_NNP Book_NNP policy_NN value_NN to_TO value_NN aligment_NN Revaluation_NNP Group_NNP 000 000 000 000_CD Fixed_JJ assets_NNS Tangible_JJ assets_NNS 7,331_CD 470_CD 7,801_CD Current_JJ assets_NNS Stocks_NNS 235 681 916_CD Debtors_NNS 2,240_CD 1,049_CD 1,191_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 33_CD 33_CD Total_JJ assets_NNS 9,839_CD 470_CD 368_CD 9,941_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Trade_NNP creditors_NNS 611_CD 611_CD Finance_NNP leases_NNS 4,169_CD 4,169_CD Other_JJ creditors_NNS 345_CD 345_CD Total_JJ liabilities_NNS 5,125_CD 5,125_CD Net_JJ assets_NNS 4,714_CD 470_CD 368_CD 4,816_CD Goodwill_NNP 7,066_CD 11,882_CD 000_CD Satisfied_VBN by_IN :_: Cash_NN consideration_NN 11,647_CD Expenses_NNS of_IN acquisition_NN 235_CD 11,882_CD At_IN the_DT time_NN of_IN acquisition_NN ,_, a_DT realignment_NN of_IN certain_JJ accounting_NN policies_NNS and_CC revaluation_NN of_IN certain_JJ assets_NNS was_VBD undertaken_VBN in_IN order_NN to_TO bring_VB those_DT of_IN APS_NNP in_IN line_NN with_IN the_DT remainder_NN of_IN the_DT Group_NNP ._.
38_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 14_CD Acquisitions_NNS and_CC disposals_NNS continued_VBD Disposals_NNP The_NNP Group_NNP completed_VBD its_PRP$ divestment_NN of_IN its_PRP$ Over_IN The_DT Counter_NNP OTC_NNP portfolio_NN on_IN 27_CD December_NNP 2002_CD ._.
This_DT was_VBD sold_VBN to_TO Perdue_NNP Pharmaceuticals_NNP Inc_NNP for_IN a_DT cash_NN consideration_NN of_IN 44.1_CD million_CD $_$ 71.0_CD million_CD ._.
The_DT following_JJ table_NN summarises_VBZ the_DT major_JJ categories_NNS of_IN assets_NNS and_CC liabilities_NNS attributed_VBD to_TO the_DT OTC_NNP portfolio_NN at_IN the_DT date_NN of_IN disposal_NN ._.
000_CD Intangible_JJ assets_NNS 37,673_CD Stocks_NNS 2,327_CD Sundry_NNP debtors_NNS 2,828_CD Other_JJ creditors_NNS 1,063_CD Profit_NN on_IN sale_NN 2,006_CD 43,771_CD Satisfied_VBN by_IN :_: Cash_NN consideration_NN 44,103_CD Deferred_JJ consideration_NN 620_CD Expenses_NNS of_IN disposal_NN 952_CD 43,771_CD 15_CD Investments_NNP in_IN joint_JJ ventures_NNS The_DT Group_NNP owns_VBZ 50_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN of_IN Qualia_NNP Computing_NNP Inc._NNP ._.
Qualia_NNP ,_, a_DT company_NN involved_VBN in_IN the_DT development_NN of_IN Computer_NNP Aided_VBD Detection_NNP technologies_NNS with_IN various_JJ applications_NNS in_IN the_DT area_NN of_IN life_NN sciences_NNS ._.
Qualia_NNP has_VBZ a_DT 31_CD March_NNP year-end_NN ,_, however_RB ,_, the_DT results_NNS disclosed_VBN are_VBP for_IN the_DT period_NN to_TO 31_CD December_NNP 2002_CD ._.
The_DT Company_NN exchanged_VBD its_PRP$ interests_NNS in_IN certain_JJ trade_NN investments_NNS for_IN a_DT 50_CD %_NN investment_NN in_IN Qualia_NNP on_IN 30_CD September_NNP 2002_CD ._.
No_DT goodwill_NN arose_VBD on_IN the_DT transaction_NN ._.
In_IN accordance_NN with_IN FRS_NNP 9_CD ,_, Associates_NNPS and_CC joint_JJ ventures_NNS ,_, the_DT following_VBG information_NN regarding_VBG the_DT Groups_NNS share_NN in_IN Qualia_NNP is_VBZ disclosed_VBN :_: 2002_CD 2001_CD Qualia_NNP 000_CD 000_CD Turnover_NN 762_CD Loss_NN before_IN tax_NN 559_CD Taxation_NNP Loss_NN after_IN tax_NN 559_CD Fixed_VBN assets_NNS 2,648_CD Current_JJ assets_NNS 2,434_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN 342_CD 16_CD Stocks_NNS Group_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Raw_NNP materials_NNS and_CC consumables_NNS 4,862_CD 5,873_CD Work_NN in_IN progress_NN 8,520_CD 12,548_CD Finished_VBN goods_NNS and_CC goods_NNS for_IN resale_NN 17,189_CD 13,659_CD 30,571_CD 32,080_CD There_EX is_VBZ no_DT material_NN difference_NN between_IN the_DT balance_NN sheet_NN value_NN of_IN stocks_NNS and_CC their_PRP$ replacement_NN cost_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 39_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 17_CD Deferred_JJ tax_NN asset_NN Deferred_JJ tax_NN Group_NNP 000_CD At_IN 1_CD January_NNP 2001_CD 22,272_CD Charged_VBN to_TO profit_VB and_CC loss_NN account_NN 762_CD Acquisition_NNP of_IN subsidiary_NN undertaking_NN 184_CD Exchange_NNP adjustment_NN 502_CD At_IN 31_CD December_NNP 2001_CD 22,196_CD Credited_VBN to_TO profit_VB and_CC loss_NN account_NN 5,829_CD Exchange_NNP adjustment_NN 2,518_CD At_IN 31_CD December_NNP 2002_CD 25,507_CD Included_VBN in_IN the_DT above_JJ balance_NN at_IN 31_CD December_NNP 2002_CD is_VBZ an_DT amount_NN of_IN 3,861,000_CD 2001_CD :_: 8,845,000_CD which_WDT is_VBZ due_JJ after_IN more_JJR than_IN one_CD year_NN ._.
Deferred_JJ tax_NN is_VBZ provided_VBN and_CC unprovided_JJ as_IN follows_VBZ :_: Unprovided_JJ Provided_VBN Unprovided_NNP Provided_VBD 2002 2001 2002 2001_CD Group_NNP 000 000 000 000_CD Accelerated_JJ capital_NN allowances_NNS 18,676_CD 18,284_CD Other_JJ timing_NN differences_NNS 11,300_CD 17,146_CD Tax_NNP losses_NNS available_JJ 92,283_CD 32,883_CD 85,873_CD 23,334_CD Deferred_JJ tax_NN asset_NN 92,283_CD 25,507_CD 85,873_CD 22,196_CD Amounts_NNS unprovided_JJ principally_RB represent_VBP the_DT deferred_JJ tax_NN assets_NNS arising_VBG from_IN overseas_JJ tax_NN operating_NN loss_NN carryforwards_NNS and_CC capital_NN loss_NN carryforwards_NNS ._.
The_DT utilisation_NN of_IN operating_VBG loss_NN carryforwards_NNS is_VBZ ,_, however_RB ,_, restricted_VBN to_TO the_DT taxable_JJ income_NN of_IN the_DT subsidiary_NN generating_VBG the_DT losses_NNS ._.
As_IN at_IN 31_CD December_NNP 2002_CD ,_, based_VBN upon_IN the_DT level_NN of_IN historical_JJ taxable_JJ income_NN and_CC projections_NNS for_IN future_JJ taxable_JJ income_NN ,_, management_NN believes_VBZ it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN the_DT Group_NNP will_MD realize_VB the_DT benefits_NNS of_IN the_DT provided_VBN deferred_VBN tax_NN assets_NNS ._.
However_RB ,_, the_DT amount_NN of_IN the_DT deferred_JJ tax_NN asset_NN considered_VBN realisable_JJ could_MD be_VB adjusted_VBN in_IN the_DT future_NN if_IN estimates_NNS of_IN taxable_JJ income_NN are_VBP revised_VBN ._.
Company_NN The_DT Company_NN has_VBZ no_DT provided_VBN or_CC unprovided_JJ deferred_VBN tax_NN assets_NNS ._.
The_DT amount_NN shown_VBN above_IN is_VBZ the_DT gross_JJ asset_NN represented_VBN by_IN non-current_JJ marketable_JJ securities_NNS ._.
A_DT related_JJ liability_NN of_IN approximately_RB 5.2_CD million_CD is_VBZ included_VBN within_IN note_NN 21_CD ._.
40_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 19_CD Current_JJ asset_NN investments_NNS Group_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 141,800_CD 328,252_CD 321,031_CD Commercial_JJ paper_NN 54,564_CD 169,145_CD 196,364_CD 497,397_CD 321,031_CD There_EX is_VBZ no_DT material_NN difference_NN between_IN book_NN value_NN and_CC fair_JJ value_NN as_IN at_IN 31_CD December_NNP 2002_CD and_CC 2001_CD ._.
20_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Group_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Convertible_JJ debt_NN Zero_NNP coupon_NN convertible_JJ unsecured_JJ loan_NN stock_NN 1,032_CD 1,032_CD Other_JJ creditors_NNS Bank_NNP loans_NNS note_VBP 21_CD ii_FW 389_CD 1,976_CD Obligations_NNS under_IN finance_NN leases_NNS 162_CD 32_CD Trade_NNP creditors_NNS 29,153_CD 39,254_CD 862_CD 1,827_CD Amounts_NNS due_JJ to_TO other_JJ Group_NNP undertakings_NNS 218,219_CD 39,197_CD Overseas_JJ corporation_NN tax_NN 8,835_CD 17,043_CD Other_JJ taxation_NN and_CC social_JJ security_NN 2,416_CD 5,762_CD 367_CD 188_CD Other_JJ creditors_NNS 2,033_CD 2,883_CD 197_CD 527_CD Accruals_NNPS and_CC deferred_VBN income_NN 88,897_CD 91,311_CD 5,630_CD 4,610_CD 131,885_CD 158,229_CD 225,307_CD 46,349_CD 131,885_CD 159,261_CD 225,307_CD 47,381_CD Obligations_NNS under_IN finance_NN leases_NNS are_VBP secured_VBN on_IN the_DT assets_NNS to_TO which_WDT they_PRP relate_VBP ._.
21_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Group_NNP Company_NNP 2002 2001 2002 2001_CD Notes_NNP 000 000 000 000_CD Convertible_JJ debt_NN 2_CD %_NN guaranteed_VBN convertible_JJ loan_NN notes_NNS 2011_CD i_FW 243,547_CD 268,178_CD Other_JJ creditors_NNS Bank_NNP loans_NNS ii_FW 778_CD 1,705_CD Obligations_NNS under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS 3,757_CD 36_CD Amounts_NNS due_JJ to_TO other_JJ Group_NNP undertakings_NNS 252,258_CD 276,643_CD Other_JJ creditors_NNS 9,247_CD 7,949_CD 13,782_CD 9,654_CD 252,294_CD 276,643_CD 257,329_CD 277,832_CD 252,294_CD 276,643_CD Included_VBN within_IN other_JJ creditors_NNS is_VBZ 5,196,000_CD relating_VBG to_TO the_DT SERP_NNP 31_CD December_NNP 2001_CD :_: 7,797,000_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 41_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 21_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN continued_VBD Subject_JJ to_TO the_DT conditions_NNS below_IN ,_, borrowings_NNS are_VBP repayable_JJ as_IN follows_VBZ :_: Group_NNP Company_NNP 2002 2001 2002 2001_CD Notes_NNP 000 000 000 000_CD Convertible_JJ loan_NN notes_NNS :_: i_FW Between_IN one_CD and_CC two_CD years_NNS 243,547_CD Between_IN two_CD and_CC five_CD years_NNS 268,178_CD Bank_NNP loans_NNS :_: ii_FW Between_IN one_CD and_CC two_CD years_NNS 389_CD 1,705_CD Between_IN two_CD and_CC five_CD years_NNS 389_CD Obligations_NNS under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS :_: Between_IN one_CD and_CC two_CD years_NNS 158_CD 36_CD After_IN five_CD years_NNS 3,599_CD 248,082_CD 269,883_CD 36_CD i_FW $_$ 400_CD million_CD 2_CD %_NN guaranteed_VBN convertible_JJ loan_NN notes_NNS 2011_CD The_DT $_$ 400_CD million_CD of_IN guaranteed_VBN convertible_JJ loan_NN notes_NNS due_JJ 2011_CD ,_, were_VBD issued_VBN on_IN 15_CD August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP the_DT Issuer_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ._.
The_DT notes_NNS bear_VBP interest_NN of_IN 2_CD %_NN per_IN annum_NN ,_, paid_VBD semi-annually_RB in_IN arrears_NNS ._.
The_DT convertible_JJ notes_NNS are_VBP guaranteed_VBN by_IN Shire_NNP and_CC are_VBP convertible_JJ into_IN redeemable_JJ preference_NN shares_NNS of_IN the_DT Issuer_NN which_WDT upon_IN issuance_NN will_MD be_VB immediately_RB exchanged_VBN for_IN either_DT i_FW Shire_FW common_JJ shares_NNS or_CC ii_FW Shire_FW ADSs_FW ,_, or_CC iii_NN at_IN the_DT Issuers_NNPS option_NN ,_, a_DT cash_NN amount_NN based_VBN upon_IN the_DT London_NNP Stock_NNP Exchange_NNP volume-weighted_JJ average_NN prices_NNS of_IN common_JJ shares_NNS on_IN the_DT fourth_JJ through_IN eighth_JJ business_NN days_NNS following_VBG conversion_NN ._.
At_IN the_DT choice_NN of_IN investors_NNS ,_, each_DT $_$ 1,000_CD of_IN nominal_JJ value_NN notes_NNS can_MD be_VB converted_VBN into_IN 49.62_CD Shire_NNP common_JJ shares_NNS subject_JJ to_TO adjustment_NN or_CC 16.54_CD Shire_NNP ADSs_NNP subject_NN to_TO adjustment_NN at_IN any_DT time_NN up_RP to_TO 21_CD August_NNP 2011_CD ._.
Alternatively_RB ,_, investors_NNS can_MD choose_VB to_TO receive_VB repayment_NN of_IN the_DT nominal_JJ principal_NN in_IN cash_NN either_CC at_IN the_DT maturity_NN date_NN of_IN 21_CD August_NNP 2011_CD or_CC by_IN exercising_VBG a_DT put_NN option_NN on_IN any_DT of_IN the_DT three_CD put_VBD dates_NNS being_VBG 21_CD August_NNP 2004_CD ,_, 21_CD August_NNP 2006_CD and_CC 21_CD August_NNP 2008_CD ._.
At_IN the_DT option_NN of_IN the_DT Company_NN ,_, repayment_NN can_MD be_VB made_VBN in_IN the_DT form_NN of_IN Shire_NNP common_JJ shares_NNS or_CC ADSs_NNS ._.
The_DT number_NN of_IN common_JJ shares_NNS that_IN a_DT note_NN holder_NN would_MD receive_VB would_MD be_VB based_VBN on_IN the_DT notional_JJ principal_NN of_IN the_DT notes_NNS divided_VBN by_IN 95_CD %_NN of_IN the_DT London_NNP Stock_NNP Exchange_NNP volume-weighted_JJ average_JJ price_NN of_IN common_JJ shares_NNS on_IN the_DT five_CD trading_NN days_NNS after_IN the_DT Company_NN gives_VBZ notice_NN of_IN the_DT exercise_NN of_IN its_PRP$ option_NN ._.
Such_JJ notice_NN will_MD be_VB on_IN or_CC before_IN the_DT tenth_NN business_NN day_NN preceding_VBG the_DT repayment_NN put_VBD date_NN ._.
On_IN or_CC after_IN 21_CD August_NNP 2004_CD ,_, the_DT Company_NN may_MD redeem_VB ,_, for_IN cash_NN ,_, all_DT or_CC part_NN of_IN the_DT notes_NNS provided_VBD the_DT ordinary_JJ share_NN price_NN has_VBZ exceeded_VBN $_$ 26.20_CD sterling_NN equivalent_NN at_IN the_DT time_NN for_IN 20_CD of_IN the_DT 30_CD consecutive_JJ dealing_VBG days_NNS in_IN the_DT period_NN prior_RB to_TO redemption_NN ._.
The_DT decision_NN as_IN to_TO whether_IN a_DT note_NN holder_NN would_MD exercise_VB a_DT put_NN option_NN will_MD depend_VB on_IN a_DT number_NN of_IN factors_NNS particularly_RB the_DT price_NN of_IN Shire_NNP shares_NNS at_IN the_DT put_JJ date_NN and_CC the_DT likelihood_NN of_IN Shires_NNP share_NN price_NN exceeding_VBG the_DT conversion_NN threshold_NN price_NN ._.
The_DT conversion_NN threshold_NN price_NN is_VBZ 12.52_CD for_IN ordinary_JJ shares_NNS ._.
If_IN the_DT price_NN of_IN Shire_NNP ordinary_JJ shares_NNS at_IN the_DT first_JJ put_JJ date_NN of_IN 21_CD August_NNP 2004_CD remains_VBZ at_IN a_DT level_NN similar_JJ to_TO the_DT year_NN end_NN price_NN of_IN 3.97_CD ,_, it_PRP is_VBZ quite_RB possible_JJ that_IN note_NN holders_NNS will_MD choose_VB to_TO exercise_VB their_PRP$ put_JJ options_NNS ._.
The_DT Group_NNP currently_RB has_VBZ adequate_JJ resources_NNS from_IN which_WDT it_PRP could_MD satisfy_VB repayment_NN of_IN the_DT entire_JJ convertible_JJ debt_NN principal_NN of_IN $_$ 400_CD million_CD ._.
ii_FW Canadian_JJ federal_JJ and_CC provincial_JJ government_NN loan_NN The_DT Group_NNP has_VBZ a_DT Canadian_JJ federal_JJ and_CC provincial_JJ government_NN loan_NN outstanding_JJ of_IN 1.2_CD million_CD CAN$_NNP 5.0_CD million_CD ._.
This_DT facility_NN is_VBZ non-interest_JJ bearing_NN and_CC is_VBZ repayable_JJ in_IN annual_JJ instalments_NNS of_IN 0.5_CD million_CD CAN$_NNP 1.2_CD million_CD commencing_VBG in_IN May_NNP 2002_CD ._.
42_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 22_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS The_DT financial_JJ review_NN on_IN pages_NNS 3_CD to_TO 5_CD provide_VBP an_DT explanation_NN of_IN the_DT role_NN that_WDT financial_JJ instruments_NNS have_VBP had_VBN during_IN the_DT year_NN ._.
The_DT explanation_NN summarises_VBZ the_DT objectives_NNS and_CC policies_NNS for_IN holding_VBG or_CC issuing_VBG financial_JJ instruments_NNS and_CC similar_JJ contracts_NNS ,_, and_CC the_DT strategies_NNS for_IN achieving_VBG those_DT objectives_NNS that_WDT have_VBP been_VBN followed_VBN during_IN the_DT year_NN ._.
No_DT foreign_JJ exchange_NN ,_, interest_NN rate_NN or_CC other_JJ derivative_JJ contracts_NNS were_VBD entered_VBN into_IN or_CC transacted_VBN during_IN 2002_CD or_CC 2001_CD ._.
The_DT numerical_JJ disclosures_NNS in_IN this_DT note_NN deal_NN with_IN financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS as_IN defined_VBN in_IN FRS_NNP 13_CD ,_, Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS :_: disclosures_NNS ._.
Certain_JJ financial_JJ assets_NNS such_JJ as_IN investments_NNS in_IN subsidiary_NN companies_NNS are_VBP excluded_VBN from_IN the_DT scope_NN of_IN these_DT disclosures_NNS ._.
As_IN permitted_VBN by_IN FRS_NNP 13_CD ,_, short-term_JJ debtors_NNS and_CC creditors_NNS have_VBP been_VBN excluded_VBN from_IN the_DT disclosures_NNS ,_, other_JJ than_IN the_DT currency_NN disclosures_NNS ._.
Interest_NN rate_NN profile_NN The_DT currency_NN and_CC interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ assets_NNS ,_, excluding_VBG short-term_JJ debtors_NNS at_IN 31_CD December_NNP 2002_CD ,_, are_VBP as_RB below_RB ._.
Current_JJ asset_NN investments_NNS comprise_VBP institutional_JJ cash_NN funds_NNS ,_, commercial_JJ paper_NN and_CC marketable_JJ securities_NNS as_IN detailed_VBN in_IN note_NN 19_CD ._.
Weighted_JJ Weighted_NNP Weighted_NNP average_JJ average_JJ average_JJ interest_NN interest_NN interest_NN Financial_NNP Financial_NNP period_NN rate_NN rate_NN instruments_NNS instruments_NNS Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Total_JJ Currency_NN Days_NNS %_NN %_NN 000 000 000_CD Pounds_NNP sterling_NN 2_CD 3.4_CD 3.9_CD 14,298_CD 3,296_CD 17,594_CD US_NNP dollars_NNS 60_CD 1.5_CD 1.9_CD 426,017_CD 237,011_CD 663,028_CD Euro_NNP 6_CD 3.1_CD 6,437_CD 3,891_CD 10,328_CD Canadian_JJ dollars_NNS 131_CD 2.9_CD 2,128_CD 61,718_CD 63,846_CD 448,880_CD 305,916_CD 754,796_CD The_DT benchmark_NN rates_NNS for_IN floating_VBG rate_NN assets_NNS are_VBP primarily_RB :_: US_NNP dollar_NN 7_CD day_NN ,_, 1_CD month_NN and_CC 3_CD month_NN LIBID_NNP ,_, and_CC pounds_NNS sterling_NN 7_CD day_NN LIBID_NNP ._.
The_DT currency_NN and_CC interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ assets_NNS excluding_VBG short-term_JJ debtors_NNS at_IN 31_CD December_NNP 2001_CD are_VBP as_RB below_RB ._.
Weighted_JJ Weighted_NNP Weighted_NNP average_JJ average_JJ average_JJ interest_NN interest_NN interest_NN Financial_NNP Financial_NNP period_NN rate_NN rate_NN instruments_NNS instruments_NNS Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Total_JJ Currency_NN Days_NNS %_NN %_NN 000 000 000_CD Pounds_NNP sterling_NN 4.1_CD 28,186_CD 28,186_CD US_NNP dollars_NNS 96_CD 1.8_CD 2.1_CD 332,314_CD 117,725_CD 450,039_CD Euro_NNP 3_CD 3.1_CD 3.4_CD 4,507_CD 2,815_CD 7,322_CD Canadian_JJ dollars_NNS 33_CD 3.1_CD 2.5_CD 9,682_CD 83,602_CD 93,284_CD 374,689_CD 204,142_CD 578,831_CD The_DT interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS at_IN 31_CD December_NNP 2002_CD was_VBD as_IN follows_VBZ :_: Floating_VBG Fixed_NNP Interest_NNP free_JJ Total_JJ Currency_NN 000 000 000 000_CD Canadian_JJ dollars_NNS federal_JJ and_CC provincial_JJ government_NN loan_NN 1,167_CD 1,167_CD US_NNP dollars_NNS convertible_JJ debt_NN 243,547_CD 243,547_CD Total_JJ 243,547_CD 1,167_CD 244,714_CD The_DT $_$ 400_CD million_CD of_IN guaranteed_VBN convertible_JJ loan_NN notes_NNS due_JJ 2011_CD were_VBD issued_VBN on_IN 15_CD August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ._.
For_IN further_JJ information_NN on_IN the_DT guaranteed_VBN convertible_JJ loan_NN notes_NNS ,_, see_VBP note_NN 21_CD i._NN Weighted_VBN average_JJ period_NN to_TO maturity_NN of_IN interest_NN free_JJ government_NN loans_NNS is_VBZ 28_CD months_NNS ._.
The_DT benchmark_NN for_IN determining_VBG the_DT interest_NN payments_NNS for_IN the_DT floating_VBG interest_NN liabilities_NNS is_VBZ Canadian_JJ prime_JJ rate_NN 4.0_CD %_NN at_IN 31_CD December_NNP 2002_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 43_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 22_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD The_DT interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS at_IN 31_CD December_NNP 2001_CD was_VBD as_IN follows_VBZ :_: Floating_VBG Fixed_NNP Interest_NNP free_JJ Total_JJ Currency_NN 000 000 000 000_CD Canadian_JJ dollars_NNS bank_NN loans_NNS 1,550_CD 1,550_CD federal_JJ and_CC provincial_JJ government_NN loan_NN 2,131_CD 2,131_CD US_NNP dollars_NNS convertible_JJ debt_NN 268,178_CD 1,032_CD 269,210_CD Total_JJ 1,550_CD 268,178_CD 3,163_CD 272,891_CD The_DT weighted_JJ average_JJ period_NN to_TO maturity_NN of_IN the_DT convertible_JJ debt_NN is_VBZ one_CD year_NN ._.
Currency_NNP exposures_NNS The_DT Groups_NNS objectives_NNS in_IN managing_VBG the_DT currency_NN exposures_NNS arising_VBG from_IN its_PRP$ net_JJ investment_NN overseas_RB in_IN other_JJ words_NNS ,_, its_PRP$ structural_JJ currency_NN exposures_NNS are_VBP to_TO maintain_VB a_DT low_JJ cost_NN of_IN borrowings_NNS and_CC minimize_VB currency_NN related_VBN exposures_NNS ._.
Gains_NNS and_CC losses_NNS arising_VBG from_IN structural_JJ currency_NN exposures_NNS are_VBP recognized_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
The_DT table_NN below_IN shows_NNS the_DT Groups_NNS currency_NN exposures_NNS :_: in_IN other_JJ words_NNS ,_, those_DT transactional_JJ or_CC non-structural_JJ exposures_NNS that_WDT give_VBP rise_VB to_TO the_DT net_JJ currency_NN gains_NNS and_CC losses_NNS recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Such_JJ exposures_NNS comprise_VBP the_DT monetary_JJ assets_NNS and_CC monetary_JJ liabilities_NNS of_IN the_DT Group_NNP that_WDT are_VBP not_RB denominated_VBN in_IN the_DT operating_NN or_CC functional_JJ currency_NN of_IN the_DT operating_VBG unit_NN involved_VBN ,_, other_JJ than_IN certain_JJ non-sterling_JJ borrowings_NNS treated_VBN as_IN hedges_NNS of_IN net_JJ investments_NNS in_IN overseas_JJ operations_NNS ._.
As_IN at_IN 31_CD December_NNP 2002_CD these_DT exposures_NNS were_VBD as_IN follows_VBZ :_: Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS Pounds_NNP US_NNP sterling_NN dollars_NNS Euro_NNP Other_JJ Total_NNP Functional_NNP currency_NN of_IN Group_NNP operation_NN 000 000 000 000_CD 000_CD Pounds_NNS sterling_JJ 330,714_CD 242_CD 49_CD 331,005_CD Euro_NNP 1,268_CD 1,830_CD 3,098_CD Canadian_JJ dollars_NNS 1,702_CD 662_CD 301_CD 40_CD 2,705_CD 2,970_CD 333,206_CD 543_CD 89_CD 336,808_CD The_DT exposures_NNS at_IN 31_CD December_NNP 2001_CD for_IN comparison_NN purposes_NNS were_VBD as_IN follows_VBZ :_: Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS liabilities_NNS Pounds_NNP US_NNP sterling_NN Dollars_NNP Euro_NNP Other_JJ Total_NNP Functional_NNP currency_NN of_IN Group_NNP operation_NN 000 000 000 000_CD 000_CD Pounds_NNS sterling_JJ 32,622_CD 2,115_CD 1,400_CD 36,137_CD Euro_NNP 147_CD 96_CD 51_CD Canadian_JJ dollars_NNS 18,811_CD 24,729_CD 43,540_CD 18,664_CD 57,447_CD 2,115_CD 1,400_CD 79,626_CD Maturity_NN of_IN financial_JJ liabilities_NNS The_DT maturity_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS at_IN 31_CD December_NNP 2002_CD is_VBZ shown_VBN below_IN :_: Convertible_NNP Bank_NNP loan_NN stock_NN loans_NNS Total_NNP Group_NNP 000 000 000_CD Less_RBR than_IN one_CD year_NN 389_CD 389_CD Between_IN one_CD and_CC two_CD years_NNS 243,547_CD 389_CD 243,936_CD Between_IN two_CD and_CC five_CD years_NNS 389 389 243_CD ,547_CD 1,167_CD 244,714_CD See_VB note_NN 21_CD i_FW and_CC 21_CD ii_NN for_IN further_JJ information_NN on_IN convertible_JJ loan_NN stock_NN and_CC bank_NN loans_NNS respectively_RB ._.
44_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 22_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Borrowing_NNP facilities_NNS The_DT Group_NNP had_VBD no_DT undrawn_JJ committed_JJ borrowing_NN facilities_NNS at_IN 31_CD December_NNP 2002_CD 2001_CD :_: 4,820,000_CD ._.
Fair_NNP values_VBZ The_DT market_NN price_NN of_IN the_DT convertible_JJ loan_NN stock_NN 2011_CD as_RB at_IN 31_CD December_NNP 2002_CD was_VBD $_$ 92.19_CD compared_VBN with_IN an_DT issue_NN price_NN of_IN $_$ 100_CD ._.
If_IN the_DT loan_NN is_VBZ not_RB converted_VBN into_IN equity_NN ,_, it_PRP would_MD be_VB repayable_JJ at_IN $_$ 100_CD per_IN note_NN ._.
The_DT total_JJ fair_JJ value_NN of_IN the_DT debt_NN as_IN at_IN 31_CD December_NNP 2002_CD ,_, based_VBN on_IN the_DT above_JJ market_NN price_NN ,_, was_VBD 229.0_CD million_CD $_$ 368.8_CD million_CD compared_VBN to_TO a_DT book_NN value_NN of_IN 248.5_CD million_CD ._.
In_IN addition_NN ,_, as_RB at_IN 31_CD December_NNP 2002_CD ,_, the_DT fair_JJ value_NN of_IN listed_VBN investments_NNS was_VBD 0.8_CD million_CD above_IN book_NN value_NN 2001_CD :_: nil_NN ._.
There_EX were_VBD no_DT other_JJ material_NN differences_NNS between_IN the_DT book_NN values_NNS and_CC fair_JJ values_NNS of_IN all_DT other_JJ Group_NNP financial_JJ assets_NNS and_CC liabilities_NNS at_IN 31_CD December_NNP 2002_CD 2001_CD :_: nil_NN ._.
Gains_NNS and_CC losses_NNS on_IN hedges_NNS The_DT Group_NNP had_VBD no_DT foreign_JJ exchange_NN ,_, interest_NN rate_NN or_CC other_JJ derivative_JJ contracts_NNS outstanding_JJ at_IN 31_CD December_NNP 2001_CD or_CC 31_CD December_NNP 2002_CD ._.
23_CD Called-up_JJ share_NN capital_NN Number_NNP Ordinary_NNP shares_NNS 000_CD 000_CD Authorised_VBN At_IN 31_CD December_NNP 2001_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 800,000_CD 40,000_CD At_IN 31_CD December_NNP 2002_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 800,000_CD 40,000_CD Allotted_NNP ,_, issued_VBN and_CC fully_RB paid_VBN At_IN 1_CD January_NNP 2002_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 481,821_CD 24,091_CD Issued_VBN on_IN exercise_NN of_IN options_NNS for_IN cash_NN consideration_NN 1,941_CD 97_CD Issued_VBN on_IN conversion_NN of_IN zero_CD coupon_NN note_NN 268_CD 14_CD Issued_VBN on_IN exchange_NN of_IN exchangeable_JJ shares_NNS 314_CD 15_CD At_IN 31_CD December_NNP 2002_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 484,344_CD 24,217_CD Number_NNP Special_JJ ordinary_JJ voting_NN shares_NNS exchangeable_JJ shares_NNS 000_CD 000_CD Authorised_VBN At_IN 31_CD December_NNP 2001_CD special_JJ ordinary_JJ voting_NN shares_NNS of_IN 0.00001_CD p_NN 17,500_CD At_IN 31_CD December_NNP 2002_CD special_JJ ordinary_JJ voting_NN shares_NNS of_IN 0.00001_CD p_NN 17,500_CD Allotted_NNP ,_, issued_VBN and_CC fully_RB paid_VBN At_IN 1_CD January_NNP 2002_CD 5,979_CD Exchanged_VBN for_IN ordinary_JJ shares_NNS 105_CD At_IN 31_CD December_NNP 2002_CD 5,874_CD Authorised_JJ share_NN capital_NN The_DT authorised_JJ share_NN capital_NN of_IN the_DT Company_NN ,_, at_IN 31_CD December_NNP 2002_CD ,_, was_VBD 40,000,000_CD divided_VBN into_IN 799,999,965_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT and_CC 17,500,000_CD special_JJ ordinary_JJ voting_NN shares_NNS exchangeable_JJ shares_NNS of_IN 0.00001_CD p_NN each_DT ._.
Issue_NN of_IN ordinary_JJ shares_NNS During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD the_DT Company_NN allotted_VBD 314,376_CD ordinary_JJ shares_NNS with_IN a_DT nominal_JJ value_NN of_IN 15,718_CD on_IN the_DT exchange_NN of_IN special_JJ ordinary_JJ voting_NN shares_NNS exchangeable_JJ shares_NNS following_VBG the_DT acquisition_NN of_IN BioChem_NNP ._.
These_DT shares_NNS were_VBD issued_VBN at_IN a_DT premium_NN of_IN 3,404,458_CD ._.
During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD the_DT Company_NN allotted_VBD a_DT total_NN of_IN 267,572_CD ordinary_JJ shares_NNS with_IN a_DT nominal_JJ value_NN of_IN 13,378_CD to_TO Arenol_NNP Corporation_NNP or_CC its_PRP$ nominee_NN broker_NN in_IN consideration_NN for_IN the_DT conversion_NN of_IN debt_NN ._.
These_DT shares_NNS were_VBD issued_VBN at_IN a_DT premium_NN of_IN 940,516_CD ._.
Issue_NN of_IN special_JJ ordinary_JJ voting_NN shares_NNS The_DT Company_NN exchanged_VBD 104,792_CD special_JJ ordinary_JJ voting_NN shares_NNS during_IN the_DT year_NN ._.
Each_DT of_IN these_DT shares_NNS is_VBZ equivalent_JJ to_TO three_CD ordinary_JJ shares_NNS and_CC is_VBZ exchangeable_JJ into_IN ordinary_JJ shares_NNS or_CC ADSs_NNS ,_, at_IN a_DT rate_NN of_IN one_CD exchangeable_JJ share_NN for_IN three_CD ordinary_JJ shares_NNS or_CC one_CD exchangeable_JJ share_NN for_IN one_CD ADS_NNPS ,_, at_IN any_DT time_NN at_IN the_DT request_NN of_IN the_DT holder_NN ._.
Only_RB BioChem_NNP shareholders_NNS with_IN Canadian_JJ residency_NN had_VBD the_DT option_NN to_TO receive_VB exchangeable_JJ shares_NNS for_IN their_PRP$ shares_NNS of_IN BioChem_NNP at_IN the_DT time_NN of_IN acquisition_NN ._.
The_DT exchangeable_JJ shares_NNS were_VBD issued_VBN by_IN Shire_NNP Acquisition_NNP Inc._NNP a_DT company_NN incorporated_VBN under_IN the_DT Canada_NNP Business_NNP Corporations_NNS Act_NNP ,_, which_WDT is_VBZ a_DT wholly-owned_JJ subsidiary_NN of_IN the_DT Company_NN ,_, and_CC is_VBZ listed_VBN on_IN the_DT Toronto_NNP Stock_NNP Exchange_NNP ._.
Holders_NNS of_IN the_DT exchangeable_JJ shares_NNS are_VBP entitled_VBN to_TO dividend_NN and_CC other_JJ rights_NNS that_WDT are_VBP economically_RB equivalent_JJ to_TO those_DT of_IN ordinary_JJ shares_NNS ._.
Through_IN a_DT voting_NN trust_NN and_CC by_IN means_NNS of_IN special_JJ voting_NN shares_NNS in_IN Shire_NNP held_VBN by_IN the_DT trustee_NN ,_, holders_NNS of_IN exchangeable_JJ shares_NNS are_VBP entitled_VBN to_TO vote_VB at_IN shareholder_NN meetings_NNS of_IN the_DT Company_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 45_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 23_CD Called-up_JJ share_NN capital_NN continued_VBD As_IN at_IN 31_CD December_NNP 2002_CD 5,874,112_CD exchangeable_JJ shares_NNS remained_VBD unconverted_JJ ._.
The_DT Company_NN can_MD redeem_VB all_DT outstanding_JJ exchangeable_JJ shares_NNS for_IN ordinary_JJ shares_NNS after_IN 11_CD May_NNP 2011_CD ,_, or_CC earlier_JJR if_IN the_DT total_JJ number_NN of_IN exchangeable_JJ shares_NNS falls_VBZ below_IN 1_CD million_CD ._.
The_DT exchangeable_JJ shares_NNS are_VBP included_VBN as_IN part_NN of_IN share_NN capital_NN in_IN the_DT consolidated_JJ balance_NN sheet_NN to_TO present_VB a_DT true_JJ and_CC fair_JJ view_NN of_IN the_DT consolidated_JJ Groups_NNS capital_NN structure_NN ,_, which_WDT differs_VBZ from_IN the_DT Companies_NNS Act_NNP 1985_CD requirements_NNS to_TO reflect_VB these_DT amounts_NNS as_IN minority_NN interests_NNS ,_, as_IN they_PRP will_MD become_VB and_CC are_VBP equivalent_JJ to_TO ordinary_JJ shares_NNS ._.
Share_NN warrants_NNS On_IN 24_CD April_NNP 2002_CD the_DT Company_NN issued_VBN 741,812_CD share_NN warrants_NNS ,_, at_IN 4.885_CD per_IN warrant_NN ,_, and_CC on_IN 21_CD November_NNP 2002_CD the_DT Company_NN issued_VBD a_DT further_JJ 604,595_CD share_NN warrants_NNS ,_, at_IN 4.895_CD per_IN warrant_NN ,_, both_DT issues_NNS being_VBG made_VBN to_TO Technology_NNP Partnership_NNP Canada_NNP ,_, pursuant_JJ to_TO an_DT agreement_NN between_IN Shire_NNP BioChem_NNP Inc._NNP and_CC the_DT Government_NN of_IN Canada_NNP ._.
Each_DT warrant_NN grants_NNS a_DT right_NN to_TO subscribe_VB for_IN a_DT corresponding_JJ number_NN of_IN ordinary_JJ shares_NNS of_IN the_DT Company_NN within_IN five_CD years_NNS from_IN the_DT date_NN of_IN issue_NN of_IN each_DT warrant_NN ._.
Convertible_JJ loan_NN notes_VBZ The_DT $_$ 400_CD million_CD of_IN guaranteed_VBN convertible_JJ loan_NN notes_NNS due_JJ 2011_CD were_VBD issued_VBN on_IN 15_CD August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ._.
The_DT Groups_NNS directors_NNS and_CC employees_NNS have_VBP been_VBN granted_VBN share_NN options_NNS over_IN ordinary_JJ shares_NNS under_IN the_DT following_JJ share_NN option_NN plans_NNS :_: the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP 2000_CD Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Holdings_NNPS Ltd_NNP Share_NNP Options_NNPS Scheme_NNP SHL_NNP Scheme_NNP ,_, the_DT Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP ,_, the_DT Richwood_NNP Stock_NNP Options_NNPS Plan_NNP Richwood_NNP Plan_NNP ,_, the_DT Roberts_NNP Stock_NNP Option_NN Plans_NNS Roberts_NNP Plan_NNP and_CC the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP ._.
The_DT highest_JJS and_CC lowest_JJS market_NN prices_NNS during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD were_VBD 8.835_CD and_CC 3.755_CD respectively_RB ._.
For_IN further_JJ details_NNS see_VBP the_DT directors_NNS remuneration_JJ report_NN on_IN pages_NNS 11_CD to_TO 20_CD ._.
24_CD Reserves_NNS Profit_NN Share_NN Exchangeable_NNP Capital_NNP Other_NNP and_CC loss_NN premium_NN shares_NNS reserves_NNS reserves_NNS account_VBP Group_NNP 000 000 000 000_CD 000_CD As_IN at_IN 1_CD January_NNP 2002_CD 3,206,280_CD 194,972_CD 2,755_CD 24,247_CD 58,439_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 3,405_CD 3,420_CD Arenol_NNP conversion_NN 941_CD Options_NNS exercised_VBN 3,886_CD Foreign_JJ exchange_NN adjustment_NN 62,739_CD Retained_VBN loss_NN for_IN the_DT year_NN 588,399_CD As_IN at_IN 31_CD December_NNP 2002_CD 3,214,512_CD 191,552_CD 2,755_CD 24,247_CD 709,577_CD The_DT cumulative_JJ goodwill_NN resulting_VBG from_IN acquisitions_NNS that_WDT has_VBZ been_VBN written_VBN off_RP directly_RB to_TO reserves_NNS amounts_NNS to_TO 208,194,000_CD as_IN at_IN 31_CD December_NNP 2002_CD and_CC 31_CD December_NNP 2001_CD ._.
The_DT capital_NN and_CC other_JJ reserves_NNS arose_VBD in_IN relation_NN to_TO various_JJ Group_NNP reconstructions_NNS and_CC certain_JJ financing_NN transactions_NNS ,_, and_CC are_VBP not_RB distributable_JJ ._.
Profit_NN Share_NN Exchangeable_NNP Capital_NNP Other_NNP and_CC loss_NN premium_NN shares_NNS reserves_NNS reserves_NNS account_VBP Company_NN 000 000 000 000_CD 000_CD As_IN at_IN 1_CD January_NNP 2002_CD 3,206,744_CD 194,972_CD 1,674_CD 18,079_CD 2,730_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 3,405_CD 3,420_CD Arenol_NNP conversion_NN 941_CD Options_NNS exercised_VBN 4,347_CD Foreign_JJ exchange_NN adjustment_NN 6,162_CD Retained_VBN loss_NN for_IN the_DT year_NN 7,038_CD As_IN at_IN 31_CD December_NNP 2002_CD 3,215,437_CD 191,552_CD 1,674_CD 18,079_CD 15,930_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 49_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 25_CD Reconciliation_NNP of_IN movements_NNS in_IN Group_NNP shareholders_NNS funds_NNS 2002 2001 000 000_CD Loss_NN profit_NN for_IN the_DT year_NN 588,399_CD 35,709_CD Other_JJ recognized_VBN gains_NNS and_CC losses_NNS relating_VBG to_TO the_DT year_NN 62,739_CD 6,640_CD 651,138_CD 29,069_CD Share_NN capital_NN issued_VBN 1,951,648_CD Issue_NN of_IN exchangeable_JJ shares_NNS 563,897_CD Issue_NN expenses_NNS 23,584_CD Arenol_NNP conversion_NN 955_CD Proceeds_NNS on_IN exercise_NN of_IN employee_NN share_NN options_NNS 3,983_CD 46,961_CD Net_JJ additions_NNS to_TO shareholders_NNS funds_NNS 646,200_CD 2,567,991_CD Opening_NN shareholders_NNS funds_NNS as_IN restated_VBN 3,393,906_CD 825,915_CD Closing_NN shareholders_NNS funds_NNS 2,747,706_CD 3,393,906_CD The_DT cumulative_JJ foreign_JJ exchange_NN differences_NNS on_IN translation_NN amount_NN to_TO 47,522,000_CD loss_NN as_IN at_IN 31_CD December_NNP 2002_CD and_CC 9,056,000_CD gain_NN as_IN at_IN 31_CD December_NNP 2001_CD ._.
26_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS a_DT Operating_NN leases_VBZ The_DT Group_NNP leases_VBZ property_NN ,_, computer_NN and_CC office_NN equipment_NN and_CC motor_NN vehicles_NNS on_IN short-term_JJ leases_NNS ._.
The_DT rents_NNS payable_JJ under_IN property_NN leases_NNS are_VBP subject_JJ to_TO renegotiation_NN at_IN various_JJ intervals_NNS specified_VBN in_IN the_DT leases_NNS ._.
The_DT Group_NNP pays_VBZ for_IN substantially_RB all_DT of_IN the_DT insurance_NN ,_, maintenance_NN and_CC repair_NN of_IN these_DT assets_NNS ._.
The_DT minimum_JJ annual_JJ rentals_NNS under_IN the_DT foregoing_VBG leases_NNS are_VBP as_IN follows_VBZ :_: 2002_CD 2001_CD Land_NNP and_CC Motor_NNP Land_NNP and_CC Motor_NNP buildings_NNS Equipment_NNP vehicles_NNS buildings_NNS Equipment_NNP vehicles_NNS Group_NNP 000 000 000 000_CD 000_CD 000_CD Operating_NN leases_NNS which_WDT expire_VBP :_: within_IN 1_CD year_NN 179_CD 333_CD 50_CD 768_CD 4_CD 120_CD within_IN 2_CD 5_CD years_NNS 1,263_CD 1,827_CD 902 522 725_CD 2,277_CD after_IN 5_CD years_NNS 245_CD 1_CD 1,687_CD 2,161_CD 952_CD 1,290_CD 729_CD 2,397_CD 2002_CD 2001_CD Land_NNP and_CC Motor_NNP Land_NNP and_CC Motor_NNP buildings_NNS Equipment_NNP vehicles_NNS buildings_NNS Equipment_NNP vehicles_NNS Company_NN 000 000 000 000_CD 000_CD 000_CD Operating_NN leases_NNS which_WDT expire_VBP :_: within_IN 1_CD year_NN 22_CD 145_CD within_IN 2_CD 5_CD years_NNS 145_CD 89_CD 114_CD after_IN 5_CD years_NNS 145 111 145 114_CD 50_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 26_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD b_NN Capital_NN commitments_NNS i_FW Interests_NNPS in_IN companies_NNS and_CC partnerships_NNS The_DT Company_NN has_VBZ undertaken_VBN to_TO subscribe_VB for_IN interests_NNS in_IN companies_NNS and_CC partnerships_NNS for_IN amounts_NNS totalling_VBG 23,905,000_CD ._.
As_IN at_IN 31_CD December_NNP 2002_CD an_DT amount_NN of_IN 17,028,000_CD has_VBZ been_VBN subscribed_VBN ._.
Shire_NNP is_VBZ ,_, therefore_RB ,_, committed_VBN to_TO investing_VBG a_DT further_JJ 6,877,000_CD ._.
Further_JJ information_NN regarding_VBG these_DT interests_NNS can_MD be_VB found_VBN in_IN note_NN 13_CD a._NN ii_FW Fluviral_NNP The_NNP Company_NNP has_VBZ a_DT ten-year_JJ contract_NN with_IN the_DT Canadian_JJ government_NN to_TO assure_VB a_DT state_NN of_IN readiness_NN in_IN the_DT case_NN of_IN an_DT influenza_NN pandemic_JJ worldwide_NN epidemic_NN and_CC to_TO manufacture_VB influenza_NN vaccine_NN for_IN all_DT Canadian_JJ citizens_NNS in_IN such_JJ an_DT event_NN ._.
Under_IN the_DT contract_NN ,_, Shire_NNP Biologics_NNPS will_MD also_RB supply_VB the_DT Government_NN of_IN Canada_NNP with_IN a_DT substantial_JJ proportion_NN of_IN its_PRP$ annual_JJ influenza_NN vaccine_NN requirements_NNS over_IN the_DT ten-year_JJ period_NN ._.
Subject_JJ to_TO mutual_JJ agreement_NN ,_, the_DT contract_NN can_MD be_VB renewed_VBN for_IN a_DT further_JJ period_NN of_IN between_IN one_CD and_CC ten_CD years_NNS from_IN 2011_CD ._.
The_DT concept_NN of_IN a_DT state_NN of_IN readiness_NN against_IN an_DT influenza_NN pandemic_JJ requires_VBZ the_DT development_NN of_IN sufficient_JJ infrastructure_NN and_CC capacity_NN in_IN Canada_NNP to_TO provide_VB 100_CD %_NN of_IN domestic_JJ vaccine_NN needs_NNS in_IN the_DT event_NN of_IN an_DT influenza_NN pandemic_NN ._.
Canada_NNP would_MD require_VB 32_CD million_CD doses_NNS of_IN single_JJ strain_NN monovalent_JJ flu_NN vaccine_NN within_IN a_DT production_NN period_NN of_IN 16_CD weeks_NNS ._.
Shire_NNP Biologics_NNPS has_VBZ therefore_RB begun_VBN to_TO expand_VB its_PRP$ current_JJ production_NN capacity_NN in_IN order_NN to_TO meet_VB this_DT objective_NN within_IN a_DT five-year_JJ period_NN ._.
A_DT performance_NN bond_NN equal_JJ to_TO 10_CD %_NN of_IN the_DT minimum_NN estimated_VBN contract_NN value_NN in_IN any_DT year_NN would_MD become_VB payable_JJ to_TO the_DT Canadian_JJ government_NN if_IN contracted_VBN penalty_NN clauses_NNS were_VBD triggered_VBN ._.
Shire_NNP Biologics_NNPS is_VBZ committed_VBN to_TO investing_VBG 11.5_CD million_CD in_IN the_DT construction_NN of_IN a_DT new_JJ global_JJ vaccine_NN research_NN center_NN in_IN Laval_NNP ,_, Canada_NNP ._.
The_DT completion_NN of_IN this_DT project_NN is_VBZ planned_VBN for_IN mid_JJ 2004_CD ._.
Under_IN the_DT Technology_NNP Partnerships_NNS Canada_NNP TPC_NNP agreement_NN ,_, Shire_NNP could_MD be_VB eligible_JJ for_IN a_DT government_NN investment_NN of_IN approximately_RB 2.2_CD million_CD ._.
c_NN Contingent_JJ liabilities_NNS Shire_NNP is_VBZ involved_VBN in_IN various_JJ legal_JJ proceedings_NNS considered_VBN typical_JJ to_TO its_PRP$ business_NN ,_, including_VBG those_DT set_VBN out_RP below_IN ._.
Although_IN there_EX can_MD be_VB no_DT assurance_NN regarding_VBG the_DT outcome_NN of_IN any_DT of_IN the_DT legal_JJ proceedings_NNS referred_VBD to_TO below_IN ,_, Shire_NNP believes_VBZ that_IN they_PRP will_MD not_RB have_VB a_DT materially_RB adverse_JJ effect_NN on_IN the_DT Groups_NNS financial_JJ position_NN ._.
i_FW Phentermine_NNP Shire_NNP US_NNP ,_, Inc._NNP ._.
Shire_NNP US_NNP is_VBZ a_DT defendant_NN in_IN 11_CD lawsuits_NNS still_RB pending_VBG ,_, in_IN both_DT US_NNP federal_JJ and_CC state_NN courts_NNS ,_, which_WDT seek_VBP damages_NNS for_IN ,_, among_IN other_JJ things_NNS ,_, personal_JJ injury_NN arising_VBG from_IN phentermine_NN products_NNS supplied_VBD for_IN the_DT treatment_NN of_IN obesity_NN by_IN Shire_NNP US_NNP and_CC several_JJ other_JJ pharmaceutical_JJ companies_NNS ._.
Shire_NNP US_NNP ,_, formerly_RB known_VBN as_IN Shire_NNP Richwood_NNP Inc._NNP has_VBZ been_VBN sued_VBN as_IN a_DT manufacturer_NN and_CC distributor_NN of_IN phentermine_NN ,_, an_DT anorectic_NN used_VBN in_IN the_DT short-term_JJ treatment_NN of_IN obesity_NN and_CC one_CD of_IN the_DT products_NNS addressed_VBN by_IN the_DT lawsuits_NNS ._.
The_DT suits_NNS relate_VBP to_TO phentermine_VB either_CC alone_RB or_CC together_RB with_IN fenfluramine_NN or_CC dexenfluramine_NN ._.
The_DT lawsuits_NNS generally_RB allege_VBP the_DT following_VBG claims_NNS :_: the_DT defendants_NNS marketed_VBN phentermine_NN and_CC other_JJ products_NNS for_IN the_DT treatment_NN of_IN obesity_NN and_CC misled_VBD users_NNS about_IN the_DT products_NNS and_CC territory_NN dangers_NNS associated_VBN with_IN them_PRP :_: the_DT defendants_NNS failed_VBD adequately_RB to_TO test_NN phentermine_NN individually_RB and_CC when_WRB taken_VBN in_IN combination_NN with_IN the_DT other_JJ drugs_NNS :_: and_CC the_DT defendants_NNS knew_VBD or_CC should_MD have_VB known_VBN about_IN the_DT negative_JJ effects_NNS of_IN the_DT drugs_NNS and_CC should_MD have_VB informed_VBN the_DT public_JJ about_IN such_JJ risks_NNS and_CC or_CC failed_VBD to_TO provide_VB appropriate_JJ warning_NN labels_NNS ._.
Shire_NNP US_NNP had_VBD been_VBN named_VBN as_IN a_DT defendant_NN in_IN a_DT total_NN of_IN 3,804_CD such_JJ phentermine_NN lawsuits_NNS ,_, in_IN respect_NN of_IN which_WDT Shire_NNP US_NNP has_VBZ been_VBN dismissed_VBN as_IN a_DT defendant_NN in_IN 3,756_CD cases_NNS ._.
Shire_NNP US_NNP is_VBZ awaiting_VBG the_DT furtherance_NN of_IN proceedings_NNS in_IN the_DT remaining_VBG 37_CD lawsuits_NNS ._.
Shire_NNP US_NNP became_VBD involved_VBN with_IN phentermine_NN through_IN its_PRP$ acquisition_NN of_IN certain_JJ assets_NNS of_IN Rexar_NNP Pharmacol_NNP Corporation_NNP Rexar_NNP in_IN January_NNP 1994_CD ._.
In_IN addition_NN to_TO Shire_NNP US_NNP potentially_RB incurring_VBG liability_NN as_IN a_DT result_NN of_IN its_PRP$ own_JJ production_NN of_IN Oby-Cap_NNP ,_, a_DT phentermine_JJ product_NN ,_, the_DT plaintiffs_NNS may_MD additionally_RB seek_VB to_TO impose_VB liability_NN on_IN Shire_NNP US_NNP as_IN successor_NN to_TO Rexar_NNP ._.
Shire_NNP US_NNP intends_VBZ vigorously_RB to_TO defend_VB all_PDT the_DT lawsuits_NNS and_CC pursue_VB all_DT available_JJ reasonable_JJ defences_NNS ._.
Shire_NNP US_NNP denies_VBZ liability_NN on_IN a_DT number_NN of_IN grounds_NNS including_VBG lack_NN of_IN scientific_JJ evidence_NN that_IN phentermine_NN ,_, properly_RB described_VBN ,_, causes_VBZ the_DT alleged_JJ side_NN effects_NNS and_CC that_IN Shire_NNP US_NNP did_VBD not_RB promote_VB phentermine_NN for_IN long-term_JJ combined_VBN use_NN as_IN part_NN of_IN the_DT fen_NN phen_NN diet_NN ._.
Accordingly_RB ,_, Shire_NNP US_NNP intends_VBZ to_TO defend_VB vigorously_RB any_DT and_CC all_DT claims_NNS made_VBN against_IN the_DT Group_NNP in_IN respect_NN of_IN phentermine_NN ._.
Legal_JJ expenses_NNS have_VBP been_VBN paid_VBN by_IN Eon_NNP Labs_NNPS Manufacturing_NNP Inc._NNP ._.
Eon_NNP ,_, the_DT supplier_NN to_TO Shire_NNP US_NNP ,_, or_CC Eons_NNS insurance_NN carriers_NNS but_CC such_JJ insurance_NN is_VBZ now_RB exhausted_VBN ._.
Eon_NNP has_VBZ agreed_VBN to_TO defend_VB and_CC indemnify_VB Shire_NNP US_NNP in_IN this_DT litigation_NN pursuant_JJ to_TO an_DT agreement_NN dated_VBN 30_CD November_NNP 2000_CD made_VBD between_IN Eon_NNP and_CC Shire_NNP US_NNP ._.
At_IN the_DT present_JJ stage_NN of_IN litigation_NN ,_, Shire_NNP is_VBZ unable_JJ to_TO estimate_VB the_DT level_NN of_IN future_JJ legal_JJ costs_NNS after_IN taking_VBG into_IN account_NN any_DT available_JJ product_NN liability_NN insurance_NN and_CC enforceable_JJ indemnities_NNS ._.
To_TO the_DT extent_NN that_IN any_DT legal_JJ costs_NNS are_VBP not_RB covered_VBN by_IN insurance_NN or_CC available_JJ indemnities_NNS ,_, these_DT will_MD be_VB expensed_VBN as_IN incurred_VBN ._.
It_PRP is_VBZ not_RB possible_JJ at_IN this_DT time_NN to_TO determine_VB the_DT legal_JJ outcome_NN or_CC financial_JJ implications_NNS of_IN any_DT of_IN these_DT claims_NNS ._.
ii_FW ADDERALL_NNP Shires_NNPS extended_VBD release_NN once_RB daily_JJ version_NN of_IN ADDERALL_NNP ,_, ADDERALL_NNP XR_NNP ,_, is_VBZ covered_VBN by_IN US_NNP patent_NN no._NN ._.
In_IN January_NNP 2003_CD Shire_NNP received_VBD a_DT Paragraph_NNP IV_NNP notice_NN from_IN Barr_NNP alleging_VBG that_IN this_DT patent_NN is_VBZ invalid_JJ and_CC not_RB infringed_VBN by_IN Barrs_NNP extended_VBD release_NN mixed_JJ amphetamine_NN salt_NN product_NN which_WDT is_VBZ the_DT subject_NN of_IN a_DT Barr_NNP pending_VBG Abbreviated_NNP New_NNP Drug_NNP Application_NNP ANDA_NNP application_NN ._.
On_IN 24_CD February_NNP 2003_CD Shire_NNP Laboratories_NNPS Inc._NNP filed_VBD suit_NN against_IN Barr_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP for_IN infringement_NN of_IN the_DT 819_CD Patent_NN with_IN respect_NN to_TO this_DT ANDA_NNP ._.
The_DT Hatch-Waxman_NNP Act_NNP provides_VBZ for_IN an_DT automatic_JJ stay_NN of_IN up_RB to_TO 30_CD months_NNS of_IN FDA_NNP approval_NN for_IN Barrs_NNP ANDA_NNP to_TO market_VB its_PRP$ generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP to_TO allow_VB the_DT Court_NNP to_TO resolve_VB the_DT patent_NN infringement_NN lawsuit_NN ._.
However_RB ,_, there_EX can_MD be_VB no_DT assurance_NN that_IN the_DT Group_NNP will_MD be_VB successful_JJ in_IN the_DT suit_NN ._.
In_IN the_DT event_NN that_IN the_DT Group_NNP does_VBZ not_RB prevail_VB ,_, then_RB Barr_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ extended_JJ release_NN mixed_JJ amphetamine_NN salt_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP application_NN ._.
This_DT may_MD have_VB a_DT material_NN adverse_JJ impact_NN on_IN the_DT Groups_NNS results_NNS and_CC financial_JJ position_NN ._.
In_IN the_DT event_NN that_IN the_DT Group_NNP does_VBZ not_RB prevail_VB in_IN the_DT suit_NN ,_, a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP could_MD not_RB be_VB launched_VBN before_IN October_NNP 2004_CD ,_, the_DT current_JJ expiry_NN of_IN the_DT existing_VBG Hatch-Waxman_NNP exclusivity_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 51_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 26_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD In_IN November_NNP 2002_CD Shire_NNP received_VBD approval_NN from_IN the_DT FDA_NNP for_IN a_DT new_JJ formulation_NN of_IN ADDERALL_NNP which_WDT is_VBZ patent_NN protected_VBN ._.
In_IN January_NNP 2003_CD Shire_NNP received_VBD a_DT Paragraph_NNP IV_NNP notice_NN from_IN Barr_NNP alleging_VBG that_IN this_DT patent_NN is_VBZ invalid_JJ and_CC not_RB infringed_VBN by_IN Barrs_NNP 7.5_CD mg_NN ,_, 12.5_CD mg_NN and_CC 15mg_JJ mixed_JJ amphetamine_NN salt_NN products_NNS ._.
The_DT Company_NN has_VBZ taken_VBN no_DT action_NN with_IN respect_NN to_TO this_DT notice_NN and_CC Barr_NNP announced_VBD in_IN March_NNP 2003_CD that_IN it_PRP has_VBZ now_RB received_VBN FDA_NNP approval_NN and_CC 180_CD days_NNS exclusivity_NN for_IN these_DT strengths_NNS ._.
The_DT Company_NN received_VBD a_DT second_JJ Paragraph_NNP IV_NNP notice_NN in_IN March_NNP 2003_CD from_IN another_DT generic_JJ alleging_VBG that_IN this_DT patent_NN is_VBZ invalid_JJ and_CC is_VBZ not_RB infringed_VBN by_IN its_PRP$ products_NNS ,_, which_WDT are_VBP the_DT subject_NN of_IN a_DT pending_VBG ANDA_NNP ._.
The_DT Company_NN has_VBZ taken_VBN no_DT action_NN and_CC this_DT company_NN will_MD be_VB able_JJ to_TO market_VB its_PRP$ product_NN upon_IN FDA_NNP approval_NN of_IN its_PRP$ ANDA_NNP application_NN ,_, subject_JJ to_TO Barrs_NNP exclusivity_NN period_NN for_IN the_DT above_JJ doses_NNS ._.
The_DT sales_NNS of_IN any_DT generic_JJ versions_NNS of_IN ADDERALL_NNP may_MD have_VB a_DT material_NN adverse_JJ impact_NN on_IN the_DT Companys_NNPS results_NNS and_CC financial_JJ position_NN ._.
Shire_NNP filed_VBD a_DT Complaint_NN against_IN Barr_NNP on_IN 30_CD April_NNP 2002_CD in_IN the_DT District_NNP Court_NNP of_IN New_NNP Jersey_NNP ._.
In_IN the_DT Complaint_NNP ,_, Shire_NNP requested_VBD a_DT preliminary_JJ and_CC permanent_JJ injunction_NN to_TO prevent_VB Barr_NNP from_IN marketing_VBG a_DT mixed_JJ amphetamine_NN salt_NN product_NN in_IN a_DT trade_NN dress_NN similar_JJ to_TO that_DT of_IN ADDERALL_NNP ._.
Shire_NNP requested_VBD that_IN Barr_NNP recall_VBP all_DT such_JJ products_NNS and_CC also_RB asked_VBD for_IN damages_NNS ._.
An_DT order_NN denying_VBG the_DT preliminary_JJ injunction_NN was_VBD issued_VBN on_IN 26_CD August_NNP 2002_CD ._.
Shire_NNP filed_VBD a_DT Notice_NNP of_IN Appeal_NNP to_TO the_DT United_NNP States_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Third_NNP Circuit_NNP on_IN 16_CD September_NNP 2002_CD appealing_VBG the_DT denial_NN of_IN Shires_NNP motion_NN for_IN a_DT preliminary_JJ injunction_NN ._.
iii_FW Emory_NNP Shire_NNP BioChem_NNP was_VBD involved_VBN in_IN worldwide_JJ patent_NN disputes_NNS with_IN Emory_NNP University_NNP Emory_NNP relating_VBG to_TO lamivudine_JJ wherein_NN Shire_NNP BioChem_NNP opposed_VBD certain_JJ patents_NNS and_CC patent_NN applications_NNS of_IN Emory_NNP and_CC wherein_JJ Emory_NNP opposed_VBD certain_JJ patents_NNS and_CC patent_NN applications_NNS of_IN Shire_NNP BioChem_NNP ._.
Pursuant_JJ to_TO a_DT global_JJ Settlement_NNP Agreement_NNP ,_, finalized_VBN in_IN May_NNP 2002_CD ,_, Emory_NNP has_VBZ granted_VBN Shire_NNP and_CC GSK_NNP an_DT exclusive_JJ licence_NN under_IN Emorys_NNP patent_NN rights_NNS for_IN lamivudine_NN ._.
The_DT Settlement_NNP Agreement_NNP provides_VBZ for_IN the_DT resolution_NN of_IN all_DT worldwide_JJ patent_NN disputes_NNS between_IN the_DT parties_NNS relating_VBG to_TO lamivudine_NN and_CC FTC_NNP ,_, including_VBG pending_VBG opposition_NN and_CC revocation_NN proceedings_NNS in_IN Europe_NNP ,_, South_NNP Korea_NNP and_CC Australia_NNP ._.
The_DT settlement_NN involves_VBZ a_DT small_JJ royalty_NN payment_NN on_IN worldwide_JJ sales_NNS of_IN lamivudine_NN and_CC a_DT licence_NN under_IN Shires_NNP FTC_NNP patent_NN rights_NNS ,_, in_IN consideration_NN for_IN the_DT settlement_NN of_IN all_DT claims_NNS against_IN Shire_NNP and_CC GSK_NNP relating_VBG to_TO lamivudine_NN ._.
Shire_NNP BioChem_NNP was_VBD also_RB involved_VBN in_IN worldwide_JJ patent_NN disputes_NNS with_IN Emory_NNP and_CC the_DT University_NNP of_IN Georgia_NNP Research_NNP Foundation_NNP Georgia_NNP relating_VBG to_TO certain_JJ dioxolane_NN nucleoside_NN analogs_NNS ._.
Shire_NNP BioChem_NNP opposed_VBD certain_JJ patents_NNS and_CC patent_NN applications_NNS of_IN Emory_NNP and_CC Georgia_NNP and_CC Emory_NNP opposed_VBD a_DT European_JJ patent_NN of_IN Shire_NNP BioChem_NNP ._.
Pursuant_JJ to_TO global_JJ Settlement_NNP and_CC License_NNP Agreements_NNP finalized_VBD in_IN August_NNP 2002_CD by_IN Shire_NNP BioChem_NNP ,_, Shire_NNP Pharmaceuticals_NNP Group_NNP ,_, Georgia_NNP and_CC Triangle_NNP Pharmaceuticals_NNP Inc._NNP ._.
Triangle_NNP ,_, Shire_NNP will_MD grant_VB an_DT exclusive_JJ royalty_NN bearing_NN licence_NN to_TO Emory_NNP ,_, sub_NN licensable_JJ to_TO Triangle_NNP ,_, for_IN certain_JJ dioxolane_NN nucleoside_NN analogs_NNS ,_, including_VBG diamino_NN purine_NN dioxolane_NN DAPD_NNP ._.
Emory_NNP ,_, Georgia_NNP and_CC Triangle_NNP will_MD grant_VB an_DT exclusive_JJ royalty_NN bearing_NN licence_NN to_TO Shire_NNP for_IN certain_JJ dioxolane_NN nucleosides_NNS ,_, including_VBG SPD756_NNP ._.
The_DT compounds_NNS the_DT subject_NN of_IN these_DT licenses_NNS are_VBP in_IN development_NN ._.
A_DT royalty_NN will_MD be_VB payable_JJ by_IN Shire_NNP upon_IN commercialisation_NN of_IN SPD756_NNP ._.
The_DT Settlement_NNP and_CC License_NNP Agreements_NNP provide_VB for_IN the_DT resolution_NN of_IN all_DT worldwide_JJ patent_NN disputes_NNS relating_VBG to_TO the_DT licensed_JJ patents_NNS ._.
iv_VB In_IN addition_NN ,_, the_DT Company_NN is_VBZ involved_VBN in_IN other_JJ claims_NNS and_CC lawsuits_NNS in_IN the_DT normal_JJ course_NN of_IN business_NN ._.
27_CD Pension_NNP arrangements_NNS The_DT Group_NNP has_VBZ a_DT number_NN of_IN defined_VBN contribution_NN retirement_NN plans_NNS that_WDT together_RB cover_VBP substantially_RB all_DT employees_NNS ._.
The_DT Company_NN contribution_NN is_VBZ fixed_VBN as_IN a_DT set_VBN percentage_NN of_IN employees_NNS pay_VBP ._.
The_DT pension_NN cost_NN charge_NN for_IN the_DT defined_VBN contribution_NN schemes_NNS for_IN the_DT year_NN was_VBD 4,702,000_CD 2001_CD :_: 3,123,000_CD ._.
The_DT closing_NN creditor_NN in_IN respect_NN of_IN pension_NN premiums_NNS at_IN 31_CD December_NNP 2002_CD is_VBZ 306,000_CD 31_CD December_NNP 2001_CD :_: 521,000_CD ._.
The_DT defined_VBN benefit_NN plan_NN operated_VBN by_IN the_DT Group_NNP was_VBD a_DT Supplemental_NNP Executive_NNP Retirement_NNP Plan_NNP SERP_NNP for_IN certain_JJ US_NNP employees_NNS of_IN the_DT acquired_VBN company_NN ,_, Roberts_NNP ,_, who_WP met_VBD certain_JJ age_NN and_CC service_NN requirements_NNS ._.
The_DT plan_NN was_VBD discontinued_VBN in_IN 2000_CD and_CC there_EX were_VBD no_DT contributions_NNS payable_JJ in_IN respect_NN of_IN the_DT years_NNS 2002_CD and_CC 2001_CD ._.
The_DT Group_NNP paid_VBD a_DT lump_NN sum_NN of_IN 11.3_CD million_CD $_$ 18_CD million_CD into_IN the_DT SERP_NNP ,_, which_WDT was_VBD accounted_VBN for_IN as_IN a_DT fair_JJ value_NN adjustment_NN on_IN the_DT acquisition_NN of_IN Roberts_NNP to_TO make_VB good_JJ the_DT deficit_NN on_IN this_DT scheme_NN at_IN the_DT time_NN of_IN acquisition_NN ._.
This_DT lump_NN sum_NN payment_NN has_VBZ led_VBN to_TO the_DT Group_NNP having_VBG no_DT future_JJ liability_NN under_IN the_DT SERP_NNP ,_, which_WDT has_VBZ been_VBN closed_VBN to_TO new_JJ members_NNS with_IN contributions_NNS no_RB longer_RB payable_JJ by_IN existing_VBG members_NNS ._.
The_DT asset_NN and_CC liability_NN of_IN 7.5_CD million_CD and_CC 5.2_CD million_CD respectively_RB are_VBP shown_VBN in_IN notes_NNS 18_CD and_CC 21_CD respectively_RB ._.
52_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 28_CD Notes_NNS to_TO the_DT consolidated_JJ cash_NN flow_NN statement_NN a_DT Reconciliation_NNP of_IN operating_NN profit_NN to_TO net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 2002 2001 000 000_CD Group_NNP operating_NN loss_NN profit_NN 533,145_CD 76,422_CD Exchange_NNP gains_NNS 962_CD 4,315_CD Depreciation_NN 9,073_CD 7,092_CD Amortisation_NNP of_IN intangible_JJ fixed_JJ assets_NNS 153,979_CD 111,254_CD Profit_NN on_IN sale_NN of_IN discontinued_VBN operations_NNS 2,006_CD Loss_NN on_IN sale_NN of_IN fixed_JJ assets_NNS 854_CD 7,646_CD Write-off_NN of_IN fixed_JJ asset_NN investments_NNS 5,809_CD 500_CD Write-off_NN of_IN intangible_JJ fixed_JJ assets_NNS 631,447_CD 3,092_CD Increase_VBP decrease_NN in_IN stocks_NNS 1,485_CD 2,836_CD Decrease_NN increase_NN in_IN debtors_NNS 51,832_CD 44,695_CD Decrease_NN increase_NN in_IN creditors_NNS 14,999_CD 43,044_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 302,321_CD 202,876_CD The_DT company_NN acquired_VBN during_IN 2002_CD contributed_VBD 3.6_CD million_CD US$_$ 5.8_CD million_CD outflow_NN to_TO the_DT Groups_NNS net_JJ operating_NN cash_NN flows_NNS and_CC utilised_JJ 3.5_CD million_CD US$_$ 5.7_CD million_CD for_IN capital_NN expenditure_NN and_CC financial_JJ investments_NNS ._.
Companies_NNS acquired_VBN during_IN 2001_CD contributed_VBD 6.3_CD million_CD CAN$_NNP 14.1_CD million_CD outflow_NN to_TO the_DT Groups_NNS net_JJ operating_NN cash_NN flows_VBZ ,_, contributed_VBD 4.6_CD million_CD CAN$_NNP 10.3_CD million_CD inflow_NN in_IN respect_NN of_IN net_JJ returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN ,_, paid_VBD 11.4_CD million_CD CAN$_NNP 25.5_CD million_CD in_IN respect_NN of_IN taxation_NN and_CC utilised_JJ 12.1_CD million_CD CAN$_NNP 27.0_CD million_CD for_IN capital_NN expenditure_NN and_CC financial_JJ investments_NNS ._.
b_NN Analysis_NN and_CC reconciliation_NN of_IN net_JJ debt_NN Acquired_VBN in_IN year_NN Other_JJ Start_NNP excluding_VBG non-cash_JJ Exchange_NNP End_NN of_IN of_IN year_NN cash_NN Cash_NN flow_NN changes_NNS movement_NN year_NN Year_NN ended_VBD 31_CD December_NNP 2002 000 000 000_CD 000 000 000_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 81,434_CD 493,102_CD 16,104_CD 558,432_CD Debt_NN due_JJ within_IN one_CD year_NN 3,008_CD 2,005_CD 565_CD 49_CD 389_CD Finance_NNP leases_NNS 243_CD 74_CD 7_CD 162_CD 78,426_CD 243_CD 495,181_CD 565_CD 16,048_CD 557,881_CD Debt_NN due_JJ after_IN one_CD year_NN 269,883_CD 1,173_CD 389_CD 26,342_CD 244,325_CD Finance_NNP leases_NNS 3,926_CD 169_CD 3,757_CD 191,457_CD 4,169_CD 494,008_CD 954_CD 10,463_CD 309,799_CD Current_JJ assets_NNS investments_NNS 497,397_CD 254,561_CD 87_CD 46,385_CD 196,364_CD Net_JJ funds_NNS 305,940_CD 4,169_CD 239,447_CD 867_CD 35,922_CD 506,163_CD Acquired_VBN in_IN year_NN Other_JJ Start_NNP excluding_VBG non-cash_JJ Exchange_NNP End_NN of_IN of_IN year_NN cash_NN Cash_NN flow_NN changes_NNS movement_NN year_NN Year_NN ended_VBD 31_CD December_NNP 2001 000 000 000_CD 000 000 000_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 31,194_CD 51,029_CD 789_CD 81,434_CD Debt_NN due_JJ within_IN one_CD year_NN 1,004_CD 2,089_CD 32_CD 1,004_CD 1,057_CD 3,008_CD 30,190_CD 2,089_CD 51,061_CD 1,004_CD 268_CD 78,426_CD Debt_NN due_JJ after_IN one_CD year_NN 84,683_CD 2,075_CD 182,840_CD 1,004_CD 1,289_CD 269,883_CD 54,493_CD 4,164_CD 131,779_CD 1,021_CD 191,457_CD Current_JJ assets_NNS investments_NNS 93,550_CD 81,995_CD 325,479_CD 3,627_CD 497,397_CD Net_JJ funds_NNS 39,057_CD 77,831_CD 193,700_CD 4,648_CD 305,940_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 53_CD Notes_NNS to_TO the_DT accounts_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 28_CD Notes_NNS to_TO the_DT consolidated_JJ cash_NN flow_NN statement_NN continued_VBD b_NN Analysis_NN and_CC reconciliation_NN of_IN net_JJ debt_NN 2002 2001 000 000_CD Increase_VBP in_IN cash_NN in_IN the_DT year_NN 493,102_CD 51,029_CD Cash_NN outflow_NN inflow_NN from_IN decrease_NN increase_NN in_IN debt_NN and_CC lease_NN financing_NN 906_CD 182,808_CD Cash_NN inflow_NN outflow_NN from_IN decrease_NN increase_NN in_IN liquid_JJ resources_NNS 254,561_CD 325,479_CD Change_NNP in_IN net_JJ debt_NN resulting_VBG from_IN cash_NN flows_NNS 239,447_CD 193,700_CD Leases_NNPS and_CC current_JJ asset_NN investments_NNS acquired_VBN with_IN subsidiary_NN undertakings_NNS 4,169_CD 77,831_CD Arenol_NNP loan_NN note_NN conversion_NN 954_CD Qualia_NNP Computing_NNP Inc._NNP joint_JJ venture_NN 87_CD Translation_NN difference_NN 35,922_CD 4,648_CD Movement_NNP in_IN net_JJ funds_NNS in_IN year_NN 200,223_CD 266,883_CD Net_JJ funds_NNS at_IN beginning_NN of_IN year_NN 305,940_CD 39,057_CD Net_JJ funds_NNS at_IN end_NN of_IN year_NN 506,163_CD 305,940_CD c_NN Major_JJ non-cash_JJ transactions_NNS i_FW Arenol_FW loan_NN note_NN conversion_NN In_IN 1999_CD the_DT Group_NNP financed_VBD the_DT purchase_NN of_IN intellectual_JJ property_NN relating_VBG to_TO the_DT manufacture_NN of_IN ADDERALL_NNP from_IN Arenol_NNP Corporation_NNP by_IN a_DT total_NN of_IN 7.9_CD million_CD $_$ 11.8_CD million_CD in_IN unsecured_JJ convertible_JJ zero_CD coupon_NN loan_NN notes_NNS ._.
On_IN 6_CD August_NNP 2002_CD ,_, the_DT Company_NN issued_VBD the_DT final_JJ instalment_NN of_IN 267,572_CD ordinary_JJ shares_NNS to_TO Arenol_NNP Corporation_NNP or_CC its_PRP$ nominee_NN broker_NN in_IN consideration_NN of_IN the_DT conversion_NN of_IN the_DT loan_NN notes_NNS in_IN the_DT Company_NN ._.
ii_FW Qualia_FW Computing_NNP Inc._NNP joint_JJ venture_NN In_IN September_NNP 2002_CD ,_, the_DT Group_NNP sold_VBD the_DT net_JJ assets_NNS of_IN its_PRP$ CADx_NNP group_NN of_IN companies_NNS ,_, to_TO Qualia_NNP Computing_NNP Inc_NNP ,_, in_IN exchange_NN for_IN 50_CD %_NN of_IN the_DT common_JJ stock_NN in_IN the_DT joint_JJ venture_NN ._.
The_DT value_NN of_IN the_DT assets_NNS in_IN the_DT CADx_NNP group_NN of_IN companies_NNS at_IN the_DT time_NN of_IN transfer_NN was_VBD 5.9_CD million_CD $_$ 9.3_CD million_CD ._.
29_CD Related_VBN party_NN transactions_NNS Transactions_NNS with_IN directors_NNS of_IN the_DT company_NN are_VBP disclosed_VBN in_IN the_DT remuneration_NN report_NN on_IN page_NN 13_CD and_CC in_IN the_DT directors_NNS report_VBP on_IN page_NN 7_CD ._.
During_IN the_DT year_NN the_DT Group_NNP incurred_VBN costs_NNS on_IN behalf_NN of_IN Qualia_NNP ,_, a_DT joint_JJ venture_NN ,_, of_IN 2.3_CD million_CD ._.
Amounts_NNS owed_VBN by_IN Qualia_NNP to_TO the_DT Group_NNP at_IN 31_CD December_NNP 2002_CD were_VBD 12,975_CD ._.
In_IN accordance_NN with_IN FRS_NNP 8_CD ,_, Related_NNP Party_NNP Disclosures_NNS ,_, transactions_NNS with_IN other_JJ companies_NNS in_IN ,_, and_CC investee_NN related_VBN parties_NNS of_IN ,_, the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP have_VBP not_RB been_VBN disclosed_VBN in_IN these_DT financial_JJ statements_NNS ._.
30_CD Post_NNP balance_NN events_NNS i_FW Resignationation_NNP of_IN Chief_NNP Executive_NNP On_IN 19_CD March_NNP 2003_CD ,_, Mr_NNP Rolf_NNP Stahel_NNP stepped_VBD down_RP as_IN Chief_NNP Executive_NNP and_CC as_IN a_DT director_NN of_IN the_DT Company_NN ._.
Details_NNS of_IN payments_NNS made_VBN to_TO Mr_NNP Stahel_NNP can_MD be_VB found_VBN in_IN the_DT remuneration_NN report_NN on_IN page_NN 14_CD ._.
ii_FW New_NNP product_NN acquisition_NN In_IN February_NNP 2003_CD ,_, Shire_NNP agreed_VBD to_TO acquire_VB ,_, from_IN Noven_NNP Pharmaceuticals_NNP Inc._NNP ._.
Noven_NNP ,_, for_IN 15.8_CD million_CD ,_, the_DT worldwide_JJ sales_NNS and_CC marketing_NN rights_NNS to_TO METHYPATCH_NNP ,_, a_DT methylphenidate_NN transdermal_JJ delivery_NN system_NN for_IN the_DT once-daily_JJ treatment_NN of_IN ADHD_NNP ._.
On_IN 28_CD April_NNP 2003_CD ,_, Shire_NNP announced_VBD that_IN Noven_NNP had_VBD received_VBN a_DT not_RB approvable_JJ letter_NN from_IN the_DT US_NNP Food_NNP and_CC Drug_NNP Administration_NNP in_IN response_NN to_TO its_PRP$ New_NNP Drug_NNP Application_NNP for_IN METHYPATCH_NNP ._.
54_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Designed_VBN and_CC produced_VBN by_IN C&FD_NNP ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Hampshire_NNP International_NNP Business_NNP Park_NNP Chineham_NNP Basingstoke_NNP Hampshire_NNP RG24_NNP 8EP_NNP Tel_NNP 44_CD 0_CD 1256 894 000_CD Fax_NNP 44_CD 0_CD 1256 894 708_CD www_NN ._.
com_NN Registered_NNP number_NN :_: 2883758_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2002_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2002_CD Contents_NNS 20_CD Advanced_NNP drug_NN delivery_NN 51_CD Consolidated_NNP balance_NN sheets_NNS 87_CD Summary_NNP financial_JJ statement_NN 22_CD Biologics_NNPS 52_CD Consolidated_NNP statements_NNS 88_CD Auditors_NNS statement_NN 2_CD 2002_CD at_IN a_DT glance_NN 24_CD Corporate_NNP social_JJ responsibility_NN of_IN operations_NNS 88_CD Summary_NNP directors_NNS report_VBP 3_CD Chairmans_NNPS statement_NN report_NN 53_CD Consolidated_NNP statements_NNS 89_CD Consolidated_NNP profit_NN and_CC 4_CD Chief_NNP Executives_NNS review_VBP 30_CD Financial_JJ review_NN of_IN changes_NNS in_IN shareholders_NNS loss_NN account_NN 6_CD Development_NNP pipeline_NN 34_CD Board_NNP of_IN Directors_NNS equity_NN 90_CD Consolidated_NNP balance_NN sheet_NN 7Product_NNP portfolio_NN 36_CD Executive_NNP Committee_NNP 54_CD Consolidated_NNP statements_NNS 91_CD Consolidated_NNP cash_NN flow_NN 8_CD Operating_NN review_NN 38_CD Directors_NNS remuneration_JJ report_NN of_IN comprehensive_JJ income_NN statement_NN 8_CD Central_NNP nervous_JJ system_NN 48_CD Corporate_JJ governance_NN losses_NNS 92_CD Notes_NNS to_TO the_DT summary_NN 12_CD Anti-infectives_NNS statement_NN 54_CD Consolidated_NNP statements_NNS financial_JJ statement_NN 14_CD Oncology_NNP and_CC hematology_JJ 50_CD Statement_NN of_IN directors_NNS of_IN cash_NN flows_VBZ 94_CD Shire_NNP head_NN office_NN and_CC main_JJ disorders_NNS responsibilities_NNS 56_CD Notes_NNS to_TO the_DT consolidated_JJ operating_NN locations_NNS 16_CD Additional_JJ Shire_NNP portfolio_NN 50_CD Report_NNP of_IN independent_JJ financial_JJ statements_NNS 95_CD Shareholder_NN information_NN 18_CD Gastrointestinal_NNP auditors_NNS 86_CD Five-year_JJ review_NN 96_CD Glossary_NNP Winning_VBG in_IN a_DT competitive_JJ world_NN Advances_NNS in_IN medical_JJ science_NN and_CC technologies_NNS allow_VBP a_DT greater_JJR understanding_NN of_IN disease_NN and_CC treatment_NN possibilities_NNS ,_, with_IN the_DT pharmaceutical_JJ industry_NN constantly_RB evolving_VBG to_TO take_VB advantage_NN of_IN these_DT changes_NNS ._.
Equally_RB challenging_JJ is_VBZ the_DT increased_JJ level_NN of_IN competition_NN ,_, including_VBG that_IN which_WDT comes_VBZ from_IN new_JJ products_NNS that_WDT are_VBP not_RB based_VBN on_IN innovative_JJ research_NN and_CC development_NN ._.
A_DT constant_JJ element_NN in_IN this_DT changing_VBG and_CC challenging_VBG environment_NN is_VBZ Shires_NNP determination_NN to_TO succeed_VB ._.
This_DT has_VBZ been_VBN evident_JJ from_IN the_DT very_RB early_JJ days_NNS of_IN Shire_NNP ,_, when_WRB it_PRP set_VBD its_PRP$ sights_NNS on_IN becoming_VBG one_CD of_IN the_DT leading_VBG pharmaceutical_JJ companies_NNS in_IN the_DT specialist_NN marketplace_NN ._.
By_IN focusing_VBG on_IN and_CC leveraging_VBG areas_NNS of_IN key_JJ strength_NN ,_, Shire_NNP is_VBZ well_RB positioned_VBN to_TO build_VB on_IN its_PRP$ success_NN in_IN the_DT face_NN of_IN ever-present_JJ challenges_NNS ,_, bringing_VBG important_JJ new_JJ medicines_NNS to_TO patients_NNS in_IN key_JJ markets_NNS worldwide_JJ and_CC continuing_VBG to_TO grow_VB its_PRP$ business_NN ._.
Shire_NNP has_VBZ built_VBN franchises_NNS in_IN the_DT therapeutic_JJ areas_NNS of_IN central_JJ nervous_JJ system_NN disorders_NNS ,_, gastrointestinal_JJ ,_, oncology_JJ and_CC anti-infectives_NNS ._.
These_DT are_VBP areas_NNS where_WRB significant_JJ medical_JJ needs_NNS remain_VBP unmet_JJ ,_, and_CC where_WRB Shire_NNP has_VBZ developed_VBN important_JJ expertise_NN both_DT in_IN the_DT market_NN and_CC in_IN research_NN and_CC development_NN ._.
The_DT strength_NN and_CC effectiveness_NN of_IN Shires_NNP sales_NNS and_CC marketing_NN organization_NN is_VBZ well_RB recognized_VBN and_CC has_VBZ been_VBN an_DT important_JJ component_NN of_IN the_DT Companys_NNP growth_NN ._.
Relationships_NNPS with_IN Shires_NNP target_NN group_NN of_IN specialist_NN physicians_NNS will_MD continue_VB to_TO be_VB strengthened_VBN as_IN the_DT Company_NN launches_VBZ additional_JJ new_JJ products_NNS over_IN the_DT coming_JJ months_NNS and_CC years_NNS ._.
Targeting_VBG an_DT R&D_NNP investment_NN of_IN 18-20_CD %_NN of_IN revenues_NNS ,_, Shire_NNP now_RB has_VBZ one_CD of_IN the_DT largest_JJS R&D_NN portfolios_NNS among_IN pharmaceutical_JJ companies_NNS of_IN a_DT similar_JJ size_NN ._.
Efforts_NNS to_TO broaden_VB this_DT portfolio_NN further_RBR are_VBP constantly_RB underway_RB through_IN two_CD avenues_NNS :_: internally_RB via_IN lead_NN optimisation_NN ,_, biologics_NNS research_NN and_CC drug_NN delivery_NN :_: externally_RB via_IN in-licensing_JJ and_CC targeted_JJ mergers_NNS &_CC acquisitions_NNS ._.
Each_DT of_IN these_DT elements_NNS allows_VBZ Shire_NNP to_TO overcome_VB challenges_NNS in_IN the_DT changing_VBG pharmaceutical_JJ industry_NN while_IN capitalising_VBG on_IN the_DT many_JJ opportunities_NNS ._.
With_IN a_DT sales_NNS and_CC marketing_NN focus_NN ,_, supported_VBN by_IN broad_JJ R&D_NNP capabilities_NNS and_CC a_DT promising_JJ project_NN portfolio_NN ,_, Shire_NNP is_VBZ very_RB well_RB positioned_VBN for_IN its_PRP$ emergence_NN as_IN a_DT strong_JJ global_JJ pharmaceutical_JJ company_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 1_CD 2002_CD at_IN a_DT glance_NN Financial_NNP highlights_VBZ Revenues_NNS $_$ m_CD R&D_NNP spend_VB $_$ m_CD Operating_NN income_NN $_$ m_CD Diluted_NNP EPS_NNP :_: Diluted_NNP EPS_NNP :_: ADS_NNPS ordinary_JJ shares_NNS 2002_CD 1,037.3_CD 2002_CD 189.2_CD 2002_CD 327.0_CD 2002_CD 49.0_CD 2002_CD 147.1_CD 2001_CD 853.0_CD 2001_CD 171.0_CD 2001_CD 143.1_CD 2001_CD 7.7_CD 2001_CD 23.0_CD 22_CD %_NN 11_CD %_NN 01_CD 02_CD 01_CD 02_CD 01_CD 02_CD 01_CD 02_CD 01_CD 02_CD Revenues_NNS by_IN product_NN royalties_NNS Revenues_NNS by_IN therapeutic_JJ area_NN Revenues_NNS by_IN geographic_JJ area_NN 1_CD ADDERALL_NNP 41_CD %_NN 1_CD Central_NNP nervous_JJ system_NN 48_CD %_NN 1_CD US_NNP 69_CD %_NN 2_CD AGRYLIN_NNP 11_CD %_NN 2_CD Gastrointestinal_NNP 8_CD %_NN 2_CD International_NNP 31_CD %_NN 3_CD PENTASA_NNP 8_CD %_NN 3_CD Oncology_NNP 12_CD %_NN 4_CD CARBATROL_NNP 4_CD %_NN 4_CD Anti-infectives_NNS 15_CD %_NN 5_CD PROAMATINE_NNP 5_CD %_NN 5_CD Others_NNS 14_CD %_NN 6_CD CALCICHEW_NNP 2_CD %_NN 5_CD 8_CD 2_CD 7_CD Others_NNS 12_CD %_NN 1_CD 4_CD 7_CD 1_CD 8_CD Royalties_NNS 17_CD %_NN 6_CD 5_CD 3_CD 1_CD 4_CD 3_CD 2_CD 2_CD In_IN 2002_CD Shires_NNP revenues_NNS exceeded_VBD $_$ 1_CD billion_CD for_IN the_DT first_JJ time_NN in_IN its_PRP$ history_NN Revenue_NN growth_NN over_IN the_DT past_JJ five_CD years_NNS $_$ 1,037.3_CD million_CD $_$ 853.0_CD million_CD $_$ 647.7_CD million_CD $_$ 515.4_CD million_CD $_$ 411.0_CD million_CD 98_CD 99_CD 00_CD 01_CD 02_CD 2_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Chairmans_NNPS statement_NN 2002_CD was_VBD a_DT challenging_JJ year_NN for_IN Shire_NNP and_CC our_PRP$ industry_NN ._.
Pressure_NN on_IN the_DT global_JJ pharmaceutical_JJ industry_NN was_VBD increased_VBN by_IN several_JJ aggressive_JJ launches_NNS of_IN generic_JJ drugs_NNS ._.
In_IN addition_NN ,_, an_DT ever-increasing_JJ population_NN of_IN ageing_NN patients_NNS and_CC inadequate_JJ third-party_JJ reimbursement_NN schedules_NNS continued_VBD to_TO exert_VB price_NN pressure_NN on_IN healthcare_NN providers_NNS ._.
Maximising_VBG returns_NNS in_IN the_DT face_NN of_IN these_DT pressures_NNS will_MD require_VB pharmaceutical_JJ companies_NNS to_TO deploy_VB resources_NNS effectively_RB to_TO drive_VB the_DT discovery_NN ,_, development_NN and_CC marketing_NN of_IN novel_NN drugs_NNS ._.
Shire_NNP is_VBZ particularly_RB well_RB placed_VBN to_TO deal_VB with_IN such_JJ challenges_NNS ._.
The_DT Executive_NNP ,_, Rolf_NNP drove_VBD Shires_NNP formidable_JJ success_NN and_CC growth_NN ._.
He_PRP Company_NN has_VBZ always_RB maintained_VBN a_DT substantial_JJ research_NN and_CC development_NN presided_VBD over_IN the_DT listing_NN of_IN the_DT Companys_NNP shares_NNS in_IN 1996_CD ,_, over_IN six_CD R&D_NNP program_NN to_TO create_VB a_DT sizeable_JJ portfolio_NN of_IN new_JJ therapies_NNS ._.
significant_JJ mergers_NNS and_CC acquisitions_NNS ,_, the_DT broadening_VBG of_IN the_DT Companys_NNP Building_NNP from_IN its_PRP$ position_NN as_IN an_DT international_JJ pharmaceutical_JJ company_NN sales_NNS and_CC marketing_NN infrastructure_NN ,_, and_CC the_DT development_NN of_IN a_DT number_NN targeting_VBG specialist_NN doctors_NNS ,_, Shire_NNP is_VBZ emerging_VBG as_IN a_DT global_JJ pharmaceutical_NN of_IN successful_JJ products_NNS through_IN the_DT Companys_NNP extensive_JJ R&D_NNP pipeline_NN ._.
Today_NN the_DT Company_NN not_RB only_RB in-licenses_JJ projects_NNS for_IN internal_JJ Today_NN Shire_NNP is_VBZ the_DT third_JJ largest_JJS pharmaceutical_JJ company_NN in_IN the_DT UK_NNP and_CC development_NN ,_, but_CC also_RB has_VBZ the_DT technological_JJ capabilities_NNS to_TO discover_VB and_CC is_VBZ the_DT US_NNP market_NN leader_NN in_IN the_DT ADHD_NNP field_NN ._.
I_PRP would_MD like_VB to_TO take_VB this_DT develop_VB its_PRP$ own_JJ molecules_NNS ._.
Our_PRP$ R&D_NNP approach_NN is_VBZ risk_NN balanced_VBN with_IN opportunity_NN to_TO thank_VB Rolf_NNP for_IN his_PRP$ outstanding_JJ contribution_NN to_TO the_DT success_NN a_DT careful_JJ and_CC objective_JJ discipline_NN that_WDT focuses_VBZ the_DT portfolio_NN on_IN low_JJ to_TO of_IN the_DT Company_NN ._.
In_IN March_NNP 2003_CD ,_, Shire_NNP took_VBD a_DT major_JJ step_NN towards_IN the_DT next_JJ stage_NN of_IN its_PRP$ In_IN 2002_CD ,_, following_VBG six_CD major_JJ mergers_NNS and_CC acquisitions_NNS during_IN the_DT growth_NN by_IN choosing_VBG Matthew_NNP Emmens_NNP as_IN Chief_NNP Executive_NNP ._.
Matthew_NNP has_VBZ past_JJ eight_CD years_NNS ,_, Shire_NNP acquired_VBD the_DT US_NNP specialty_NN pharmaceutical_NN a_DT strong_JJ track_NN record_NN of_IN success_NN over_IN a_DT pharmaceutical_JJ career_NN spanning_VBG manufacturing_NN facility_NN of_IN Atlantic_NNP Pharmaceutical_NNP Services_NNPS Inc._NNP ._.
APS_NNP ,_, nearly_RB 30_CD years_NNS ._.
He_PRP was_VBD a_DT founder_NN of_IN the_DT Astra_NNP Merck_NNP Inc._NNP joint_JJ venture_NN ,_, and_CC more_RBR recently_RB ,_, the_DT rights_NNS to_TO METHYPATCH_NNP methylphenidate_NN and_CC later_RB its_PRP$ President_NNP and_CC Chief_NNP Executive_NNP ._.
Most_RBS recently_RB ,_, Matthew_NNP a_DT transdermal_JJ delivery_NN system_NN ,_, an_DT important_JJ new_JJ ADHD_NNP attention_NN was_VBD President_NNP of_IN the_DT global_JJ pharmaceutical_JJ business_NN of_IN Merck_NNP KGaA_NNP deficit_NN and_CC hyperactivity_NN disorder_NN product_NN under_IN registration_NN ._.
He_PRP had_VBD established_VBN its_PRP$ US_NNP prescription_NN pharmaceutical_JJ business_NN ,_, EMD_NNP Pharmaceuticals_NNP ,_, before_IN moving_VBG to_TO Germany_NNP ._.
Matthews_NNP 2002_CD results_NNS extensive_JJ experience_NN and_CC leadership_NN should_MD prove_VB crucial_JJ drivers_NNS as_IN the_DT Shire_NNP achieved_VBD strong_JJ financial_JJ results_NNS in_IN 2002_CD which_WDT saw_VBD revenues_NNS business_NN moves_VBZ ahead_RB ._.
exceed_VB $_$ 1_CD billion_CD for_IN the_DT first_JJ time_NN in_IN its_PRP$ history_NN ._.
Group_NNP revenues_NNS increased_VBN by_IN 22_CD %_NN and_CC income_NN from_IN continuing_VBG operations_NNS ,_, before_IN People_NNS income_NN taxes_NNS and_CC equity_NN method_NN investees_NNS ,_, increased_VBD to_TO $_$ 329.1_CD million_CD ._.
Shire_NNP had_VBD 1,847_CD employees_NNS worldwide_JJ as_IN of_IN 31_CD December_NNP 2002_CD ._.
The_DT Diluted_JJ earnings_NNS per_IN ordinary_JJ share_NN was_VBD 49.0_CD ._.
Group_NNP believes_VBZ in_IN the_DT importance_NN of_IN hiring_VBG well-qualified_JJ ,_, experienced_JJ staff_NN with_IN proven_JJ records_NNS of_IN success_NN ._.
The_DT Groups_NNS future_JJ success_NN depends_VBZ The_DT US_NNP product_NN portfolio_NN ,_, which_WDT includes_VBZ ADDERALL_NNP XR_NNP mixed_JJ upon_IN its_PRP$ ability_NN to_TO attract_VB and_CC retain_VB such_JJ individuals_NNS ._.
Shire_NNP will_MD continue_VB amphetamine_JJ salts_NNS ,_, ADDERALL_NNP mixed_JJ amphetamine_NN salts_NNS ,_, AGRYLIN_NNP to_TO apply_VB and_CC develop_VB a_DT strong_JJ focus_NN on_IN staff_NN development_NN at_IN all_DT levels_NNS ._.
anagrelide_NN hydrochloride_NN ,_, CARBATROL_NNP carbamazepine_NN ,_, PENTASA_NNP mesalamine_NN and_CC PROAMATINE_NNP midodrine_NN hydrochloride_NN has_VBZ ,_, once_RB Future_JJ prospects_NNS again_RB ,_, delivered_VBN strong_JJ revenue_NN growth_NN ._.
Notwithstanding_IN aggressive_JJ ADDERALL_NNP XR_NNP is_VBZ now_RB well_RB established_VBN as_IN a_DT leading_VBG once-daily_RB ADHD_NNP generic_JJ competition_NN ,_, our_PRP$ US_NNP sales_NNS and_CC marketing_NN team_NN delivered_VBN 22_CD %_NN treatment_NN and_CC ,_, in_IN its_PRP$ first_JJ year_NN of_IN launch_NN ,_, has_VBZ become_VBN the_DT preferred_JJ revenue_NN growth_NN in_IN our_PRP$ US_NNP business_NN ,_, including_VBG 22_CD %_NN growth_NN in_IN the_DT choice_NN of_IN top-prescribing_JJ physicians_NNS for_IN their_PRP$ patients_NNS in_IN the_DT US_NNP ._.
ADDERALL_NNP franchise_NN during_IN the_DT year_NN ._.
In_IN conjunction_NN with_IN continued_JJ growth_NN of_IN our_PRP$ key_JJ revenue_NN streams_NNS ,_, including_VBG the_DT relaunch_VBP of_IN CARBATROL_NNP ,_, and_CC three_CD pending_VBG product_NN Augmenting_VBG its_PRP$ strong_JJ US_NNP business_NN ,_, Shire_NNP continued_VBD to_TO develop_VB its_PRP$ registrations_NNS ADDERALL_NNP XR_NNP adults_NNS in_IN the_DT US_NNP ,_, FOSRENOL_NNP international_JJ strategy_NN ,_, launching_VBG two_CD specialty_NN pharmaceutical_JJ products_NNS lanthanum_VBP carbonate_JJ US_NNP EU_NNP ,_, XAGRID_NNP EU_NNP ,_, our_PRP$ sales_NNS and_CC marketing_NN in_IN Europe_NNP ,_, SOLARAZE_NNP diclofenac_NN sodium_NN 3_CD %_NN and_CC ADEPT_JJ 4_CD %_NN organization_NN is_VBZ poised_VBN to_TO continue_VB driving_VBG the_DT performance_NN of_IN Shires_NNP icodextrin_NN solution_NN ._.
Total_JJ revenues_NNS in_IN the_DT international_JJ pharmaceutical_JJ revenues_NNS ._.
segment_NN grew_VBD by_IN 29_CD %_NN in_IN 2002_CD ,_, with_IN a_DT meaningful_JJ contribution_NN from_IN XAGRID_NNP anagrelide_NN hydrochloride_NN ._.
The_DT Board_NNP is_VBZ committed_VBN to_TO continuing_VBG to_TO develop_VB the_DT Companys_NNPS global_JJ strategy_NN and_CC growth_NN ._.
Shires_NNP strong_JJ investment_NN in_IN R&D_NNP will_MD continue_VB to_TO The_DT Board_NNP support_NN the_DT future_JJ growth_NN of_IN Shire_NNP ,_, with_IN a_DT total_NN of_IN four_CD further_JJ projects_NNS It_PRP is_VBZ with_IN much_JJ regret_NN that_IN we_PRP report_VBP the_DT passing_NN of_IN Dr_NNP Bernard_NNP Canavan_NNP ,_, scheduled_VBN to_TO move_VB into_IN phase_NN III_NNP development_NN this_DT year_NN ._.
We_PRP have_VBP all_PDT the_DT former_JJ President_NNP of_IN Wyeth_NNP Pharmaceuticals_NNP Inc._NNP a_DT member_NN of_IN Shires_NNP witnessed_VBD the_DT dramatic_JJ growth_NN of_IN Shire_NNP over_IN the_DT last_JJ few_JJ years_NNS and_CC I_PRP believe_VBP Board_NNP of_IN Directors_NNS and_CC Chairman_NNP of_IN our_PRP$ Audit_NNP Committee_NNP ._.
Dr_NNP Canavan_NNP we_PRP can_MD look_VB forward_RB to_TO even_RB more_RBR opportunities_NNS in_IN the_DT years_NNS ahead_RB ._.
His_PRP$ guidance_NN and_CC dedication_NN to_TO the_DT Shire_NNP Board_NNP will_MD be_VB greatly_RB missed_VBN ._.
In_IN October_NNP 2002_CD ,_, we_PRP announced_VBD that_IN Rolf_NNP Stahel_NNP ,_, our_PRP$ Chief_NNP Executive_NNP ,_, Dr_NNP James_NNP Cavanaugh_NNP Chairman_NNP would_MD be_VB stepping_VBG down_RB in_IN 2003_CD ._.
During_IN his_PRP$ nine_CD years_NNS as_IN Chief_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 3_CD Chief_NNP Executives_NNS review_NN During_IN 2002_CD ,_, for_IN the_DT first_JJ time_NN in_IN Shires_NNP history_NN ,_, the_DT Company_NN faced_VBD generic_JJ competition_NN to_TO one_CD of_IN its_PRP$ key_JJ products_NNS ,_, ADDERALL_NNP ,_, an_DT immediate-release_NN ADHD_NNP drug_NN ._.
For_IN many_JJ successful_JJ pharmaceutical_JJ companies_NNS ,_, it_PRP is_VBZ accepted_VBN that_IN such_PDT an_DT event_NN can_MD have_VB a_DT significant_JJ negative_JJ impact_NN on_IN a_DT companys_NNS financial_JJ performance_NN ._.
I_PRP am_VBP pleased_JJ to_TO say_VB that_IN Shires_NNP ADDERALL_NNP franchise_NN remained_VBD the_DT US_NNP ADHD_NNP market_NN leader_NN and_CC our_PRP$ US_NNP sales_NNS and_CC marketing_NN team_NN was_VBD able_JJ to_TO grow_VB our_PRP$ ADHD_NNP franchise_NN by_IN 22_CD %_NN despite_IN this_DT challenge_NN ._.
The_DT conversion_NN of_IN patients_NNS from_IN immediate-release_JJ ADDERALL_NNP to_TO to_TO R&D_NNP risk_NN management_NN by_IN weighting_NN our_PRP$ portfolio_NN of_IN projects_NNS towards_IN our_PRP$ new_JJ product_NN ,_, ADDERALL_NNP XR_NNP ,_, has_VBZ been_VBN a_DT great_JJ success_NN ,_, with_IN those_DT projects_NNS viewed_VBN as_RB low_JJ to_TO medium_JJ risk_NN ._.
Part_NN of_IN this_DT strategy_NN is_VBZ ADDERALL_NNP XR_NNP being_VBG welcomed_VBN as_IN a_DT substantially_RB improved_VBN oral_JJ ,_, the_DT acquisition_NN of_IN projects_NNS at_IN a_DT given_VBN stage_NN of_IN development_NN ._.
Its_PRP$ recognition_NN as_IN a_DT preferred_JJ treatment_NN opportunities_NNS typically_RB reduce_VB exposure_NN to_TO the_DT high_JJ risks_NNS associated_VBN with_IN combined_VBN with_IN a_DT very_RB successful_JJ sales_NNS and_CC marketing_NN campaign_NN gave_VBD the_DT early_JJ stages_NNS of_IN R&D_NNP ._.
Shire_NNP believes_VBZ ,_, as_IN a_DT consequence_NN ,_, that_IN the_DT ADDERALL_NNP XR_NNP a_DT 23.8_CD %_NN share_NN of_IN the_DT US_NNP ADHD_NNP prescription_NN market_NN average_JJ risk_NN profile_NN of_IN projects_NNS in_IN our_PRP$ R&D_NNP portfolio_NN is_VBZ lower_JJR than_IN the_DT in_IN December_NNP 2002_CD ._.
Shires_NNS combined_VBN ADHD_NNP franchise_NN prescription_NN industry_NN average_NN ._.
Going_VBG forward_RB we_PRP will_MD focus_VB our_PRP$ R&D_NNP resources_NNS to_TO share_VB in_IN December_NNP 2002_CD was_VBD 28.8_CD %_NN ,_, which_WDT includes_VBZ both_DT ADDERALL_NNP ensure_VB we_PRP foster_VBP depth_NN in_IN a_DT few_JJ areas_NNS rather_RB than_IN spreading_VBG thinly_RB in_IN the_DT and_CC ADDERALL_NNP XR_NNP ._.
pursuit_NN of_IN breadth_NN in_IN many_JJ ._.
The_DT year_NN 2002_CD also_RB highlighted_VBD the_DT growing_VBG value_NN of_IN our_PRP$ international_JJ Shires_NNP sales_NNS and_CC marketing_NN function_NN is_VBZ another_DT essential_JJ factor_NN operations_NNS ,_, with_IN 29_CD %_NN revenue_NN growth_NN ._.
Two_CD new_JJ specialty_NN pharmaceutical_JJ contributing_VBG to_TO its_PRP$ success_NN ._.
Shire_NNP takes_VBZ pride_NN in_IN its_PRP$ well-trained_JJ and_CC products_NNS ,_, SOLARAZE_NNP and_CC ADEPT_NNP ,_, were_VBD launched_VBN in_IN several_JJ European_JJ highly_RB motivated_JJ sales_NNS forces_NNS which_WDT have_VBP ,_, through_IN the_DT success_NN countries_NNS ,_, leveraging_VBG the_DT existing_VBG European_JJ infrastructure_NN ._.
of_IN Shires_NNP key_JJ marketed_VBN products_NNS ,_, demonstrated_VBD outstanding_JJ professionalism_NN and_CC performance_NN ._.
Shire_NNP has_VBZ a_DT risk-balanced_JJ R&D_NNP portfolio_NN with_IN a_DT clear_JJ focus_NN on_IN future_JJ product_NN needs_NNS ._.
To_TO enhance_VB the_DT potential_NN for_IN future_JJ growth_NN ,_, Shire_NNP follows_VBZ Customer_NN focus_NN two_CD main_JJ approaches_NNS :_: to_TO start_VB projects_NNS in-house_RB through_IN research_NN and_CC Shire_NNP has_VBZ a_DT particular_JJ interest_NN in_IN innovative_JJ therapies_NNS that_WDT are_VBP advanced_VBN drug_NN delivery_NN :_: and_CC to_TO in-license_JJ projects_NNS and_CC products_NNS on_IN prescribed_VBN by_IN specialist_NN doctors_NNS ,_, as_IN opposed_VBN to_TO those_DT prescribed_VBN reasonable_JJ commercial_JJ terms_NNS ,_, and_CC then_RB to_TO develop_VB and_CC launch_VB them_PRP ._.
by_IN primary_JJ care_NN or_CC general_JJ practitioners_NNS ._.
Shire_NNP targets_VBZ specialists_NNS This_DT broad_JJ approach_NN strengthens_VBZ Shires_NNP strategy_NN ._.
because_IN they_PRP usually_RB lead_VBP innovations_NNS in_IN prescribing_VBG as_RB well_RB as_IN being_VBG smaller_JJR in_IN number_NN and_CC easier_JJR for_IN a_DT company_NN of_IN Shires_NNP size_NN Shire_NN remains_VBZ an_DT acquisitive_JJ company_NN and_CC in_IN the_DT past_JJ eight_CD years_NNS has_VBZ to_TO target_VB effectively_RB ._.
completed_VBN six_CD major_JJ mergers_NNS and_CC acquisitions_NNS ,_, each_DT one_CD providing_VBG or_CC building_VBG on_IN our_PRP$ internal_JJ platforms_NNS for_IN growth_NN ._.
Shire_NNP will_MD continue_VB to_TO Therapeutic_JJ focus_NN evaluate_VBP companies_NNS ,_, products_NNS and_CC project_NN opportunities_NNS that_WDT offer_VBP a_DT Shires_NNP main_JJ areas_NNS of_IN therapeutic_JJ focus_NN are_VBP :_: central_JJ nervous_JJ system_NN good_JJ strategic_JJ fit_NN and_CC enhance_VB shareholder_NN value_NN ._.
disorders_NNS ,_, gastrointestinal_JJ ,_, oncology_JJ and_CC anti-infectives_NNS ._.
Functional_JJ focus_NN In_IN December_NNP 2002_CD ,_, Shire_NNP completed_VBD the_DT sale_NN of_IN its_PRP$ US_NNP over-the-counter_JJ Shire_NNP focuses_VBZ on_IN specific_JJ functional_JJ areas_NNS of_IN the_DT business_NN that_WDT are_VBP OTC_NNP product_NN portfolio_NN to_TO Purdue_NNP Pharmaceuticals_NNP Inc._NNP ._.
This_DT divestment_NN identified_VBN as_IN key_JJ drivers_NNS for_IN success_NN ,_, such_JJ as_IN R&D_NNP and_CC sales_NNS and_CC marks_NNS Shires_NNP complete_JJ exit_NN from_IN OTC_NNP operations_NNS and_CC will_MD allow_VB the_DT marketing_NN ._.
Company_NN to_TO focus_VB resources_NNS on_IN its_PRP$ core_NN strategy_NN of_IN providing_VBG prescription_NN pharmaceuticals_NNS to_TO specialist_JJ doctors_NNS ._.
Shires_NNP current_JJ R&D_NNP pipeline_NN includes_VBZ 13_CD projects_NNS that_WDT are_VBP either_RB in_IN or_CC post_IN phase_NN II_NNP development_NN ._.
In_IN order_NN to_TO reduce_VB financial_JJ and_CC business_NN Geographic_JJ focus_NN risk_NN ,_, Shire_NNP maintains_VBZ a_DT careful_JJ and_CC objective_JJ discipline_NN in_IN its_PRP$ approach_NN Shire_NNP currently_RB markets_VBZ its_PRP$ products_NNS using_VBG its_PRP$ sales_NNS forces_NNS in_IN seven_CD major_JJ pharmaceutical_JJ markets_NNS of_IN the_DT world_NN ._.
Shire_NNP covers_VBZ other_JJ significant_JJ pharmaceutical_JJ markets_NNS indirectly_RB through_IN distributors_NNS ._.
4_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Chief_NNP Executives_NNS review_NN Technology_NN focus_NN Shires_VBZ current_JJ business_NN model_NN has_VBZ five_CD levels_NNS Shires_NNP three_CD platform_NN technologies_NNS lead_VBP optimisation_NN for_IN small_JJ of_IN focus_NN :_: functional_JJ ,_, customer_NN ,_, therapeutic_JJ ,_, molecules_NNS ,_, biologics_NNS research_NN and_CC advanced_VBN drug_NN delivery_NN are_VBP an_DT technology_NN and_CC geographic_JJ ._.
important_JJ part_NN of_IN its_PRP$ risk-balanced_JJ approach_NN ._.
Importantly_RB these_DT three_CD platform_NN technologies_NNS also_RB widen_VBP our_PRP$ ability_NN to_TO in-license_JJ research_NN programs_NNS ,_, development_NN projects_NNS and_CC products_NNS ._.
These_DT technologies_NNS Therapeutic_NNP Customer_NN focus_NN focus_NN can_MD also_RB be_VB used_VBN to_TO manage_VB the_DT lifecycle_NN of_IN existing_VBG products_NNS ._.
CNS_NNP ,_, GI_NNP ,_, Specialty_NNP Moving_VBG forward_RB Oncology_NNP ,_, doctors_NNS AntiShire_NNP is_VBZ moving_VBG forward_RB with_IN confidence_NN as_IN a_DT strong_JJ ,_, independent_JJ infectives_NNS company_NN well_RB positioned_VBD for_IN continued_JJ growth_NN ._.
We_PRP have_VBP a_DT strong_JJ track_NN record_NN of_IN successful_JJ mergers_NNS and_CC acquisitions_NNS and_CC this_DT will_MD continue_VB to_TO Functional_NNP Geographic_NNP be_VB a_DT major_JJ focus_NN for_IN our_PRP$ future_JJ expansion_NN ._.
Shire_NNP has_VBZ recently_RB launched_VBN focus_NN focus_NN a_DT number_NN of_IN new_JJ products_NNS ,_, both_DT in_IN the_DT US_NNP and_CC in_IN its_PRP$ international_JJ USA_NNP ,_, Search_NNP Germany_NNP ,_, Research_NNP ,_, markets_NNS ,_, and_CC it_PRP continues_VBZ to_TO invest_VB in_IN focused_JJ R&D_NNP capabilities_NNS to_TO sustain_VB UK_NNP ,_, France_NNP ,_, Development_NNP ,_, Technology_NNP Italy_NNP ,_, Spain_NNP ,_, growth_NN in_IN future_JJ years_NNS ._.
Marketing_NNP Canada_NNP focus_NN Small_JJ molecules_NNS ,_, I_PRP would_MD like_VB to_TO thank_VB all_DT employees_NNS for_IN their_PRP$ diligence_NN and_CC dedication_NN ,_, Biologics_NNP ,_, which_WDT were_VBD the_DT key_JJ drivers_NNS of_IN our_PRP$ success_NN in_IN 2002_CD ,_, probably_RB Advanced_NNP drug_NN one_CD of_IN the_DT most_RBS challenging_JJ and_CC equally_RB most_RBS successful_JJ in_IN Shires_NNP delivery_NN 16-year_JJ history_NN ._.
Their_PRP$ hard_JJ work_NN and_CC innovative_JJ ideas_NNS will_MD help_VB Shire_VB to_TO achieve_VB even_RB greater_JJR results_NNS in_IN the_DT years_NNS ahead_RB ._.
Matthew_NNP Emmens_NNP Chief_NNP Executive_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 5_CD Development_NNP pipeline_NN One_CD of_IN the_DT largest_JJS R&D_NN portfolios_NNS for_IN a_DT company_NN of_IN its_PRP$ size_NN Shire_NNP has_VBZ a_DT long-term_JJ commitment_NN to_TO annual_JJ R&D_NNP investment_NN In_IN 2003_CD Shire_NNP expects_VBZ the_DT following_VBG late-stage_JJ milestones_NNS to_TO occur_VB :_: of_IN 18-20_CD %_NN of_IN its_PRP$ revenues_NNS ._.
The_DT benefit_NN of_IN this_DT level_NN of_IN spending_NN is_VBZ gaining_VBG visibility_NN as_IN the_DT late_JJ stage_NN pipeline_NN emerges_VBZ ._.
The_DT Approval_NNP regulatory_JJ action_NN :_: Progress_NNP into_IN phase_NN III_NNP clinical_JJ trials_NNS :_: Company_NN has_VBZ a_DT total_NN of_IN 22_CD projects_NNS in_IN full_JJ development_NN of_IN FOSRENOL_NNP hyperphosphatemia_NN US_NNP EU_NNP SPD503_NNP ADHD_NNP already_RB occurred_VBD which_WDT 13_CD are_VBP in_IN phase_NN II_NNP or_CC beyond_IN ._.
XAGRID_NNP essential_JJ thombocythemia_NN EU_NNP SPD476_NNP ulcerative_JJ colitis_NN ADDERALL_NNP XR_NNP adult_NN ADHD_NNP US_NNP TROXATYL_NNP troxacitabine_NN acute_JJ myelogenous_JJ leukemia_NN TROXATYL_NNP pancreatic_JJ cancer_NN Indication_NNP Product_NNP Preclinical_NNP Phase_NN I_PRP Phase_NN II_NNP Phase_NN III_NNP Registration_NNP CNS_NNP Bipolar_NNP disorder_NN SPD417_NNP Attention_NN deficit_NN hyperactivity_NN disorder_NN ADHD_NNP SPD465_CD ADHD_NNP SPD483_CD ADHD_NNP SPD503_CD ADHD_NNP SPD473_CD ADHD_NNP METHYPATCH_NNP Parkinsons_NNPS disease_NN SPD451_NNP Gastrointestinal_NNP Inflammatory_NNP bowel_NN disease_NN IBD_NNP PENTASA_NNP IBD_NNP COLAZIDE_NNP IBD_NNP SPD476_NNP IBD_NNP SPD480_NNP Oncology_NNP Essential_NNP thrombocythemia_NN AGRYLIN_NNP Acute_NNP myeloid_VBD leukemia_NN TROXATYL_NNP Pancreatic_NNP cancer_NN TROXATYL_NNP Anti-infectives_NNS Influenza_NNP SPD701_NNP Influenza_NNP SPD707_NNP Meningitis_NNP ,_, septicemia_NN SPD704_NNP Opportunistic_NNP infections_NNS SPD705_NNP HIV_NNP SPD754_NNP HIV_NNP SPD756_NNP Pneumonia_NNP ,_, meningitis_VBZ SPD703_NNP Other_JJ disease_NN areas_NNS Hyperphosphatemia_NNP FOSRENOL_NNP 6_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Product_NNP portfolio_NN A_DT strong_JJ range_NN of_IN effective_JJ marketed_VBN products_NNS Shire_NNP has_VBZ a_DT strategic_JJ focus_NN on_IN four_CD therapeutic_JJ areas_NNS central_JJ nervous_JJ system_NN disorders_NNS ,_, gastrointestinal_JJ disorders_NNS ,_, oncology_NN and_CC anti-infectives_NNS ._.
The_DT wide_JJ ranging_VBG portfolio_NN of_IN products_NNS that_WDT Shire_NNP sells_VBZ in_IN countries_NNS worldwide_JJ includes_VBZ some_DT key_JJ products_NNS featured_VBN here_RB ._.
ADDERALL_NNP mixed_JJ amphetamine_NN ADDERALL_NNP XR_NNP mixed_JJ ADEPT_NNP 4_CD %_NN icodextrin_NN solution_NN ._.
ADDERALL_NNP is_VBZ an_DT amphetamine_JJ salts_NNS ._.
ADDERALL_NNP XR_NNP ADEPT_NNP is_VBZ indicated_VBN for_IN use_NN as_IN hydrochloride_NN ._.
AGRYLIN_NNP is_VBZ immediate-release_JJ product_NN is_VBZ indicated_VBN for_IN the_DT treatment_NN of_IN ADHD_NNP an_DT intraperitoneal_JJ instillate_NN for_IN indicated_VBN for_IN the_DT treatment_NN of_IN indicated_VBN for_IN the_DT treatment_NN of_IN and_CC is_VBZ a_DT once-daily_JJ formulation_NN of_IN reduction_NN of_IN adhesions_NNS following_VBG thrombocythemia_NN ._.
Research_NNP attention_NN deficit_NN hyperactivity_NN ADDERALL_NNP ._.
It_PRP offers_VBZ convenience_NN abdominal_NN surgery_NN ._.
It_PRP acts_VBZ by_IN indicates_VBZ that_IN a_DT key_JJ benefit_NN of_IN disorder_NN ADHD_NNP ._.
to_TO patients_NNS and_CC caregivers_NNS ,_, and_CC the_DT providing_VBG a_DT temporary_JJ separation_NN AGRYLIN_NNP is_VBZ its_PRP$ platelet_NN selectivity_NN ,_, potential_NN for_IN improved_VBN compliance_NN ._.
of_IN peritoneal_JJ surfaces_NNS by_IN targeting_VBG only_RB those_DT cells_NNS that_WDT hydroflotation_NN ._.
CALCICHEW_NNP range_NN calcium_NN FLUVIRAL_NNP S_NNP F_NN split-virion_NN PENTASA_NNP mesalamine_NN ._.
CARBATROL_NNP is_VBZ indicated_VBN for_IN use_NN carbonate_NN ._.
FLUVIRAL_NNP is_VBZ PENTASA_NNP is_VBZ indicated_VBN for_IN the_DT as_IN an_DT anticonvulsant_JJ drug_NN and_CC is_VBZ range_NN of_IN products_NNS are_VBP calcium_NN a_DT vaccine_NN indicated_VBD for_IN active_JJ induction_NN of_IN remission_NN and_CC marketed_VBN for_IN the_DT treatment_NN of_IN supplements_NNS with_IN or_CC without_IN immunisation_NN against_IN the_DT treatment_NN of_IN patients_NNS with_IN mildly_RB to_TO epilepsy_NN ,_, combining_VBG proven_JJ vitamin_NN D_NNP used_VBD as_IN adjunctive_JJ influenza_NN virus_NN ._.
moderately_RB active_JJ ulcerative_JJ colitis_NN ,_, medication_NN with_IN drug_NN delivery_NN treatments_NNS for_IN osteoporosis_NN ._.
technology_NN to_TO enable_VB a_DT convenient_JJ twice-daily_JJ treatment_NN ._.
PROAMATINE_NNP midodrine_NN REMINYL_NNP galantamine_NN SOLARAZE_NNP diclofenac_JJ sodium_NN ZEFFIX_NNP lamivudine_NN ._.
SOLARAZE_NNP is_VBZ indicated_VBN for_IN is_VBZ indicated_VBN for_IN the_DT treatment_NN the_DT only_JJ FDA_NNP approved_VBD product_NN indicated_VBD for_IN the_DT symptomatic_JJ the_DT treatment_NN of_IN actinic_JJ keratosis_NN ,_, of_IN chronic_JJ hepatitis_NN B_NNP infection_NN indicated_VBD for_IN the_DT treatment_NN treatment_NN of_IN mild_JJ to_TO moderately_RB a_DT precancerous_JJ skin_NN condition_NN ._.
associated_VBN with_IN evidence_NN of_IN of_IN symptomatic_JJ orthostatic_JJ severe_JJ dementia_NN of_IN the_DT Alzheimer_NNP hepatitis_NNP B_NNP viral_JJ replication_NN and_CC hypotension_NN ._.
REMINYL_NNP differs_VBZ from_IN other_JJ acute_JJ liver_NN inflammation_NN ._.
compounds_NNS in_IN its_PRP$ class_NN in_IN that_DT it_PRP has_VBZ a_DT dual_JJ mechanism_NN of_IN action_NN ._.
3TC_CD ,_, in_IN combination_NN with_IN other_JJ antiretroviral_JJ agents_NNS ,_, is_VBZ indicated_VBN for_IN the_DT treatment_NN of_IN human_JJ Trade_NNP mark_NN of_IN ML_NNP Laboratories_NNP plc._NN ._.
Trade_NNP mark_NN of_IN Johnson_NNP &_CC Johnson_NNP ._.
Lamivudine_NNP is_VBZ a_DT component_NN of_IN the_DT Trade_NNP mark_NN of_IN GSK_NNP ._.
GSK_NNP is_VBZ the_DT owner_NN combination_NN HIV_NNP treatments_NNS ,_, licensor_NN of_IN some_DT rights_NNS in_IN these_DT products_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 7_CD ADHD_NNP Patients_NNPS with_IN ADHD_NNP can_MD present_VB with_IN symptoms_NNS of_IN inattention_NN ,_, impulsivity_NN hyperactivity_NN or_CC both_DT ._.
This_DT can_MD lead_VB to_TO impaired_VBN functioning_VBG in_IN social_JJ and_CC educational_JJ settings_NNS with_IN resultant_JJ educational_JJ and_CC family_NN disruption_NN ._.
8_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Central_NNP nervous_JJ system_NN Experience_NN and_CC innovation_NN With_IN a_DT central_JJ nervous_JJ system_NN CNS_NNP franchise_NN founded_VBN on_IN established_VBN ,_, tried_VBD and_CC tested_VBD therapies_NNS ,_, Shire_NNP is_VBZ committed_VBN to_TO developing_VBG products_NNS to_TO meet_VB the_DT current_JJ and_CC future_JJ needs_NNS of_IN CNS_NNP patients_NNS ._.
Attention_NN deficit_NN hyperactivity_NN disorder_NN 584_CD children_NNS ,_, concluded_VBD that_IN one_CD morning_NN Adult_NNP ADHD_NNP ADHD_NNP dose_NN of_IN ADDERALL_NNP XR_NNP was_VBD well-tolerated_JJ and_CC At_IN the_DT end_NN of_IN 2002_CD Shire_NNP filed_VBD a_DT supplemental_JJ ADHD_NNP is_VBZ estimated_VBN to_TO affect_VB between_IN 3_CD %_NN and_CC effective_JJ at_IN controlling_VBG symptoms_NNS of_IN ADHD_NNP New_NNP Drug_NNP Application_NNP sNDA_NNP with_IN the_DT Food_NNP 7_CD %_NN of_IN children_NNS in_IN the_DT US_NNP ._.
Often_RB presenting_VBG throughout_IN the_DT day_NN ._.
A_DT second_JJ study_NN ,_, the_DT and_CC Drug_NNP Administration_NNP FDA_NNP for_IN use_NN of_IN with_IN symptoms_NNS of_IN inattention_NN ,_, impulsivity_NN largest-ever_JJ ADHD_NNP clinical_JJ trial_NN the_DT Long_NNP ADDERALL_NNP XR_NNP in_IN the_DT treatment_NN of_IN adult_NN ADHD_NNP ._.
hyperactivity_NN ,_, or_CC both_DT ,_, the_DT sufferer_NN can_MD Acting_NNP Adderall_NNP Community_NNP Assessment_NNP Trial_NNP It_PRP is_VBZ estimated_VBN that_IN up_RB to_TO 8_CD million_CD adults_NNS in_IN the_DT experience_NN impaired_VBN functioning_VBG in_IN social_JJ and_CC or_CC LADD_NNP ._.
CAT_NNP study_NN ,_, was_VBD presented_VBN at_IN the_DT US_NNP have_VBP ADHD_VBN ._.
However_RB ,_, this_DT is_VBZ a_DT relatively_RB educational_JJ settings_NNS with_IN resultant_JJ educational_JJ American_JJ Psychiatric_NNP Association_NNP Annual_JJ underdeveloped_JJ market_NN with_IN only_JJ approximately_RB and_CC family_NN disruption_NN ._.
In_IN approximately_RB 66_CD %_NN of_IN Meeting_VBG in_IN Philadelphia_NNP ,_, in_IN 2002_CD ._.
Involving_VBG 5_CD %_NN of_IN those_DT affected_JJ receiving_VBG treatment_NN ._.
children_NNS ,_, symptoms_NNS will_MD persist_VB into_IN adulthood_NN nearly_RB 3,000_CD children_NNS ,_, the_DT study_NN demonstrated_VBD This_DT may_MD result_VB from_IN limited_JJ awareness_NN and_CC with_IN estimates_NNS of_IN up_RB to_TO 8_CD million_CD adults_NNS in_IN the_DT that_WDT ADDERALL_NNP XR_NNP significantly_RB improves_VBZ the_DT diagnosis_NN of_IN ADHD_NNP in_IN the_DT adult_NN population_NN ._.
hallmark_NN symptoms_NNS of_IN ADHD_NNP and_CC the_DT quality_NN of_IN life_NN of_IN children_NNS living_VBG with_IN the_DT condition_NN ._.
ADHD_NNP pipeline_NN Since_IN the_DT launch_NN of_IN its_PRP$ first_JJ products_NNS for_IN the_DT SPD503_NNP ,_, a_DT novel_NN formulation_NN of_IN a_DT nonmanagement_NN of_IN ADHD_NNP DEXTROSTAT_NNP The_DT most_RBS successful_JJ switch_NN scheduled_VBN compound_NN ,_, entered_VBD phase_NN III_NNP of_IN dextroamphetamine_NN salt_NN and_CC ADDERALL_NNP ,_, Launched_VBN in_IN November_NNP 2001_CD ,_, ADDERALL_NNP XR_NNP clinical_JJ development_NN in_IN children_NNS in_IN early_JJ 2003_CD ._.
Shire_NNP has_VBZ remained_VBN committed_JJ to_TO the_DT has_VBZ become_VBN one_CD of_IN the_DT most_RBS widely_RB prescribed_VBN Studies_NNS to_TO assess_VB its_PRP$ potential_NN in_IN adult_NN ADHD_NNP development_NN of_IN products_NNS for_IN ADHD_NNP ._.
The_DT ADHD_NNP treatments_NNS in_IN the_DT US_NNP ._.
Over_IN 4.5_CD million_CD patients_NNS are_VBP being_VBG designed_VBN ._.
latest_JJS addition_NN to_TO the_DT marketed_VBN ADHD_NNP portfolio_NN prescriptions_NNS have_VBP been_VBN written_VBN ,_, and_CC by_IN the_DT is_VBZ ADDERALL_NNP XR_NNP ,_, a_DT patented_JJ once-daily_JJ end_NN of_IN 2002_CD the_DT product_NN claimed_VBD 23.8_CD %_NN of_IN SPD473_CD is_VBZ a_DT mixed_JJ monoamine_NN reuptake_NN dosing_VBG formulation_NN of_IN ADDERALL_NNP that_WDT uses_VBZ the_DT ADHD_NNP market_NN in_IN the_DT US_NNP ._.
Its_PRP$ unique_JJ mode_NN of_IN action_NN ,_, affecting_VBG Shire_NNP Laboratories_NNPS MICROTROL_NNP drug_NN success_NN in_IN switching_VBG patients_NNS from_IN the_DT original_JJ three_CD neurotransmitters_NNS that_WDT may_MD be_VB implicated_VBN delivery_NN technology_NN ._.
Once-daily_RB dosing_VBG offers_NNS immediate-release_JJ product_NN to_TO the_DT once-daily_JJ in_IN ADHD_NNP noradrenaline_NN ,_, serotonin_NN and_CC a_DT significant_JJ convenience_NN to_TO patients_NNS and_CC brand_NN ._.
Underpinning_VBG the_DT successful_JJ launch_NN of_IN dopamine_NN makes_VBZ this_DT an_DT interesting_JJ candidate_NN caregivers_NNS ,_, removing_VBG the_DT need_NN for_IN duringADDERALL_NNP XR_NNP Shire_NNP continues_VBZ to_TO promote_VB for_IN ADHD_NNP treatment_NN ._.
A_DT phase_NN II_NNP proof-ofschool_NN or_CC after-school_JJ treatment_NN ,_, and_CC provides_VBZ awareness_NN and_CC understanding_NN of_IN ADHD_NNP to_TO the_DT concept_NN study_NN in_IN ADHD_NNP is_VBZ planned_VBN for_IN 2003_CD ._.
the_DT potential_NN for_IN improved_VBN compliance_NN ._.
METHYPATCH_NNP is_VBZ a_DT recent_JJ acquisition_NN to_TO the_DT Largest-ever_JJ ADHD_NNP clinical_JJ trial_NN New_NNP strengths_NNS Shire_NNP portfolio_NN ,_, and_CC was_VBD filed_VBN with_IN the_DT FDA_NNP on_IN Results_NNS from_IN two_CD key_JJ trials_NNS have_VBP contributed_VBN The_DT addition_NN of_IN three_CD new_JJ strengths_NNS of_IN 27_CD June_NNP 2002_CD ._.
Subject_JJ to_TO regulatory_JJ approval_NN it_PRP to_TO the_DT strong_JJ demand_NN for_IN ADDERALL_NNP XR_NNP ._.
ADDERALL_NNP XR_NNP 5mg_CD ,_, 15mg_CD ,_, 25mg_CD to_TO the_DT will_MD be_VB the_DT first_JJ transdermal_JJ drug_NN delivery_NN based_VBN A_DT multi-centre_JJ ,_, randomised_JJ ,_, double-blind_JJ ,_, product_NN range_NN complements_VBZ the_DT existing_VBG product_NN offered_VBN for_IN the_DT treatment_NN of_IN ADHD_NNP ._.
placebo_NN controlled_VBD study_NN published_VBN in_IN the_DT strengths_NNS 10mg_VBP ,_, 20mg_JJ and_CC 30mg_JJ providing_VBG journal_NN Pediatrics_NNP August_NNP 2002_CD ,_, involving_VBG patients_NNS and_CC clinicians_NNS with_IN additional_JJ flexibility_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 9_CD Operating_NN review_NN :_: Central_NNP nervous_JJ system_NN Alzheimers_NNP disease_NN dementia_NN Epilepsy_NNP phase_NN III_NNP demonstrated_VBD the_DT potential_NN of_IN Alzheimers_NNP disease_NN AD_NNP affects_VBZ over_IN 12_CD million_CD Epilepsy_NNP is_VBZ one_CD of_IN the_DT most_RBS common_JJ CARBATROL_NNP SPD417_NNP in_IN treating_VBG bipolar_JJ mood_NN people_NNS worldwide_JJ ._.
It_PRP is_VBZ a_DT progressive_JJ ,_, neuroneurological_JJ disorders_NNS and_CC is_VBZ estimated_VBN to_TO disorder_NN in_IN adults_NNS ._.
Shire_NNP has_VBZ initiated_VBN a_DT further_JJ degenerative_JJ disorder_NN characterised_VBN by_IN a_DT loss_NN affect_VB approximately_RB 2.5_CD million_CD people_NNS in_IN phase_NN III_NNP study_NN to_TO support_VB these_DT findings_NNS ._.
of_IN memory_NN and_CC cognition_NN ,_, ability_NN to_TO perform_VB the_DT US_NNP ._.
Characterised_VBN by_IN a_DT propensity_NN for_IN activities_NNS of_IN daily_JJ living_NN ,_, and_CC changes_NNS in_IN personality_NN recurrent_NN seizures_NNS ,_, it_PRP is_VBZ defined_VBN by_IN two_CD or_CC Discontinued_VBN research_NN projects_NNS and_CC behavior_NN ._.
REMINYL_NNP is_VBZ indicated_VBN for_IN the_DT more_RBR unprovoked_JJ seizures_NNS ._.
In_IN 2002_CD following_VBG poor_JJ pre-clinical_JJ results_NNS ,_, work_NN symptomatic_JJ treatment_NN of_IN mild_JJ to_TO moderately_RB on_IN SPD474_CD ,_, a_DT potential_JJ Parkinsons_NNP disease_NN severe_JJ dementia_NN of_IN the_DT Alzheimer_NNP type_NN ._.
CARBATROL_NNP ,_, a_DT twice-daily_JJ extended-release_NN treatment_NN ,_, was_VBD discontinued_VBN ._.
The_DT option_NN to_TO formulation_NN of_IN carbamazepine_NN ,_, is_VBZ marketed_VBN for_IN develop_VB SPD420_NNP for_IN ADHD_NNP was_VBD also_RB stopped_VBN An_DT acetylcholinesterase_NN inhibitor_NN ,_, REMINYL_NNP epilepsy_NN in_IN the_DT US_NNP ._.
In_IN 2002_CD it_PRP attained_VBD 36.3_CD %_NN following_VBG poor_JJ phase_NN II_NNP trial_NN results_NNS ._.
Following_VBG differs_VBZ from_IN other_JJ compounds_NNS in_IN this_DT class_NN of_IN the_DT US_NNP extended-release_NN carbamezapine_NN a_DT portfolio_NN review_NN ,_, development_NN of_IN DIRAME_NNP in_IN that_DT it_PRP has_VBZ a_DT dual_JJ mechanism_NN of_IN action_NN :_: market_NN ._.
ceased_VBN and_CC the_DT project_NN was_VBD made_VBN available_JJ for_IN inhibiting_VBG acetylcholinesterase_NN and_CC ,_, uniquely_RB ,_, potential_JJ outsourcing_NN ._.
enhancing_VBG the_DT effect_NN of_IN acetylcholine_NN on_IN Epilepsy_NNP projects_NNS nicotinic_JJ receptors_NNS which_WDT are_VBP known_VBN to_TO Shire_NNP is_VBZ actively_RB pursuing_VBG epilepsy_NN projects_NNS be_VB important_JJ in_IN maintaining_VBG attention_NN and_CC for_IN in-licensing_JJ ._.
Initial_JJ results_NNS from_IN a_DT comparator_NN study_NN demonstrated_VBD a_DT superior_JJ treatment_NN During_IN the_DT year_NN Shire_NNP reviewed_VBD results_NNS from_IN profile_NN for_IN REMINYL_NNP on_IN measures_NNS of_IN attention_NN studies_NNS on_IN its_PRP$ epilepsy_NN projects_NNS SPD421_NNP ,_, and_CC cognition_NN compared_VBN to_TO the_DT market_NN leader_NN SPD452_NNP and_CC SPD453_NNP ._.
Recent_JJ data_NNS published_VBN in_IN The_DT that_IN results_NNS from_IN studies_NNS on_IN SPD421_CD did_VBD not_RB Lancet_NNP April_NNP 2002_CD suggest_VBP that_IN it_PRP is_VBZ effective_JJ meet_VBP the_DT Companys_NNPS criteria_NNS to_TO warrant_VB in_IN treating_VBG a_DT broad_JJ range_NN of_IN symptoms_NNS in_IN investment_NN in_IN phase_NN III_NNP studies_NNS ._.
The_DT licensor_NN ,_, AD_NN patients_NNS with_IN additional_JJ cerebrovascular_JJ D-Pharm_NNP Ltd._NNP has_VBZ indicated_VBN its_PRP$ intent_NN to_TO disease_NN CVD_NNP which_WDT represents_VBZ another_DT continue_VBP development_NN ._.
Shire_NNP also_RB decided_VBD important_JJ market_NN ._.
not_RB to_TO pursue_VB the_DT two_CD reformulation_NN projects_NNS SPD452_NNP and_CC SPD453_NNP ._.
Shire_NNP receives_VBZ royalties_NNS on_IN sales_NNS of_IN REMINYL_NNP from_IN Janssen_NNP Pharmaceutica_NNP NV_NNP worldwide_NN ,_, Bipolar_NNP disorder_NN except_IN in_IN the_DT UK_NNP and_CC Ireland_NNP where_WRB Shire_NNP Bipolar_NNP disorder_NN ,_, a_DT life-long_JJ illness_NN ,_, is_VBZ associated_VBN co-promotes_NNS REMINYL_NNP with_IN Janssen_NNP ._.
with_IN a_DT high_JJ incidence_NN of_IN comorbidity_NN ._.
There_EX are_VBP an_DT estimated_VBN 1.5_CD million_CD adults_NNS with_IN bipolar_JJ disorder_NN in_IN the_DT US_NNP alone_RB ._.
Initial_JJ results_NNS from_IN Alzheimers_NNP disease_NN affects_VBZ over_IN 12_CD million_CD people_NNS worldwide_JJ ._.
Initial_JJ results_NNS from_IN a_DT comparator_NN study_NN demonstrated_VBD a_DT superior_JJ treatment_NN profile_NN for_IN REMINYL_NNP on_IN measures_NNS of_IN attention_NN and_CC cognition_NN ._.
REMINYL_NNP is_VBZ indicated_VBN for_IN the_DT symptomatic_JJ treatment_NN of_IN mild_JJ to_TO moderately_RB severe_JJ dementia_NN of_IN the_DT Alzheimer_NNP type_NN ._.
10_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Epilepsy_NNP Epilepsy_NNP is_VBZ one_CD of_IN the_DT most_RBS common_JJ neurological_JJ disorders_NNS and_CC is_VBZ estimated_VBN to_TO affect_VB approximately_RB 2.5_CD million_CD people_NNS in_IN the_DT US_NNP ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 11_CD HIV_NNP HIV_NNP has_VBZ established_VBN itself_PRP as_IN one_CD of_IN the_DT most_RBS serious_JJ epidemics_NNS of_IN modern_JJ time_NN and_CC a_DT significant_JJ source_NN of_IN morbidity_NN ,_, mortality_NN and_CC cost_NN to_TO society_NN ._.
12_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Anti-infectives_NNS According_VBG to_TO UNAIDS_NNP ,_, in_IN December_NNP 2002_CD there_EX were_VBD 42_CD million_CD adults_NNS and_CC children_NNS living_VBG with_IN the_DT HIV_NNP infection_NN worldwide_NN ._.
Reducing_VBG Estimates_NNS suggest_VBP that_IN there_EX are_VBP 16,000_CD new_JJ infections_NNS each_DT day_NN ._.
Over_IN 2_CD billion_CD people_NNS alive_JJ today_NN have_VBP been_VBN infected_VBN with_IN hepatitis_NNP B_NNP virus_NN HBV_NNP at_IN some_DT time_NN in_IN their_PRP$ lives_NNS ._.
the_DT load_NN There_EX is_VBZ an_DT ever-increasing_JJ need_NN for_IN anti-infective_JJ treatments_NNS ,_, as_IN new_JJ diseases_NNS and_CC treatment_NN resistance_NN continues_VBZ to_TO emerge_VB ._.
With_IN a_DT strong_JJ track_NN record_NN in_IN this_DT field_NN ,_, Shire_NNP continues_VBZ to_TO develop_VB innovative_JJ products_NNS for_IN the_DT prevention_NN and_CC treatment_NN of_IN infectious_JJ diseases_NNS ._.
HIV_NNP that_IN contain_VBP lamivudine_JJ COMBIVIR_NNP and_CC cirrhosis_NNS and_CC hepatocellular_JJ carcinoma_NN HCC_NNP ._.
Since_IN the_DT early_JJ 1980s_CD when_WRB the_DT human_JJ TRIZIVIR_NNP ,_, with_IN the_DT exception_NN of_IN Canada_NNP In_IN addition_NN HBV_NNP carriers_NNS can_MD transmit_VB the_DT disease_NN immunodeficiency_NN virus_NN HIV_NNP was_VBD first_JJ identified_VBN where_WRB there_EX is_VBZ a_DT marketing_NN partnership_NN with_IN for_IN many_JJ years_NNS ._.
Although_IN vaccines_NNS to_TO prevent_VB it_PRP has_VBZ established_VBN itself_PRP as_IN one_CD of_IN the_DT most_RBS GSK_NNP ._.
COMBIVIR_NNP and_CC TRIZIVIR_NNP combine_VBP HBV_NNP are_VBP currently_RB available_JJ ,_, they_PRP have_VBP not_RB been_VBN serious_JJ epidemics_NNS of_IN modern_JJ time_NN and_CC a_DT lamivudine_NN with_IN one_CD or_CC two_CD other_JJ agents_NNS shown_VBN to_TO be_VB effective_JJ in_IN people_NNS who_WP are_VBP significant_JJ source_NN of_IN morbidity_NN ,_, mortality_NN and_CC respectively_RB ,_, in_IN a_DT single_JJ tablet_NN ._.
Compliance_NN already_RB infected_VBN with_IN HBV_NNP ._.
HIV_NNP is_VBZ a_DT retrovirus_NN recognized_VBN to_TO multi-drug_JJ regimes_NNS has_VBZ been_VBN greatly_RB as_IN the_DT causative_JJ agent_NN of_IN acquired_VBN immunoimproved_VBN by_IN these_DT advancements_NNS and_CC further_JJ Lamivudine_NNP is_VBZ indicated_VBN for_IN the_DT treatment_NN of_IN deficiency_NN syndrome_NN AIDS_NNP ._.
There_EX are_VBP many_JJ investigations_NNS of_IN new_JJ combinations_NNS and_CC chronic_JJ hepatitis_NN B_NNP associated_VBN with_IN evidence_NN of_IN strains_NNS of_IN HIV_NNP throughout_IN the_DT world_NN ,_, although_IN formulations_NNS involving_VBG lamivudine_NN are_VBP underway_NN ._.
hepatitis_NNP B_NNP viral_JJ replication_NN ,_, and_CC is_VBZ marketed_VBN as_IN they_PRP all_DT exhibit_VBP the_DT same_JJ disease_NN mechanism_NN ._.
ZEFFIX_NNP and_CC various_JJ other_JJ trademarks_NNS around_IN The_DT RNA_NNP of_IN the_DT virus_NN is_VBZ converted_VBN to_TO DNA_NNP Shire_NNP holds_VBZ the_DT worldwide_NN rights_NNS to_TO SPD754_CD ,_, the_DT world_NN ._.
In_IN an_DT agreement_NN similar_JJ to_TO that_DT for_IN using_VBG the_DT reverse_NN transcriptase_NN enzyme_NN and_CC a_DT nucleoside_NN analog_NN reverse_VB transcriptase_NN lamivudine_NN for_IN the_DT treatment_NN of_IN HIV_NNP ,_, Shire_NNP the_DT DNA_NNP is_VBZ integrated_VBN into_IN the_DT host_NN organisms_NNS inhibitor_VBP NRTI_NNP that_IN selectively_RB blocks_NNS HIV-1_JJ receives_VBZ royalties_NNS on_IN sales_NNS of_IN lamivudine_NN by_IN genome_NN where_WRB it_PRP is_VBZ replicated_VBN ._.
Granted_VBN fast_JJ track_NN review_NN status_NN GSK_NNP for_IN HBV_NNP ,_, except_IN in_IN Canada_NNP where_WRB Shire_NNP by_IN the_DT US_NNP FDA_NNP it_PRP has_VBZ demonstrated_VBN activity_NN has_VBZ a_DT commercialisation_NN partnership_NN with_IN GSK_NNP ._.
According_VBG to_TO UNAIDS_NNP ,_, in_IN December_NNP 2002_CD there_EX against_IN HIV_NNP strains_NNS resistant_JJ to_TO other_JJ were_VBD 42_CD million_CD adults_NNS and_CC children_NNS living_VBG with_IN nucleoside_NN analogs_NNS ,_, including_VBG AZT_NNP and_CC 3TC_NNP ._.
Estimates_NNS suggest_VBP Resistance_NNP to_TO SPD754_CD appears_VBZ to_TO develop_VB that_IN there_EX are_VBP 16,000_CD new_JJ infections_NNS each_DT day_NN ._.
Currently_RB under_IN development_NN ,_, phase_NN I_PRP trials_NNS have_VBP shown_VBN it_PRP to_TO be_VB well_RB tolerated_JJ and_CC Treatment_NNP guidelines_NNS now_RB specify_VBP that_IN people_NNS rapidly_RB absorbed_VBN ,_, and_CC the_DT first_JJ phase_NN II_NNP trial_NN receive_VBP combination_NN therapy_NN ._.
was_VBD initiated_VBN in_IN the_DT fourth_JJ quarter_NN of_IN 2002_CD ._.
Lamivudine_NNP forms_NNS a_DT key_JJ component_NN in_IN most_JJS of_IN SPD756_NNP ,_, a_DT guanosine_NN analog_NN reverse_VB the_DT combination_NN regimes_VBZ ._.
Discovered_VBN by_IN Shire_NNP transcriptase_NN inhibitor_NN ,_, is_VBZ Shires_NNP second_JJ BioChem_NNP ,_, lamivudine_NN was_VBD licensed_VBN to_TO Glaxo_NNP antiretroviral_JJ compound_NN ._.
An_DT internal_JJ review_NN now_RB GlaxoSmithKline_NNP plc_NN or_CC GSK_NNP in_IN 1990_CD ._.
of_IN preclinical_JJ data_NNS is_VBZ currently_RB underway_NN ._.
Available_JJ in_IN more_JJR than_IN 100_CD countries_NNS worldwide_VBP it_PRP is_VBZ sold_VBN in_IN most_JJS markets_NNS as_IN 3TC_NNP or_CC EPIVIR_NNP ._.
Hepatitis_NNP B_NNP A_NNP once-daily_RB formulation_NN of_IN 3TC_NNP is_VBZ also_RB Over_IN 2_CD billion_CD people_NNS alive_JJ today_NN have_VBP been_VBN available_JJ in_IN the_DT US_NNP and_CC Europe_NNP ._.
infected_VBN with_IN the_DT hepatitis_NNP B_NNP virus_NN HBV_NNP at_IN some_DT time_NN in_IN their_PRP$ lives_NNS ._.
The_DT consequence_NN Shire_NNP receives_VBZ royalties_NNS from_IN GSK_NNP on_IN the_DT of_IN persistent_JJ HBV_NNP infections_NNS includes_VBZ the_DT 3TC_NNP ,_, EPIVIR_NNP ,_, COMBIVIR_NNP ,_, TRIZIVIR_NNP ,_, AZT_NNP and_CC ZEFFIX_NNP worldwide_JJ sales_NNS of_IN lamivudine_NN and_CC products_NNS development_NN of_IN chronic_JJ hepatic_JJ insufficiency_NN ,_, are_VBP registered_VBN trade_NN marks_NNS of_IN GSK_NNP ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 13_CD Operating_NN review_NN :_: Oncology_NNP and_CC hematology_JJ disorders_NNS In_IN 2002_CD the_DT estimated_VBN number_NN of_IN new_JJ cases_NNS of_IN AML_NNP in_IN the_DT US_NNP alone_RB was_VBD 10,600_CD with_IN mortality_NN of_IN approximately_RB 7,400_CD ._.
Managing_VBG Cancer_NN of_IN the_DT pancreas_NNS ranks_VBZ as_IN the_DT fifth_JJ leading_VBG cause_NN of_IN cancer_NN in_IN the_DT US_NNP with_IN 30,300_CD new_JJ cases_NNS reported_VBN in_IN 2002_CD ._.
In_IN December_NNP 2002_CD at_IN the_DT American_JJ challenges_NNS Society_NNP of_IN Hematology_NNP meeting_NN ,_, positive_JJ results_NNS from_IN a_DT long-term_JJ efficacy_NN and_CC safety_NN trial_NN were_VBD reported_VBN ._.
These_DT data_NNS will_MD support_VB the_DT continued_VBN strong_JJ prescription_NN growth_NN An_DT estimated_VBN one_CD in_IN three_CD people_NNS will_MD be_VB diagnosed_VBN with_IN of_IN AGRYLIN_NNP in_IN the_DT US_NNP ,_, which_WDT was_VBD 21.8_CD %_NN in_IN the_DT US_NNP during_IN 2002_CD ._.
cancer_NN during_IN their_PRP$ lifetime_NN and_CC one_CD in_IN four_CD people_NNS will_MD die_VB from_IN cancer_NN ._.
The_DT risk_NN of_IN getting_VBG the_DT disease_NN rises_VBZ significantly_RB with_IN age_NN and_CC as_IN a_DT result_NN of_IN improved_JJ life_NN expectancy_NN the_DT population_NN at_IN risk_NN of_IN cancer_NN is_VBZ increasing_VBG ._.
Shire_NNP is_VBZ committed_VBN to_TO the_DT development_NN of_IN products_NNS for_IN oncology_NN and_CC hematological_JJ disorders_NNS that_WDT may_MD provide_VB patients_NNS with_IN more_JJR effective_JJ treatment_NN options_NNS than_IN those_DT currently_RB available_JJ ._.
Haematology_NNP disorders_NNS number_NN of_IN new_JJ cases_NNS of_IN AML_NNP in_IN the_DT US_NNP gemcitabine_NN for_IN the_DT treatment_NN of_IN pancreatic_JJ AGRYLIN_NNP ,_, which_WDT is_VBZ marketed_VBN by_IN Shire_NNP in_IN the_DT alone_JJ was_VBD 10,600_CD with_IN a_DT mortality_NN rate_NN of_IN cancer_NN is_VBZ planned_VBN for_IN the_DT second_JJ half_NN of_IN 2003_CD ._.
US_NNP and_CC Canada_NNP and_CC filed_VBD as_IN XAGRID_NNP in_IN Europe_NNP ,_, approximately_RB 7,400_CD ._.
is_VBZ used_VBN as_IN an_DT effective_JJ treatment_NN for_IN patients_NNS In_IN the_DT US_NNP ,_, Shire_NNP markets_NNS FARESTON_NNP suffering_VBG from_IN this_DT chronic_JJ disorder_NN ._.
AGRYLIN_NNP Shires_NNPS TROXATYL_NNP ,_, a_DT dioxolane_NN nucleoside_NN toremifene_NN ,_, an_DT anti-oestrogen_NN for_IN metastatic_JJ XAGRID_NNP reduces_VBZ elevated_JJ platelet_NN count_NN ._.
analog_NN ,_, is_VBZ scheduled_VBN to_TO enter_VB phase_NN III_NNP trials_NNS breast_NN cancer_NN ._.
FARESTON_NNP offers_VBZ a_DT treatment_NN Platelet_NNP reduction_NN is_VBZ associated_VBN with_IN a_DT reduced_VBN in_IN 2003_CD in_IN combination_NN with_IN cytarabine_NN for_IN the_DT alternative_NN in_IN this_DT rapidly_RB changing_VBG environment_NN ._.
risk_NN of_IN blood_NN clots_NNS and_CC other_JJ bleeding_VBG events_NNS ._.
TROXATYL_NNP is_VBZ a_DT complete_JJ Other_JJ treatments_NNS used_VBN in_IN the_DT management_NN of_IN DNA_NNP chain_NN terminator_NN and_CC DNA_NN polymerase_NN Actinic_NNP keratosis_NN essential_JJ thrombocythemia_NN ET_NNP can_MD cause_VB inhibitor_NN ._.
This_DT mechanism_NN of_IN action_NN interferes_VBZ Actinic_NNP keratosis_NN AK_NNP is_VBZ a_DT skin_NN condition_NN serious_JJ side-effects_NNS by_IN decreasing_VBG white_JJ or_CC red_JJ with_IN the_DT ability_NN of_IN cancer_NN cells_NNS to_TO replicate_VB ._.
associated_VBN with_IN prolonged_JJ exposure_NN to_TO the_DT sun_NN blood_NN cell_NN counts_NNS ._.
Research_NNP indicates_VBZ that_IN a_DT In_IN addition_NN ,_, data_NN suggests_VBZ that_IN unlike_IN other_JJ and_CC it_PRP is_VBZ estimated_VBN to_TO affect_VB up_RP to_TO 10_CD million_CD key_JJ benefit_NN of_IN AGRYLIN_NNP XAGRID_NNP is_VBZ its_PRP$ platelet_NN cytidine_NN analogs_NNS used_VBN in_IN oncology_NN ,_, TROXATYL_NNP people_NNS across_IN Europe_NNP ._.
If_IN left_VBN untreated_JJ it_PRP can_MD selectivity_NN ,_, targeting_VBG only_RB those_DT cells_NNS that_WDT is_VBZ not_RB degraded_JJ by_IN cytidine_JJ deaminase_NN ,_, lead_NN to_TO squamous_JJ cell_NN carcinoma_NN ,_, a_DT form_NN of_IN develop_VB into_IN platelets_NNS ._.
an_DT enzyme_NN used_VBN by_IN cancer_NN cells_NNS to_TO resist_VB skin_NN cancer_NN ,_, in_IN up_RB to_TO 16_CD %_NN of_IN sufferers_NNS ._.
Skin_NN a_DT number_NN of_IN other_JJ cancer_NN treatments_NNS ._.
cancers_NNS are_VBP the_DT most_RBS common_JJ cancer_NN in_IN In_IN March_NNP 2002_CD ,_, Shire_NNP submitted_VBD its_PRP$ marketing_NN white_JJ populations_NNS ._.
In_IN 2002_CD Shire_NNP in-licensed_JJ authorisation_NN application_NN for_IN XAGRID_NNP through_IN Solid_JJ tumors_NNS SOLARAZE_NNP ,_, a_DT novel_NN gel_NN preparation_NN for_IN the_DT treatthe_NN European_JJ Medicines_NNP Evaluation_NNP Agency_NNP ._.
Shire_NNP is_VBZ also_RB developing_VBG TROXATYL_NNP for_IN the_DT ment_NN of_IN AK_NNP ._.
SOLARAZE_NNP gel_NN offers_VBZ an_DT alternative_JJ Granted_NNP orphan_JJ drug_NN OD_NNP designation_NN by_IN treatment_NN of_IN pancreatic_JJ cancer_NN ._.
Symptoms_NNS to_TO existing_VBG treatment_NN options_NNS ,_, which_WDT may_MD burn_VB the_DT European_JJ Commission_NNP and_CC the_DT Japanese_NNPS of_IN pancreatic_JJ cancer_NN are_VBP not_RB usually_RB obvious_JJ or_CC peel_JJ during_IN the_DT treatment_NN of_IN AK_NNP lesions_NNS ._.
Authorities_NNP ,_, it_PRP will_MD have_VB up_RP to_TO ten_VB years_NNS during_IN the_DT initial_JJ stages_NNS of_IN the_DT disease_NN and_CC this_DT market_NN exclusivity_NN upon_IN approval_NN ._.
AGRYLIN_NNP makes_VBZ early_JJ diagnosis_NN difficult_JJ ._.
When_WRB obvious_JJ ,_, Shire_NNP initially_RB acquired_VBD the_DT rights_NNS for_IN SOLARAZE_NNP has_VBZ OD_VBN exclusivity_NN status_NN in_IN the_DT US_NNP that_WDT will_MD symptoms_NNS can_MD include_VB abdominal_JJ pain_NN ,_, for_IN Europe_NNP from_IN SkyePharma_NNP plc_NN and_CC the_DT expire_VBP in_IN 2004_CD ._.
unexpected_JJ weight_NN loss_NN ,_, digestive_JJ problems_NNS administrators_NNS of_IN Bioglan_NNP Pharma_NNP plc_NN in_IN May_NNP and_CC jaundice_NN ._.
Cancer_NN of_IN the_DT pancreas_NNS ranks_VBZ 2002_CD and_CC relaunched_VBD the_DT product_NN within_IN two_CD Development_NNP work_NN on_IN SPD427_NNP ,_, a_DT reformulation_NN as_IN the_DT fifth_JJ leading_VBG cause_NN of_IN cancer_NN in_IN the_DT US_NNP months_NNS in_IN the_DT UK_NNP and_CC Germany_NNP ._.
Further_JJ work_NN of_IN an_DT existing_VBG hematology_NN product_NN ,_, was_VBD with_IN 30,300_CD estimated_VBD new_JJ cases_NNS reported_VBD has_VBZ seen_VBN SOLARAZE_NNP launched_VBN by_IN Shire_NNP in_IN terminated_VBN during_IN the_DT year_NN as_IN it_PRP failed_VBD to_TO meet_VB in_IN 2002_CD ._.
Prognosis_NN is_VBZ poor_JJ and_CC typical_JJ patient_NN Italy_NNP and_CC Sweden_NNP and_CC additional_JJ regulatory_JJ the_DT required_VBN target_NN profile_NN ._.
survival_NN post-diagnosis_NN is_VBZ short_JJ ,_, with_IN US_NNP submissions_NNS were_VBD completed_VBN for_IN approval_NN of_IN mortality_NN figures_NNS reaching_VBG 29,700_CD in_IN 2002_CD ._.
SOLARAZE_NNP for_IN other_JJ countries_NNS in_IN the_DT European_JJ Haematology_NNP malignancies_NNPS Union_NNP in_IN December_NNP 2002_CD ._.
Additionally_RB ,_, Acute_JJ myeloid_JJ leukemia_NN AML_NNP is_VBZ a_DT form_NN of_IN TROXATYL_NNP has_VBZ shown_VBN equivalent_JJ activity_NN to_TO Shire_NNP acquired_VBD the_DT rights_NNS to_TO SOLARAZE_NNP for_IN cancer_NN that_IN affects_VBZ the_DT proliferation_NN of_IN white_JJ gemcitabine_NN ,_, another_DT widely_RB used_VBN chemoAustralia_NNP ,_, New_NNP Zealand_NNP and_CC South_NNP Africa_NNP as_IN blood_NN cells_NNS ._.
Uncontrolled_JJ production_NN of_IN white_JJ therapeutic_JJ agent_NN ,_, when_WRB used_VBN as_IN monotherapy_JJ well_RB as_IN access_NN to_TO future_JJ data_NNS from_IN studies_NNS blood_NN cells_NNS can_MD lead_VB to_TO anemia_NN ,_, infection_NN for_IN pancreatic_JJ cancer_NN ._.
A_DT phase_NN III_NNP clinical_JJ trial_NN being_VBG conducted_VBN in_IN Australia_NNP where_WRB up_RB to_TO 60_CD %_NN and_CC severe_JJ bleeding_NN ._.
In_IN 2002_CD the_DT estimated_VBN investigating_VBG TROXATYL_NNP in_IN combination_NN with_IN of_IN the_DT population_NN may_MD have_VB AK_NNP ._.
14_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Essential_NNP thrombocythemia_NN Essential_NNP thrombocythemia_NN is_VBZ a_DT chronic_JJ disorder_NN of_IN the_DT bone_NN marrow_NN associated_VBN with_IN increased_JJ production_NN of_IN blood_NN platelets_NNS ._.
Excessive_JJ platelet_NN production_NN can_MD result_VB in_IN abnormal_JJ blood_NN clot_NN formation_NN and_CC bleeding_NN ,_, thereby_RB increasing_VBG the_DT risk_NN of_IN stroke_NN ,_, heart_NN attack_NN and_CC gastrointestinal_JJ bleeding_NN ._.
AGRYLIN_NNP is_VBZ used_VBN as_IN an_DT effective_JJ treatment_NN for_IN patients_NNS suffering_VBG from_IN this_DT chronic_JJ disorder_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 15_CD Additional_JJ Shire_NNP portfolio_NN In_IN end-stage_JJ renal_JJ disease_NN ESRD_NNP poor_JJ control_NN of_IN phosphate_NN levels_NNS can_MD result_VB in_IN hyperphosphatemia_NN which_WDT can_MD lead_VB to_TO bone_NN disorders_NNS and_CC is_VBZ associated_VBN with_IN the_DT development_NN of_IN cardiovascular_JJ disease_NN ._.
FOSRENOL_NNP has_VBZ been_VBN shown_VBN to_TO effectively_RB reduce_VB phosphate_NN levels_NNS and_CC control_NN hyperphosphatemia_NN ._.
16_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Additional_JJ Shire_NNP portfolio_NN It_PRP is_VBZ estimated_VBN that_IN nearly_RB 1_CD million_CD patients_NNS worldwide_JJ have_VBP end-stage_JJ renal_JJ disease_NN ._.
Looking_VBG to_TO Recent_JJ research_NN also_RB suggests_VBZ that_IN hyperphosphatemia_NN is_VBZ associated_VBN with_IN the_DT development_NN of_IN cardiovascular_JJ disease_NN which_WDT accounts_VBZ for_IN nearly_RB 50_CD %_NN of_IN all_DT deaths_NNS in_IN dialysis_NN patients_NNS ._.
the_DT future_JJ FOSRENOL_NNP lanthanum_NN carbonate_NN ,_, previously_RB known_VBN as_IN LAMBDA_NNP and_CC FOZNOL_NNP ,_, a_DT phosphate_NN binder_NN ,_, will_MD be_VB the_DT first_JJ global_JJ product_NN launched_VBN by_IN Shire_NNP ._.
Hyperphosphatemia_NNP two_CD phase_NN III_NNP studies_NNS that_WDT demonstrated_VBD unconsciousness_NN ._.
Shire_JJ markets_NNS midodrine_VB It_PRP is_VBZ estimated_VBN that_IN there_EX are_VBP nearly_RB one_CD million_CD FOSRENOL_NNP to_TO be_VB an_DT effective_JJ binder_NN of_IN dietary_JJ hydrochloride_NN in_IN the_DT US_NNP as_IN PROAMATINE_NNP patients_NNS worldwide_VBP with_IN end-stage_JJ renal_JJ phosphate_NN ,_, reducing_VBG high_JJ phosphate_NN levels_NNS and_CC in_IN Canada_NNP as_IN AMATINE_NNP for_IN the_DT treatment_NN disease_NN ._.
In_IN this_DT condition_NN the_DT kidneys_NNS are_VBP unable_JJ and_CC ,_, in_IN long-term_JJ use_NN ,_, controlling_VBG the_DT of_IN OH_NNP ._.
The_DT product_NN demonstrated_VBD good_JJ to_TO regulate_VB the_DT balance_NN of_IN phosphate_NN in_IN the_DT hyperphosphatemia_NN of_IN chronic_JJ renal_JJ failure_NN ._.
underlying_VBG prescription_NN growth_NN and_CC increased_VBD body_NN ._.
If_IN untreated_JJ the_DT resultant_JJ retention_NN FOSRENOL_NNP also_RB has_VBZ the_DT notable_JJ advantage_NN market_NN share_NN during_IN 2002_CD ._.
and_CC elevated_JJ blood_NN phosphate_NN levels_NNS that_WDT hypercalcemia_NN is_VBZ much_RB less_JJR common_JJ hyperphosphatemia_NN can_MD combine_VB with_IN other_JJ than_IN with_IN calcium-based_JJ treatments_NNS ._.
PROAMATINE_NNP currently_RB has_VBZ orphan_JJ drug_NN status_NN biochemical_JJ disturbances_NNS and_CC result_NN in_IN bone_NN in_IN the_DT US_NNP :_: the_DT term_NN of_IN this_DT market_NN exclusivity_NN disorders_NNS described_VBD as_IN renal_JJ osteodystrophy_NN ._.
Following_VBG comprehensive_JJ regulatory_JJ will_MD expire_VB in_IN September_NNP 2003_CD ._.
Recent_JJ research_NN also_RB suggests_VBZ that_IN submissions_NNS for_IN FOSRENOL_NNP containing_VBG data_NNS hyperphosphatemia_NN is_VBZ associated_VBN with_IN the_DT on_IN over_IN 2,400_CD patients_NNS ,_, Shire_NNP has_VBZ received_VBN an_DT Surgical_NNP adhesions_NNS development_NN of_IN cardiovascular_JJ disease_NN which_WDT Approvable_JJ letter_NN from_IN the_DT US_NNP Food_NNP and_CC Drug_NNP Adhesions_NNP occur_VBP in_IN up_RB to_TO 95_CD %_NN of_IN patients_NNS accounts_NNS for_IN nearly_RB 50_CD %_NN of_IN all_DT deaths_NNS in_IN dialysis_NN Administration_NNP FDA_NNP and_CC submissions_NNS remain_VBP undergoing_VBG abdominal_JJ surgery_NN ._.
under_IN review_NN in_IN Europe_NNP and_CC Canada_NNP ._.
internal_JJ scars_NNS formed_VBN post_NN trauma_NN from_IN complex_JJ processes_NNS involving_VBG tissues_NNS that_WDT have_VBP FOSRENOL_NNP is_VBZ Shires_NNP phosphate_NN binder_NN for_IN use_NN Other_JJ specialist_NN products_NNS been_VBN damaged_VBN during_IN surgery_NN ._.
They_PRP are_VBP a_DT in_IN end-stage_JJ renal_JJ failure_NN patients_NNS receiving_VBG major_JJ cause_NN of_IN pain_NN ,_, infertility_NN ,_, small_JJ bowel_NN dialysis_NN ._.
Binding_VBG dietary_JJ phosphate_NN in_IN the_DT Osteoporosis_NNP obstruction_NN ,_, and_CC are_VBP a_DT potentially_RB fatal_JJ stomach_NN to_TO prevent_VB it_PRP passing_VBG through_IN the_DT Osteoporosis_NNP is_VBZ characterised_VBN by_IN a_DT progressive_JJ complication_NN of_IN abdominal_JJ surgery_NN ._.
Up_IN to_TO gut_NN lining_NN ,_, FOSRENOL_NNP is_VBZ formulated_VBN as_IN a_DT loss_NN of_IN bone_NN mass_NN that_WDT renders_VBZ bone_NN fragile_JJ 10_CD %_NN of_IN patients_NNS are_VBP re-admitted_JJ to_TO hospital_NN convenient_JJ chewable_JJ tablet_NN to_TO aid_NN in_IN patient_NN and_CC liable_JJ to_TO fracture_NN ._.
More_JJR than_IN 3_CD million_CD within_IN 12_CD months_NNS of_IN colon_NN surgery_NN with_IN an_DT compliance_NN and_CC ,_, importantly_RB in_IN this_DT population_NN ,_, people_NNS in_IN the_DT UK_NNP are_VBP estimated_VBN to_TO suffer_VB with_IN adhesion-related_JJ problem_NN making_VBG adhesions_NNS it_PRP requires_VBZ reduced_JJ levels_NNS of_IN fluid_NN to_TO ingest_VB ._.
Osteoporosis_NNP affects_VBZ both_DT sexes_NNS a_DT significant_JJ cost_NN burden_NN to_TO health_NN services_NNS ._.
but_CC is_VBZ more_RBR rapid_JJ and_CC profound_JJ in_IN women_NNS ,_, In_IN 2002_CD Shire_NNP made_VBD a_DT series_NN of_IN detailed_VBN largely_RB as_IN a_DT result_NN of_IN the_DT decline_NN in_IN estrogen_NN In_IN 2002_CD Shire_NNP completed_VBD the_DT European_JJ launch_NN research_NN presentations_NNS that_WDT highlighted_VBD the_DT production_NN following_VBG the_DT menopause_NN ._.
Our_PRP$ of_IN ADEPT_NNP ,_, a_DT novel_NN solution_NN for_IN the_DT prevention_NN efficacy_NN and_CC safety_NN of_IN FOSRENOL_NNP ._.
The_DT principal_JJ products_NNS for_IN the_DT adjunctive_JJ treatment_NN of_IN adhesions_NNS following_VBG abdominal_JJ surgery_NN ._.
outcome_NN of_IN a_DT phase_NN III_NNP study_NN was_VBD that_IN ,_, following_VBG of_IN osteoporosis_NN are_VBP the_DT CALCICHEW_NNP range_NN of_IN ADEPT_NNP is_VBZ now_RB marketed_VBN in_IN 19_CD countries_NNS across_IN 12_CD months_NNS of_IN treatment_NN with_IN FOSRENOL_NNP ,_, no_DT calcium_NN and_CC calcium_NN vitamin_NN D_NNP supplements_NNS ._.
adverse_JJ effects_NNS on_IN bone_NN were_VBD observed_VBN ._.
Symptomatic_JJ orthostatic_JJ hypotension_NN During_IN the_DT American_NNP Society_NNP of_IN Nephrologys_NNP Symptomatic_NNP orthostatic_JJ hypotension_NN OH_NNP ,_, 35th_JJ Annual_JJ Meeting_VBG and_CC Scientific_NNP Exposition_NNP ,_, which_WDT is_VBZ due_JJ to_TO a_DT marked_JJ fall_NN in_IN blood_NN pressure_NN November_NNP 2002_CD ,_, Shire_NNP reported_VBD the_DT results_NNS of_IN on_IN standing_NN ,_, causes_VBZ dizziness_NN ,_, weakness_NN and_CC Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 17_CD Operating_NN review_NN :_: Gastrointestinal_NNP Ulcerative_NNP colitis_VBZ UC_NNP is_VBZ estimated_VBN to_TO affect_VB upwards_NNS of_IN 1.12_CD million_CD people_NNS worldwide_JJ A_DT new_JJ Shire_NNP markets_NNS COLAZIDE_NNP and_CC PENTASA_NNP for_IN UC_NNP ._.
emphasis_NN An_DT increasingly_RB important_JJ strategic_JJ focus_NN for_IN Shire_NNP is_VBZ the_DT gastrointestinal_JJ GI_NNP therapeutic_JJ area_NN ._.
With_IN the_DT addition_NN of_IN two_CD new_JJ development_NN projects_NNS in_IN 2002_CD ,_, the_DT GI_NNP portfolio_NN continues_VBZ to_TO evolve_VB ._.
Ulcerative_JJ colitis_NNS New_JJ projects_NNS Ulcerative_JJ colitis_NN UC_NNP ,_, a_DT serious_JJ chronic_NN Shire_NNP introduced_VBD two_CD new_JJ products_NNS for_IN UC_NNP and_CC inflammatory_JJ disease_NN of_IN the_DT colon_NN and_CC rectum_NN ,_, potentially_RB other_JJ forms_NNS of_IN inflammatory_JJ bowel_NN is_VBZ estimated_VBN to_TO affect_VB upwards_NNS of_IN 1.12_CD million_CD disease_NN IBD_NNP to_TO its_PRP$ development_NN pipeline_NN in_IN people_NNS worldwide_JJ ._.
The_DT key_JJ worldwide_NN rights_NNS to_TO project_VB intermittent_JJ attacks_NNS separated_VBN by_IN periods_NNS of_IN SPD476_CD were_VBD acquired_VBN from_IN Giuliani_NNP S._NNP p._NNP A._NN remission_NN ._.
Clinical_JJ features_NNS include_VBP diarrhea_NN ,_, Based_VBN on_IN a_DT novel_NN proprietary_NN system_NN for_IN bleeding_VBG and_CC abdominal_JJ pain_NN and_CC within_IN ten_NN targeting_VBG the_DT release_NN of_IN high_JJ concentrations_NNS years_NNS of_IN diagnosis_NN approximately_RB 25_CD %_NN of_IN of_IN mesalamine_NN to_TO the_DT bowel_NN ,_, the_DT formulation_NN sufferers_NNS are_VBP required_VBN to_TO undergo_VB surgery_NN ._.
enables_VBZ even_RB delivery_NN of_IN the_DT highest_JJS available_JJ market_NN dose_NN of_IN mesalamine_NN to_TO the_DT colon_NN ._.
This_DT Shire_JJ markets_NNS COLAZIDE_NNP balsalazide_NN for_IN includes_VBZ the_DT descending_VBG colon_NN ,_, which_WDT can_MD be_VB UC_NNP in_IN the_DT UK_NNP and_CC other_JJ European_JJ markets_NNS ._.
With_IN this_DT profile_NN SPD476_NNP COLAZIDE_NNP is_VBZ a_DT pro-drug_NN of_IN 5-ASA_JJ mesalamine_NN may_MD offer_VB a_DT reduced_VBN tablet_NN burden_NN for_IN UC_NNP that_WDT is_VBZ joined_VBN to_TO an_DT inert_JJ carrier_NN molecule_NN ._.
patients_NNS ,_, promote_VB greater_JJR patient_NN compliance_NN COLAZIDE_NNP is_VBZ swallowed_VBN in_IN capsule_NN form_NN and_CC and_CC a_DT better_JJR quality_NN of_IN life_NN ._.
SPD476_CD is_VBZ currently_RB activated_VBN in_IN the_DT colon_NN at_IN the_DT site_NN of_IN UC_NNP by_IN the_DT in_IN phase_NN II_NNP trials_NNS and_CC phase_NN III_NNP trials_NNS are_VBP planned_VBN action_NN of_IN gut_NN bacteria_NNS whose_WP$ enzymes_NNS cleave_VBP for_IN the_DT second_JJ half_NN of_IN 2003_CD ._.
the_DT inert_JJ molecule_NN and_CC release_NN 5-ASA_NN ._.
In_IN an_DT agreement_NN that_WDT gives_VBZ Shire_NNP rights_NNS to_TO PENTASA_NNP is_VBZ marketed_VBN for_IN UC_NNP in_IN the_DT US_NNP ._.
develop_VB ,_, manufacture_NN and_CC market_NN in_IN key_JJ A_DT sustained-release_NN formulation_NN ,_, it_PRP enables_VBZ territories_NNS worldwide_JJ ,_, a_DT second_JJ product_NN drug_NN delivery_NN not_RB only_RB in_IN the_DT colon_NN but_CC also_RB SPD480_CD for_IN the_DT treatment_NN of_IN UC_NNP was_VBD inthroughout_VBG the_DT small_JJ and_CC large_JJ intestine_JJ ._.
licensed_VBN from_IN Giuliani_NNP S._NNP p._NNP A._NNP A_NNP single-dose_JJ ,_, Development_NNP of_IN a_DT double_JJ strength_NN 500mg_CD 2g_CD or_CC 4g_CD mesalamine_JJ rectally_RB administered_VBN version_NN of_IN the_DT product_NN ,_, which_WDT should_MD support_VB foam_NN ,_, it_PRP is_VBZ considered_VBN more_JJR acceptable_JJ and_CC greater_JJR convenience_NN and_CC patient_NN compliance_NN ,_, easier_JJR to_TO use_VB than_IN conventional_JJ liquid_JJ enema_NN is_VBZ currently_RB underway_NN ._.
treatments_NNS ,_, thereby_RB offering_VBG better_JJR compliance_NN ._.
SPD480_CD is_VBZ currently_RB in_IN phase_NN II_NNP of_IN development_NN ._.
18_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Ulcerative_NNP colitis_VBZ Shires_NNP portfolio_NN contains_VBZ a_DT number_NN of_IN products_NNS that_WDT can_MD offer_VB different_JJ treatment_NN options_NNS in_IN the_DT management_NN of_IN ulcerative_JJ colitis_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 19_CD Shire_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Utilising_VBG its_PRP$ proven_VBN proprietary_JJ technologies_NNS ,_, SLI_NNP works_VBZ with_IN Shire_NNP and_CC the_DT pharmaceutical_JJ industry_NN to_TO solve_VB drug_NN delivery_NN problems_NNS ._.
20_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Advanced_NNP drug_NN delivery_NN Building_NN business_NN on_IN proven_JJ technologies_NNS Innovative_JJ drug_NN delivery_NN provides_VBZ a_DT strategic_JJ advantage_NN for_IN product_NN enhancement_NN ._.
Oral_JJ drug_NN delivery_NN applied_VBD alone_RB or_CC in_IN combination_NN with_IN SLIs_NNP Shire_NNP Laboratories_NNPS ,_, Inc._NNP ._.
SLI_NNP ,_, a_DT subsidiary_NN of_IN bioavailability_NN enhancement_NN systems_NNS ._.
MICROTROL_NNP is_VBZ a_DT proven_JJ and_CC the_DT Shire_NNP Group_NNP ,_, is_VBZ a_DT specialist_NN provider_NN of_IN commercialised_JJ family_NN of_IN drug_NN delivery_NN innovative_JJ oral_JJ drug_NN delivery_NN technologies_NNS ._.
SLIs_NNS bioavailability_NN enhancement_NN technologies_NNS technologies_NNS based_VBN on_IN the_DT use_NN of_IN beadlets_NNS Adaptations_NNS to_TO the_DT delivery_NN profile_NN of_IN a_DT product_NN include_VBP PROSCREEN_NNP ,_, OPTISCREEN_NNP ,_, that_WDT can_MD be_VB customised_VBN based_VBN on_IN API_NNP involve_VBP modification_NN of_IN its_PRP$ release_NN characteristics_NNS RAPITROL_NNP and_CC EMUTROL_NNP ._.
A_DT bioavailability_NN characteristics_NNS ,_, targeted_VBN release_NN profile_NN either_RB by_IN increasing_VBG its_PRP$ absorption_NN bioavailability_NN enhancement_NN program_NN typically_RB starts_VBZ with_IN and_CC desired_VBN dosage_NN form_NN ._.
enhancement_NN or_CC controlling_VBG the_DT rate_NN of_IN its_PRP$ the_DT application_NN of_IN PROSCREEN_NNP in_IN conjunction_NN absorption_NN into_IN the_DT bloodstream_NN controlled_VBN with_IN in-silico_JJ modelling_NN to_TO characterise_VB the_DT drug_NN SOLUTROL_NNP is_VBZ a_DT patented_JJ matrix_NN tablet_NN release_NN ._.
By_IN such_PDT an_DT approach_NN the_DT effectiveness_NN and_CC identify_VB its_PRP$ barriers_NNS to_TO oral_JJ absorption_NN ._.
This_DT formulation_NN that_WDT is_VBZ designed_VBN to_TO provide_VB and_CC convenience_NN of_IN the_DT original_JJ product_NN can_MD be_VB work_NN will_MD then_RB be_VB followed_VBN by_IN OPTISCREEN_NNP ,_, an_DT extended-release_JJ drug_NN delivery_NN profile_NN ._.
which_WDT aims_VBZ at_IN designing_VBG and_CC screening_VBG several_JJ It_PRP is_VBZ well_RB suited_VBN for_IN highly_RB soluble_JJ formulations_NNS to_TO address_VB those_DT absorption_NN compounds_VBZ ._.
Utilising_VBG its_PRP$ proven_VBN proprietary_JJ technologies_NNS ,_, barriers_NNS and_CC optimise_JJ bioavailability_NN ._.
The_DT final_JJ SLI_NNP works_VBZ with_IN Shire_NNP and_CC the_DT pharmaceutical_JJ selected_VBN formulation_NN could_MD incorporate_VB one_CD or_CC ENSOTROL_NNP is_VBZ a_DT patented_JJ osmotic_JJ drug_NN industry_NN to_TO solve_VB drug_NN delivery_NN problems_NNS ._.
SLI_NNP a_DT combination_NN of_IN solubility_NN and_CC permeability_NN delivery_NN system_NN designed_VBN to_TO solubilise_NN has_VBZ successfully_RB collaborated_VBN with_IN Shire_NNP in_IN the_DT enhancers_NNS as_RB well_RB as_IN delivery_NN systems_NNS ._.
drugs_NNS and_CC provide_VB extended_VBN drug_NN release_NN development_NN of_IN CARBATROL_NNP ,_, the_DT twice-daily_JJ properties_NNS ._.
formulation_NN of_IN carbamazepine_NN ,_, and_CC ADDERALL_NNP SLI_NNP screens_NNS new_JJ formulations_NNS using_VBG a_DT range_NN XR_NNP ,_, both_DT of_IN which_WDT are_VBP based_VBN on_IN the_DT SLI_NNP of_IN cell_NN lines_NNS that_WDT can_MD predict_VB absorption_NN of_IN PROSCREEN_NNP is_VBZ a_DT family_NN of_IN technologies_NNS MICROTROL_NNP technology_NN ._.
drugs_NNS in_IN the_DT gastrointestinal_JJ tract_NN ._.
In_IN 2002_CD ,_, that_DT identify_VB barriers_NNS and_CC mechanisms_NNS SLI_NNP developed_VBD a_DT new_JJ buccal_JJ cell_NN line_NN model_NN to_TO oral_JJ delivery_NN and_CC select_VB best_JJS drug_NN SLIs_NNS oral_JJ controlled-release_NN technologies_NNS that_WDT expresses_VBZ similar_JJ characteristics_NNS to_TO those_DT candidates_NNS for_IN development_NN ._.
It_PRP consists_VBZ include_VBP MICROTROL_NNP ,_, which_WDT consists_VBZ of_IN of_IN real_JJ human_JJ buccal_JJ tissue_NN ._.
This_DT novel_NN cell_NN of_IN in-silico_NN ,_, solubility_NN and_CC permeability_NN beadlets_NNS that_WDT can_MD be_VB coated_VBN to_TO provide_VB line_NN allows_VBZ SLI_NNP to_TO study_VB the_DT barriers_NNS to_TO delivering_VBG models_NNS ,_, physico-chemical_JJ property_NN customised_VBN release_NN profiles_NNS such_JJ as_IN extended_JJ drugs_NNS in_IN the_DT buccal_JJ cavity_NN ,_, to_TO screen_VB formulations_NNS prediction_NN and_CC PK_NN profiling_NN and_CC prediction_NN ._.
delivery_NN MICROTROL_NNP XR_NNP ,_, pulsed_VBD delivery_NN to_TO address_VB such_JJ barriers_NNS ,_, and_CC to_TO select_VB MICROTROL_NNP PR_NNP or_CC delayed_VBN delivery_NN those_DT formulations_NNS that_WDT are_VBP most_RBS effective_JJ OPTISCREEN_NNP is_VBZ a_DT family_NN of_IN technologies_NNS MICROTROL_NNP DR_NNP :_: SOLUTROL_NNP ,_, a_DT in_IN enhancing_VBG absorption_NN ._.
SLI_NNP is_VBZ establishing_VBG that_IN enhance_VB bioavailability_NN of_IN drugs_NNS proprietary_JJ matrix_NN tablet_NN which_WDT can_MD provide_VB the_DT capability_NN of_IN this_DT cell_NN line_NN in_IN predicting_VBG the_DT through_IN the_DT use_NN of_IN solubility_NN and_CC extended_VBD release_NN of_IN highly_RB soluble_JJ and_CC pH_JJ impact_NN of_IN various_JJ enhancers_NNS and_CC formulation_NN permeability_NN enhancers_NNS ,_, efflux_NN and_CC dependent_JJ compounds_NNS :_: and_CC ENSOTROL_NNP systems_NNS on_IN bioavailability_NN ._.
Also_RB in_IN 2002_CD ,_, SLI_NNP enzyme_NN inhibitors_NNS ,_, and_CC a_DT wide_JJ range_NN osmotic_JJ tablet_NN technology_NN which_WDT can_MD facilitate_VB identified_VBN four_CD new_JJ bioavailability_NN enhancers_NNS of_IN formulation_NN systems_NNS ._.
absorption_NN of_IN poorly_RB soluble_JJ and_CC soluble_JJ that_WDT can_MD be_VB used_VBN to_TO enhance_VB the_DT absorption_NN compounds_VBZ ._.
These_DT technologies_NNS can_MD be_VB of_IN drugs_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 21_CD Operating_NN review_NN :_: Biologics_NNP Apart_RB from_IN epidemics_NNS ,_, at_IN least_JJS 1.2_CD million_CD cases_NNS of_IN bacterial_JJ meningitis_NNS are_VBP estimated_VBN to_TO occur_VB every_DT year_NN ,_, 135,000_CD of_IN which_WDT are_VBP Future_JJ fatal_JJ according_VBG to_TO WHO_WP statistics_NNS ._.
Some_DT 500,000_CD of_IN these_DT cases_NNS and_CC 50,000_CD of_IN the_DT deaths_NNS are_VBP attributable_JJ to_TO N._NNP meningitidis_NNS ._.
protection_NN Use_NN of_IN modern_JJ vaccines_NNS is_VBZ recognized_VBN as_IN one_CD of_IN the_DT most_RBS cost-effective_JJ health_NN interventions_NNS available_JJ ._.
As_IN a_DT result_NN the_DT global_JJ vaccine_NN market_NN is_VBZ expanding_VBG ,_, and_CC it_PRP is_VBZ estimated_VBN that_IN it_PRP will_MD be_VB a_DT US$_$ 10_CD billion_CD market_NN by_IN 2007_CD ._.
Shire_NNP has_VBZ a_DT strong_JJ vaccine_NN capability_NN and_CC aims_VBZ to_TO safeguard_VB future_JJ health_NN by_IN developing_VBG vaccines_NNS that_WDT provide_VBP greater_JJR protection_NN against_IN illnesses_NNS such_JJ as_IN influenza_NN ,_, meningitis_NN ,_, pneumonia_NN and_CC hepatitis_NN ._.
In_IN 2002_CD Shire_NNP invested_VBN in_IN a_DT new_JJ vaccine_NN research_NN facility_NN that_WDT will_MD be_VB operational_JJ in_IN 2004_CD ._.
Influenza_NNP vaccines_NNS primarily_RB the_DT US_NNP and_CC Europe_NNP :_: this_DT project_NN is_VBZ Streptococcus_NNP pneumoniae_NN vaccine_NN For_IN most_JJS healthy_JJ people_NNS influenza_JJ amounts_NNS now_RB at_IN the_DT end_NN of_IN phase_NN II_NNP ._.
Phase_NN III_NNP data_NNS will_MD Streptococcus_NNP pneumoniae_NN can_MD cause_VB a_DT variety_NN to_TO a_DT high_JJ fever_NN ,_, headaches_NNS and_CC coughing_VBG be_VB needed_VBN to_TO support_VB the_DT marketing_NN approval_NN of_IN infections_NNS including_VBG meningitis_NNS ,_, pneumonia_NN followed_VBN by_IN a_DT complete_JJ recovery_NN ._.
For_IN the_DT elderly_JJ applications_NNS in_IN the_DT major_JJ markets_NNS ._.
and_CC acute_JJ otitis_NN media_NNS ear_NN infection_NN ._.
The_DT US_NNP and_CC chronically_RB ill_JJ influenza_NN often_RB leads_VBZ to_TO Centers_NNPS for_IN Disease_NNP Control_NNP and_CC Protection_NNP hospitalisation_NN or_CC death_NN ._.
According_VBG to_TO the_DT World_NNP As_IN part_NN of_IN the_DT commercial_JJ agreement_NN with_IN estimate_NN that_IN each_DT year_NN in_IN the_DT US_NNP S._NNP pneumoniae_NNP Health_NNP Organisation_NNP WHO_WP ,_, during_IN the_DT annual_JJ Berna_NNP Biotech_NNP ,_, Shire_NNP gains_VBZ exclusive_JJ rights_NNS to_TO infections_NNS cause_VB up_RP to_TO 135,000_CD hospitalisations_NNS influenza_JJ epidemics_NNS the_DT disease_NN infects_VBZ as_IN sell_NN Bernas_NNP hepatitis_NNP B_NNP vaccines_NNS ,_, HEPAVAX_NNP for_IN pneumonia_NN ,_, 6_CD million_CD cases_NNS of_IN otitis_NN media_NNS ,_, many_JJ as_IN 100_CD million_CD people_NNS in_IN the_DT northern_JJ GENE_NNP and_CC BIO-HEP_NNP B_NNP in_IN Europe_NNP ._.
and_CC approximately_RB 3,300_CD cases_NNS of_IN meningitis_NNS ._.
hemisphere_NN and_CC causes_VBZ approximately_RB 20,000_CD There_EX are_VBP over_IN 90_CD different_JJ serogroups_NNS or_CC deaths_NNS in_IN the_DT US_NNP alone_RB ._.
In_IN addition_NN to_TO the_DT In_NNP addition_NN to_TO FLUVIRAL_NNP S_NNP F_NN ,_, SPD701_NNP ,_, a_DT variants_NNS of_IN the_DT bacteria_NNS ,_, but_CC the_DT currently_RB annual_JJ epidemic_JJ there_EX is_VBZ also_RB the_DT continued_VBN cell-based_JJ influenza_NN vaccine_NN ,_, is_VBZ in_IN early-stage_JJ available_JJ paediatric_JJ vaccine_NN elicits_VBZ an_DT immune_JJ threat_NN of_IN an_DT influenza_NN pandemic_NN ._.
development_NN awaiting_VBG a_DT partner_NN prior_RB to_TO response_NN to_TO only_RB seven_CD of_IN these_DT ._.
existing_VBG polysaccharide_NN vaccines_NNS fail_VBP to_TO elicit_VB Shires_NNP commercial_JJ biologics_NNS portfolio_NN contains_VBZ much_RB of_IN a_DT response_NN in_IN the_DT elderly_JJ or_CC in_IN healthy_JJ FLUVIRAL_NNP S_NNP F_NN ,_, a_DT split-virion_JJ influenza_NN vaccine_NN Neisseria_NNP meningitidis_VBZ vaccine_NN children_NNS under_IN the_DT age_NN of_IN two_CD years_NNS ._.
for_IN the_DT prevention_NN of_IN influenza_NN infection_NN ._.
Shire_NNP Two_CD of_IN the_DT most_RBS common_JJ outcomes_NNS of_IN infection_NN signed_VBD a_DT ten-year_JJ contract_NN with_IN the_DT Government_NN by_IN Neisseria_NNP meningitidis_NNS are_VBP meningococcal_JJ SPD703_NNP is_VBZ a_DT vaccine_NN designed_VBN to_TO prevent_VB of_IN Canada_NNP to_TO ensure_VB a_DT state_NN of_IN readiness_NN in_IN the_DT meningitis_NNS ,_, a_DT bacterial_JJ infection_NN which_WDT causes_VBZ S._NNP pneumoniae_NN infections_NNS ._.
This_DT vaccine_NN should_MD event_NN of_IN an_DT influenza_NN pandemic_NN and_CC to_TO provide_VB inflammation_NN of_IN the_DT membranes_NNS covering_VBG the_DT stimulate_VB the_DT immune_JJ system_NN more_RBR effectively_RB influenza_JJ vaccine_NN for_IN all_DT Canadian_JJ citizens_NNS in_IN brain_NN and_CC spinal_JJ cord_NN ,_, and_CC septicemia_NN ,_, an_DT than_IN existing_VBG vaccines_NNS and_CC has_VBZ the_DT potential_JJ to_TO such_PDT an_DT event_NN ._.
Under_IN the_DT contract_NN Shire_NNP will_MD infection_NN of_IN the_DT blood_NN stream_NN giving_VBG rise_NN to_TO fever_NN ,_, provide_VBP improved_JJ protection_NN for_IN children_NNS and_CC also_RB supply_VB the_DT Government_NN of_IN Canada_NNP with_IN hypotension_NN and_CC infection_NN of_IN secondary_JJ sites_NNS such_JJ old_JJ people_NNS alike_RB across_IN all_DT S._NNP pneumoniae_NN a_DT substantial_JJ proportion_NN of_IN its_PRP$ annual_JJ influenza_NN as_IN lungs_NNS ,_, urinary_JJ tract_NN and_CC gastrointestinal_JJ tract_NN ._.
Phase_NN I_PRP clinical_JJ trials_NNS are_VBP underway_JJ ._.
vaccine_NN requirements_NNS over_IN the_DT ten-year_JJ period_NN ._.
NEISVAC-C_NNP vaccine_NN is_VBZ used_VBN in_IN the_DT prevention_NN of_IN meningitis_NN caused_VBN by_IN N._NNP meningitidis_NNS serogroup_VBP Other_JJ activities_NNS To_TO expand_VB its_PRP$ position_NN in_IN the_DT influenza_NN vaccines_NNS C._NNP Shire_NNP acquired_VBD Canadian_JJ rights_NNS to_TO sell_VB the_DT Pseudomonas_NNP aeruginosa_NN is_VBZ a_DT bacterium_NN market_NN ,_, Shire_NNP entered_VBD a_DT commercial_JJ agreement_NN vaccine_NN from_IN Baxter_NNP International_NNP ,_, and_CC Health_NNP responsible_JJ for_IN severe_JJ hospital_NN acquired_VBN with_IN Berna_NNP Biotech_NNP AG_NNP of_IN Switzerland_NNP in_IN which_WDT Canada_NNP approved_VBD the_DT vaccine_NN in_IN January_NNP 2002_CD ._.
infections_NNS ,_, life-threatening_JJ infections_NNS in_IN Shire_NNP will_MD manufacture_VB and_CC supply_VB FLUVIRAL_NNP immunocompromised_JJ individuals_NNS and_CC chronic_JJ S_NNP F_NN for_IN sale_NN by_IN Berna_NNP Biotech_NNP in_IN international_JJ Building_NN on_IN the_DT success_NN of_IN NEISVAC-C_NNP Shire_NNP infections_NNS in_IN cystic_JJ fibrosis_NN patients_NNS ._.
Shire_NNP is_VBZ territories_NNS excluding_VBG Europe_NNP and_CC North_NNP Biologics_NNPS is_VBZ also_RB developing_VBG SPD704_CD that_WDT collaborating_VBG with_IN Cytovax_NNP Biotechnologies_NNPS Inc._NNP ._.
America_NNP ._.
Shire_NNP also_RB continues_VBZ to_TO capitalize_VB appears_VBZ to_TO protect_VB against_IN all_DT serogroups_NNS of_IN in_IN the_DT development_NN of_IN SPD705_CD ,_, a_DT vaccine_NN on_IN the_DT global_JJ rights_NNS to_TO FLUVIRAL_NNP S_NNP F_NN by_IN N._NNP meningitidis_NNS infections_NNS including_VBG serogroup_NN against_IN P._NNP aeruginosa_NN ._.
investigating_VBG its_PRP$ potential_NN for_IN other_JJ markets_NNS ,_, B_NNP for_IN which_WDT no_DT vaccine_NN is_VBZ available_JJ ._.
HEPAVAX_NNP GENE_NNP and_CC BIO-HEP_NNP B_NNP are_VBP trade_NN marks_NNS of_IN Berna_NNP Biotech_NNP AG_NNP ._.
22_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN NEISVAC-C_NNP is_VBZ a_DT trade_NN mark_NN of_IN Baxter_NNP International_NNP Inc._NNP ._.
Shire_NNP Biologics_NNP Existing_VBG polysaccharide-based_JJ vaccines_NNS offer_VBP protection_NN against_IN a_DT limited_JJ range_NN of_IN bacterial_JJ strains_NNS serogroups_NNS ._.
Shires_NNP research_NN focuses_VBZ on_IN the_DT identification_NN and_CC development_NN of_IN vaccines_NNS based_VBN on_IN universal_JJ surface_NN protein_NN antigens_NNS ._.
Universal_NNP products_NNS elicit_VBP an_DT immune_JJ response_NN to_TO all_DT different_JJ serogroups_NNS or_CC variants_NNS of_IN pathogenic_JJ organisms_NNS ,_, while_IN proteins_NNS are_VBP the_DT antigen_NN of_IN choice_NN in_IN many_JJ vaccines_NNS ._.
This_DT approach_NN could_MD eventually_RB render_VB some_DT existing_VBG vaccines_NNS obsolete_JJ ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 23_CD Corporate_NNP social_JJ responsibility_NN report_NN Shire_NNP commitment_NN Shire_NNP takes_VBZ its_PRP$ corporate_JJ social_JJ responsibility_NN CSR_NNP seriously_RB ._.
We_PRP believe_VBP that_IN sound_JJ social_JJ ,_, ethical_JJ and_CC environmental_JJ practices_NNS make_VBP good_JJ business_NN sense_NN and_CC we_PRP consider_VBP these_DT issues_NNS as_IN implicit_JJ to_TO the_DT success_NN of_IN our_PRP$ Company_NN ,_, as_RB well_RB as_IN to_TO the_DT recruitment_NN ,_, motivation_NN and_CC retention_NN of_IN talented_JJ people_NNS ._.
During_IN the_DT reporting_NN year_NN we_PRP have_VBP continued_VBN to_TO develop_VB and_CC improve_VB the_DT way_NN in_IN which_WDT we_PRP manage_VBP ,_, measure_NN and_CC report_NN on_IN this_DT important_JJ aspect_NN of_IN our_PRP$ business_NN ._.
Shire_NNP conducts_VBZ its_PRP$ business_NN based_VBN on_IN the_DT department_NN ._.
This_DT document_NN is_VBZ presented_VBN to_TO the_DT Shire_NNP has_VBZ been_VBN a_DT constituent_NN of_IN the_DT values_NNS it_PRP considers_VBZ important_JJ It_PRP is_VBZ our_PRP$ aim_NN Board_NNP and_CC the_DT Executive_NNP Committee_NNP annually_RB FTSE4Good_CD index_NN and_CC has_VBZ participated_VBN in_IN the_DT to_TO be_VB innovative_JJ and_CC dynamic_JJ :_: we_PRP apply_VBP for_IN discussion_NN ._.
Business_NN in_IN the_DT Community_NNP Environmental_NNP BiE_NNP high_JJ standards_NNS of_IN integrity_NN and_CC we_PRP care_VBP for_IN Index_NNP since_IN 2001_CD ._.
the_DT interests_NNS of_IN those_DT with_IN whom_WP we_PRP have_VBP During_IN 2002_CD ,_, Shire_NNP used_VBD independent_JJ expert_JJ relationships_NNS our_PRP$ patients_NNS ,_, our_PRP$ customers_NNS ,_, consultants_NNS to_TO conduct_VB a_DT comprehensive_JJ CSR_NNP We_PRP were_VBD also_RB one_CD of_IN 53_CD FTSE_NNP 100_CD companies_NNS our_PRP$ suppliers_NNS ,_, our_PRP$ shareholders_NNS ,_, our_PRP$ employees_NNS assessment_NN ._.
The_DT findings_NNS of_IN the_DT review_NN were_VBD that_IN completed_VBD the_DT 1st_CD Corporate_JJ Responsibility_NN and_CC the_DT communities_NNS in_IN which_WDT we_PRP conduct_VBP our_PRP$ shared_VBN with_IN the_DT Executive_NNP Committee_NNP and_CC the_DT Index_NNP CRI_NNP 2002_CD ,_, run_VBN by_IN Business_NN in_IN the_DT activities_NNS ._.
Shire_NNP is_VBZ in_IN the_DT process_NN of_IN implementing_VBG Community_NNP ._.
The_DT Company_NN was_VBD pleased_VBN with_IN several_JJ key_JJ recommendations_NNS ._.
These_DT include_VBP its_PRP$ above-sector_NN and_CC overall_JJ index_NN rating_NN for_IN The_DT CSR_NNP policy_NN is_VBZ the_DT cornerstone_NN of_IN the_DT the_DT establishment_NN of_IN a_DT CSR_NNP Committee_NNP ,_, corporate_JJ strategy_NN ,_, integration_NN and_CC assurance_NN Companys_NNP CSR_NNP management_NN framework_NN ._.
chaired_VBN by_IN Angus_NNP Russell_NNP ,_, the_DT Group_NNP Finance_NNP as_RB well_RB as_IN for_IN its_PRP$ profile_NN gradings_NNS ,_, which_WDT were_VBD This_DT policy_NN identifies_VBZ and_CC assesses_VBZ the_DT Director_NNP ,_, and_CC the_DT formation_NN of_IN specific_JJ work_NN As_IN and_CC Bs_NNS ._.
significant_JJ issues_NNS and_CC stakeholder_NN groups_NNS that_WDT groups_NNS to_TO examine_VB the_DT specialist_NN areas_NNS of_IN the_DT Shire_NNP Board_NNP of_IN Directors_NNS believes_VBZ should_MD be_VB environment_NN ,_, health_NN and_CC safety_NN ,_, and_CC contractor_NN In_IN the_DT national_JJ UK_NNP newspaper_NN The_DT Guardians_NNPS managed_VBD as_IN part_NN of_IN the_DT Companys_NNP approach_NN and_CC supplier_NN relationships_NNS ._.
survey_NN The_DT Giving_NNP List_NN 25_CD November_NNP 2002_CD ,_, to_TO day-to-day_JJ business_NN activities_NNS ._.
The_DT policy_NN Shire_NNP appeared_VBD in_IN 17th_JJ position_NN in_IN a_DT ranking_NN of_IN is_VBZ available_JJ internally_RB to_TO our_PRP$ staff_NN through_IN its_PRP$ External_NNP surveys_NNS and_CC indexes_NNS FTSE_VBP 100_CD giving_VBG companies_NNS ,_, compared_VBN with_IN intranet_NN ,_, and_CC publicly_RB accessible_JJ on_IN the_DT During_IN the_DT reporting_NN year_NN ,_, Shire_NNP responded_VBD 86th_CD in_IN the_DT previous_JJ year_NN ._.
The_DT result_NN highlights_VBZ Company_NN website_NN ._.
constructively_RB to_TO numerous_JJ external_JJ requests_NNS our_PRP$ continual_JJ support_NN for_IN charitable_JJ activities_NNS for_IN information_NN on_IN its_PRP$ CSR_NNP and_CC related_JJ activities_NNS and_CC the_DT significant_JJ improvements_NNS that_IN the_DT Angus_NNP Russell_NNP ,_, Group_NNP Finance_NNP Director_NNP ,_, has_VBZ from_IN a_DT range_NN of_IN research_NN bodies_NNS including_VBG PIRC_NNP Company_NNP has_VBZ made_VBN tracking_NN and_CC measuring_VBG assumed_JJ responsibility_NN for_IN CSR_NNP on_IN the_DT Shire_NNP Pensions_NNP Investment_NNP Research_NNP Consultants_NNPS ,_, time_NN and_CC resource_NN allocation_NN in_IN this_DT type_NN of_IN Board_NNP and_CC led_VBD activities_NNS in_IN this_DT field_NN during_IN 2002_CD EIRIS_NNP Ethical_NNP Investment_NNP Research_NNP Service_NNP activity_NN and_CC reflecting_VBG it_PRP more_RBR accurately_RB in_IN the_DT in_IN co-ordination_NN with_IN the_DT Chief_NNP Executive_NNP and_CC and_CC the_DT ABI_NNP Association_NNP of_IN British_NNP Insurers_NNP ._.
The_DT Board_NNP is_VBZ kept_VBN We_PRP recognize_VBP the_DT value_NN in_IN participating_VBG in_IN informed_VBN of_IN significant_JJ developments_NNS and_CC independent_JJ voluntary_JJ benchmarking_VBG surveys_NNS consulted_VBN on_IN major_JJ CSR_NNP initiatives_NNS and_CC policy_NN and_CC welcome_VB their_PRP$ outcome_NN as_IN a_DT driver_NN to_TO approvals_NNS ._.
further_JJ improvement_NN in_IN our_PRP$ management_NN systems_NNS helping_VBG to_TO identify_VB priority_NN areas_NNS for_IN The_DT Board_NNP uses_VBZ the_DT corporate_JJ risk_NN management_NN development_NN and_CC contribute_VBP to_TO our_PRP$ thinking_NN process_NN to_TO monitor_VB risks_NNS and_CC opportunities_NNS around_IN how_WRB to_TO define_VB targets_NNS and_CC objectives_NNS arising_VBG from_IN social_JJ ,_, ethical_JJ and_CC environmental_JJ for_IN the_DT future_NN ._.
A_DT summary_NN risk_NN schedule_NN is_VBZ reviewed_VBN regularly_RB by_IN the_DT Companys_NNPS risk_NN management_NN www_NN ._.
com_NN 24_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ social_JJ responsibility_NN report_NN CSR_NNP policy_NN Shire_NNP CSR_NNP policy_NN addresses_VBZ the_DT following_VBG issues_NNS to_TO support_VB managing_VBG risks_NNS and_CC maintaining_VBG and_CC improving_VBG Shires_NNP position_NN as_IN a_DT good_JJ corporate_JJ citizen_NN in_IN its_PRP$ dealings_NNS with_IN its_PRP$ patients_NNS ,_, customers_NNS ,_, suppliers_NNS ,_, shareholders_NNS ,_, employees_NNS and_CC the_DT communities_NNS where_WRB it_PRP conducts_VBZ its_PRP$ activities_NNS :_: Ethics_NNS Employee_NN practices_NNS Health_NNP and_CC safety_NN Environment_NNP Animal_NNP welfare_NN Community_NNP relations_NNS ._.
The_DT policy_NN itself_PRP has_VBZ spawned_VBN additional_JJ specific_JJ policies_NNS for_IN example_NN ,_, during_IN 2002_CD the_DT Board_NNP www_NN ._.
com_NN agreed_VBD a_DT new_JJ charity_NN policy_NN that_WDT governs_VBZ community_NN affairs_NNS and_CC charitable_JJ giving_VBG during_IN the_DT year_NN ,_, as_RB well_RB as_IN a_DT whistle_VBP blowing_VBG policy_NN which_WDT enables_VBZ concerns_NNS to_TO be_VB raised_VBN confidentially_RB inside_RB ,_, and_CC if_IN necessary_JJ ,_, outside_IN the_DT organization_NN ._.
Shire_NNP values_VBZ The_DT Shire_NNP values_NNS innovation_NN ,_, dynamism_NN ,_, integrity_NN At_IN Shire_NNP ,_, we_PRP demonstrate_VBP our_PRP$ caring_NN by_IN constantly_RB displaying_VBG respect_NN and_CC and_CC caring_NN govern_VBP daily_JJ behavior_NN and_CC actions_NNS consideration_NN to_TO each_DT other_JJ ,_, by_IN recognizing_VBG contribution_NN and_CC efforts_NNS and_CC by_IN within_IN Shire_NNP ._.
A_DT set_NN of_IN values_NNS first_RB identified_VBN by_IN listening_VBG to_TO others_NNS views_NNS ._.
We_PRP care_VBP for_IN the_DT patients_NNS through_IN our_PRP$ commitment_NN Shire_NNP senior_JJ management_NN was_VBD presented_VBN ,_, to_TO health_NN and_CC we_PRP care_VBP for_IN our_PRP$ shareholders_NNS by_IN our_PRP$ commitment_NN to_TO the_DT Companys_NNPS goals_NNS and_CC objectives_NNS ._.
challenged_VBN and_CC enhanced_VBN by_IN employees_NNS through_IN a_DT major_JJ consultative_JJ exercise_NN across_IN all_DT geographic_JJ areas_NNS and_CC levels_NNS of_IN responsibility_NN ._.
At_IN Shire_NNP we_PRP strongly_RB believe_VBP in_IN integrity_NN as_IN evidenced_VBN by_IN the_DT creation_NN Employees_NNS represent_VBP a_DT key_JJ stakeholder_NN group_NN ._.
of_IN an_DT environment_NN characterised_VBN by_IN trust_NN and_CC openness_NN ,_, quality_NN and_CC The_DT values_NNS identification_NN and_CC daily_JJ implementation_NN professionalism_NN ,_, honesty_NN ,_, high_JJ ethical_JJ standards_NNS and_CC reliability_NN ._.
demonstrate_VB that_IN the_DT Shire_NNP commitment_NN to_TO CSR_NNP runs_VBZ throughout_IN the_DT Company_NN ._.
The_DT Companys_NNPS people_NNS policies_NNS and_CC practices_NNS ,_, including_VBG objective_JJ setting_NN and_CC appraisals_NNS ,_, all_DT now_RB include_VBP At_IN Shire_NNP we_PRP strive_VBP to_TO maintain_VB our_PRP$ dynamism_NN by_IN keeping_VBG an_DT the_DT assessment_NN of_IN individual_JJ and_CC team_NN entrepreneurial_JJ spirit_NN ,_, by_IN being_VBG result_NN oriented_VBN ,_, focused_VBN on_IN value-creating_JJ implementation_NN of_IN the_DT values_NNS ._.
activities_NNS and_CC by_IN being_VBG flexible_JJ adaptable_JJ ._.
Our_PRP$ dynamism_NN will_MD be_VB shown_VBN in_IN the_DT passion_NN we_PRP have_VBP for_IN health_NN and_CC for_IN reaching_VBG our_PRP$ objectives_NNS ._.
At_IN Shire_NNP we_PRP are_VBP innovative_JJ because_IN we_PRP dare_VBP to_TO challenge_VB the_DT usual_JJ practices_NNS in_IN an_DT effort_NN to_TO constantly_RB improve_VB the_DT way_NN we_PRP do_VBP things_NNS ._.
We_PRP value_VBP creativity_NN and_CC initiative_NN ._.
We_PRP accept_VBP mistakes_NNS as_IN they_PRP create_VBP opportunities_NNS for_IN learning_VBG ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 25_CD Innovation_NN Dynamism_NNP Integrity_NNP Caring_NNP Corporate_NNP social_JJ responsibility_NN report_NN Our_PRP$ people_NNS Shire_VBP people_NNS comment_VB on_IN the_DT values_NNS Shire_NNP employs_VBZ over_IN 1,800_CD people_NNS globally_RB Our_PRP$ job_NN in_IN the_DT Professional_NNP Education_NNP throughout_IN its_PRP$ operations_NNS ._.
Shires_NNP goal_NN is_VBZ to_TO manage_VB department_NN is_VBZ to_TO make_VB sure_JJ that_IN the_DT correct_JJ its_PRP$ human_JJ resources_NNS actively_RB with_IN a_DT decentralised_JJ messages_NNS about_IN all_DT our_PRP$ products_NNS are_VBP being_VBG approach_NN ._.
A_DT small-scale_JJ global_JJ HR_NNP function_NN aims_VBZ conveyed_VBN ._.
The_DT integrity_NN of_IN our_PRP$ team_NN is_VBZ proven_VBN to_TO create_VB common_JJ HR_NNP strategies_NNS and_CC initiatives_NNS by_IN the_DT messages_NNS we_PRP are_VBP presenting_VBG on_IN a_DT daily_JJ to_TO support_VB the_DT growth_NN and_CC the_DT success_NN of_IN the_DT basis_NN ._.
Caring_NN was_VBD demonstrated_VBN when_WRB our_PRP$ Company_NN ._.
The_DT global_JJ function_NN interacts_VBZ regularly_RB whole_JJ team_NN was_VBD included_VBN to_TO develop_VB our_PRP$ own_JJ with_IN local_JJ HR_NN managers_NNS within_IN the_DT operational_JJ units_NNS departmental_JJ values_NNS which_WDT spin_VBP out_RP from_IN to_TO ensure_VB consistency_NN and_CC the_DT sharing_NN of_IN best_JJS Shires_NNPS core_NN values_NNS ._.
Our_PRP$ particular_JJ values_NNS for_IN practice_NN across_IN Shire_NNP ._.
Professional_NNP Education_NNP Marketing_NNP are_VBP Excellence_NNP ,_, Work-Family_NNP Balance_NNP ,_, Integrity_NNP ,_, In_IN 2002_CD ,_, new_JJ Company-wide_JJ human_JJ resources_NNS Communication_NNP ,_, Synergy_NNP and_CC No_NNP Surprises_NNS initiatives_NNS included_VBD the_DT following_NN :_: Kathy_NNP Driscoll_NNP ,_, Administrative_NNP and_CC are_VBP framed_VBN in_IN all_DT our_PRP$ offices_NNS !_.
My_PRP$ favorite_JJ Assistant_NNP Professional_NNP Education_NNP value_NN is_VBZ Caring_VBG ._.
All_DT of_IN the_DT support_NN staff_NN in_IN myShire_NNP introduced_VBD a_DT global_JJ framework_NN for_IN Marketing_NNP ,_, Shire_NNP US_NNP ._.
department_NN consider_VB each_DT other_JJ an_DT equal_JJ performance_NN assessment_NN ,_, which_WDT includes_VBZ and_CC we_PRP go_VBP out_IN of_IN our_PRP$ way_NN to_TO make_VB sure_JJ that_IN feedback_JJ sessions_NNS between_IN employees_NNS and_CC we_PRP are_VBP all_DT supported_VBN in_IN our_PRP$ daily_JJ activities_NNS their_PRP$ managers_NNS ._.
The_DT assessment_NN includes_VBZ our_PRP$ own_JJ Shire_NNP band_NN of_IN brothers_NNS ._.
We_PRP are_VBP corporate_JJ criteria_NNS and_CC implementation_NN of_IN values_NNS ,_, committed_VBN to_TO making_VBG our_PRP$ work_NN environment_NN a_DT objective_JJ setting_NN and_CC professional_JJ development_NN rewarding_JJ and_CC preferably_RB enjoyable_JJ experience_NN ._.
We_PRP respect_VBP and_CC value_VBP each_DT other_JJ and_CC revel_VB in_IN each_DT and_CC everyones_NNS unique_JJ talents_NNS ._.
Shire_NNP expanded_VBD its_PRP$ Stock_NNP Purchase_NNP Plan_NNP for_IN all_DT employees_NNS worldwide_VBP with_IN the_DT aim_NN of_IN developing_VBG a_DT sense_NN of_IN ownership_NN amongst_IN staff_NN ._.
More_JJR than_IN 70_CD %_NN of_IN employees_NNS are_VBP already_RB participating_VBG worldwide_NN ._.
In_IN addition_NN ,_, all_DT employees_NNS have_VBP share_NN options_NNS and_CC can_MD therefore_RB benefit_VB from_IN the_DT future_JJ growth_NN of_IN Global_JJ assignments_NNS often_RB present_JJ unique_JJ the_DT Company_NN ._.
challenges_NNS ,_, but_CC invariably_RB employees_NNS come_VBP away_RB enriched_VBN and_CC with_IN a_DT deeper_JJR A_DT Code_NNP of_IN Ethics_NNPS was_VBD introduced_VBN and_CC understanding_NN of_IN Shires_NNP global_JJ operations_NNS :_: communicated_VBN to_TO all_DT employees_NNS :_: it_PRP is_VBZ also_RB a_DT key_JJ part_NN of_IN the_DT Companys_NNP induction_NN process_NN ._.
I_PRP am_VBP responsible_JJ for_IN the_DT Health_NNP Care_NNP The_NNP Code_NNP includes_VBZ the_DT Companys_NNPS policy_NN on_IN business_NN units_NNS marketing_NN and_CC sales_NNS force_NN ._.
equal_JJ opportunities_NNS and_CC a_DT discrimination-free_JJ Being_VBG physically_RB located_VBN in_IN the_DT UK_NNP is_VBZ vital_JJ environment_NN :_: it_PRP also_RB includes_VBZ a_DT specific_JJ because_IN you_PRP can_MD not_RB be_VB successful_JJ without_IN statement_NN on_IN sexual_JJ harassment_NN ._.
being_VBG close_JJ to_TO your_PRP$ team_NN and_CC your_PRP$ market_NN ._.
Working_VBG in_IN another_DT country_NN has_VBZ always_RB Internal_NNP communications_NNS have_VBP also_RB been_VBN been_VBN one_CD of_IN my_PRP$ dreams_NNS and_CC I_PRP am_VBP grateful_JJ a_DT priority_NN in_IN 2002_CD ._.
Shire_NNP makes_VBZ a_DT significant_JJ to_TO Shire_VB for_IN making_VBG it_PRP possible_JJ and_CC for_IN helping_VBG effort_NN to_TO share_VB and_CC provide_VB all_DT of_IN its_PRP$ people_NNS Natascha_NNP Sellschopp_NNP transferred_VBD from_IN with_IN the_DT logistics_NNS ._.
with_IN information_NN about_IN the_DT Company_NN and_CC its_PRP$ Germany_NNP to_TO the_DT UK_NNP in_IN January_NNP 2002_CD ._.
activities_NNS ._.
The_DT new_JJ intranet_NN ,_, Orbit_NNP ,_, was_VBD Current_JJ position_NN :_: Business_NNP Unit_NNP Director_NNP ,_, I_PRP believe_VBP that_IN a_DT global_JJ assignment_NN broadens_VBZ introduced_VBN this_DT year_NN :_: an_DT electronic_JJ news_NN letter_NN is_VBZ Health_NNP Care_NNP Business_NNP Unit_NNP ,_, Shire_NNP UK_NNP ._.
your_PRP$ experience_NN immensely_RB ,_, makes_VBZ you_PRP more_RBR issued_VBN globally_RB every_DT six_CD weeks_NNS and_CC a_DT Company_NN open_JJ and_CC flexible_JJ and_CC teaches_VBZ you_PRP to_TO look_VB at_IN magazine_NN is_VBZ sent_VBN to_TO all_DT staff_NN three_CD times_NNS a_DT year_NN ._.
In_IN Dynamic_NNP people_NNS things_NNS from_IN different_JJ perspectives_NNS ._.
I_PRP love_VBP addition_NN ,_, senior_JJ management_NN hosts_NNS regular_JJ staff_NN One_CD of_IN Shires_NNP greatest_JJS strengths_NNS is_VBZ changes_NNS and_CC challenges_NNS and_CC this_DT makes_VBZ you_PRP meetings_NNS in_IN all_PDT the_DT major_JJ Company_NN locations_NNS ._.
the_DT ability_NN of_IN its_PRP$ employees_NNS to_TO work_VB break_NN with_IN old_JJ habits_NNS ,_, giving_VBG you_PRP a_DT start_NN all_DT seamlessly_RB across_IN national_JJ borders_NNS ,_, new_JJ again_RB feeling_NN ._.
Shire_NNP offers_VBZ career_NN development_NN expertly_RB navigate_VBP through_IN a_DT variety_NN of_IN opportunities_NNS and_CC leverages_VBZ its_PRP$ global_JJ status_NN economic_JJ ,_, social_JJ and_CC political_JJ systems_NNS ,_, The_DT most_RBS challenging_JJ aspect_NN has_VBZ been_VBN through_IN making_VBG these_DT available_JJ throughout_IN and_CC successfully_RB adapt_VB to_TO different_JJ language_NN I_PRP still_RB have_VBP a_DT long_JJ way_NN to_TO go_VB to_TO be_VB the_DT organization_NN ._.
as_IN spontaneous_JJ in_IN English_NNP as_IN I_PRP am_VBP in_IN German_JJ !_.
transfers_NNS and_CC secondments_NNS at_IN a_DT range_NN of_IN levels_NNS But_CC overall_JJ ,_, this_DT is_VBZ a_DT perfect_JJ opportunity_NN to_TO have_VB taken_VBN place_NN during_IN the_DT year_NN ._.
improve_VB your_PRP$ career_NN and_CC help_VB you_PRP with_IN your_PRP$ personal_JJ development_NN ._.
My_PRP$ advice_NN is_VBZ :_: overcome_VB Shire_NNP has_VBZ a_DT proactive_JJ people_NNS management_NN any_DT concerns_NNS you_PRP might_MD have_VB this_DT is_VBZ an_DT strategy_NN which_WDT aims_VBZ to_TO attract_VB and_CC retain_VB the_DT experience_NN which_WDT is_VBZ really_RB worth_JJ having_VBG and_CC most_RBS talented_JJ employees_NNS ._.
Global_JJ turnover_NN of_IN which_WDT you_PRP will_MD remember_VB all_DT your_PRP$ life_NN ._.
staff_NN for_IN 2002_CD was_VBD around_RB 10_CD %_NN ,_, which_WDT is_VBZ low_JJ by_IN industry_NN standards_NNS ._.
26_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ social_JJ responsibility_NN report_NN 2001_CD and_CC 2002_CD environmental_JJ data_NNS Transport_VBP Water_NNP usage_NN Effluent_JJ 3_CD km_NN m_NN discharge_VB 3_CD m_NNP Energy_NNP Solid_JJ waste_NN consumption_NN metric_JJ kWh_NNP tonnes_NNS 2002_CD 52,770,000_CD 70,118,500_CD 2,800_CD 226,500_CD 56,000_CD 2001_CD 41,022,500_CD 48,430,000_CD 2,000_CD 215,000_CD 43,500_CD The_DT 2001_CD data_NNS covers_VBZ figures_NNS of_IN Shire_NNP Biologics_NNPS starting_VBG from_IN the_DT date_NN of_IN merger_NN between_IN BioChem_NNP Pharma_NNP and_CC Shire_NNP in_IN May_NNP 2001_CD ._.
The_DT data_NN covers_VBZ 8085_CD %_NN of_IN Shires_NNP activity_NN ,_, based_VBN on_IN the_DT number_NN of_IN employees_NNS located_VBN at_IN the_DT sites_NNS ,_, which_WDT were_VBD included_VBN in_IN the_DT data_NNS collection_NN process_NN ._.
The_DT 2002_CD figures_NNS do_VBP not_RB include_VB data_NNS from_IN the_DT newly_RB acquired_VBN Shire_NNP US_NNP Manufacturing_NNP Inc._NNP ._.
SUMI_NNP ,_, formerly_RB APS_NNP Inc._NNP ._.
Numbers_NNS given_VBN for_IN 2001_CD do_VBP not_RB always_RB correspond_VB exactly_RB to_TO numbers_NNS reported_VBN previously_RB due_JJ to_TO improvements_NNS made_VBN in_IN our_PRP$ measurement_NN and_CC data_NNS gathering_NN process_NN ._.
Health_NNP and_CC safety_NN we_PRP are_VBP endeavoring_VBG to_TO manage_VB these_DT supply_NN 2003_CD these_DT working_VBG groups_NNS intend_VBP to_TO make_VB Shire_NNP developed_VBD a_DT global_JJ health_NN and_CC safety_NN chain_NN issues_NNS in_IN a_DT responsible_JJ manner_NN ._.
recommendations_NNS to_TO the_DT CSR_NNP Committee_NNP for_IN policy_NN during_IN the_DT year_NN which_WDT was_VBD published_VBN on_IN actions_NNS to_TO be_VB undertaken_VBN to_TO deliver_VB improved_VBN the_DT staff_NN intranet_NN ._.
This_DT is_VBZ the_DT template_NN for_IN the_DT With_IN the_DT acquisition_NN of_IN Shire_NNP US_NNP Manufacturing_NNP environmental_JJ performance_NN ._.
way_NN health_NN and_CC safety_NN issues_NNS are_VBP managed_VBN in_IN Owings_NNP Mills_NNP ,_, Maryland_NNP ,_, USA_NNP ,_, our_PRP$ commitment_NN throughout_IN the_DT organization_NN ._.
Depending_VBG on_IN the_DT to_TO environmental_JJ concerns_NNS remains_VBZ at_IN the_DT During_IN 2002_CD we_PRP introduced_VBD new_JJ Group_NNP nature_NN of_IN the_DT particular_JJ site_NN ,_, the_DT amount_NN of_IN highest_JJS level_NN ._.
Shire_NNP works_VBZ to_TO ensure_VB compliance_NN reporting_VBG processes_NNS for_IN regularly_RB measuring_VBG our_PRP$ additional_JJ attention_NN and_CC detailed_JJ local_JJ policy_NN with_IN local_JJ ,_, state_NN and_CC national_JJ regulations_NNS ._.
We_PRP seek_VBP further_RB ,_, through_IN our_PRP$ environmental_JJ of_IN our_PRP$ 2001_CD and_CC 2002_CD data-gathering_JJ exercises_NNS and_CC safety_NN officer_NN and_CC outside_JJ consultants_NNS ,_, to_TO are_VBP reported_VBN above_IN ._.
Current_JJ indicators_NNS are_VBP Health_NNP and_CC safety_NN committees_NNS operate_VBP in_IN most_JJS remain_VBP abreast_NN of_IN current_JJ scientific_JJ thinking_NN and_CC related_VBN to_TO energy_NN consumption_NN ,_, transport_NN ,_, of_IN the_DT major_JJ Shire_NNP sites_NNS and_CC the_DT Company_NN is_VBZ programs_NNS aimed_VBN at_IN improving_VBG environmental_JJ water_NN use_NN ,_, effluent_JJ discharge_VB and_CC solid_JJ waste_NN ._.
examining_VBG the_DT introduction_NN of_IN central_JJ data_NNS quality_NN for_IN the_DT next_JJ generation_NN ._.
Based_VBN on_IN an_DT analysis_NN of_IN current_JJ performance_NN ,_, collection_NN and_CC measurement_NN ._.
a_DT key_JJ task_NN for_IN the_DT EHS_NNP work_NN group_NN during_IN During_IN 2002_CD we_PRP established_VBD a_DT corporate_JJ 2003_CD will_MD be_VB to_TO evaluate_VB and_CC provide_VB Dr_NNP Wilson_NNP Totten_NNP ,_, Group_NNP R&D_NNP Director_NNP ,_, is_VBZ the_DT framework_NN within_IN which_WDT to_TO manage_VB on_IN respective_JJ targets_NNS for_IN Board_NNP member_NN responsible_JJ for_IN Shires_NNP approach_NN mental_JJ issues_NNS ._.
Jeff_NNP Devlin_NNP ,_, Corporate_NNP Affairs_NNPS performance_NN improvement_NN on_IN these_DT direct_JJ to_TO health_NN and_CC safety_NN ._.
Director_NNP and_CC member_NN of_IN the_DT Companys_NNP environmental_JJ impacts_NNS identified_VBN for_IN Shire_NNP Executive_NNP Committee_NNP ,_, leads_VBZ Shires_NNP environmental_JJ at_IN Group_NNP and_CC site_NN levels_NNS ._.
Environment_NNP issues_NNS at_IN Group_NNP level_NN ._.
Operational_JJ responsibility_NN Shire_NNP recognizes_VBZ its_PRP$ corporate_JJ responsibility_NN rests_VBZ with_IN senior_JJ management_NN in_IN each_DT of_IN the_DT towards_IN the_DT environment_NN and_CC believes_VBZ in_IN business_NN units_NNS ,_, supported_VBN through_IN a_DT network_NN the_DT importance_NN of_IN environmental_JJ protection_NN of_IN environmental_JJ and_CC facility_NN managers_NNS at_IN site_NN and_CC improvement_NN ._.
Our_PRP$ environmental_JJ policy_NN ,_, available_JJ on_IN our_PRP$ relevant_JJ environmental_JJ laws_NNS and_CC regulations_NNS website_NN ,_, www_NN ._.
com_NN ,_, guides_NNS our_PRP$ activities_NNS is_VBZ a_DT minimum_JJ standard_JJ across_IN the_DT business_NN ,_, in_IN this_DT field_NN ._.
It_PRP identifies_VBZ objectives_NNS such_JJ as_IN and_CC we_PRP are_VBP committed_VBN to_TO achieving_VBG minimizing_VBG resource_NN consumption_NN ,_, improving_VBG improvements_NNS in_IN environmental_JJ performance_NN pollution_NN control_NN and_CC waste_NN management_NN ,_, continually_RB ._.
and_CC promoting_VBG good_JJ practices_NNS amongst_IN our_PRP$ employees_NNS and_CC in_IN our_PRP$ supply_NN chain_NN ._.
With_IN our_PRP$ activities_NNS focused_VBD on_IN research_NN and_CC development_NN of_IN new_JJ drugs_NNS and_CC marketing_NN to_TO We_PRP are_VBP establishing_VBG two_CD CSR_NNP work_NN groups_NNS ,_, specialist_NN doctors_NNS ,_, our_PRP$ direct_JJ impact_NN on_IN the_DT one_CD to_TO manage_VB our_PRP$ direct_JJ environmental_JJ ,_, health_NN environment_NN is_VBZ relatively_RB limited_VBN ._.
Our_PRP$ indirect_JJ and_CC safety_NN EHS_NNP issues_NNS and_CC another_DT dedicated_VBN impacts_NNS are_VBP potentially_RB more_RBR significant_JJ ,_, and_CC to_TO contractor_NN and_CC supplier_NN relationships_NNS ._.
During_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 27_CD Corporate_NNP social_JJ responsibility_NN report_NN Shire_NNP in_IN the_DT community_NN Six_CD Shire_NNP employees_NNS are_VBP volunteering_VBG their_PRP$ time_NN every_DT week_NN to_TO listen_VB to_TO young_JJ children_NNS read_VBP at_IN a_DT local_JJ elementary_JJ school_NN as_IN part_NN of_IN the_DT UKs_NNP Business_NNP in_IN the_DT Community_NNP Reading_VBG Volunteers_NNS program_NN ._.
Heres_VBZ what_WP some_DT of_IN the_DT volunteers_NNS said_VBD :_: I_PRP had_VBD one_CD girl_NN this_DT term_NN who_WP could_MD barely_RB read_VB :_: I_PRP thought_VBD she_PRP was_VBD dyslexic_JJ ._.
Now_RB seven_CD weeks_NNS on_IN ,_, you_PRP would_MD not_RB think_VB it_PRP was_VBD the_DT same_JJ child_NN ._.
She_PRP doesnt_JJ mind_NN missing_VBG the_DT start_NN of_IN her_PRP$ PE_NN -LRB-_-LRB- physical_JJ education_NN -RRB-_-RRB- class_NN just_RB to_TO sit_VB and_CC do_VB extra_JJ words_NNS with_IN me_PRP ._.
I_PRP think_VBP the_DT process_NN of_IN interaction_NN with_IN the_DT children_NNS puts_VBZ a_DT different_JJ perspective_NN on_IN your_PRP$ working_VBG life_NN ._.
The_DT process_NN of_IN coming_VBG down_RB to_TO the_DT childs_NNS level_NN helps_VBZ to_TO focus_VB ones_NNS own_JJ daily_JJ activities_NNS ,_, especially_RB in_IN communication_NN ._.
It_PRP improves_VBZ the_DT patience_NN levels_NNS and_CC replenishes_NNS you_PRP spiritually_RB after_IN a_DT hectic_JJ day_NN in_IN the_DT office_NN ._.
I_PRP certainly_RB feel_VBP refreshed_VBN when_WRB I_PRP return_VBP from_IN a_DT session_NN and_CC invariably_RB leave_VBP the_DT school_NN with_IN a_DT smile_NN on_IN my_PRP$ face_NN ._.
Shire_NNP in_IN the_DT communityFinancial_JJ support_NN for_IN the_DT 2002_CD BritishFunding_NNP for_IN the_DT Epilepsy_NNP Foundation_NNP of_IN Shire_NNP is_VBZ committed_VBN to_TO its_PRP$ role_NN as_IN a_DT socially_RB Transplant_NNP Games_NNPS America_NNP ,_, at_IN both_DT the_DT national_JJ level_NN ,_, responsible_JJ company_NN and_CC has_VBZ the_DT aim_NN that_WDT and_CC locally_RB to_TO the_DT Epilepsy_NNP Foundation_NNP communities_NNS in_IN which_WDT it_PRP operates_VBZ should_MD benefitFinancial_NNP support_NN for_IN the_DT National_NNP of_IN Cincinnati_NNP ,_, where_WRB Shire_NNP US_NNP has_VBZ its_PRP$ directly_RB from_IN the_DT wealth_NN and_CC jobs_NNS created_VBN and_CC Association_NNP of_IN Crohns_NNPS and_CC Colitis_NNPS headquarters_NN from_IN the_DT investment_NN of_IN time_NN and_CC money_NN in_IN the_DT community_NN ._.
As_IN part_NN of_IN its_PRP$ marketing_NN support_NN activity_NN ,_, In_IN partnership_NN with_IN GlaxoSmithKline_NNP ,_, jointly_RB with_IN marketing_NN partner_NN J&J_NNP funding_NN sponsorship_NN to_TO support_VB the_DT AIDS_NNP Walks_VBZ A_DT charity_NN policy_NN was_VBD established_VBN during_IN 2002_CD for_IN educational_JJ meetings_NNS for_IN doctors_NNS ,_, the_DT across_IN Canada_NNP three_CD major_JJ walks_VBZ in_IN outlining_VBG the_DT approach_NN that_IN the_DT Company_NN memoryclinic_NN ._.
com_NN website_NN ,_, provision_NN Montreal_NNP ,_, Toronto_NNP ,_, Vancouver_NNP and_CC 100_CD takes_VBZ to_TO corporate_JJ sponsorships_NNS ,_, bursaries_NNS ,_, of_IN educational_JJ materials_NNS and_CC funding_NN of_IN walks_VBZ in_IN smaller_JJR cities_NNS fundraising_VBG and_CC charitable_JJ contributions_NNS ._.
It_PRP memory_NN clinic_NN nurses_NNS and_CC a_DT hospital_NN registrar_NN sets_VBZ clear_JJ parameters_NNS as_IN to_TO the_DT charities_NNS and_CC to_TO assist_VB with_IN the_DT support_NN of_IN AlzheimersA_NNP donation_NN to_TO The_DT Teresa_NNP Group_NNP to_TO assist_VB causes_NNS that_IN we_PRP choose_VBP to_TO support_VB at_IN both_DT treatment_NN publication_NN of_IN Bye_NNP Bye_NNP Secrets_NNPS ,_, a_DT book_NN a_DT local_JJ and_CC corporate_JJ level_NN ._.
The_DT overarching_JJ about_IN children_NNS living_VBG with_IN HIV_NNP or_CC AIDS_NNP in_IN principle_NN behind_IN this_DT policy_NN is_VBZ to_TO allow_VB localFinancial_JJ contribution_NN to_TO the_DT Crohns_NNPS and_CC their_PRP$ family_NN flexibility_NN to_TO make_VB decisions_NNS that_WDT are_VBP appropriate_JJ Colitis_NNP Foundation_NNP of_IN America_NNP CCFA_NNP and_CC to_TO support_VB both_DT Group_NNP and_CC local_JJ objectives_NNS ._.
membership_NN of_IN its_PRP$ Presidents_NNS CircleDonation_NNP of_IN FLUVIRAL_NNP vaccine_NN to_TO the_DT Columbian_NNP Ministry_NNP of_IN Healths_NNP national_JJ During_IN the_DT year_NN ,_, Shire_NNP supported_VBD a_DT wide_JJ rangeFinancial_JJ support_NN for_IN CHADD_NNP Children_NNP and_CC immunisation_NN program_NN for_IN the_DT of_IN charities_NNS and_CC causes_NNS :_: Adults_NNS with_IN Attention_NN Deficit_NNP Hyperactivity_NNP disadvantaged_JJ Disorder_NN ,_, the_DT leading_VBG non-profit_JJ organization_NN The_DT Basingstoke_NNP Alzheimers_NNP Society_NNP serving_VBG individuals_NNS with_IN ADHD_NNP in_IN the_DT United_NNP providing_VBG funding_NN to_TO enable_VB increased_VBN States_NNPS support_NN for_IN carers_NNS in_IN the_DT area_NN where_WRB the_DT Companys_NNPS head_VBP office_NN is_VBZ basedFinancial_JJ support_NN for_IN the_DT American_NNP Academy_NNP of_IN Child_NNP and_CC Adolescent_NNP Child_NNP Victims_NNPS of_IN Crime_NNP making_VBG a_DT donation_NN Psychiatry_NNP AACAP_NNP ,_, the_DT leading_JJ national_JJ instead_RB of_IN sending_VBG Company_NN Christmas_NNP cards_NNS professional_JJ medical_JJ association_NN dedicated_VBN to_TO treating_VBG and_CC improving_VBG the_DT quality_NN of_IN Provision_NNP of_IN Maxolon_NNP product_NN for_IN the_DT life_NN for_IN children_NNS ,_, adolescents_NNS and_CC families_NNS pharmacy_VBP supporting_VBG the_DT athletes_NNS at_IN the_DT affected_VBN by_IN mental_JJ ,_, behavioural_JJ or_CC Commonwealth_NNP Games_NNPS in_IN Manchester_NNP developmental_JJ disorders_NNS 28_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ social_JJ responsibility_NN report_NN Marking_VBG Breast_NNP Awareness_NNP Month_NNP the_DT Shire_NNP matched_VBD funds_NNS raised_VBN by_IN head_NN office_NN Human_NNP Resources_NNP and_CC Marketing_NNP Departments_NNP employees_NNS in_IN a_DT sponsored_VBN run_NN to_TO support_VB at_IN Shire_NNP in_IN the_DT US_NNP hosted_VBD an_DT educational_JJ meeting_NN Cancer_NNP Research_NNP ._.
The_DT American_NNP Cancer_NNP Society_NNP presented_VBD information_NN on_IN its_PRP$ research_NN ,_, early_RB detection_NN and_CC treatment_NN of_IN breast_NN cancer_NN and_CC had_VBD a_DT breast_NN cancer_NN survivor_NN give_VB her_PRP$ testimonial_NN ._.
Several_JJ employees_NNS also_RB showed_VBD their_PRP$ support_NN by_IN participating_VBG in_IN the_DT walk_NN Making_VBG Strides_NNP Against_IN Breast_NNP Cancer_NNP in_IN Cincinnati_NNP and_CC more_JJR than_IN US$_$ 3,000_CD was_VBD raised_VBN ._.
Sponsorship_NN of_IN the_DT sixth_JJ Organic_NNP Workshop_NNP for_IN Leading_VBG Young_JJ Canadian_JJ Chemists_NNS Actions_NNS on_IN CSR_NNP planned_VBD for_IN 2003_CD organised_VBN by_IN the_DT Simon_NNP Fraser_NNP University_NNP in_IN In_NNP 2003_CD ,_, the_DT Group_NNP intends_VBZ to_TO continue_VB British_JJ Columbia_NNP ,_, Canada_NNP to_TO embed_VB CSR_NNP issues_NNS into_IN its_PRP$ corporate_JJ governance_NN framework_NN ._.
A_DT number_NN of_IN Support_NN of_IN the_DT Daffodil_NNP Ball_NNP ,_, a_DT fundraising_VBG specific_JJ projects_NNS are_VBP underway_JJ ,_, including_VBG :_: event_NN of_IN the_DT Canadian_JJ Cancer_NN Society_NNP Strengthening_NNP our_PRP$ engagement_NN with_IN Employee_NNP involvement_NN and_CC fundraising_VBG to_TO stakeholders_NNS support_VBP Centraide_NNP ,_, a_DT Canadian_JJ organization_NN that_WDT encourages_VBZ community_NN volunteering_NN ._.
Setting_VBG up_RP Group_NNP and_CC site_NN Its_PRP$ mission_NN is_VBZ to_TO help_VB build_VB caring_VBG environmental_JJ objectives_NNS and_CC targets_NNS communities_NNS and_CC provide_VB direct_JJ financial_JJ support_NN to_TO people_NNS in_IN needSetting_VBG up_RP Group_NNP and_CC site_NN health_NN and_CC safety_NN objectives_NNS and_CC targets_NNS Support_NN for_IN the_DT Worcester_NNP Regional_NNP Science_NNP and_CC Engineering_NNP Fair_NNP inIntegrating_NNP CSR_NNP topics_NNS into_IN the_DT Northborough_NNP Massachussets_NNPS ,_, US_NNP ,_, and_CC management_NN of_IN our_PRP$ contractors_NNS and_CC sponsorship_NN of_IN a_DT scholarship_NN program_NN suppliers_NNS for_IN community_NN schools_NNS ._.
Improving_NN our_PRP$ CSR_NNP data_NNS gathering_NN and_CC reporting_NN Building_NN up_IN employee_NN awareness_NN and_CC commitment_NN to_TO CSR_NNP Improving_NN Shire_NNP ranking_NN in_IN key_JJ CSR_NNP indices_NNS ._.
Over_IN time_NN ,_, additional_JJ information_NN will_MD be_VB made_VBN available_JJ regarding_VBG our_PRP$ policies_NNS and_CC practices_NNS in_IN this_DT area_NN both_DT on_IN our_PRP$ website_NN ,_, www_NN ._.
com_NN ,_, and_CC in_IN future_JJ Annual_JJ Reviews_NNS ._.
We_PRP welcome_VBP any_DT comments_NNS and_CC ideas_NNS for_IN improvement_NN in_IN our_PRP$ practices_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 29_CD Financial_NNP review_NN The_DT following_VBG review_NN should_MD be_VB read_VBN in_IN conjunction_NN with_IN the_DT Groups_NNS consolidated_JJ financial_JJ statements_NNS and_CC related_JJ notes_NNS appearing_VBG elsewhere_RB in_IN this_DT report_NN ._.
Material_NNP acquisitions_NNS and_CC disposals_NNS Sales_NNS of_IN ADDERALL_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD were_VBD On_IN 27_CD September_NNP 2002_CD ,_, Shire_NNP completed_VBD its_PRP$ acquisition_NN of_IN Atlantic_NNP $_$ 109.8_CD million_CD compared_VBN to_TO $_$ 317.7_CD million_CD in_IN the_DT comparative_JJ period_NN ._.
Pharmaceutical_NNP Services_NNPS Inc._NNP ._.
APS_NNP from_IN Niro_NNP Inc._NNP for_IN cash_NN consideration_NN This_DT decline_NN in_IN ADDERALL_NNP sales_NNS is_VBZ largely_RB due_JJ to_TO the_DT success_NN in_IN of_IN $_$ 17.3_CD million_CD ,_, including_VBG $_$ 0.3_CD million_CD costs_NNS of_IN acquisition_NN ._.
This_DT converting_VBG patients_NNS to_TO the_DT new_JJ ,_, once-a-day_JJ formulation_NN of_IN the_DT drug_NN ,_, transaction_NN provides_VBZ an_DT in-house_JJ facility_NN in_IN which_WDT to_TO manufacture_VB several_JJ ADDERALL_NNP XR_NNP ._.
key_JJ US_NNP products_NNS ,_, thus_RB ensuring_VBG dual_JJ sourcing_VBG of_IN major_JJ growth_NN drivers_NNS for_IN the_DT Company_NN and_CC attendant_JJ cost_NN benefits_NNS ._.
The_DT acquisition_NN was_VBD On_IN a_DT combined_VBN basis_NN ,_, product_NN sales_NNS from_IN the_DT ADHD_NNP franchise_NN in_IN 2002_CD accounted_VBD for_IN using_VBG the_DT purchase_NN method_NN and_CC goodwill_NN of_IN $_$ 10.2_CD million_CD were_VBD up_RB $_$ 77.4_CD million_CD ,_, a_DT 22_CD %_NN increase_NN compared_VBN to_TO the_DT prior_JJ year_NN ._.
Over_IN the_DT same_JJ period_NN ,_, the_DT number_NN of_IN prescriptions_NNS written_VBN for_IN ADDERALL_NNP XR_NNP and_CC ADDERALL_NNP was_VBD marginally_RB higher_JJR ,_, by_IN 0.6_CD %_NN ._.
On_IN 27_CD December_NNP 2002_CD ,_, Shire_NNP completed_VBD its_PRP$ divestment_NN of_IN a_DT group_NN of_IN In_IN December_NNP 2002_CD ,_, these_DT products_NNS achieved_VBD a_DT 28.8_CD %_NN share_NN of_IN the_DT non-strategic_JJ US_NNP products_NNS ,_, known_VBN collectively_RB as_IN the_DT over-the-counter_JJ US_NNP ADHD_NNP prescription_NN market_NN December_NNP 2001_CD :_: 34.4_CD %_NN ._.
Shire_NNP received_VBD sale_NN proceeds_NNS of_IN $_$ 72_CD million_CD ADHD_NNP market_NN grew_VBD by_IN 14_CD %_NN during_IN 2002_CD and_CC thus_RB provided_VBN further_RB around_IN three_CD times_NNS annual_JJ sales_NNS and_CC recorded_VBD a_DT gain_NN on_IN disposal_NN support_NN to_TO the_DT excellent_JJ result_NN in_IN switching_VBG patients_NNS to_TO ADDERALL_NNP XR_NNP ._.
Our_PRP$ extended-release_JJ product_NN ADDERALL_NNP XR_NNP is_VBZ covered_VBN by_IN a_DT US_NNP patent_NN ._.
Results_NNS of_IN operations_NNS In_IN January_NNP 2003_CD we_PRP received_VBD a_DT Paragraph_NNP IV_NNP notice_NN from_IN Barr_NNP alleging_VBG Income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS and_CC equity_NN that_IN this_DT patent_NN is_VBZ invalid_JJ and_CC not_RB infringed_VBN by_IN Barrs_NNP extended-release_NN method_NN investees_NNS ,_, for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD was_VBD mixed_JJ amphetamine_NN salt_NN product_NN ._.
In_IN February_NNP 2003_CD ,_, Shire_NNP Laboratories_NNPS $_$ 329.1_CD million_CD compared_VBN to_TO $_$ 101.5_CD million_CD in_IN 2001_CD ._.
Included_VBN in_IN the_DT Inc._NNP filed_VBD suit_NN against_IN Barr_NNP for_IN infringement_NN of_IN this_DT US_NNP patent_NN ._.
For_IN more_JJR results_NNS for_IN 2001_CD were_VBD charges_NNS of_IN $_$ 177.0_CD million_CD relating_VBG to_TO the_DT merger_NN details_NNS see_VBP note_NN 19_CD to_TO this_DT report_NN and_CC financial_JJ statements_NNS ._.
There_EX can_MD be_VB with_IN BioChem_NNP Pharma_NNP Inc._NNP ._.
Diluted_JJ earnings_NNS per_IN share_NN ,_, for_IN the_DT year_NN no_DT assurance_NN that_IN the_DT Group_NNP will_MD prevail_VB in_IN the_DT suit_NN and_CC in_IN the_DT event_NN it_PRP ended_VBD 31_CD December_NNP 2002_CD was_VBD 49.0_CD compared_VBN to_TO 7.7_CD in_IN 2001_CD ._.
does_VBZ not_RB this_DT may_MD have_VB a_DT material_NN adverse_JJ impact_NN on_IN the_DT Groups_NNS results_NNS and_CC financial_JJ position_NN ._.
The_DT current_JJ year_NN results_NNS include_VBP the_DT results_NNS of_IN APS_NNP from_IN the_DT acquisition_NN date_NN ._.
The_DT results_NNS ,_, for_IN all_DT periods_NNS other_JJ than_IN 2002_CD ,_, have_VBP been_VBN restated_VBN to_TO AGRYLIN_NNP reflect_VBP the_DT disposal_NN of_IN our_PRP$ OTC_NNP business_NN which_WDT has_VBZ been_VBN accounted_VBN for_IN Total_JJ AGRYLIN_NNP sales_NNS for_IN the_DT year_NN to_TO 31_CD December_NNP 2002_CD were_VBD as_IN a_DT discontinued_VBN operation_NN ._.
$_$ 119.2_CD million_CD ,_, an_DT increase_NN of_IN 39_CD %_NN compared_VBN to_TO the_DT prior_JJ year_NN 2001_CD :_: $_$ 85.5_CD million_CD ._.
Turnover_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, total_JJ revenues_NNS increased_VBN by_IN Underlying_JJ prescriptions_NNS for_IN AGRYLIN_NNP in_IN the_DT US_NNP ,_, where_WRB it_PRP is_VBZ the_DT only_JJ 22_CD %_NN to_TO $_$ 1,037.3_CD million_CD ,_, compared_VBN to_TO $_$ 853.0_CD million_CD in_IN 2001_CD ._.
product_NN licensed_VBD for_IN the_DT treatment_NN of_IN essential_JJ thrombocythemia_NN ,_, increased_VBN by_IN 22_CD %_NN ._.
Shire_NNP achieved_VBD 26.5_CD %_NN of_IN the_DT total_JJ US_NNP AGRYLIN_NNP ,_, Turnover_NN is_VBZ primarily_RB derived_VBN from_IN sales_NNS of_IN pharmaceutical_JJ products_NNS with_IN hydrea_NN and_CC generic_JJ hydroxyurea_NN prescription_NN market_NN in_IN December_NNP 2002_CD ,_, the_DT balance_NN coming_VBG from_IN royalties_NNS earned_VBN on_IN products_NNS out-licensed_JJ to_TO compared_VBN to_TO 24.4_CD %_NN in_IN December_NNP 2001_CD ._.
third_JJ parties_NNS ._.
For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, 83_CD %_NN of_IN turnover_NN was_VBD in_IN respect_NN of_IN product_NN sales_NNS 2001_CD :_: 82_CD %_NN ._.
PENTASA_NNP Sales_NNS of_IN PENTASA_NNP ,_, for_IN the_DT treatment_NN of_IN ulcerative_JJ colitis_NNS ,_, were_VBD up_RB 15_CD %_NN Product_NN sales_NNS at_IN $_$ 87.2_CD million_CD 2001_CD :_: $_$ 75.5_CD million_CD ._.
PENTASA_NNP had_VBD a_DT prescription_NN share_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, product_NN sales_NNS increased_VBN by_IN 23_CD %_NN of_IN 17.6_CD %_NN of_IN the_DT US_NNP oral_JJ mesalamine_NN olsalazine_NN market_NN in_IN December_NNP to_TO $_$ 859.4_CD million_CD ,_, compared_VBN to_TO $_$ 699.4_CD million_CD in_IN the_DT prior_JJ year_NN ._.
ADDERALL_NNP franchise_NN PROAMATINE_NNP At_IN the_DT outset_NN ,_, 2002_CD was_VBD to_TO be_VB a_DT challenging_JJ year_NN for_IN the_DT ADDERALL_NNP Sales_NNS of_IN PROAMATINE_NNP ,_, for_IN the_DT treatment_NN of_IN postural_JJ hypotension_NN ,_, were_VBD franchise_NN ,_, as_IN it_PRP was_VBD expected_VBN to_TO face_VB strong_JJ competition_NN from_IN generic_JJ $_$ 50.9_CD million_CD ,_, 34_CD %_NN higher_JJR than_IN 2001_CD sales_NNS of_IN $_$ 38.0_CD million_CD ._.
For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, sales_NNS of_IN ADDERALL_NNP prescription_NN market_NN for_IN PROAMATINE_NNP and_CC fludrocortisone_JJ acetate_NN XR_NNP were_VBD $_$ 317.9_CD million_CD compared_VBN to_TO $_$ 32.6_CD million_CD in_IN the_DT last_JJ two_CD prescriptions_NNS indicated_VBD that_IN PROAMATINE_NNP had_VBD a_DT 25.3_CD %_NN market_NN share_NN for_IN months_NNS of_IN 2001_CD the_DT year_NN of_IN launch_NN ._.
the_DT month_NN of_IN December_NNP 2002_CD ,_, an_DT increase_NN from_IN 23.6_CD %_NN in_IN December_NNP 2001_CD ._.
30_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Financial_NNP review_NN CARBATROL_NNP $_$ 31.4_CD million_CD ._.
The_DT underlying_VBG charge_NN for_IN the_DT year_NN decreased_VBD because_IN Sales_NNS of_IN CARBATROL_NNP ,_, for_IN the_DT treatment_NN of_IN epilepsy_NN ,_, were_VBD $_$ 45.3_CD million_CD in_IN accordance_NN with_IN US_NNP Accounting_NNP Standards_NNPS goodwill_NN is_VBZ no_RB longer_RBR in_IN 2002_CD ,_, an_DT increase_NN of_IN 23_CD %_NN over_IN prior_JJ year_NN sales_NNS of_IN $_$ 36.8_CD million_CD ._.
amortised_JJ and_CC is_VBZ instead_RB tested_VBN at_IN least_JJS annually_RB for_IN impairment_NN ._.
Goodwill_NNP CARBATROL_NNP achieved_VBD 36.3_CD %_NN of_IN the_DT US_NNP extended-release_NN amortisation_NN was_VBD $_$ 10.8_CD million_CD in_IN 2001_CD ._.
The_DT depreciation_NN charge_NN for_IN carbamazepine_NN prescription_NN market_NN in_IN December_NNP 2002_CD ,_, compared_VBN with_IN 2002_CD was_VBD $_$ 12.9_CD million_CD ,_, a_DT decrease_NN of_IN $_$ 1.5_CD million_CD compared_VBN to_TO 2001_CD ._.
Capital_NNP structure_NN Royalties_NNS The_DT Group_NNP has_VBZ financed_VBN its_PRP$ operations_NNS since_IN inception_NN through_IN private_JJ Royalty_NN revenue_NN increased_VBD 20_CD %_NN to_TO $_$ 174.8_CD million_CD for_IN the_DT year_NN ended_VBD and_CC public_JJ offerings_NNS of_IN equity_NN securities_NNS ,_, the_DT issuance_NN of_IN loan_NN notes_NNS and_CC 31_CD December_NNP 2002_CD compared_VBN to_TO $_$ 145.2_CD million_CD in_IN 2001_CD ._.
Shire_NNP receives_VBZ convertible_JJ notes_NNS ,_, collaborative_JJ licensing_NN and_CC development_NN fees_NNS ,_, product_NN royalties_NNS from_IN GSK_NNP on_IN the_DT worldwide_JJ sales_NNS of_IN 3TC_NNP and_CC ZEFFIX_NNP ,_, with_IN the_DT sales_NNS and_CC investment_NN income_NN ._.
exception_NN of_IN Canada_NNP ,_, where_WRB a_DT partnership_NN with_IN GSK_NNP exists_VBZ ._.
The_DT Groups_NNS funding_NN requirements_NNS depend_VBP on_IN a_DT number_NN of_IN factors_NNS ,_, Other_JJ royalties_NNS are_VBP received_VBN in_IN respect_NN of_IN REMINYL_NNP from_IN Johnson_NNP &_CC including_VBG the_DT Groups_NNS product_NN development_NN programs_NNS ,_, business_NN and_CC Johnson_NNP ,_, and_CC in_IN addition_NN a_DT number_NN of_IN hormone-replacement_NN therapy_NN product_NN acquisitions_NNS ,_, the_DT level_NN of_IN resources_NNS required_VBN for_IN the_DT expansion_NN HRT_NNP products_NNS from_IN various_JJ licensees_NNS ._.
of_IN marketing_NN capabilities_NNS as_IN the_DT product_NN base_NN expands_VBZ ,_, increased_VBD investment_NN in_IN trade_NN debtors_NNS and_CC stock_NN levels_NNS which_WDT may_MD arise_VB as_IN sales_NNS Cost_NN of_IN sales_NNS levels_NNS increase_NN ,_, competitive_JJ and_CC technological_JJ developments_NNS ,_, the_DT timing_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, cost_NN of_IN sales_NNS amounted_VBD to_TO 16_CD %_NN and_CC cost_NN of_IN obtaining_VBG required_JJ regulatory_JJ approvals_NNS for_IN new_JJ products_NNS ,_, of_IN product_NN sales_NNS ,_, consistent_JJ with_IN 2001_CD ._.
A_DT slight_JJ favourable_JJ mix_NN of_IN higherand_NN the_DT continuing_VBG revenues_NNS generated_VBD from_IN sales_NNS of_IN key_JJ products_NNS ._.
margin_NN products_NNS largely_RB offset_VBP costs_NNS associated_VBN with_IN enhancing_VBG internal_JJ and_CC external_JJ production_NN facility_NN capabilities_NNS ._.
As_IN of_IN 31_CD December_NNP 2002_CD ,_, the_DT Group_NNP had_VBD cash_NN ,_, cash_NN equivalents_NNS and_CC marketable_JJ securities_NNS of_IN $_$ 1,213.8_CD million_CD 31_CD December_NNP 2001_CD :_: Research_NNP and_CC development_NN expenses_NNS $_$ 842.0_CD million_CD ,_, which_WDT consisted_VBD of_IN immediately_RB available_JJ money_NN market_NN R&D_NNP expenditure_NN increased_VBD to_TO $_$ 189.2_CD million_CD in_IN 2002_CD ,_, from_IN $_$ 171.0_CD million_CD fund_NN balances_NNS and_CC investment_NN grade_NN securities_NNS ._.
Total_JJ long-term_JJ debt_NN ,_, in_IN 2001_CD ,_, representing_VBG an_DT overall_JJ increase_NN of_IN 11_CD %_NN ._.
As_IN a_DT percentage_NN of_IN excluding_VBG capital_NN leases_NNS ,_, as_IN of_IN 31_CD December_NNP 2002_CD was_VBD $_$ 401.9_CD million_CD turnover_NN ,_, research_NN and_CC development_NN costs_NNS were_VBD 18_CD %_NN 2001_CD :_: 20_CD %_NN ._.
31_CD December_NNP 2001_CD :_: $_$ 406.8_CD million_CD of_IN which_WDT $_$ 400_CD million_CD was_VBD in_IN Shire_NNP aims_VBZ to_TO invest_VB between_IN 18_CD %_NN and_CC 20_CD %_NN of_IN total_JJ turnover_NN in_IN R&D_NNP ,_, respect_NN of_IN guaranteed_VBN convertible_JJ loan_NN notes_NNS which_WDT were_VBD issued_VBN on_IN although_IN the_DT actual_JJ level_NN of_IN expenditure_NN required_VBN each_DT year_NN is_VBZ driven_VBN 15_CD August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP the_DT Issuer_NNP ,_, a_DT wholly_RB owned_VBN by_IN the_DT progress_NN and_CC development_NN phase_NN of_IN existing_VBG and_CC new_JJ projects_NNS ._.
These_DT convertible_JJ notes_NNS due_JJ 2011_CD were_VBD issued_VBN to_TO international_JJ institutional_JJ investors_NNS and_CC bear_NN interest_NN at_IN a_DT rate_NN of_IN 2_CD %_NN per_IN annum_NN ._.
Selling_VBG ,_, general_JJ and_CC administrative_JJ expenses_NNS Selling_VBG ,_, general_JJ and_CC administrative_JJ expenses_NNS increased_VBD from_IN The_DT convertible_JJ notes_NNS are_VBP guaranteed_VBN by_IN Shire_NNP and_CC are_VBP convertible_JJ into_IN $_$ 303.5_CD million_CD in_IN 2001_CD to_TO $_$ 386.0_CD million_CD in_IN 2002_CD ,_, an_DT increase_NN of_IN 27_CD %_NN ._.
redeemable_JJ preference_NN shares_NNS of_IN the_DT Issuer_NN which_WDT upon_IN issuance_NN will_MD be_VB As_IN a_DT percentage_NN of_IN product_NN sales_NNS ,_, these_DT expenses_NNS were_VBD 45_CD %_NN immediately_RB exchanged_VBD for_IN either_DT i_FW Shire_FW common_JJ shares_NNS or_CC ii_FW Shire_FW 2001_CD :_: 43_CD %_NN ._.
American_JJ Depository_NNP Shares_NNP ADSs_NNP ,_, or_CC iii_NN at_IN the_DT Issuers_NNPS option_NN ,_, a_DT cash_NN amount_NN based_VBN upon_IN the_DT London_NNP Stock_NNP Exchange_NNP volume-weighted_JJ Higher_JJR selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS were_VBD primarily_RB average_JJ prices_NNS of_IN common_JJ shares_NNS on_IN the_DT fourth_JJ through_IN eighth_JJ business_NN due_JJ to_TO increased_VBN selling_NN and_CC marketing_NN expenses_NNS supporting_VBG higher_JJR days_NNS following_VBG conversion_NN ._.
See_VB note_NN 16_CD to_TO the_DT consolidated_JJ financial_JJ field_NN headcount_NN and_CC promotional_JJ efforts_NNS for_IN recent_JJ product_NN launches_NNS ,_, statements_NNS for_IN further_JJ information_NN ._.
The_DT only_JJ other_JJ long-term_JJ debt_NN outstanding_JJ at_IN 31_CD December_NNP 2002_CD was_VBD A_DT component_NN of_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS is_VBZ in_IN respect_NN of_IN a_DT Canadian_JJ federal_JJ and_CC provincial_JJ government_NN loan_NN of_IN depreciation_NN and_CC amortisation_NN ,_, which_WDT increased_VBD from_IN $_$ 45.8_CD million_CD in_IN $_$ 1.9_CD million_CD CAN$_NNP 3.0_CD million_CD ._.
This_DT facility_NN is_VBZ non-interest-bearing_JJ and_CC 2001_CD to_TO $_$ 55.2_CD million_CD in_IN 2002_CD ._.
For_IN 2002_CD ,_, the_DT amortisation_NN expense_NN of_IN is_VBZ repayable_JJ in_IN annual_JJ instalments_NNS of_IN $_$ 0.6_CD million_CD CAN$_NNP 1.0_CD million_CD ._.
$_$ 42.3_CD million_CD included_VBD amortisation_NN charged_VBN for_IN the_DT year_NN of_IN $_$ 23.5_CD million_CD and_CC $_$ 18.8_CD million_CD in_IN respect_NN of_IN impairments_NNS recorded_VBN on_IN tail-end_JJ products_NNS Treasury_NNP policies_NNS and_CC financial_JJ risk_NN management_NN in_IN Europe_NNP and_CC the_DT US_NNP ._.
In_IN the_DT prior_JJ year_NN the_DT annual_JJ charge_NN was_VBD Shires_NNP principal_JJ treasury_NN operations_NNS are_VBP managed_VBN by_IN the_DT corporate_JJ Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 31_CD Financial_NNP review_NN treasury_NN function_NN based_VBN in_IN the_DT UK_NNP ._.
All_DT treasury_NN operations_NNS are_VBP conducted_VBN was_VBD $_$ 92.19_CD ,_, compared_VBN with_IN an_DT issue_NN price_NN of_IN $_$ 100_CD ._.
If_IN the_DT loan_NN is_VBZ not_RB within_IN a_DT framework_NN of_IN policies_NNS and_CC procedures_NNS approved_VBN by_IN the_DT Board_NNP ._.
converted_VBN into_IN equity_NN ,_, it_PRP would_MD be_VB repayable_JJ at_IN $_$ 100_CD per_IN note_NN ._.
The_DT total_JJ As_IN a_DT matter_NN of_IN policy_NN ,_, the_DT Company_NN does_VBZ not_RB undertake_VB speculative_JJ fair_JJ value_NN of_IN the_DT debt_NN as_IN at_IN 31_CD December_NNP 2002_CD ,_, based_VBN on_IN the_DT above_JJ transactions_NNS which_WDT would_MD increase_VB currency_NN or_CC interest_NN rate_NN exposure_NN ._.
There_EX is_VBZ no_DT material_NN difference_NN between_IN The_DT Board_NNP reviews_NNS and_CC agrees_VBZ policies_NNS for_IN managing_VBG these_DT risks_NNS and_CC the_DT book_NN and_CC fair_JJ value_NN of_IN the_DT remainder_NN of_IN the_DT Companys_NNPS debt_NN ._.
These_DT convertible_JJ notes_NNS are_VBP guaranteed_VBN by_IN Shire_NNP and_CC are_VBP convertible_JJ into_IN Foreign_JJ currency_NN risk_NN redeemable_JJ preference_NN shares_NNS of_IN the_DT Issuer_NN which_WDT upon_IN issuance_NN will_MD be_VB The_DT Company_NN is_VBZ exposed_VBN to_TO movements_NNS in_IN foreign_JJ exchange_NN rates_NNS immediately_RB exchanged_VBD for_IN either_DT Shire_NNP i_FW common_JJ shares_NNS or_CC ii_FW ADSs_FW ,_, against_IN US_NNP dollars_NNS for_IN trading_NN transactions_NNS and_CC the_DT translation_NN of_IN net_JJ or_CC ,_, iii_FW at_IN the_DT Issuers_NNPS option_NN ,_, cash_NN ._.
The_DT convertible_JJ notes_NNS bear_VBP interest_NN of_IN assets_NNS and_CC earnings_NNS of_IN non-US_JJ subsidiaries_NNS ._.
The_DT main_JJ trading_NN currencies_NNS 2_CD %_NN per_IN annum_NN ,_, payable_JJ semi-annually_RB ._.
This_DT interest_NN rate_NN is_VBZ fixed_VBN over_IN of_IN the_DT Company_NN are_VBP the_DT US_NNP dollar_NN ,_, the_DT Canadian_JJ dollar_NN ,_, pounds_NNS sterling_NN the_DT period_NN of_IN the_DT debt_NN ,_, thus_RB reducing_VBG any_DT cash_NN flow_NN risk_NN associated_VBN with_IN and_CC the_DT euro_NN ._.
The_DT financial_JJ statements_NNS of_IN foreign_JJ entities_NNS are_VBP translated_VBN movements_NNS in_IN interest_NN rates_NNS ._.
using_VBG the_DT accounting_NN policies_NNS described_VBN in_IN note_NN 2_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
The_DT interest_NN rate_NN risk_NN that_WDT has_VBZ been_VBN mitigated_VBN by_IN obtaining_VBG a_DT fixed_JJ rate_NN debt_NN is_VBZ equivalent_JJ to_TO a_DT $_$ 4.0_CD million_CD saving_NN per_IN 1_CD %_NN rise_NN in_IN interest_NN rates_NNS A_DT small_JJ proportion_NN of_IN debt_NN is_VBZ denominated_VBN in_IN foreign_JJ currencies_NNS ._.
Conversely_RB a_DT fall_NN in_IN interest_NN rates_NNS by_IN 1_CD %_NN would_MD effectively_RB 31_CD December_NNP 2002_CD ,_, a_DT total_NN of_IN $_$ 1.9_CD million_CD was_VBD outstanding_JJ 31_CD December_NNP cost_NN the_DT Company_NN $_$ 4.0_CD million_CD ._.
Investors_NNS have_VBP the_DT right_NN to_TO require_VB the_DT 2001_CD :_: $_$ 5.4_CD million_CD in_IN respect_NN of_IN loans_NNS denominated_VBN in_IN Canadian_JJ dollars_NNS ._.
Issuer_NN to_TO redeem_VB the_DT notes_NNS at_IN par_NN on_IN 21_CD August_NNP 2004_CD ,_, 2006_CD or_CC 2008_CD ._.
Subject_JJ to_TO certain_JJ conditions_NNS ,_, the_DT convertible_JJ notes_NNS will_MD be_VB callable_JJ after_IN The_DT exposure_NN to_TO foreign_JJ exchange_NN market_NN risk_NN is_VBZ managed_VBN and_CC 21_CD August_NNP 2004_CD ._.
monitored_VBN by_IN the_DT treasury_NN function_NN ,_, using_VBG forecasts_NNS provided_VBN by_IN the_DT operating_VBG units_NNS ._.
The_DT Company_NN has_VBZ not_RB undertaken_VBN any_DT foreign_JJ currency_NN In_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, the_DT average_JJ interest_NN rate_NN received_VBD hedges_NNS through_IN the_DT use_NN of_IN spot_NN or_CC forward_RB foreign_JJ exchange_NN contracts_NNS on_IN cash_NN and_CC liquid_JJ investments_NNS was_VBD approximately_RB 1.8_CD %_NN per_IN annum_NN ._.
during_IN the_DT year_NN to_TO 31_CD December_NNP 2002_CD ._.
Instead_RB ,_, exposures_NNS have_VBP been_VBN The_DT largest_JJS proportion_NN of_IN investments_NNS was_VBD in_IN US_NNP dollar_NN deposits_NNS ._.
managed_VBN through_IN natural_JJ hedging_NN via_IN the_DT currency_NN denomination_NN of_IN cash_NN balances_NNS ._.
Taxation_NNP The_NNP effective_JJ tax_NN rate_NN for_IN 2002_CD was_VBD 27_CD %_NN 2001_CD :_: 68_CD %_NN ._.
The_DT effective_JJ The_DT Company_NN has_VBZ subsidiaries_NNS in_IN European_JJ countries_NNS that_WDT have_VBP tax_NN rate_NN for_IN 2001_CD was_VBD affected_VBN by_IN the_DT $_$ 177.0_CD million_CD of_IN charges_NNS in_IN converted_VBN to_TO the_DT euro_NN ._.
All_DT such_JJ subsidiaries_NNS successfully_RB converted_VBD to_TO connection_NN with_IN the_DT BioChem_NNP merger_NN ._.
Income_NN taxes_NNS in_IN respect_NN of_IN the_DT euro_NN in_IN a_DT timely_JJ and_CC efficient_JJ manner_NN ._.
continuing_VBG operations_NNS increased_VBN by_IN $_$ 19.5_CD million_CD to_TO $_$ 88.4_CD million_CD 2001_CD :_: $_$ 68.9_CD million_CD ._.
At_IN 31_CD December_NNP 2002_CD ,_, net_JJ deferred_VBN tax_NN assets_NNS Market_NN risk_NN of_IN investments_NNS of_IN $_$ 41.1_CD million_CD were_VBD recognized_VBN 31_CD December_NNP 2001_CD :_: $_$ 39.7_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2002_CD ,_, the_DT Company_NN has_VBZ $_$ 72.0_CD million_CD of_IN investments_NNS on_IN its_PRP$ books_NNS comprising_VBG equity_NN investment_NN funds_NNS ,_, private_JJ companies_NNS and_CC A_DT reconciliation_NN of_IN the_DT current_JJ tax_NN charge_NN for_IN 2002_CD and_CC 2001_CD to_TO the_DT profit_NN public_JJ quoted_VBN equities_NNS 31_CD December_NNP 2001_CD :_: $_$ 68.7_CD million_CD ._.
The_DT public_NN before_IN tax_NN for_IN those_DT years_NNS at_IN the_DT statutory_JJ tax_NN rate_NN of_IN 30_CD %_NN is_VBZ given_VBN in_IN quoted_VBN equities_NNS are_VBP exposed_VBN to_TO market_NN risk_NN ._.
No_DT financial_JJ instruments_NNS or_CC note_NN 26_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
derivatives_NNS have_VBP been_VBN employed_VBN to_TO hedge_VB this_DT risk_NN ._.
Cash_NN flows_VBZ Interest_NN rate_NN risk_NN As_IN of_IN 31_CD December_NNP 2002_CD cash_NN ,_, cash_NN equivalents_NNS and_CC marketable_JJ Due_JJ to_TO the_DT proportion_NN of_IN fixed_JJ rate_NN debt_NN ,_, the_DT Companys_NNPS interest_NN charge_NN securities_NNS totalled_VBD $_$ 1,213.8_CD million_CD ,_, an_DT increase_NN of_IN $_$ 371.8_CD million_CD from_IN has_VBZ limited_VBN exposure_NN to_TO interest_NN rate_NN movements_NNS ._.
Marketable_JJ securities_NNS consisted_VBD of_IN money_NN market_NN fund_NN balances_NNS and_CC investment_NN grade_NN securities_NNS ._.
Total_JJ debt_NN as_IN of_IN 31_CD December_NNP 2002_CD was_VBD $_$ 408.2_CD million_CD 31_CD December_NNP 2001_CD :_: $_$ 406.8_CD million_CD ._.
The_DT main_JJ component_NN was_VBD $_$ 400_CD million_CD in_IN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD net_JJ cash_NN inflow_NN from_IN operating_VBG guaranteed_VBN convertible_JJ notes_NNS due_JJ 2011_CD ._.
These_DT were_VBD issued_VBN in_IN August_NNP activities_NNS amounted_VBD to_TO $_$ 356.5_CD million_CD compared_VBN to_TO $_$ 196.8_CD million_CD in_IN 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP the_DT Issuer_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ._.
Net_JJ income_NN of_IN $_$ 250.6_CD million_CD is_VBZ stated_VBN after_IN accounting_VBG for_IN nonThe_JJ market_NN price_NN of_IN the_DT convertible_JJ notes_NNS as_IN at_IN 31_CD December_NNP 2002_CD ,_, cash_NN depreciation_NN and_CC amortisation_NN of_IN $_$ 55.2_CD million_CD and_CC other_JJ non-cash_JJ 32_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Financial_NNP review_NN items_NNS totalling_VBG $_$ 9.4_CD million_CD ._.
There_EX has_VBZ also_RB been_VBN an_DT overall_JJ inflow_NN of_IN The_DT Company_NN has_VBZ a_DT ten-year_JJ contract_NN with_IN the_DT Canadian_JJ government_NN $_$ 41.3_CD million_CD from_IN working_VBG capital_NN items_NNS due_JJ to_TO changes_NNS in_IN receivables_NN ,_, to_TO assure_VB a_DT state_NN of_IN readiness_NN in_IN the_DT case_NN of_IN an_DT influenza_NN pandemic_JJ inventories_NNS and_CC payables_NNS ._.
worldwide_JJ epidemic_JJ and_CC to_TO manufacture_VB influenza_NN vaccine_NN for_IN all_DT Canadian_JJ citizens_NNS in_IN such_JJ an_DT event_NN ._.
Under_IN the_DT contract_NN ,_, Shire_NNP Biologics_NNP During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, cash_NN generated_VBD from_IN will_MD also_RB supply_VB the_DT Government_NN of_IN Canada_NNP with_IN a_DT substantial_JJ proportion_NN operations_NNS was_VBD used_VBN primarily_RB to_TO fund_VB capital_NN expenditures_NNS ,_, including_VBG of_IN its_PRP$ annual_JJ influenza_NN vaccine_NN requirements_NNS over_IN the_DT ten-year_JJ period_NN ._.
the_DT purchase_NN of_IN the_DT APS_NNP manufacturing_NN facility_NN for_IN $_$ 17.0_CD million_CD ,_, Subject_NNP to_TO mutual_JJ agreement_NN ,_, the_DT contract_NN can_MD be_VB renewed_VBN for_IN a_DT further_JJ the_DT purchase_NN of_IN SOLARAZE_NNP for_IN $_$ 20.1_CD million_CD and_CC various_JJ capital_NN period_NN of_IN between_IN one_CD and_CC ten_CD years_NNS from_IN 2011_CD ._.
expenditures_NNS on_IN property_NN ,_, plant_NN and_CC equipment_NN ._.
The_DT sale_NN of_IN the_DT US_NNP OTC_NNP business_NN generated_VBD a_DT cash_NN inflow_NN of_IN $_$ 71.0_CD million_CD ._.
The_DT concept_NN of_IN a_DT state_NN of_IN readiness_NN against_IN an_DT influenza_NN pandemic_JJ requires_VBZ the_DT development_NN of_IN sufficient_JJ infrastructure_NN and_CC capacity_NN in_IN Balance_NNP sheet_NN value_NN Canada_NNP to_TO provide_VB 100_CD %_NN of_IN domestic_JJ vaccine_NN needs_NNS in_IN the_DT event_NN of_IN an_DT The_DT consolidated_JJ net_JJ assets_NNS of_IN the_DT Group_NNP increased_VBN by_IN $_$ 310.2_CD million_CD influenza_NN pandemic_NN ._.
Canada_NNP would_MD require_VB 32_CD million_CD doses_NNS of_IN singleto_JJ $_$ 1,573.2_CD million_CD at_IN 31_CD December_NNP 2002_CD ._.
The_DT increase_NN reflects_VBZ mainly_RB strain_NN monovalent_JJ flu_NN vaccine_NN within_IN a_DT production_NN period_NN of_IN 16_CD weeks_NNS ._.
net_JJ income_NN of_IN $_$ 250.6_CD million_CD generated_VBN in_IN the_DT year_NN ._.
Gross_NNP cash_NN and_CC cash_NN Shire_NNP Biologics_NNP has_VBZ therefore_RB begun_VBN to_TO expand_VB its_PRP$ current_JJ production_NN equivalents_NNS ,_, inclusive_NN of_IN marketable_JJ securities_NNS and_CC debt_NN ,_, have_VBP increased_VBN capacity_NN in_IN order_NN to_TO meet_VB this_DT objective_NN within_IN a_DT five-year_JJ period_NN ._.
The_DT Arenol_NNP loan_NN conversion_NN of_IN $_$ 1.5_CD million_CD was_VBD the_DT performance_NN bond_NN equal_JJ to_TO 10_CD %_NN of_IN the_DT minimum_NN estimated_VBN contract_NN only_RB significant_JJ debt_NN movement_NN during_IN the_DT year_NN ._.
value_NN in_IN any_DT year_NN would_MD become_VB payable_JJ to_TO the_DT Canadian_JJ government_NN if_IN contracted_VBN penalty_NN clauses_NNS were_VBD triggered_VBN ._.
Accounts_NNPS receivable_JJ decreased_VBN by_IN $_$ 55.5_CD million_CD ,_, from_IN $_$ 193.9_CD million_CD at_IN 31_CD December_NNP 2001_CD to_TO $_$ 138.4_CD million_CD at_IN 31_CD December_NNP 2002_CD ._.
There_EX Shire_NNP Biologics_NNPS is_VBZ committed_VBN to_TO investing_VBG $_$ 18.5_CD million_CD in_IN the_DT were_VBD no_DT other_JJ net_JJ significant_JJ movements_NNS in_IN working_VBG capital_NN ._.
construction_NN of_IN a_DT new_JJ global_JJ vaccine_NN research_NN center_NN in_IN Laval_NNP ,_, Canada_NNP ._.
Under_IN the_DT The_DT book_NN value_NN of_IN long-term_JJ assets_NNS has_VBZ decreased_VBN by_IN $_$ 28.6_CD million_CD ._.
Technology_NNP Partnerships_NNS Canada_NNP TPC_NNP agreement_NN ,_, Shire_NNP could_MD be_VB This_DT is_VBZ due_JJ to_TO an_DT increase_NN of_IN $_$ 29.3_CD million_CD to_TO assets_NNS used_VBN in_IN continuing_VBG eligible_JJ for_IN a_DT government_NN investment_NN of_IN approximately_RB $_$ 3.5_CD million_CD ._.
operations_NNS ,_, offset_VBN by_IN $_$ 57.9_CD million_CD book_NN value_NN of_IN assets_NNS included_VBN in_IN the_DT OTC_NNP disposal_NN ._.
Capital_NNP expenditure_NN and_CC commitments_NNS Capital_NNP expenditure_NN on_IN property_NN ,_, plant_NN and_CC equipment_NN in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD was_VBD $_$ 22.6_CD million_CD ._.
This_DT expenditure_NN included_VBD Angus_NNP Russell_NNP Group_NNP Finance_NNP Director_NNP $_$ 5.7_CD million_CD within_IN Shire_NNP US_NNP and_CC $_$ 4.8_CD million_CD on_IN leasehold_NN improvements_NNS at_IN Shire_NNP Laboratories_NNPS Inc._NNP ._.
During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, we_PRP acquired_VBD exclusive_JJ rights_NNS to_TO manufacture_VB ,_, distribute_VB and_CC sell_VB SOLARAZE_NNP for_IN the_DT treatment_NN of_IN actinic_JJ keratosis_NN from_IN SkyePharma_NNP plc._NNP ._.
In_IN May_NNP 2002_CD ,_, we_PRP paid_VBD $_$ 18.9_CD million_CD 12.9_CD million_CD in_IN respect_NN of_IN SOLARAZE_NNP rights_NNS for_IN certain_JJ European_JJ territories_NNS ,_, followed_VBD in_IN December_NNP 2002_CD by_IN a_DT further_JJ $_$ 1.2_CD million_CD 0.7_CD million_CD in_IN respect_NN of_IN the_DT rights_NNS for_IN Australia_NNP ,_, New_NNP Zealand_NNP ,_, South_NNP Africa_NNP and_CC certain_JJ other_JJ countries_NNS in_IN the_DT Pacific_NNP Rim_NNP ._.
The_DT Company_NN has_VBZ undertaken_VBN to_TO subscribe_VB to_TO interests_NNS in_IN companies_NNS and_CC partnerships_NNS for_IN amounts_NNS totalling_VBG $_$ 38.1_CD million_CD 2001_CD :_: $_$ 37.7_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2002_CD an_DT amount_NN of_IN $_$ 20.3_CD million_CD 2001_CD :_: $_$ 20.1_CD million_CD has_VBZ been_VBN subscribed_VBN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 33_CD Board_NNP of_IN Directors_NNS 1_CD 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD The_DT Board_NNP meets_VBZ at_IN least_JJS four_CD times_NNS a_DT year_NN and_CC the_DT meetings_NNS are_VBP well_RB attended_VBN ._.
The_DT Board_NNP seeks_VBZ to_TO provide_VB effective_JJ leadership_NN and_CC the_DT control_NN required_VBN for_IN a_DT listed_VBN company_NN ._.
Specific_JJ powers_NNS and_CC authorities_NNS are_VBP delegated_VBN to_TO the_DT Executive_NNP Committee_NNP and_CC to_TO various_JJ other_JJ Board_NNP committees_NNS :_: the_DT Audit_NNP Committee_NNP ,_, the_DT Remuneration_NNP Committee_NNP ,_, and_CC the_DT Nomination_NNP Committee_NNP ._.
Each_DT committee_NN has_VBZ its_PRP$ own_JJ written_VBN terms_NNS of_IN reference_NN that_WDT have_VBP been_VBN approved_VBN by_IN the_DT Board_NNP ._.
Details_NNS of_IN each_DT committee_NN are_VBP on_IN page_NN 48_CD ._.
34_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Board_NNP of_IN Directors_NNS 1_CD Dr_NNP James_NNP Cavanaugh_NNP 66_CD Mr_NNP Stahel_NNP received_VBD the_DT Chief_NNP Executive_NNP 7_CD The_DT Hon_NNP James_NNP Grant_NNP 65_CD Chairman_NNP and_CC Non-executive_JJ Director_NNP Officer_NNP of_IN the_DT Year_NN Award_NNP 2001_CD for_IN the_DT global_JJ Non-executive_JJ Director_NNP Joined_VBD the_DT Board_NNP on_IN 24_CD March_NNP 1997_CD and_CC was_VBD pharmaceutical_JJ industry_NN ._.
On_IN 19_CD March_NNP 2003_CD Joined_VBD the_DT Board_NNP on_IN 11_CD May_NNP 2001_CD as_IN a_DT nonappointed_JJ as_IN non-executive_JJ Chairman_NN with_IN effect_NN Mr_NNP Stahel_NNP stepped_VBD down_RP as_IN Chief_NNP Executive_NNP executive_NN director_NN ._.
He_PRP was_VBD formerly_RB a_DT director_NN from_IN 11_CD May_NNP 1999_CD ._.
Dr_NNP Cavanaugh_NNP is_VBZ President_NNP and_CC as_IN a_DT director_NN of_IN the_DT Company_NN ._.
of_IN BioChem_NNP since_IN 1986_CD ,_, and_CC is_VBZ a_DT partner_NN with_IN of_IN HealthCare_NNP Ventures_NNP LLC_NNP ._.
Formerly_RB he_PRP was_VBD the_DT law_NN firm_NN of_IN Stikeman_NNP Elliot_NNP in_IN Montreal_NNP ._.
President_NNP of_IN SmithKline_NNP &_CC French_NNP Laboratories_NNPS ,_, 4_CD Mr_NNP Angus_NNP Russell_NNP 46_CD Mr_NNP Grant_NNP sits_VBZ on_IN the_DT boards_NNS of_IN two_CD other_JJ the_DT US_NNP pharmaceutical_JJ division_NN of_IN SmithKline_NNP Group_NNP Finance_NNP Director_NNP Canadian_NNP corporations_NNS ,_, in_IN addition_NN to_TO other_JJ Beecham_NNP Corporation_NNP ._.
Prior_RB to_TO that_DT ,_, he_PRP was_VBD Joined_VBN Shire_NNP on_IN 13_CD December_NNP 1999_CD as_IN Group_NNP foundations_NNS and_CC councils_NNS that_WDT are_VBP not-for-profit_JJ President_NNP of_IN SmithKline_NNP Beecham_NNP Corporations_NNS Finance_NNP Director_NNP ._.
Mr_NNP Russell_NNP worked_VBD for_IN ICI_NNP ,_, organizations_NNS ._.
He_PRP attended_VBD McGill_NNP University_NNP ,_, clinical_JJ laboratory_NN business_NN and_CC ,_, before_IN that_DT ,_, Zeneca_NNP and_CC AstraZeneca_NNP for_IN a_DT total_NN of_IN 19_CD receiving_VBG a_DT BA_NNP in_IN Arts_NNS in_IN 1958_CD and_CC a_DT BCL_NNP in_IN President_NNP of_IN Allergan_NNP International_NNP ._.
His_PRP$ last_JJ position_NN was_VBD Vice_NNP President_NNP Law_NNP in_IN 1961_CD ._.
Mr_NNP Grant_NNP is_VBZ a_DT member_NN of_IN the_DT industry_NN experience_NN ,_, Dr_NNP Cavanaugh_NNP served_VBD as_IN Corporate_JJ Finance_NNP at_IN AstraZeneca_NNP PLC_NNP ,_, where_WRB Nomination_NNP Committee_NNP ._.
Deputy_NNP Assistant_NNP to_TO the_DT President_NNP of_IN the_DT US_NNP he_PRP was_VBD responsible_JJ for_IN financial_JJ input_NN into_IN for_IN Health_NNP Affairs_NNPS on_IN the_DT White_NNP House_NNP Staff_NNP M&A_NNP activities_NNS ,_, management_NN of_IN tax_NN ,_, legal_JJ and_CC 8_CD Mr_NNP Ronald_NNP Nordmann_NNP 61_CD in_IN Washington_NNP ,_, DC_NNP ._.
He_PRP is_VBZ Non-executive_JJ finance_NN structure_NN ,_, investor_NN relations_NNS activities_NNS Non-executive_JJ Director_NNP Chairman_NNP of_IN Diversa_NNP Corporation_NNP and_CC Vicuron_NNP ,_, and_CC the_DT management_NN of_IN various_JJ financial_JJ risks_NNS ._.
Joined_VBN the_DT Board_NNP on_IN 23_CD December_NNP 1999_CD Inc._NNP and_CC a_DT non-executive_JJ director_NN of_IN Prior_RB to_TO this_DT ,_, he_PRP held_VBD a_DT number_NN of_IN positions_NNS having_VBG previously_RB served_VBN as_IN a_DT non-executive_JJ MedImmune_NNP Inc._NNP ._.
Dr_NNP Cavanaugh_NNP is_VBZ a_DT member_NN within_IN Zeneca_NNP Group_NNP PLC_NNP from_IN 1993_CD until_IN director_NN of_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP of_IN the_DT Remuneration_NNP Committee_NNP ,_, the_DT Audit_NNP 1999_CD ,_, including_VBG Group_NNP Treasurer_NNP ,_, and_CC before_IN since_IN May_NNP 1999_CD and_CC has_VBZ been_VBN a_DT financial_JJ Committee_NNP and_CC the_DT Nomination_NNP Committee_NNP ._.
Mr_NNP Russell_NNP analyst_NN in_IN healthcare_NN equities_NNS since_IN 1971_CD ._.
From_IN is_VBZ a_DT chartered_JJ accountant_NN ,_, having_VBG qualified_VBN September_NNP 1994_CD to_TO January_NNP 2000_CD he_PRP was_VBD an_DT 2_CD Mr_NNP Matthew_NNP Emmens_NNP 51_CD with_IN Coopers_NNP &_CC Lybrand_NNP ,_, and_CC is_VBZ a_DT fellow_NN of_IN analyst_NN and_CC partner_NN at_IN Deerfield_NNP Management_NNP ._.
Chief_NNP Executive_NNP the_DT Association_NNP of_IN Corporate_NNP Treasurers_NNPS ._.
He_PRP has_VBZ held_VBN senior_JJ positions_NNS with_IN PaineWebber_NNP ,_, Joined_VBN Shire_NNP as_IN Chief_NNP Executive_NNP and_CC member_NN Mr_NNP Russell_NNP is_VBZ a_DT member_NN of_IN the_DT Executive_NNP Oppenheimer_NNP &_CC Co._NNP ._.
F_NN Eberstadt_NNP &_CC Co._NNP and_CC of_IN the_DT Board_NNP on_IN 12_CD March_NNP 2003_CD ._.
Warner-Chilcott_NNP Laboratories_NNPS ,_, a_DT division_NN of_IN began_VBD his_PRP$ career_NN in_IN international_JJ pharmaceuticals_NNS Warner-Lambert_NNP ._.
Mr_NNP Nordmann_NNP received_VBD his_PRP$ in_IN 1974_CD when_WRB he_PRP joined_VBD Merck_NNP &_CC Co._NNP ._.
He_PRP held_VBD 5_CD Dr_NNP Wilson_NNP Totten_NNP 47_CD undergraduate_NN degree_NN from_IN The_DT John_NNP Hopkins_NNP a_DT wide_JJ range_NN of_IN sales_NNS ,_, marketing_NN and_CC training_NN Group_NNP R&D_NNP Director_NNP University_NNP and_CC an_DT MBA_NNP from_IN Fairleigh_NNP Dickinson_NNP positions_NNS with_IN Merck_NNP &_CC Co_NNP before_IN moving_VBG to_TO Joined_VBN Shire_NNP on_IN 17_CD January_NNP 1998_CD as_IN Group_NNP University_NNP ._.
Mr_NNP Nordmann_NNP is_VBZ also_RB a_DT director_NN of_IN help_NN establish_VB Astra_NNP Merck_NNP ,_, the_DT joint_JJ venture_NN Research_NN and_CC Development_NNP Director_NNP ._.
Dr_NNP Totten_NNP Guilford_NNP Pharmaceuticals_NNP Inc._NNP ._.
Neurochem_NNP Inc._NNP with_IN Astra_NNP Pharmaceuticals_NNP ._.
He_PRP later_RB became_VBD is_VBZ a_DT medical_JJ doctor_NN and_CC has_VBZ wide_JJ experience_NN in_IN and_CC Pharmaceutical_NNP Resources_NNPS Inc._NNP ._.
Mr_NNP its_PRP$ President_NNP and_CC Chief_NNP Executive_NNP ._.
Astra_NNP Merck_NNP the_DT pharmaceutical_JJ industry_NN covering_VBG all_DT phases_NNS Nordmann_NNP is_VBZ Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP Inc._NNP became_VBD an_DT independent_JJ ,_, top_JJ 20_CD US_NNP of_IN drug_NN development_NN ._.
He_PRP has_VBZ substantial_JJ and_CC a_DT member_NN of_IN the_DT Nomination_NNP Committee_NNP ._.
pharmaceutical_JJ company_NN with_IN annualised_JJ sales_NNS experience_NN in_IN the_DT field_NN of_IN central_JJ nervous_JJ in_IN excess_NN of_IN $_$ 4_CD billion_CD and_CC 4,000_CD employees_NNS ._.
His_PRP$ last_JJ position_NN was_VBD Vice_NNP 9_CD Dr_NNP Barry_NNP Price_NNP 59_CD In_IN 1999_CD he_PRP joined_VBD Merck_NNP KGaA_NNP and_CC established_VBN President_NNP of_IN Clinical_NNP Research_NNP &_CC Development_NNP Senior_NNP Non-executive_JJ Director_NNP EMD_NNP Pharmaceuticals_NNP ,_, the_DT companys_NNS US_PRP with_IN Astra_NNP Charnwood_NNP where_WRB he_PRP served_VBD from_IN Joined_VBN the_DT Board_NNP on_IN 24_CD January_NNP 1996_CD having_VBG prescription_NN pharmaceutical_JJ business_NN ._.
Until_IN 1995_CD to_TO 1997_CD ,_, having_VBG previously_RB worked_VBN for_IN spent_VBN 28_CD years_NNS with_IN Glaxo_NNP holding_VBG a_DT succession_NN Mr_NNP Emmens_NNP joined_VBD Shire_NNP he_PRP was_VBD based_VBN in_IN Fisons_NNP Pharmaceuticals_NNP from_IN 1989_CD to_TO 1995_CD ,_, of_IN key_JJ executive_NN positions_NNS with_IN Glaxo_NNP Group_NNP Darmstadt_NNP ,_, Germany_NNP ,_, as_IN President_NNP of_IN Mercks_NNPS and_CC prior_RB to_TO that_DT with_IN 3M_NNP Health_NNP Care_NNP and_CC Research_NNP ._.
He_PRP is_VBZ Chairman_NNP of_IN Antisoma_NNP plc_NN global_JJ prescription_NN pharmaceuticals_NNS business_NN ,_, Eli_NNP Lilly_NNP ._.
Dr_NNP Totten_NNP is_VBZ a_DT member_NN of_IN the_DT Executive_NNP and_CC also_RB Biowisdom_NNP Ltd._NNP ._.
He_PRP is_VBZ also_RB on_IN the_DT which_WDT in_IN the_DT year_NN 2002_CD achieved_VBD sales_NNS of_IN Committee_NNP ._.
board_NN of_IN directors_NNS of_IN Pharmagene_NNP plc._NN ._.
Mr_NNP Emmens_NNP graduated_VBD from_IN is_VBZ Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP Fairleigh_NNP Dickenson_NNP University_NNP in_IN Rutherford_NNP ,_, 6_CD Dr_NNP Francesco_NNP Bellini_NNP 55_CD and_CC a_DT member_NN of_IN both_DT the_DT Audit_NNP Committee_NNP New_NNP Jersey_NNP ,_, US_NNP ,_, with_IN a_DT BS_NNP in_IN Business_NNP Non-executive_JJ Director_NNP and_CC the_DT Nomination_NNP Committee_NNP ._.
Mr_NNP Emmens_NNP is_VBZ a_DT member_NN Joined_VBD the_DT Board_NNP on_IN 11_CD May_NNP 2001_CD as_IN a_DT nonof_JJ the_DT Executive_NNP Committee_NNP ._.
Dr_NNP Bellini_NNP is_VBZ Chairman_NNP of_IN 10_CD Mr_NNP Grard_NNP Veilleux_NNP 60_CD Picchio_NNP International_NNP Inc._NNP and_CC Neurochem_NNP Inc._NNP ._.
Non-executive_JJ Director_NNP 3_CD Mr_NNP Rolf_NNP Stahel_NNP 58_CD and_CC is_VBZ also_RB on_IN the_DT board_NN of_IN several_JJ companies_NNS Joined_VBD the_DT Board_NNP on_IN 11_CD May_NNP 2001_CD as_IN a_DT nonFormer_NNP Chief_NNP Executive_NNP and_CC organizations_NNS such_JJ as_IN Molson_NNP Inc._NNP and_CC executive_JJ director_NN ._.
He_PRP was_VBD formerly_RB a_DT director_NN Joined_VBN Shire_NNP in_IN March_NNP 1994_CD as_IN Chief_NNP Executive_NNP Industrial-Alliance_NNP Life_NNP Insurance_NNP Co._NNP ._.
He_PRP is_VBZ President_NNP of_IN from_IN Wellcome_NNP plc_NN where_WRB he_PRP worked_VBD for_IN 27_CD he_PRP was_VBD Chairman_NNP and_CC CEO_NNP of_IN BioChem_NNP Power_NNP Communications_NNPS Inc._NNP and_CC Vice_NNP years_NNS in_IN Switzerland_NNP ,_, Italy_NNP ,_, Thailand_NNP ,_, Singapore_NNP Pharma_NNP which_WDT he_PRP co-founded_VBD in_IN 1986_CD ._.
President_NNP of_IN Power_NNP Corporation_NNP ,_, a_DT diversified_JJ and_CC the_DT UK_NNP ._.
As_IN Regional_NNP Director_NNP of_IN Wellcome_NNP management_NN and_CC holding_VBG company_NN ._.
Mr_NNP Veilleux_NNP based_VBN in_IN Singapore_NNP ,_, Mr_NNP Stahel_NNP was_VBD responsible_JJ is_VBZ a_DT director_NN of_IN several_JJ public_JJ and_CC private_JJ for_IN 18_CD Pacific_NNP Rim_NNP countries_NNS ._.
From_IN April_NNP 1990_CD companies_NNS as_RB well_RB as_IN a_DT member_NN of_IN the_DT Board_NNP until_IN February_NNP 1994_CD ,_, he_PRP served_VBD as_IN Director_NNP of_IN Governors_NNP of_IN McGill_NNP University_NNP ._.
He_PRP has_VBZ a_DT of_IN Group_NNP Marketing_NNP reporting_VBG to_TO the_DT Chief_NNP Masters_NNP degree_NN in_IN Public_NNP Administration_NNP from_IN Executive_NNP ._.
A_DT Business_NN Studies_NNPS graduate_NN of_IN Carleton_NNP University_NNP and_CC a_DT Bachelor_NNP of_IN KSL_NNP Lucerne_NNP ,_, Switzerland_NNP ,_, he_PRP attended_VBD Commerce_NNP from_IN Laval_NNP University_NNP ._.
Mr_NNP Veilleux_NNP is_VBZ the_DT 97th_JJ Advanced_NNP Managers_NNPS Program_NNP at_IN a_DT member_NN of_IN the_DT Remuneration_NNP Committee_NNP ._.
On_IN 15_CD March_NNP 2001_CD ,_, Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 35_CD Executive_NNP Committee_NNP 1_CD 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD The_DT Executive_NNP Committee_NNP meets_VBZ at_IN least_JJS 11_CD times_NNS a_DT year_NN and_CC has_VBZ the_DT day-to-day_JJ management_NN of_IN the_DT Company_NN delegated_VBD to_TO it_PRP by_IN the_DT Board_NNP and_CC operates_VBZ within_IN clear_JJ and_CC formal_JJ parameters_NNS ._.
The_DT Chief_NNP Executive_NNP is_VBZ the_DT Chairman_NNP of_IN the_DT Committee_NNP ,_, which_WDT consists_VBZ of_IN nine_CD senior_JJ executives_NNS including_VBG the_DT three_CD executive_NN directors_NNS ._.
The_DT Executive_NNP Committee_NNP reports_VBZ to_TO and_CC seeks_VBZ guidance_NN from_IN the_DT Board_NNP on_IN a_DT regular_JJ basis_NN ._.
36_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Executive_NNP Committee_NNP Rolf_NNP Stahel_NNP was_VBD Chief_NNP Executive_NNP and_CC 5_CD Jack_NNP Khattar_NNP 41_CD 8_CD Richard_NNP fide_NNP Souza_NNP 50_CD Chairman_NNP of_IN the_DT Executive_NNP Committee_NNP until_IN President_NNP and_CC Chief_NNP Executive_NNP ,_, SLI_NNP Director_NNP International_NNP he_PRP stepped_VBD down_RP on_IN 19_CD March_NNP 2003_CD ._.
Joined_VBN Shire_NNP as_IN President_NNP and_CC CEO_NNP of_IN Shire_NNP Joined_VBD Shire_NNP in_IN September_NNP 2000_CD as_IN Director_NNP Biography_NNP and_CC photograph_NN on_IN pages_NNS 34_CD and_CC 35_CD ._.
Prior_RB to_TO this_DT he_PRP worked_VBD as_IN came_VBD to_TO Shire_VB from_IN CIMA_NNP ,_, a_DT drug_NN delivery_NN President_NNP ,_, Pharmaceuticals_NNP Europe_NNP and_CC 1_CD Mr_NNP Matthew_NNP Emmens_NNP 51_CD company_NN ,_, where_WRB he_PRP last_JJ served_VBD as_IN an_DT executive_NN Asia_NNP in_IN Warner_NNP Lambert_NNP Parke-Davis_NNP ._.
He_PRP Chief_NNP Executive_NNP and_CC Chairman_NNP of_IN the_DT officer_NN and_CC the_DT Chairman_NNP of_IN the_DT Operating_NN was_VBD previously_RB with_IN SmithKline_NNP Beecham_NNP Executive_NNP Committee_NNP Management_NNP Committee_NNP ._.
Prior_RB to_TO CIMA_NNP ,_, for_IN 22_CD years_NNS ,_, where_WRB he_PRP was_VBD Chairman_NNP ,_, Biography_NNP on_IN page_NN 35_CD ._.
Mr_NNP Khattar_NNP held_VBD several_JJ marketing_NN and_CC Pharmaceuticals_NNP Europe_NNP ._.
business_NN development_NN positions_NNS at_IN Merck_NNP &_CC 2_CD Angus_NNP Russell_NNP 46_CD Co._NNP ._.
Novartis_NNP ,_, Playtex_NNP and_CC Kodak_NNP in_IN the_DT US_NNP ,_, 9_CD Mark_NNP Webster_NNP 41_CD Group_NNP Finance_NNP Director_NNP Europe_NNP and_CC the_DT Middle_NNP East_NNP ._.
In_IN 1985_CD ,_, he_PRP Commercial_JJ Director_NNP Biography_NNP on_IN page_NN 35_CD ._.
received_VBD his_PRP$ MBA_NNP from_IN the_DT Wharton_NNP School_NNP Responsible_JJ for_IN Global_NNP Business_NNP Development_NNP ,_, of_IN the_DT University_NNP of_IN Pennsylvania_NNP ._.
Mergers_NNPS &_CC Acquisitions_NNPS and_CC Strategic_NNP Marketing_NNP ._.
3_CD Dr_NNP Wilson_NNP Totten_NNP 47_CD He_PRP has_VBZ worked_VBN in_IN the_DT pharmaceutical_JJ industry_NN Group_NNP R&D_NNP Director_NNP 6_CD Tatjana_NNP May_NNP 38_CD for_IN 20_CD years_NNS in_IN a_DT number_NN of_IN general_JJ management_NN Biography_NN on_IN page_NN 35_CD ._.
General_NNP Counsel_NNP and_CC Company_NNP Secretary_NNP and_CC senior_JJ sales_NNS and_CC marketing_NN roles_NNS in_IN the_DT Joined_VBN Shire_NNP in_IN May_NNP 2001_CD from_IN AstraZeneca_NNP UK_NNP ,_, Canada_NNP and_CC the_DT US_NNP ._.
Mr_NNP Webster_NNP worked_VBD 4_CD Jeff_NNP Devlin_NNP 50_CD PLC_NNP formerly_RB Zeneca_NNP Group_NNP where_WRB she_PRP for_IN Abbott_NNP Laboratories_NNP for_IN 13_CD years_NNS ,_, where_WRB Director_NNP Corporate_NNP Affairs_NNP was_VBD Assistant_NNP General_NNP Counsel_NNP in_IN Corporate_NNP immediately_RB before_IN joining_VBG Shire_NNP he_PRP held_VBD the_DT Joined_VBN Shire_NNP in_IN January_NNP 2000_CD as_IN Director_NNP of_IN Headquarters_NNP ._.
Ms_NNS May_NNP has_VBZ substantial_JJ post_NN of_IN Vice-President_NNP and_CC General_NNP Manager_NNP Corporate_NNP Affairs_NNPS ._.
Prior_RB to_TO joining_VBG Shire_NNP he_PRP was_VBD experience_NN and_CC knowledge_NN of_IN undertaking_VBG large_JJ Anti-Virals_NNP ,_, Abbott_NNP Labs_NNPS USA_NNP ._.
He_PRP has_VBZ a_DT BSc_NNP a_DT partner_NN at_IN Ernst_NNP &_CC Young_NNP and_CC also_RB a_DT member_NN M&A_NNP transactions_NNS as_RB well_RB as_IN the_DT negotiation_NN and_CC Hons_NNS in_IN Chemistry_NNP from_IN Durham_NNP University_NNP ._.
of_IN its_PRP$ Global_NNP Executive_NNP Steering_NNP Group_NNP for_IN Life_NNP implementation_NN of_IN a_DT large_JJ number_NN of_IN commercial_JJ Sciences_NNPS ._.
He_PRP was_VBD previously_RB with_IN Arthur_NNP D_NNP agreements_NNS ._.
Prior_RB to_TO joining_VBG AstraZeneca_NNP she_PRP Little_RB ,_, Management_NNP Consultancy_NNP ,_, where_WRB he_PRP was_VBD worked_VBN at_IN Slaughter_NNP and_CC May_NNP ._.
a_DT European_JJ Director_NNP in_IN its_PRP$ Healthcare_NNP and_CC Pharmaceuticals_NNP practice_NN ._.
7_CD William_NNP Nuerge_NNP 51_CD President_NNP and_CC Chief_NNP Executive_NNP ,_, Shire_NNP US_NNP Inc._NNP ._.
Joined_VBN Shire_NNP US_NNP in_IN 1994_CD as_IN Chief_NNP Operating_NNP Officer_NNP ._.
Mr_NNP Nuerge_NNP has_VBZ over_IN 25_CD years_NNS experience_NN within_IN the_DT industry_NN and_CC has_VBZ held_VBN several_JJ senior_JJ pharmaceutical_JJ positions_NNS ._.
Mr_NNP Nuerge_NNP holds_VBZ a_DT Bachelor_NNP of_IN Science_NNP degree_NN from_IN Purdue_NNP University_NNP and_CC an_DT MBA_NNP from_IN Indiana_NNP Wesleyan_NNP University_NNP ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 37_CD Directors_NNS remuneration_JJ report_NN Introduction_NNP There_EX are_VBP six_CD main_JJ elements_NNS of_IN the_DT remuneration_NN package_NN for_IN executive_NN This_DT Report_NNP has_VBZ been_VBN prepared_VBN in_IN accordance_NN with_IN the_DT Directors_NNS directors_NNS and_CC senior_JJ management_NN :_: basic_JJ annual_JJ salary_NN :_: benefits_NNS :_: annual_JJ Remuneration_NNP Report_NNP Regulations_NNPS 2002_CD which_WDT introduced_VBD new_JJ statutory_JJ bonus_NN payments_NNS :_: share_NN options_NNS :_: long_JJ term_NN incentive_NN awards_NNS :_: and_CC requirements_NNS for_IN the_DT disclosure_NN of_IN directors_NNS remuneration_NN in_IN respect_NN of_IN pension_NN arrangements_NNS ._.
Executive_NNP directors_NNS contracts_NNS of_IN employment_NN periods_NNS ending_VBG on_IN or_CC after_IN 31_CD December_NNP 2002_CD ._.
This_DT Report_NNP also_RB meets_VBZ which_WDT include_VBP details_NNS of_IN remuneration_NN will_MD be_VB available_JJ for_IN inspection_NN at_IN the_DT relevant_JJ requirements_NNS of_IN the_DT Listing_NNP Rules_NNP of_IN the_DT Financial_NNP Services_NNPS the_DT Annual_JJ General_NNP Meeting_VBG ._.
Authority_NNP and_CC describes_VBZ how_WRB the_DT Board_NNP has_VBZ applied_VBN the_DT Principles_NNPS of_IN Basic_JJ salary_NN Good_JJ Governance_NN relating_VBG to_TO directors_NNS remuneration_NN as_IN set_VBN out_RP in_IN the_DT The_DT Remuneration_NNP Committee_NNP annually_RB reviews_VBZ base_NN salaries_NNS in_IN the_DT light_JJ Combined_NNP Code_NNP ._.
As_IN required_VBN by_IN the_DT Regulations_NNPS ,_, a_DT resolution_NN to_TO of_IN a_DT number_NN of_IN factors_NNS such_JJ as_IN competitive_JJ market_NN data_NNS provided_VBN by_IN approve_VB this_DT Report_NNP will_MD be_VB proposed_VBN at_IN the_DT Annual_JJ General_NNP Meeting_VBG independent_JJ external_JJ consultants_NNS ,_, local_JJ market_NN conditions_NNS and_CC individual_NN of_IN the_DT Company_NN at_IN which_WDT the_DT financial_JJ statements_NNS will_MD be_VB approved_VBN ._.
The_DT Remuneration_NNP Committees_NNS policy_NN is_VBZ for_IN base_NN pay_NN to_TO be_VB set_VBN at_IN the_DT median_NN of_IN the_DT appropriate_JJ comparator_NN group_NN Unaudited_JJ information_NN for_IN executive_JJ directors_NNS this_DT is_VBZ the_DT FTSE_NNP 100_CD unless_IN individual_JJ performance_NN The_DT Remuneration_NNP Committee_NNP and_CC or_CC skills_NNS shortages_NNS require_VBP a_DT different_JJ stance_NN ._.
In_IN addition_NN to_TO basic_JJ The_DT Company_NN has_VBZ established_VBN a_DT Remuneration_NNP Committee_NNP which_WDT is_VBZ salary_NN ,_, the_DT executive_JJ directors_NNS receive_VBP certain_JJ benefits_NNS in_IN kind_NN ,_, principally_RB constituted_VBN in_IN accordance_NN with_IN the_DT Combined_NNP Code_NNP ._.
The_DT members_NNS of_IN a_DT car_NN or_CC car_NN allowance_NN ,_, participation_NN in_IN the_DT Shire_NNP defined_VBD contribution_NN the_DT Remuneration_NNP Committee_NNP in_IN 2002_CD were_VBD Dr_NNP Barry_NNP Price_NNP Chairman_NNP ,_, pension_NN plan_NN see_VBP below_IN ,_, life_NN insurance_NN and_CC private_JJ medical_JJ insurance_NN ._.
Dr_NNP James_NNP Cavanaugh_NNP and_CC Mr_NNP Grard_NNP Veilleux_NNP ._.
Dr_NNP Bernard_NNP Canavan_NNP Annual_JJ bonus_NN payments_NNS was_VBD also_RB a_DT member_NN of_IN the_DT Committee_NNP until_IN his_PRP$ death_NN in_IN August_NNP 2002_CD ._.
Shire_NNP operates_VBZ an_DT annual_JJ bonus_NN plan_NN ._.
The_DT structure_NN of_IN this_DT plan_NN was_VBD The_DT Company_NN views_VBZ all_DT members_NNS of_IN the_DT Committee_NNP as_IN independent_JJ reviewed_VBN in_IN 2002_CD ._.
A_DT key_JJ objective_NN of_IN the_DT plan_NN is_VBZ to_TO encourage_VB and_CC non-executive_JJ directors_NNS ._.
The_DT Chief_NNP Executive_NNP attends_VBZ meetings_NNS of_IN the_DT reward_NN the_DT achievement_NN of_IN stretch_JJ performance_NN objectives_NNS at_IN both_DT Committee_NNP at_IN its_PRP$ invitation_NN ,_, but_CC is_VBZ not_RB involved_VBN in_IN any_DT discussions_NNS on_IN his_PRP$ the_DT Group_NNP level_NN and_CC the_DT individual_JJ level_NN ._.
objectives_NNS are_VBP set_VBN at_IN the_DT start_NN of_IN each_DT financial_JJ year_NN by_IN the_DT Remuneration_NNP The_NNP Remuneration_NNP Committee_NNP has_VBZ been_VBN materially_RB assisted_VBN in_IN 2002_CD by_IN Committee_NNP and_CC the_DT individuals_NNS performance_NN against_IN objectives_NNS is_VBZ also_RB Rolf_NNP Stahel_NNP ,_, the_DT Companys_NNP Chief_NNP Executive_NNP in_IN 2002_CD ,_, Jeff_NNP Devlin_NNP ,_, Director_NNP ,_, assessed_VBN by_IN the_DT Remuneration_NNP Committee_NNP ._.
The_DT objectives_NNS are_VBP tailored_VBN Corporate_JJ Affairs_NNPS ,_, Christian_NNP Proulx_NNP ,_, Senior_NNP VP_NNP Global_NNP Human_NNP Resources_NNPS ,_, to_TO the_DT requirements_NNS of_IN the_DT business_NN and_CC in_IN 2002_CD included_VBD objectives_NNS and_CC by_IN the_DT following_VBG external_JJ advisers_NNS :_: Towers_NNP Perrin_NNP ,_, Slaughter_NNP and_CC relating_VBG to_TO growth_NN in_IN revenue_NN and_CC net_JJ income_NN ._.
The_DT annual_JJ bonus_NN is_VBZ May_NNP and_CC Deloitte_NNP &_CC Touche_NNP ._.
Slaughter_NN and_CC May_NNP also_RB provided_VBD general_JJ payable_JJ in_IN cash_NN and_CC is_VBZ not_RB pensionable_JJ ._.
Target_NN bonus_NN is_VBZ paid_VBN pro_JJ rata_JJ legal_JJ advice_NN to_TO the_DT Company_NN in_IN 2002_CD and_CC Deloitte_NNP &_CC Touche_NNP are_VBP also_RB to_TO the_DT objectives_NNS which_WDT have_VBP been_VBN achieved_VBN ,_, up_IN to_TO the_DT maximum_NN target_NN the_DT Companys_NNPS auditors_NNS and_CC provided_VBD some_DT general_JJ accountancy_NN advice_NN bonus_NN ._.
The_DT Remuneration_NNP Committee_NNP also_RB has_VBZ the_DT discretion_NN to_TO make_VB and_CC taxation_NN advice_NN in_IN 2002_CD ._.
The_DT Remuneration_NNP Committee_NNP approved_VBD further_JJ awards_NNS under_IN the_DT plan_NN for_IN exceptional_JJ achievement_NN beyond_IN the_DT appointment_NN of_IN Slaughter_NNP and_CC May_NNP and_CC Deloitte_NNP &_CC Touche_NNP Executive_NNP and_CC or_CC in_IN addition_NN to_TO the_DT objectives_NNS set_VBN at_IN the_DT start_NN of_IN the_DT year_NN ._.
The_DT Compensation_NNP Consulting_NNP Practice_NNP as_IN advisers_NNS to_TO the_DT Remuneration_NNP maximum_NN bonus_NN is_VBZ capped_VBN at_IN 100_CD %_NN of_IN salary_NN for_IN the_DT Chief_NNP Executive_NNP Committee_NNP ._.
and_CC 75_CD %_NN of_IN salary_NN for_IN other_JJ executive_JJ directors_NNS ._.
Details_NNS of_IN the_DT bonus_NN structure_NN and_CC the_DT relative_JJ weighting_NN of_IN objectives_NNS are_VBP shown_VBN in_IN the_DT Remuneration_NNP policy_NN table_NN below_IN ._.
To_TO ensure_VB that_IN the_DT Company_NN can_MD compete_VB effectively_RB for_IN high_JJ calibre_NN Target_NNP Maximum_NNP individuals_NNS ,_, the_DT Remuneration_NNP Committee_NNP has_VBZ adopted_VBN a_DT durable_JJ bonus_NN bonus_NN Weighting_NN of_IN target_NN compensation_NN and_CC benefits_NNS policy_NN based_VBN on_IN the_DT following_VBG principles_NNS :_: up_RB to_TO %_NN up_RP to_TO %_NN bonus_NN objectives_NNS of_IN salary_NN of_IN salary_NN Group_NNP Personal_NNP compensation_NN should_MD ,_, as_IN far_RB as_IN possible_JJ ,_, be_VB market-driven_JJ :_: Mr_NNP R_NNP Stahel_NNP compensation_NN should_MD be_VB performance-related_JJ and_CC reflect_VBP an_DT Former_JJ Chief_NNP Executive_NNP 55_CD %_NN 100_CD %_NN 80_CD %_NN 20_CD %_NN appropriate_JJ mix_NN of_IN corporate_JJ and_CC individual_JJ performance_NN :_: Mr_NNP A_NNP Russell_NNP share-based_JJ remuneration_NN is_VBZ a_DT key_JJ element_NN of_IN pay_NN which_WDT the_DT Finance_NNP Director_NNP 50_CD %_NN 75_CD %_NN 60_CD %_NN 40_CD %_NN Committee_NNP believes_VBZ aligns_IN the_DT interests_NNS of_IN the_DT Companys_NNPS executives_NNS Dr_VBP W_NNP Totten_NNP with_IN the_DT interests_NNS of_IN its_PRP$ shareholders_NNS :_: and_CC Group_NNP R&D_NNP Director_NNP 50_CD %_NN 75_CD %_NN 60_CD %_NN 40_CD %_NN compensation_NN and_CC benefits_NNS arrangements_NNS should_MD be_VB clear_JJ and_CC well_RB understood_VBN ._.
Deferred_JJ bonus_NN plan_NN To_TO ensure_VB that_IN the_DT approach_NN to_TO remuneration_VB at_IN senior_JJ levels_NNS is_VBZ aligned_VBN Consistent_JJ with_IN the_DT desired_VBN emphasis_NN on_IN share-based_JJ remuneration_NN ,_, to_TO market_VB practice_NN ,_, whilst_NN being_VBG consistent_JJ with_IN the_DT principles_NNS of_IN the_DT the_DT Remuneration_NNP Committee_NNP has_VBZ been_VBN considering_VBG the_DT implementation_NN Companys_NNP compensation_NN and_CC benefits_NNS policy_NN described_VBN above_IN ,_, the_DT of_IN a_DT deferred_VBN bonus_NN plan_NN for_IN senior_JJ management_NN ,_, including_VBG the_DT executive_NN Remuneration_NNP Committee_NNP reviewed_VBD and_CC made_VBD a_DT number_NN of_IN changes_NNS to_TO directors_NNS ,_, under_IN which_WDT they_PRP can_MD elect_VB to_TO defer_VB a_DT portion_NN of_IN their_PRP$ annual_JJ executive_NN remuneration_NN during_IN the_DT course_NN of_IN 2002_CD ._.
These_DT are_VBP described_VBN bonus_NN to_TO buy_VB shares_NNS in_IN the_DT Company_NN ,_, with_IN the_DT Company_NN matching_VBG the_DT below_RB ._.
It_PRP is_VBZ intended_VBN that_IN the_DT remuneration_NN policy_NN as_IN described_VBN will_MD be_VB shares_NNS so_RB acquired_VBN ._.
The_DT Company_NN will_MD seek_VB shareholder_NN approval_NN for_IN appropriate_JJ for_IN the_DT foreseeable_JJ future_NN ._.
The_DT plan_NN will_MD be_VB designed_VBN to_TO balance_VB the_DT need_NN for_IN the_DT delivery_NN of_IN and_CC reward_VB for_IN short-term_JJ operating_NN targets_NNS with_IN the_DT The_DT Remuneration_NNP Committee_NNP is_VBZ responsible_JJ for_IN the_DT performance_NN longer-term_JJ interests_NNS of_IN the_DT Company_NN and_CC its_PRP$ shareholders_NNS ._.
The_DT management_NN of_IN the_DT executive_JJ directors_NNS and_CC of_IN key_JJ members_NNS of_IN Remuneration_NNP Committee_NNP believes_VBZ that_IN share-based_JJ remuneration_NN for_IN senior_JJ management_NN and_CC for_IN the_DT determination_NN of_IN the_DT elements_NNS of_IN their_PRP$ executives_NNS and_CC encouraging_JJ share_NN ownership_NN are_VBP critical_JJ for_IN maximizing_VBG remuneration_NN package_NN ._.
No_DT director_NN is_VBZ present_JJ when_WRB his_PRP$ own_JJ remuneration_NN shareholder_NN value_NN ._.
The_DT remuneration_NN of_IN the_DT non-executive_JJ directors_NNS is_VBZ determined_VBN by_IN the_DT Board_NNP within_IN limits_NNS set_VBN out_RP in_IN the_DT Companys_NNP Articles_NNPS of_IN Association_NNP see_VBP below_IN ._.
38_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Share_NN options_NNS Number_NN of_IN Exercise_NNP Executive_NNP director_NN and_CC Date_NN of_IN ordinary_JJ price_NN At_IN the_DT Companys_NNP Annual_JJ General_NNP Meeting_VBG in_IN June_NNP 2001_CD ,_, shareholders_NNS share_NN option_NN scheme_NN grant_NN shares_NNS agreed_VBD that_IN the_DT grant_NN of_IN options_NNS under_IN the_DT 2000_CD Executive_NNP Share_NNP Option_NN Mr_NNP Rolf_NNP Stahel_NNP Scheme_NNP the_DT Scheme_NN should_MD be_VB made_VBN subject_JJ to_TO a_DT performance_NN 2000_CD Executive_NNP Scheme_NNP 04.03.02_CD 209,211_CD 5.065_CD condition_NN on_IN grant_NN ._.
If_IN Shires_NNP share_NN price_NN increased_VBN by_IN an_DT annualised_JJ compound_NN rate_NN of_IN 20.5_CD %_NN over_IN a_DT minimum_JJ three-year_JJ period_NN options_NNS Dr_NNP Wilson_NNP Totten_NNP could_MD be_VB granted_VBN ._.
During_IN 2002_CD the_DT performance_NN condition_NN was_VBD reviewed_VBN ._.
2000_CD Executive_NNP Scheme_NNP 04.03.02_CD 122,368_CD 5.065_CD Following_VBG consultation_NN with_IN major_JJ institutional_JJ shareholders_NNS ,_, the_DT Sharesave_NNP Scheme_NNP 23.09.02_CD 1,882_CD 5.02_CD Remuneration_NNP Committee_NNP decided_VBD that_IN a_DT performance_NN condition_NN based_VBN Mr_NNP Angus_NNP Russell_NNP on_IN real_JJ growth_NN in_IN earnings_NNS per_IN share_NN EPS_NNP should_MD be_VB attached_VBN to_TO the_DT 2000_CD Executive_NNP Scheme_NNP 04.03.02_CD 114,474_CD 5.065_CD exercise_NN of_IN options_NNS granted_VBN under_IN the_DT Scheme_NNP ._.
Diluted_VBN EPS_NNP will_MD be_VB Sharesave_NNP Scheme_NNP 23.09.02_CD 1,882_CD 5.02_CD measured_VBN as_IN shown_VBN in_IN the_DT Annual_JJ Report_NNP and_CC Accounts_NNPS ._.
Earnings_NNS per_IN share_NN provides_VBZ both_DT a_DT direct_JJ and_CC transparent_JJ link_NN to_TO overall_JJ corporate_JJ performance_NN and_CC is_VBZ regarded_VBN by_IN the_DT Committee_NNP as_IN the_DT most_RBS appropriate_JJ During_IN 2002_CD ,_, Mr_NNP Angus_NNP Russell_NNP and_CC Dr_NNP Wilson_NNP Totten_NNP let_VBD lapse_NN options_NNS measure_NN in_IN the_DT light_NN of_IN Shires_NNP business_NN strategy_NN and_CC the_DT growth_NN of_IN the_DT granted_VBN to_TO them_PRP in_IN April_NNP 2000_CD under_IN the_DT Sharesave_NNP Scheme_NNP ,_, over_IN 1,971_CD Company_NN in_IN the_DT last_JJ two_CD years_NNS ._.
To_TO balance_VB the_DT higher_JJR grants_NNS to_TO executive_NN and_CC 1,139_CD shares_NNS respectively_RB ,_, at_IN the_DT option_NN price_NN of_IN 8.56_CD per_IN share_NN ._.
directors_NNS ,_, a_DT higher_JJR target_NN has_VBZ been_VBN set_VBN as_IN detailed_JJ below_IN ._.
Share_NN options_NNS Both_DT Mr_NNP Russell_NNP and_CC Dr_NNP Totten_NNP subsequently_RB used_VBD their_PRP$ maximum_NN are_VBP intended_VBN to_TO be_VB long-term_JJ compensation_NN and_CC to_TO provide_VB an_DT incentive_NN contributions_NNS from_IN salary_NN allowed_VBN under_IN the_DT rules_NNS of_IN the_DT Sharesave_NNP for_IN employees_NNS to_TO deliver_VB sustained_VBN long-term_JJ performance_NN ,_, whilst_NN Scheme_NN to_TO participate_VB in_IN the_DT Sharesave_NNP offer_NN made_VBN in_IN 2002_CD ._.
aligning_VBG the_DT interests_NNS of_IN Shires_NNP executive_NN directors_NNS and_CC employees_NNS with_IN Long_NNP Term_NNP Incentive_NNP Plan_NNP those_DT of_IN shareholders_NNS ._.
The_DT Long_NNP Term_NNP Incentive_NNP Plan_NNP the_DT Plan_NN was_VBD adopted_VBN at_IN the_DT Companys_NNPS The_DT grant_NN of_IN options_NNS is_VBZ wholly_RB at_IN the_DT discretion_NN of_IN the_DT Remuneration_NNP 1998_CD Annual_JJ General_NNP Meeting_VBG and_CC amended_VBN in_IN 2001_CD ._.
In_IN granting_VBG share_NN options_NNS ,_, the_DT Committee_NNP takes_VBZ into_IN account_NN awards_NNS of_IN shares_NNS subject_JJ to_TO a_DT maximum_NN of_IN 100_CD %_NN of_IN salary_NN a_DT year_NN may_MD be_VB the_DT advice_NN and_CC recommendations_NNS of_IN the_DT Chief_NNP Executive_NNP and_CC individual_JJ made_VBN at_IN the_DT discretion_NN of_IN the_DT Remuneration_NNP Committee_NNP ._.
The_DT performance_NN salary_NN levels_NNS and_CC roles_NNS within_IN the_DT Group_NNP ._.
The_DT face_NN value_NN of_IN options_NNS condition_NN attached_VBN to_TO the_DT vesting_NN of_IN the_DT share_NN awards_NNS made_VBN under_IN the_DT granted_VBN under_IN the_DT Scheme_NNP is_VBZ normally_RB capped_VBN at_IN three_CD times_NNS salary_NN Plan_NN is_VBZ Shires_NNP relative_JJ Total_JJ Shareholder_NN Return_NN TSR_NNP against_IN the_DT FTSE_NNP per_IN year_NN ,_, except_IN in_IN exceptional_JJ circumstances_NNS ._.
This_DT grant_NN level_NN is_VBZ very_RB 100_CD index_NN ._.
Under_IN the_DT amended_VBN Plan_NN ,_, all_PDT the_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP competitive_JJ in_IN the_DT UK_NNP market_NN and_CC is_VBZ consistent_JJ with_IN the_DT emphasis_NN the_DT is_VBZ in_IN the_DT top_JJ 10_CD %_NN of_IN the_DT FTSE_NNP 100_CD :_: half_PDT the_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP Company_NNP places_VBZ on_IN share-based_JJ remuneration_NN for_IN its_PRP$ executives_NNS ._.
It_PRP is_VBZ performance_NN is_VBZ at_IN median_NN :_: and_CC no_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ below_IN also_RB in_IN accordance_NN with_IN the_DT Committees_NNS view_VBP that_IN well_RB over_IN half_NN of_IN each_DT median_NN ._.
The_DT Remuneration_NNP Committee_NNP believes_VBZ that_IN Shires_NNP TSR_NNP relative_JJ directors_NNS remuneration_NN should_MD be_VB linked_VBN to_TO Company_NNP performance_NN ._.
to_TO the_DT FTSE_NNP 100_CD is_VBZ the_DT most_RBS appropriate_JJ measure_NN of_IN shareholder_NN value_NN for_IN the_DT purpose_NN of_IN the_DT vesting_NN of_IN awards_NNS under_IN the_DT Plan_NNP given_VBN that_IN Shire_NNP The_NNP performance_NN condition_NN attaching_VBG to_TO the_DT exercise_NN of_IN share_NN options_NNS ,_, has_VBZ been_VBN a_DT constituent_NN of_IN the_DT FTSE_NNP 100_CD for_IN over_IN two_CD years_NNS ._.
Moreover_RB ,_, which_WDT is_VBZ somewhat_RB higher_JJR for_IN executive_JJ directors_NNS than_IN for_IN other_JJ shareholders_NNS are_VBP likely_JJ to_TO assess_VB Shires_NNP performance_NN in_IN the_DT context_NN employees_NNS ,_, operates_VBZ as_IN follows_VBZ and_CC applies_VBZ to_TO all_DT options_NNS granted_VBN after_IN of_IN this_DT comparator_NN group_NN ._.
The_DT Remuneration_NNP Committee_NNP will_MD at_IN the_DT August_NNP 2002_CD :_: appropriate_JJ time_NN decide_VB whether_IN and_CC to_TO what_WP extent_NN the_DT performance_NN Grant_NNP condition_NN has_VBZ been_VBN met_VBN on_IN the_DT basis_NN of_IN data_NNS provided_VBN by_IN an_DT %_NN of_IN salary_NN EPS_NNP growth_NN independent_JJ third_JJ party_NN ._.
To_TO date_VB all_DT awards_NNS made_VBN under_IN the_DT Plan_NN have_VBP Up_IN to_TO 100_CD %_NN Retail_NNP Price_NNP Index_NNP RPI_NNP plus_CC 3_CD %_NN been_VBN made_VBN as_IN a_DT conditional_JJ allocation_NN ,_, as_IN defined_VBN in_IN the_DT Plan_NN ,_, thereby_RB directors_NNS ,_, RPI_NNP plus_CC 5_CD %_NN allowing_VBG for_IN a_DT cash_NN equivalent_NN to_TO be_VB paid_VBN on_IN maturity_NN of_IN the_DT award_NN ._.
101_CD %_NN to_TO 200_CD %_NN RPI_NNP plus_CC 5_CD %_NN Directors_NNS were_VBD granted_VBN an_DT award_NN under_IN the_DT Plan_NN in_IN 2002_CD as_IN 201_CD %_NN to_TO 300_CD %_NN RPI_NNP plus_CC 7_CD %_NN a_DT conditional_JJ allocation_NN ,_, as_IN defined_VBN in_IN the_DT Plan_NN ,_, as_IN follows_VBZ :_: Over_IN 301_CD %_NN RPI_NNP plus_CC 9_CD %_NN Earliest_JJS date_NN Value_NN of_IN on_IN which_WDT Details_NNS of_IN the_DT share_NN option_NN schemes_NNS are_VBP set_VBN out_RP below_IN and_CC in_IN note_NN 28_CD conditional_JJ Total_NNP an_DT award_NN award_NN at_IN number_NN of_IN can_MD be_VB to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
Except_IN as_IN mentioned_VBN below_IN ,_, Date_NNP of_IN grant_NN date_NN ordinary_JJ made_VBN to_TO none_NN of_IN the_DT executive_JJ directors_NNS who_WP served_VBD during_IN the_DT year_NN were_VBD granted_VBN award_NN 000_CD shares_NNS a_DT director_NN additional_JJ options_NNS under_IN any_DT of_IN the_DT Companys_NNP share_NN option_NN schemes_NNS in_IN Mr_NNP Rolf_NNP Stahel_NNP 04.03.02_CD 232_CD 34,868_CD 04.03.06_CD the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ._.
Dr_NNP Wilson_NNP Totten_NNP 04.03.02_CD 136_CD 20,394_CD 04.03.06_CD Share_NN options_NNS under_IN the_DT Sharesave_NNP Scheme_NNP see_VBP note_NN iv_NN on_IN page_NN 82_CD Mr_NNP Angus_NNP Russell_NNP 04.03.02_CD 127_CD 19,078_CD 04.03.06_CD are_VBP offered_VBN at_IN a_DT discount_NN as_IN permitted_VBN by_IN paragraph_NN 13.31_CD of_IN the_DT Listing_NNP Rules_NNPS ._.
Share_NN options_NNS are_VBP not_RB otherwise_RB offered_VBN at_IN a_DT discount_NN ._.
For_IN awards_NNS made_VBN under_IN the_DT Plan_NNP prior_RB to_TO June_NNP 2001_CD ,_, performance_NN is_VBZ The_DT following_JJ share_NN options_NNS were_VBD granted_VBN to_TO executive_JJ directors_NNS during_IN measured_VBN over_IN a_DT three-year_JJ period_NN but_CC the_DT performance_NN conditions_NNS are_VBP 2002_CD and_CC were_VBD granted_VBN prior_RB to_TO the_DT Companys_NNPS review_NN of_IN the_DT based_VBN on_IN criteria_NNS of_IN i_FW 50_CD %_NN TSR_NNP benchmarked_VBD against_IN the_DT FTSE_NNP midperformance_NN conditions_NNS attaching_VBG to_TO the_DT grant_NN of_IN options_NNS ._.
Accordingly_RB 250_CD index_NN and_CC ii_FW 50_CD %_NN subject_NN to_TO an_DT EPS_NNP condition_NN measured_VBN against_IN the_DT performance_NN conditions_NNS attaching_VBG to_TO each_DT option_NN were_VBD determined_VBN the_DT diluted_VBN EPS_NNP of_IN the_DT Company_NN for_IN the_DT financial_JJ year_NN ended_VBD before_IN the_DT prior_JJ to_TO the_DT grant_NN ,_, namely_RB that_IN the_DT Companys_NNP share_NN price_NN had_VBD increased_VBN commencement_NN of_IN the_DT performance_NN period_NN and_CC the_DT diluted_VBN EPS_NNP of_IN the_DT by_IN an_DT annualised_JJ compound_NN rate_NN of_IN 20.5_CD %_NN over_IN a_DT minimum_JJ three-year_JJ Company_NN for_IN the_DT financial_JJ year_NN ended_VBN on_IN or_CC before_IN the_DT end_NN of_IN the_DT period_NN ._.
Shares_NNP granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP not_RB performance_NN period_NN ._.
Performance_NNP conditions_NNS attaching_VBG to_TO previous_JJ executive_NN option_NN grants_NNS are_VBP detailed_VBN on_IN pages_NNS 81_CD and_CC 82_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 39_CD Directors_NNS remuneration_JJ report_NN Pension_NN arrangements_NNS Mr_NNP Stahels_NNP employment_NN with_IN the_DT Company_NN commenced_VBD on_IN 28_CD March_NNP A_NNP defined_VBD contribution_NN pension_NN scheme_NN operates_VBZ in_IN the_DT UK_NNP ._.
1994_CD ,_, Mr_NNP Russells_NNPS employment_NN commenced_VBD on_IN 13_CD December_NNP 1999_CD and_CC Dr_NNP Tottens_NNP employment_NN commenced_VBD on_IN 17_CD January_NNP 1998_CD ._.
The_DT Companys_NNPS policy_NN is_VBZ to_TO ensure_VB that_IN pension_NN benefits_NNS are_VBP competitive_JJ in_IN the_DT markets_NNS in_IN which_WDT Shire_NNP operates_VBZ ._.
A_DT review_NN of_IN the_DT Companys_NNPS Non-executive_JJ directors_NNS pension_NN arrangements_NNS in_IN July_NNP 2002_CD recognized_VBD a_DT shortfall_NN in_IN the_DT level_NN of_IN The_DT Companys_NNPS policy_NN on_IN non-executive_JJ directors_NNS remuneration_NN is_VBZ that_IN pension_NN benefits_NNS provided_VBN to_TO our_PRP$ executive_JJ directors_NNS in_IN relation_NN to_TO market_NN each_DT director_NN is_VBZ paid_VBN a_DT fee_NN for_IN acting_VBG as_IN a_DT non-executive_JJ director_NN and_CC competitive_JJ practice_NN ._.
additional_JJ fees_NNS are_VBP paid_VBN for_IN being_VBG a_DT member_NN of_IN the_DT Audit_NNP ,_, Remuneration_NNP and_CC or_CC Nomination_NNP Committee_NNP ,_, as_RB well_RB as_IN for_IN being_VBG the_DT Chairman_NNP of_IN any_DT In_IN line_NN with_IN its_PRP$ remuneration_NN principles_NNS ,_, the_DT Remuneration_NNP Committee_NNP of_IN these_DT Committees_NNS ._.
The_DT Chairman_NNP of_IN the_DT Company_NN is_VBZ a_DT non-executive_JJ agreed_VBD that_IN the_DT Companys_NNP contribution_NN for_IN the_DT Chief_NNP Executive_NNP be_VB director_NN and_CC receives_VBZ a_DT separate_JJ fee_NN ._.
Fees_NNS are_VBP benchmarked_VBN against_IN increased_VBN to_TO 30_CD %_NN of_IN salary_NN per_IN annum_NN and_CC for_IN the_DT Finance_NNP Director_NNP comparable_JJ companies_NNS in_IN the_DT sector_NN and_CC are_VBP determined_VBN by_IN the_DT Board_NNP ._.
and_CC the_DT Group_NNP R&D_NNP Director_NNP to_TO 25_CD %_NN of_IN salary_NN per_IN annum_NN ,_, which_WDT the_DT Details_NNS of_IN fees_NNS paid_VBN to_TO non-executive_JJ directors_NNS in_IN 2002_CD are_VBP set_VBN out_RP in_IN Committee_NNP believes_VBZ is_VBZ more_RBR appropriately_RB competitive_JJ ._.
The_DT Remuneration_NNP the_DT table_NN on_IN page_NN 42_CD ._.
All_DT fees_NNS paid_VBN to_TO non-executive_JJ directors_NNS are_VBP not_RB Committee_NNP agreed_VBD a_DT supplemental_JJ pension_NN payment_NN to_TO Mr_NNP Stahel_NNP of_IN performance_NN related_VBN ._.
Non-executive_JJ directors_NNS do_VBP not_RB participate_VB in_IN any_DT 94,333_CD in_IN 2002_CD ._.
of_IN the_DT Company_NN share_NN schemes_NNS or_CC other_JJ employee_NN benefit_NN schemes_NNS A_DT defined_VBN contribution_NN pension_NN arrangement_NN was_VBD established_VBN for_IN Mr_NNP and_CC no_DT options_NNS have_VBP been_VBN granted_VBN to_TO non-executive_JJ directors_NNS in_IN their_PRP$ Stahel_NNP with_IN the_DT intention_NN that_IN his_PRP$ pension_NN arrangements_NNS on_IN leaving_VBG Shire_NNP capacity_NN as_IN non-executive_JJ directors_NNS of_IN Shire_NNP ._.
Non-executive_JJ directors_NNS were_VBD commensurate_JJ with_IN his_PRP$ position_NN as_IN a_DT FTSE_NNP 100_CD Chief_NNP Executive_NNP are_VBP not_RB eligible_JJ to_TO join_VB the_DT Companys_NNPS pension_NN scheme_NN ._.
Certain_JJ nonand_NN reflected_VBD his_PRP$ past_JJ contribution_NN to_TO the_DT Companys_NNPS business_NN ._.
A_DT one-off_JJ executive_NN directors_NNS hold_VBP share_NN options_NNS relating_VBG to_TO their_PRP$ service_NN with_IN payment_NN of_IN 4.3_CD million_CD to_TO this_DT arrangement_NN has_VBZ been_VBN made_VBN by_IN the_DT companies_NNS that_WDT have_VBP been_VBN acquired_VBN or_CC merged_VBN with_IN Shire_NNP ._.
The_DT grant_NN Company_NN in_IN 2003_CD see_VBP page_NN 41_CD ._.
of_IN these_DT options_NNS was_VBD made_VBN on_IN the_DT same_JJ terms_NNS as_IN applicable_JJ to_TO other_JJ employees_NNS at_IN the_DT time_NN and_CC ,_, by_IN the_DT nature_NN of_IN those_DT plans_NNS ,_, the_DT exercise_NN Service_NNP contracts_NNS of_IN those_DT options_NNS are_VBP not_RB subject_JJ to_TO any_DT performance_NN conditions_NNS ._.
All_DT nonThe_NNP Remuneration_NNP Committee_NNP reviewed_VBD the_DT contracts_NNS of_IN employment_NN executive_NN directors_NNS have_VBP letters_NNS of_IN appointment_NN detailing_VBG the_DT specific_NN for_IN executive_JJ directors_NNS and_CC other_JJ senior_JJ managers_NNS in_IN the_DT course_NN of_IN 2002_CD terms_NNS of_IN engagement_NN which_WDT are_VBP for_IN a_DT two-year_JJ term_NN and_CC which_WDT may_MD and_CC a_DT number_NN of_IN changes_NNS have_VBP been_VBN made_VBN to_TO the_DT directors_NNS service_NN be_VB renewed_VBN ._.
These_DT included_VBD clarification_NN of_IN current_JJ provisions_NNS and_CC amendments_NNS to_TO introduce_VB obligations_NNS on_IN the_DT executive_JJ directors_NNS in_IN Details_NNS of_IN the_DT unexpired_JJ terms_NNS of_IN the_DT non-executive_JJ directors_NNS letters_NNS respect_NN of_IN intellectual_JJ property_NN and_CC to_TO update_VB and_CC introduce_VB postof_JJ appointments_NNS and_CC notice_NN periods_NNS are_VBP as_IN follows_VBZ :_: termination_NN restrictions_NNS ,_, to_TO ensure_VB that_IN shareholders_NNS interests_NNS are_VBP best_JJS Date_NN of_IN Notice_NNP met_VBD in_IN the_DT event_NN of_IN early_JJ termination_NN of_IN a_DT director_NN ._.
Each_DT of_IN the_DT executive_NN Director_NNP term_NN expiry_NN period_NN directors_NNS was_VBD asked_VBN to_TO enter_VB into_IN a_DT new_JJ contract_NN of_IN employment_NN Dr_NNP Cavanaugh_NNP 23.03.05_CD 3_CD months_NNS reflecting_VBG these_DT changes_NNS ._.
The_DT revised_VBN contract_NN of_IN employment_NN for_IN Dr_NNP Bellini_NNP 10.05.03_CD 3_CD months_NNS Mr_NNP Russell_NNP is_VBZ dated_VBN 29_CD November_NNP 2002_CD ,_, for_IN Mr_NNP Stahel_NNP 28_CD February_NNP 2003_CD ,_, Dr_NNP Price_NNP 24.01.04_CD 3_CD months_NNS and_CC for_IN Dr_NNP Totten_NNP 17_CD December_NNP 2002_CD ._.
The_DT Hon_NNP James_NNP Grant_NNP 10.05.03_CD 3_CD months_NNS The_DT Remuneration_NNP Committees_NNS policy_NN is_VBZ and_CC has_VBZ been_VBN that_IN executive_JJ Mr_NNP Nordmann_NNP 22.12.03_CD 3_CD months_NNS directors_NNS service_NN contracts_NNS should_MD be_VB for_IN a_DT rolling_JJ term_NN ,_, subject_NN at_IN any_DT Mr_NNP Veilleux_NNP 10.05.03_CD 3_CD months_NNS time_NN to_TO a_DT 12-month_JJ notice_NN period_NN from_IN the_DT Company_NN ._.
In_IN the_DT event_NN of_IN termination_NN for_IN cause_NN no_DT such_JJ notice_NN period_NN would_MD apply_VB ._.
Related_VBN party_NN transactions_NNS The_DT Committee_NNP also_RB believes_VBZ that_IN the_DT Company_NN should_MD retain_VB the_DT right_JJ Details_NNS relating_VBG to_TO Mr_NNP John_NNP Spitznagel_NNP ,_, a_DT former_JJ director_NN who_WP entered_VBD to_TO make_VB a_DT payment_NN in_IN lieu_NN of_IN notice_NN to_TO a_DT director_NN ,_, except_IN in_IN the_DT event_NN of_IN into_IN a_DT consultancy_NN agreement_NN with_IN the_DT Company_NN ,_, and_CC The_DT Hon_NNP James_NNP termination_NN for_IN cause_NN ._.
In_IN accordance_NN with_IN policy_NN ,_, the_DT revised_VBN contracts_NNS Grant_NNP ,_, who_WP is_VBZ a_DT partner_NN of_IN a_DT Canadian_JJ law_NN firm_NN with_IN which_WDT the_DT Group_NNP allow_VBP the_DT Company_NN ,_, at_IN its_PRP$ discretion_NN ,_, to_TO pay_VB up_RP to_TO a_DT maximum_NN of_IN incurred_VBN professional_JJ fees_NNS during_IN the_DT year_NN ,_, are_VBP given_VBN in_IN note_NN 20_CD to_TO the_DT 12_CD months_NNS salary_NN ,_, 12_CD months_NNS maximum_JJ annual_JJ bonus_NN ,_, 12_CD months_NNS consolidated_JJ financial_JJ statements_NNS on_IN page_NN 73_CD ._.
pension_NN contribution_NN and_CC up_RB to_TO 12_CD months_NNS of_IN the_DT actual_JJ cost_NN to_TO the_DT employee_NN of_IN the_DT other_JJ contractual_JJ benefits_NNS to_TO which_WDT the_DT director_NN is_VBZ entitled_VBN ,_, in_IN the_DT event_NN of_IN termination_NN ,_, as_IN payment_NN in_IN lieu_NN of_IN notice_NN ._.
The_DT Committee_NNP takes_VBZ the_DT view_NN that_IN this_DT approach_NN will_MD enable_VB contractual_JJ termination_NN to_TO be_VB managed_VBN fairly_RB and_CC appropriately_RB taking_VBG into_IN account_NN individual_JJ circumstances_NNS ._.
As_IN part_NN of_IN its_PRP$ review_NN and_CC in_IN light_NN of_IN growing_VBG business_NN uncertainty_NN in_IN the_DT pharmaceutical_JJ sector_NN ,_, the_DT Remuneration_NNP Committee_NNP also_RB decided_VBD that_IN it_PRP would_MD be_VB in_IN shareholders_NNS interests_NNS to_TO provide_VB in_IN the_DT directors_NNS service_NN contracts_NNS that_IN ,_, in_IN the_DT event_NN of_IN a_DT change_NN of_IN control_NN of_IN the_DT Company_NN and_CC the_DT termination_NN ,_, other_JJ than_IN for_IN cause_NN ,_, by_IN the_DT Company_NN of_IN an_DT executive_JJ directors_NNS employment_NN within_IN 12_CD months_NNS thereof_RB ,_, the_DT executive_NN in_IN such_JJ circumstances_NNS would_MD be_VB entitled_VBN to_TO receive_VB 24_CD months_NNS salary_NN and_CC 24_CD months_NNS bonus_NN ,_, inclusive_NN of_IN all_DT other_JJ benefits_NNS ._.
Executive_NNP directors_NNS would_MD not_RB be_VB entitled_VBN ,_, in_IN addition_NN ,_, to_TO any_DT other_JJ severance_NN arrangements_NNS ._.
The_DT Committee_NNP takes_VBZ the_DT view_NN that_IN this_DT level_NN of_IN enhanced_JJ compensation_NN is_VBZ in_IN the_DT interests_NNS of_IN shareholders_NNS on_IN the_DT grounds_NNS that_IN it_PRP both_DT reduces_VBZ the_DT potential_NN for_IN insecurity_NN and_CC enhances_VBZ levels_NNS of_IN commitment_NN ._.
40_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Performance_NNP graph_NN Rolf_NNP Stahel_NNP The_NNP graph_NN below_IN sets_NNS out_IN the_DT total_JJ shareholder_NN return_NN for_IN the_DT five_CD years_NNS It_PRP was_VBD announced_VBN on_IN 29_CD October_NNP 2002_CD that_WDT Mr_NNP Stahel_NNP would_MD be_VB ending_VBG 31_CD December_NNP 2002_CD ._.
The_DT graph_NN sets_VBZ out_RP a_DT comparison_NN of_IN a_DT stepping_VBG down_RP as_IN Chief_NNP Executive_NNP once_RB a_DT successor_NN had_VBD been_VBN identified_VBN ._.
holding_VBG of_IN the_DT Companys_NNP shares_NNS over_IN this_DT period_NN contrasted_VBN with_IN a_DT Mr_NNP Stahels_NNP contract_NN of_IN employment_NN was_VBD terminated_VBN by_IN notice_NN given_VBN by_IN holding_VBG of_IN shares_NNS of_IN UK_NNP pharma_NN and_CC biotech_JJ companies_NNS in_IN the_DT FTSE_NNP the_DT Company_NN on_IN 12_CD March_NNP 2003_CD and_CC his_PRP$ employment_NN terminated_VBN on_IN over_IN the_DT relevant_JJ periods_NNS ,_, calculated_VBN in_IN accordance_NN with_IN the_DT Directors_NNS 19_CD March_NNP 2003_CD ._.
The_DT Remuneration_NNP Committee_NNP In_IN connection_NN with_IN the_DT termination_NN of_IN his_PRP$ employment_NN ,_, the_DT Company_NN is_VBZ of_IN the_DT view_NN that_IN this_DT is_VBZ the_DT most_RBS relevant_JJ broad_JJ equity_NN market_NN index_NN has_VBZ made_VBN a_DT payment_NN to_TO Mr_NNP Stahel_NNP under_IN the_DT payment_NN in_IN lieu_NN of_IN notice_NN against_IN which_WDT to_TO compare_VB Shires_NNP TSR_NNP performance_NN for_IN this_DT period_NN ._.
To_TO provisions_NNS of_IN his_PRP$ employment_NN contract_NN ._.
In_IN addition_NN ,_, the_DT Remuneration_NNP note_NN is_VBZ that_IN the_DT methodology_NN for_IN assessing_VBG Shires_NNP TSR_NNP performance_NN for_IN Committee_NNP awarded_VBD Mr_NNP Stahel_NNP an_DT amount_NN equal_JJ to_TO the_DT full_JJ bonus_NN for_IN that_IN the_DT purposes_NNS of_IN establishing_VBG whether_IN and_CC to_TO what_WP extent_NN shares_NNS under_IN proportion_NN of_IN 2003_CD which_WDT fell_VBD prior_RB to_TO the_DT date_NN on_IN which_WDT his_PRP$ employment_NN the_DT Plan_NN should_MD vest_NN is_VBZ somewhat_RB different_JJ from_IN the_DT methodology_NN used_VBN terminated_VBN ._.
in_IN the_DT compilation_NN of_IN this_DT graph_NN ._.
The_DT Remuneration_NNP Committee_NNP has_VBZ agreed_VBN to_TO exercise_VB its_PRP$ discretion_NN to_TO allow_VB Mr_NNP Stahel_NNP to_TO retain_VB his_PRP$ subsisting_VBG share_NN options_NNS ._.
However_RB ,_, this_DT is_VBZ Five-year_JJ historical_JJ TSR_NNP performance_NN Change_NNP in_IN the_DT value_NN of_IN a_DT hypothetical_JJ 100_CD holding_NN over_IN five_CD years_NNS subject_JJ to_TO Mr_NNP Stahel_NNP agreeing_VBG not_RB to_TO exercise_VB these_DT options_NNS for_IN a_DT FTSE_NNP UK_NNP Pharma_NNP and_CC Biotech_NNP Index_NNP comparison_NN based_VBN on_IN spot_NN values_NNS phased_VBD period_NN of_IN time_NN of_IN up_RB to_TO two_CD years_NNS following_VBG his_PRP$ termination_NN date_NN ._.
Mr_NNP Stahels_NNP options_NNS may_MD not_RB be_VB exercised_VBN if_IN he_PRP is_VBZ in_IN breach_NN of_IN certain_JJ 400.00_CD post_NN termination_NN restrictive_JJ covenants_NNS and_CC or_CC if_IN he_PRP engages_VBZ in_IN activity_NN detrimental_JJ to_TO the_DT Company_NN over_IN that_DT period_NN ._.
The_DT Remuneration_NNP Committee_NNP and_CC the_DT Board_NNP also_RB decided_VBD ,_, in_IN 350.00_CD recognition_NN of_IN Mr_NNP Stahels_NNP exceptional_JJ services_NNS to_TO the_DT Group_NNP over_IN his_PRP$ period_NN of_IN employment_NN ,_, to_TO make_VB an_DT additional_JJ one-off_JJ payment_NN ,_, to_TO a_DT defined_VBN contribution_NN pension_NN arrangement_NN established_VBN for_IN him_PRP ,_, of_IN 300.00_CD 4.3_CD million_CD ._.
This_DT is_VBZ the_DT amount_NN that_IN the_DT Remuneration_NNP Committee_NNP and_CC the_DT Board_NNP considered_VBN necessary_JJ ,_, taking_VBG into_IN account_NN amounts_NNS already_RB contributed_VBN by_IN the_DT Company_NN to_TO his_PRP$ personal_JJ pension_NN arrangements_NNS and_CC 250.00_CD his_PRP$ service_NN with_IN and_CC contribution_NN to_TO the_DT Company_NN ,_, to_TO make_VB appropriate_JJ pension_NN provision_NN for_IN him_PRP and_CC his_PRP$ dependants_NNS ._.
200.00_CD The_DT Remuneration_NNP Committee_NNP satisfied_VBD itself_PRP ,_, on_IN the_DT basis_NN of_IN actuarial_JJ advice_NN ,_, that_IN this_DT would_MD provide_VB Mr_NNP Stahel_NNP with_IN an_DT amount_NN that_WDT broadly_RB would_MD allow_VB the_DT acquisition_NN of_IN an_DT annuity_NN capable_JJ of_IN delivering_VBG a_DT pension_NN 150.00_CD equivalent_NN to_TO that_DT which_WDT he_PRP would_MD have_VB received_VBN ,_, given_VBN his_PRP$ years_NNS of_IN service_NN ,_, had_VBD he_PRP been_VBN in_IN a_DT defined_VBN benefit_NN scheme_NN with_IN an_DT accrual_NN rate_NN of_IN between_IN 1_CD 45th_CD and_CC 1_CD 30th_JJ of_IN his_PRP$ final_JJ salary_NN for_IN each_DT year_NN of_IN his_PRP$ service_NN ._.
100.00_CD 50.00_CD Dec_NNP 1997_CD Dec_NNP 1998_CD Dec_NNP 1999_CD Dec_NNP 2000_CD Dec_NNP 2001_CD Dec_NNP 2002_CD FTSE_NNP UK_NNP Pharma_NNP and_CC Biotech_NNP Index_NNP Shire_NNP Pharmaceuticals_NNP LON_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 41_CD Value_NN of_IN hypothetical_JJ 100_CD holding_VBG Directors_NNS remuneration_JJ report_NN Audited_VBN information_NN Aggregate_NNP directors_NNS remuneration_VBP The_DT total_JJ amounts_NNS for_IN directors_NNS remuneration_NN were_VBD as_IN follows_VBZ :_: 2002 2001 000 000_CD Emoluments_NNP 2,300_CD 2,019_CD Compensation_NNP for_IN loss_NN of_IN office_NN 2,754_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 2,962_CD 22,005_CD Money_NN purchase_NN pension_NN contributions_NNS 383_CD 103_CD 5,645_CD 26,881_CD Directors_NNS emoluments_NNS and_CC compensation_NN for_IN loss_NN of_IN office_NN Cash_NN Non-cash_JJ Basic_JJ Annual_JJ benefits_NNS benefits_NNS Total_JJ Total_JJ salary_NN bonuses_NNS Fees_NNS in_IN kind_NN in_IN kind_NN 2002_CD 2001_CD Director_NNP 000 000 000 000_CD 000 000 000_CD Executive_NNP Mr_NNP Rolf_NNP Stahel_NNP 559_CD 559_CD 26_CD 1,144_CD 726_CD Mr_NNP Angus_NNP Russell_NNP 290_CD 128_CD 7_CD 19 444 393_CD Dr_NNP Wilson_NNP Totten_NNP 310_CD 141 30 481 419_CD 1,159_CD 828_CD 7_CD 75_CD 2,069_CD 1,538_CD Non-executive_JJ Dr_NNP James_NNP Cavanaugh_NNP 45_CD 45_CD 42_CD Dr_NNP Barry_NNP Price_NNP 37_CD 37_CD 31_CD Dr_NNP Francesco_NNP Bellini_NNP 30_CD 30_CD 3,012_CD The_DT late_JJ Dr_NNP Bernard_NNP Canavan_NNP 23_CD 23_CD 60_CD The_DT Hon_NNP James_NNP Grant_NNP 30_CD 30_CD 19_CD Dr_NNP Zola_NNP Horovitz_NNP 7_CD Mr_NNP Ronald_NNP Nordmann_NNP 34_CD 34_CD 29_CD Mr_NNP Joseph_NNP Smith_NNP 7_CD Mr_NNP John_NNP Spitznagel_NNP 7_CD Mr_NNP Grard_NNP Veilleux_NNP 32_CD 32 21 231 231_CD 3,235_CD Total_JJ 1,159_CD 828_CD 231_CD 7_CD 75_CD 2,300_CD 4,773_CD These_DT directors_NNS resigned_VBD on_IN 11_CD May_NNP 2001_CD ._.
Cash_NN benefits_NNS in_IN kind_NN represent_VBP expense_NN allowances_NNS and_CC non-cash_JJ benefits_NNS represent_VBP emoluments_NNS ._.
Non-cash_JJ benefits_NNS in_IN kind_NN consist_VBP of_IN a_DT car_NN and_CC private_JJ medical_JJ insurance_NN including_VBG dental_JJ costs_NNS ._.
Details_NNS of_IN exercise_NN of_IN share_NN options_NNS are_VBP disclosed_VBN on_IN pages_NNS 43_CD to_TO 46_CD ._.
Non-executive_JJ director_NN remuneration_NN is_VBZ to_TO from_IN the_DT date_NN of_IN resignation_NN appointment_NN ._.
42_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Directors_NNS shareholdings_NNS Directors_NNS who_WP held_VBD office_NN at_IN the_DT end_NN of_IN the_DT year_NN had_VBD interests_NNS in_IN the_DT share_NN capital_NN of_IN the_DT Company_NN as_IN follows_VBZ :_: 31_CD December_NNP 31_CD December_NNP Notes_NNP 2002_CD 2001_CD Dr_NNP James_NNP Cavanaugh_NNP i_FW 8,806,368_CD 8,806,368_CD Mr_NNP Rolf_NNP Stahel_NNP ii_FW 601,779_CD 23,684_CD Mr_NNP Angus_NNP Russell_NNP Dr_NNP Wilson_NNP Totten_NNP iii_FW 6,061_CD Dr_NNP Barry_NNP Price_NNP 31,350_CD 31,350_CD Dr_NNP Francesco_NNP Bellini_NNP iv_NNP 6,586,708_CD 6,486,708_CD The_DT Hon_NNP James_NNP Grant_NNP v_VBD 4,551_CD 4,551_CD Mr_NNP Ronald_NNP Nordmann_NNP 46,968_CD 46,968_CD Mr_NNP Grard_NNP Veilleux_NNP All_NNP interests_NNS are_VBP beneficial_JJ unless_IN otherwise_RB stated_VBN ._.
Notes_NNP i_FW Dr_NNP Cavanaugh_NNP is_VBZ the_DT President_NNP of_IN HealthCare_NNP Ventures_NNP LLC_NNP ,_, which_WDT is_VBZ the_DT management_NN company_NN for_IN a_DT number_NN of_IN limited_JJ partnerships_NNS which_WDT have_VBP interests_NNS in_IN 8,690,090_CD ordinary_JJ shares_NNS ._.
Dr_NNP Cavanaugh_NNP is_VBZ also_RB the_DT beneficial_JJ owner_NN of_IN 116,278_CD ordinary_JJ shares_NNS ._.
ii_FW On_IN 4_CD March_NNP 2002_CD Mr_NNP Stahel_NNP purchased_VBD 19,000_CD ordinary_JJ shares_NNS at_IN a_DT price_NN of_IN 5.195_CD per_IN share_NN ._.
On_IN 16_CD August_NNP 2002_CD Mr_NNP Stahel_NNP exercised_VBD options_NNS granted_VBN to_TO him_PRP under_IN the_DT Shire_NNP Holdings_NNP Limited_NNP Share_NNP Option_NN Scheme_NN totalling_VBG 269,520_CD shares_NNS at_IN the_DT option_NN price_NN of_IN 1.00_CD per_IN share_NN ._.
All_DT 269,520_CD shares_NNS were_VBD subsequently_RB sold_VBN on_IN 20_CD December_NNP 2002_CD at_IN a_DT price_NN of_IN 3.887_CD per_IN share_NN ._.
Also_RB on_IN 20_CD December_NNP 2002_CD Mr_NNP Stahel_NNP exercised_VBD options_NNS granted_VBN to_TO him_PRP under_IN the_DT Shire_NNP Holdings_NNP Limited_NNP Share_NNP Option_NN Scheme_NN totalling_VBG 270,480_CD shares_NNS at_IN the_DT option_NN price_NN of_IN 1.00_CD per_IN share_NN and_CC 329,095_CD shares_NNS at_IN the_DT option_NN price_NN of_IN 1.75_CD per_IN share_NN granted_VBN to_TO him_PRP under_IN Part_NN B_NN of_IN the_DT Shire_NNP Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NN ._.
On_IN the_DT same_JJ day_NN 40,480_CD shares_NNS were_VBD sold_VBN from_IN the_DT Part_NNP B_NNP option_NN at_IN the_DT price_NN of_IN 3.887_CD per_IN share_NN ._.
iii_FW On_IN 6_CD March_NNP 2002_CD Dr_NNP Totten_NNP purchased_VBD 6,061_CD ordinary_JJ shares_NNS at_IN a_DT price_NN of_IN 4.90_CD per_IN share_NN ._.
iv_VB On_IN 1_CD March_NNP 2002_CD Dr_NNP Bellini_NNP purchased_VBD 100,000_CD ordinary_JJ shares_NNS at_IN a_DT price_NN of_IN 5.29_CD per_IN share_NN ._.
v_FW On_IN 5_CD June_NNP 2002_CD The_DT Hon_NNP James_NNP Grant_NNP exercised_VBD an_DT option_NN granted_VBN to_TO him_PRP under_IN the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN for_IN 31,859_CD shares_NNS at_IN the_DT option_NN price_NN of_IN 2.08_CD per_IN share_NN ._.
All_PDT these_DT shares_NNS were_VBD sold_VBN on_IN the_DT same_JJ day_NN at_IN a_DT price_NN of_IN 6.032_CD per_IN share_NN ._.
Directors_NNS share_VBP options_NNS Aggregate_JJ emoluments_NNS disclosed_VBN above_IN do_VBP not_RB include_VB any_DT amounts_NNS for_IN the_DT value_NN of_IN options_NNS to_TO acquire_VB ordinary_JJ shares_NNS in_IN the_DT Company_NN granted_VBN to_TO or_CC held_VBN by_IN the_DT directors_NNS ._.
Directors_NNS and_CC employees_NNS have_VBP been_VBN granted_VBN options_NNS over_IN ordinary_JJ shares_NNS under_IN the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP 2000_CD Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Holdings_NNP Limited_NNP Share_NNP Option_NN Scheme_NN SHL_NNP Scheme_NNP ,_, the_DT Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP ,_, the_DT Richwood_NNP 1993_CD and_CC 1995_CD Stock_NNP Option_NN Plans_NNS SRI_NNP Plan_NNP ,_, the_DT Roberts_NNP Stock_NNP Option_NN Plan_NNP Roberts_NNP Plan_NNP and_CC the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP ._.
There_EX have_VBP been_VBN no_DT variations_NNS to_TO the_DT terms_NNS and_CC conditions_NNS or_CC performance_NN criteria_NNS for_IN share_NN options_NNS during_IN the_DT financial_JJ year_NN except_IN as_IN detailed_VBN in_IN note_NN vi_FW below_IN ._.
In_IN addition_NN to_TO the_DT above_JJ disclosures_NNS ,_, the_DT following_JJ directors_NNS who_WP served_VBD during_IN the_DT year_NN under_IN review_NN have_VBP been_VBN granted_VBN ,_, or_CC have_VBP exercised_VBN the_DT following_JJ executive_NN options_NNS and_CC long-term_JJ incentive_NN awards_NNS during_IN the_DT period_NN between_IN 1_CD January_NNP 2003_CD and_CC 1_CD May_NNP 2003_CD ._.
Options_NNS granted_VBD Exercise_NNP Earliest_NNP Latest_JJS Number_NN price_NN Date_NN of_IN exercise_NN exercise_NN Director_NNP Scheme_NNP of_IN options_NNS grant_NN date_NN date_NN Dr_NNP Wilson_NNP Totten_NNP 2000_CD Executive_NNP Scheme_NNP B_NNP 301,775_CD 3.38_CD 04.03.03_CD 04.03.06_CD 03.03.13_CD Mr_NNP Angus_NNP Russell_NNP 2000_CD Executive_NNP Scheme_NNP B_NNP 284,024_CD 3.38_CD 04.03.03_CD 04.03.06_CD 03.03.13_CD 585,799_CD Options_NNS exercised_VBN Market_NN Exercise_NN price_NN at_IN Number_NNP price_NN Date_NN of_IN exercise_NN Gain_NN on_IN Director_NNP Scheme_NNP of_IN options_NNS exercise_NN date_NN exercise_NN Mr_NNP Rolf_NNP Stahel_NNP Executive_NNP Scheme_NNP A_NNP 13,761_CD 2.18_CD 18.03.03_CD 3.68_CD 20,676_CD Long_NNP Term_NNP Incentive_NNP Plan_NNP awards_NNS Value_NNP at_IN date_NN of_IN Earliest_NNP Award_NNP award_NN Date_NNP of_IN date_NN of_IN Director_NNP Scheme_NNP made_VBD award_NN award_NN Dr_NNP Wilson_NNP Totten_NNP Long_NNP Term_NNP Incentive_NNP Plan_NNP 47,459_CD 169,998_CD 20.03.03_CD 20.03.07_CD Mr_NNP Angus_NNP Russell_NNP Long_NNP Term_NNP Incentive_NNP Plan_NNP 44,667_CD 159,995_CD 20.03.03_CD 20.03.07_CD 92,126_CD Long_NNP Term_NNP Incentive_NNP Plan_NNP maturities_NNS Actual_NNP Initial_JJ performance_NN Value_NN at_IN award_NN related_VBN date_NN of_IN Date_NNP of_IN Director_NNP Scheme_NNP made_VBD award_NN maturity_NN maturity_NN Mr_NNP Rolf_NNP Stahel_NNP Long_NNP Term_NNP Incentive_NNP Plan_NNP 68,015_CD 49,934_CD 183,882_CD 18.03.03_CD Dr_NNP Wilson_NNP Totten_NNP Long_NNP Term_NNP Incentive_NNP Plan_NNP 15,255_CD 11,289_CD 46,623_CD 08.03.03_CD 65,189_CD In_IN addition_NN to_TO the_DT above_JJ ,_, on_IN 18_CD March_NNP 2003_CD ,_, the_DT remaining_VBG 55,949_CD of_IN Mr_NNP Stahels_NNP Long_NNP Term_NNP Incentive_NNP Plan_NNP awards_NNS lapsed_VBD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 45_CD Dir_NNP Directors_NNS r_SYM ectors_NNS remuneration_VBP r_NN emuneration_NN report_NN eport_NN Notes_NNS i_FW These_DT options_NNS have_VBP been_VBN granted_VBN over_IN shares_NNS in_IN Shire_NNP Holdings_NNP Limited_NNP ,_, a_DT previous_JJ holding_VBG company_NN of_IN the_DT Group_NNP ._.
The_DT exercise_NN of_IN these_DT options_NNS is_VBZ not_RB subject_JJ to_TO any_DT performance_NN criteria_NNS and_CC results_NNS in_IN the_DT option_NN holder_NN receiving_VBG ordinary_JJ shares_NNS in_IN the_DT Company_NN ._.
ii_FW Options_NNPS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ ,_, unless_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ._.
If_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN 14.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS may_MD be_VB exercised_VBN ._.
If_IN these_DT conditions_NNS are_VBP not_RB met_VBN after_IN the_DT initial_JJ three_CD years_NNS ,_, they_PRP are_VBP thereafter_RB tested_VBN quarterly_JJ by_IN reference_NN to_TO share_VB price_NN growth_NN over_IN the_DT extended_JJ period_NN ._.
If_IN the_DT share_NN price_NN does_VBZ not_RB meet_VB these_DT conditions_NNS at_IN any_DT time_NN ,_, none_NN of_IN the_DT options_NNS will_MD become_VB exercisable_JJ ._.
iii_FW Options_NNPS granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS ._.
Employees_NNS may_MD enter_VB into_IN three_CD or_CC five-year_JJ savings_NNS contracts_NNS ._.
The_DT exercise_NN of_IN options_NNS under_IN this_DT Scheme_NN is_VBZ not_RB subject_JJ to_TO any_DT performance_NN criteria_NNS ._.
iv_NN These_DT options_NNS have_VBP been_VBN granted_VBN over_IN shares_NNS in_IN Shire_NNP Laboratories_NNPS Inc._NNP ._.
SLI_NNP ,_, formerly_RB Pharmavene_NNP Inc._NNP a_DT US_NNP company_NN acquired_VBN by_IN the_DT Group_NNP on_IN 23_CD March_NNP 1997_CD ._.
Exercise_NN of_IN these_DT options_NNS results_NNS in_IN the_DT option_NN holder_NN receiving_VBG ordinary_JJ shares_NNS in_IN the_DT Company_NN ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN SLI_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ SLI_NNP Plan_NNP ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN and_CC were_VBD not_RB subject_JJ to_TO performance_NN criteria_NNS ._.
v_FW These_DT options_NNS have_VBP been_VBN granted_VBN over_IN shares_NNS in_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP ,_, a_DT US_NNP company_NN acquired_VBN by_IN the_DT Group_NNP on_IN 23_CD December_NNP 1999_CD ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN Roberts_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ Roberts_NNP Plan_NNP ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN and_CC were_VBD not_RB subject_JJ to_TO any_DT performance_NN criteria_NNS ._.
vi_FW Options_NNPS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP following_VBG the_DT Companys_NNPS 2000_CD Annual_JJ General_NNP Meeting_VBG are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ ,_, unless_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ period_NN ._.
If_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 14.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS will_MD be_VB exercisable_JJ ._.
If_IN these_DT conditions_NNS are_VBP not_RB met_VBN after_IN the_DT initial_JJ three-year_JJ measurement_NN period_NN ,_, they_PRP will_MD thereafter_RB be_VB tested_VBN quarterly_JJ by_IN reference_NN to_TO compound_VB annual_JJ share_NN price_NN growth_NN over_IN an_DT extended_JJ period_NN ._.
If_IN the_DT share_NN price_NN does_VBZ not_RB meet_VB these_DT conditions_NNS at_IN any_DT time_NN ,_, none_NN of_IN these_DT options_NNS will_MD become_VB exercisable_JJ ._.
At_IN the_DT Annual_JJ General_NNP Meeting_VBG of_IN the_DT Company_NN ,_, held_VBN on_IN 5_CD June_NNP 2001_CD ,_, a_DT resolution_NN was_VBD passed_VBN to_TO permit_VB the_DT grant_NN of_IN options_NNS under_IN the_DT 2000_CD Executive_NNP Scheme_NNP to_TO be_VB made_VBN subject_JJ to_TO performance_NN criteria_NNS being_VBG satisfied_JJ prior_RB to_TO the_DT date_NN of_IN grant_NN ._.
Subsequent_JJ to_TO the_DT passing_NN of_IN this_DT resolution_NN options_NNS have_VBP been_VBN granted_VBN based_VBN on_IN performance_NN criteria_NNS being_VBG satisfied_VBN before_IN grant_NN ,_, namely_RB that_IN the_DT Companys_NNP share_NN price_NN had_VBD increased_VBN by_IN an_DT annualised_JJ compound_NN rate_NN of_IN 20.5_CD %_NN over_IN a_DT minimum_JJ three-year_JJ period_NN ._.
During_IN 2002_CD ,_, the_DT performance_NN criteria_NNS were_VBD again_RB reviewed_VBN to_TO ensure_VB the_DT criteria_NNS reflected_VBD the_DT market_NN in_IN which_WDT the_DT Company_NN operates_VBZ ._.
Given_VBN the_DT Companys_NNPS development_NN it_PRP was_VBD felt_VBN appropriate_JJ that_IN an_DT EPS_NNP based_VBN measure_NN should_MD be_VB adopted_VBN in_IN place_NN of_IN share_NN price_NN growth_NN targets_NNS ._.
Therefore_RB option_NN grants_NNS made_VBN after_IN July_NNP 2002_CD will_MD only_RB become_VB exercisable_JJ in_IN full_JJ if_IN the_DT Companys_NNPS EPS_NNP growth_NN exceeds_VBZ the_DT RPI_NNP over_IN a_DT three-year_JJ period_NN for_IN the_DT following_VBG tranches_NNS of_IN grants_NNS :_: Options_NNS with_IN a_DT grant_NN value_NN of_IN up_RB to_TO 100_CD %_NN of_IN salary_NN RPI_NNP plus_CC 3_CD %_NN directors_NNS ,_, RPI_NNP plus_CC 5_CD %_NN Between_IN 101_CD %_NN and_CC 200_CD %_NN of_IN salary_NN RPI_NNP plus_CC 5_CD %_NN Between_IN 201_CD %_NN and_CC 300_CD %_NN of_IN salary_NN RPI_NNP plus_CC 7_CD %_NN Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 9_CD %_NN The_DT adoption_NN of_IN the_DT new_JJ criteria_NNS applies_VBZ to_TO all_DT options_NNS granted_VBN from_IN August_NNP 2002_CD onwards_NNS ._.
vii_FW Following_VBG the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP ,_, Inc._NNP on_IN 11_CD May_NNP 2001_CD ,_, the_DT BioChem_NNP Plan_NNP was_VBD amended_VBN such_JJ that_IN options_NNS over_IN BioChems_NNPS common_JJ stock_NN became_VBD options_NNS over_IN ordinary_JJ shares_NNS of_IN the_DT Company_NN ._.
All_DT BioChem_NNP options_NNS ,_, which_WDT were_VBD not_RB already_RB exercisable_JJ ,_, vested_JJ and_CC became_VBD exercisable_JJ as_IN a_DT result_NN of_IN the_DT acquisition_NN and_CC were_VBD not_RB subject_JJ to_TO any_DT performance_NN conditions_NNS ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT BioChem_NNP Plan_NNP ._.
viii_FW Under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP options_NNS are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, whichever_WDT is_VBZ the_DT lower_JJR ._.
The_DT offering_NN period_NN is_VBZ for_IN 27_CD months_NNS ._.
The_DT exercise_NN of_IN options_NNS under_IN this_DT plan_NN is_VBZ not_RB subject_JJ to_TO any_DT performance_NN condition_NN ._.
The_DT market_NN price_NN of_IN the_DT ordinary_JJ shares_NNS at_IN 31_CD December_NNP 2002_CD was_VBD 3.975_CD and_CC the_DT range_NN during_IN the_DT year_NN was_VBD 8.835_CD to_TO 3.755_CD ._.
Performance_NNP conditions_NNS attaching_VBG to_TO awards_NNS made_VBN under_IN the_DT Long_NNP Term_NNP Incentive_NNP Plan_NNP are_VBP detailed_VBN on_IN page_NN 39_CD ._.
46_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Directors_NNS pension_NN entitlements_NNS Four_CD directors_NNS are_VBP members_NNS of_IN money_NN purchase_NN schemes_NNS ._.
Contributions_NNS paid_VBN by_IN the_DT Company_NN in_IN respect_NN the_DT current_JJ year_NN were_VBD as_IN follows_VBZ :_: 2002_CD 2001_CD Director_NNP 000_CD 000_CD Mr_NNP Rolf_NNP Stahel_NNP 216_CD 48_CD Dr_NNP Wilson_NNP Totten_NNP 46_CD 29_CD Mr_NNP Angus_NNP Russell_NNP 56_CD 26_CD Dr_NNP Francesco_NNP Bellini_NNP 65 383 103_CD The_DT pension_NN payment_NN to_TO Dr_NNP Bellini_NNP ,_, the_DT former_JJ Chief_NNP Executive_NNP of_IN BioChem_NNP Pharma_NNP Inc_NNP ,_, arises_VBZ from_IN Dr_NNP Bellinis_NNP termination_NN arrangement_NN ,_, which_WDT is_VBZ based_VBN on_IN his_PRP$ pre-merger_JJ employment_NN contract_NN ._.
The_DT Companys_NNP obligation_NN to_TO make_VB pension_NN payment_NN to_TO Dr_NNP Bellini_NNP shall_MD end_VB on_IN 13_CD May_NNP 2003_CD ._.
Approval_NN This_DT report_NN was_VBD approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS on_IN 1_CD May_NNP 2003_CD and_CC signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: Dr_NNP Barry_NNP Price_NNP Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 47_CD Corporate_JJ governance_NN statement_NN The_DT Company_NN is_VBZ committed_VBN to_TO high_JJ standards_NNS of_IN corporate_JJ Committees_NNS of_IN the_DT Board_NNP governance_NN The_DT standing_NN Board_NNP committees_NNS are_VBP the_DT Audit_NNP Committee_NNP ,_, the_DT The_DT Combined_NNP Code_NNP on_IN Corporate_NNP Governance_NNP appended_VBD to_TO the_DT Listing_NNP Remuneration_NNP Committee_NNP ,_, the_DT Nomination_NNP Committee_NNP and_CC the_DT Executive_NNP Rules_NNP of_IN the_DT Financial_NNP Services_NNPS Authority_NNP requires_VBZ companies_NNS listed_VBN on_IN Committee_NNP ._.
Each_DT committee_NN has_VBZ its_PRP$ own_JJ written_VBN terms_NNS of_IN reference_NN that_IN the_DT London_NNP Stock_NNP Exchange_NNP to_TO make_VB a_DT disclosure_NN statement_NN on_IN its_PRP$ have_VBP been_VBN approved_VBN by_IN the_DT Board_NNP ._.
Details_NNS of_IN each_DT committee_NN are_VBP as_IN application_NN of_IN the_DT principles_NNS of_IN and_CC compliance_NN with_IN the_DT provisions_NNS of_IN follows_VBZ :_: good_JJ governance_NN set_VBN out_RP in_IN the_DT Combined_NNP Code_NNP ._.
Throughout_IN the_DT period_NN i_FW The_DT Audit_NNP Committee_NNP is_VBZ chaired_VBN by_IN Mr_NNP Ronald_NNP Nordmann_NNP and_CC under_IN review_NN the_DT Company_NN has_VBZ been_VBN committed_VBN to_TO high_JJ standards_NNS of_IN usually_RB meets_VBZ four_CD times_NNS a_DT year_NN ._.
Other_JJ members_NNS of_IN the_DT Committee_NNP corporate_JJ governance_NN and_CC ,_, in_IN the_DT directors_NNS opinion_NN ,_, has_VBZ complied_VBN ,_, are_VBP Dr_NNP James_NNP Cavanaugh_NNP and_CC Dr_NNP Barry_NNP Price_NNP ._.
Under_IN its_PRP$ terms_NNS of_IN subject_JJ as_IN below_IN ,_, with_IN the_DT provisions_NNS of_IN the_DT Combined_NNP Code_NNP ._.
reference_NN the_DT Committee_NNP is_VBZ required_VBN ,_, amongst_IN other_JJ things_NNS ,_, to_TO review_VB The_DT Board_NNP the_DT effectiveness_NN of_IN internal_JJ control_NN systems_NNS ,_, to_TO monitor_VB the_DT The_NNP Board_NNP ,_, which_WDT comprises_VBZ three_CD executive_NN and_CC six_CD non-executive_JJ relationship_NN with_IN external_JJ auditors_NNS ,_, including_VBG discussing_VBG the_DT scope_NN of_IN directors_NNS ,_, meets_VBZ at_IN least_JJS four_CD times_NNS a_DT year_NN and_CC the_DT meetings_NNS are_VBP well_RB the_DT audit_NN and_CC any_DT issues_NNS arising_VBG from_IN it_PRP ,_, to_TO review_VB the_DT Companys_NNPS attended_VBD ._.
The_DT Board_NNP seeks_VBZ to_TO provide_VB effective_JJ leadership_NN and_CC the_DT statutory_JJ accounts_NNS and_CC other_JJ financial_JJ statements_NNS and_CC information_NN ,_, control_NN required_VBN for_IN a_DT listed_VBN company_NN and_CC in_IN so_RB doing_VBG has_VBZ formally_RB and_CC to_TO review_VB the_DT business_NN risks_NNS faced_VBN by_IN the_DT Company_NN ._.
reserved_VBN specific_JJ matters_NNS to_TO itself_PRP for_IN determination_NN ._.
Specific_JJ powers_NNS ii_VBP The_DT Remuneration_NNP Committee_NNP ,_, under_IN the_DT chairmanship_NN of_IN Dr_NNP Barry_NNP and_CC authorities_NNS are_VBP also_RB delegated_VBN to_TO the_DT Executive_NNP Committee_NNP and_CC Price_NNP ,_, usually_RB meets_VBZ four_CD times_NNS a_DT year_NN ._.
Dr_NNP James_NNP Cavanaugh_NNP and_CC to_TO various_JJ other_JJ Board_NNP committees_NNS set_VBD out_RP below_IN ._.
Mr_NNP Grard_NNP Veilleux_NNP are_VBP the_DT other_JJ members_NNS of_IN this_DT Committee_NNP ._.
Under_IN The_DT Company_NN views_VBZ all_DT of_IN the_DT non-executive_JJ directors_NNS as_IN independent_JJ its_PRP$ terms_NNS of_IN reference_NN the_DT Committee_NNP is_VBZ required_VBN ,_, amongst_IN other_JJ of_IN management_NN and_CC free_JJ from_IN any_DT business_NN or_CC other_JJ relationship_NN which_WDT things_NNS ,_, to_TO determine_VB the_DT policy_NN for_IN the_DT remuneration_NN and_CC could_MD materially_RB interfere_VB with_IN the_DT exercise_NN of_IN their_PRP$ independent_JJ judgement_NN ._.
The_DT remuneration_NN of_IN nonexecutive_JJ directors_NNS is_VBZ determined_VBN by_IN the_DT Board_NNP ._.
The_DT directors_NNS The_DT Company_NN does_VBZ ,_, however_RB ,_, accept_VB that_DT on_IN a_DT strict_JJ interpretation_NN of_IN remuneration_NN report_NN appears_VBZ on_IN pages_NNS 38_CD to_TO 47_CD and_CC provides_VBZ further_RB the_DT Combined_NNP Code_NNP the_DT interests_NNS that_WDT Dr_VBP Cavanaugh_NNP has_VBZ as_IN President_NNP information_NN on_IN this_DT Committee_NNP ._.
of_IN HealthCare_NNP Ventures_NNP LLC_NNP and_CC the_DT position_NN The_DT Hon_NNP James_NNP Grant_NNP has_VBZ as_IN a_DT partner_NN of_IN Stikeman_NNP Elliot_NNP ,_, a_DT law_NN firm_NN retained_VBN by_IN BioChem_NNP prior_RB to_TO iii_VB The_DT Nomination_NNP Committee_NNP has_VBZ been_VBN delegated_VBN with_IN responsibility_NN the_DT merger_NN ,_, prevents_VBZ the_DT strict_JJ application_NN of_IN independence_NN ._.
The_DT same_JJ for_IN nominations_NNS of_IN directors_NNS to_TO the_DT Board_NNP ._.
This_DT Committee_NNP meets_VBZ is_VBZ also_RB relevant_JJ to_TO Dr_NNP Francesco_NNP Bellini_NNP by_IN virtue_NN of_IN the_DT executive_NN as_IN required_VBN and_CC is_VBZ chaired_VBN by_IN Dr_NNP James_NNP Cavanaugh_NNP ._.
Mr_NNP Ronald_NNP directorship_NN that_WDT Dr_NNP Bellini_NNP held_VBD with_IN BioChem_NNP ._.
Nordmann_NNP ,_, The_DT Hon_NNP James_NNP Grant_NNP and_CC Dr_NNP Barry_NNP Price_NNP also_RB serve_VBP on_IN this_DT Committee_NNP ._.
All_DT directors_NNS have_VBP access_NN to_TO the_DT advice_NN and_CC guidance_NN of_IN the_DT Company_NNP Secretary_NNP and_CC are_VBP encouraged_VBN to_TO seek_VB independent_JJ advice_NN at_IN the_DT iv_NN The_DT Executive_NNP Committee_NNP has_VBZ the_DT day-to-day_JJ management_NN of_IN the_DT Companys_NNP expense_NN ,_, where_WRB they_PRP feel_VBP it_PRP is_VBZ appropriate_JJ ._.
No_DT such_JJ Company_NN delegated_VBD to_TO it_PRP by_IN the_DT Board_NNP and_CC operates_VBZ within_IN clear_JJ independent_JJ advice_NN has_VBZ been_VBN sought_VBN ._.
The_DT Board_NNP is_VBZ confident_JJ that_IN all_DT its_PRP$ and_CC formal_JJ parameters_NNS ._.
The_DT Chief_NNP Executive_NNP is_VBZ the_DT Chairman_NNP of_IN the_DT members_NNS have_VBP the_DT knowledge_NN ,_, aptitude_NN and_CC experience_NN to_TO perform_VB the_DT Committee_NNP ,_, which_WDT consists_VBZ of_IN nine_CD senior_JJ executives_NNS including_VBG the_DT functions_NNS required_VBN of_IN a_DT director_NN of_IN a_DT listed_VBN company_NN ._.
Biographical_NNP details_NNS of_IN the_DT Board_NNP are_VBP shown_VBN on_IN page_NN 35_CD ._.
Directors_NNS remuneration_VBP Chairman_NNP and_CC Chief_NNP Executive_NNP The_NNP Companys_NNP remuneration_NN policy_NN appears_VBZ as_IN part_NN of_IN the_DT directors_NNS The_DT offices_NNS of_IN Chairman_NNP and_CC Chief_NNP Executive_NNP are_VBP held_VBN separately_RB ._.
The_DT report_NN details_NNS the_DT level_NN of_IN The_DT non-executive_JJ Chairman_NNP ,_, Dr_NNP James_NNP Cavanaugh_NNP ,_, is_VBZ responsible_JJ for_IN remuneration_NN for_IN directors_NNS and_CC the_DT basis_NN upon_IN which_WDT executive_NN the_DT conduct_NN of_IN the_DT Board_NNP and_CC ensures_VBZ that_IN Board_NNP discussions_NNS are_VBP remuneration_NN is_VBZ fixed_VBN ._.
conducted_VBN in_IN such_JJ a_DT way_NN that_IN all_DT views_NNS are_VBP taken_VBN into_IN account_NN ,_, so_RB that_IN no_DT individual_JJ director_NN or_CC small_JJ group_NN of_IN directors_NNS dominates_VBZ proceedings_NNS ._.
Relations_NNS with_IN shareholders_NNS The_DT Chief_NNP Executive_NNP is_VBZ responsible_JJ for_IN running_VBG the_DT business_NN and_CC chairs_NNS The_DT Company_NN is_VBZ committed_VBN to_TO maintaining_VBG good_JJ relations_NNS with_IN the_DT Executive_NNP Committee_NNP ._.
shareholders_NNS through_IN the_DT announcement_NN of_IN quarterly_JJ results_NNS and_CC the_DT provision_NN of_IN annual_JJ reports_NNS ._.
The_DT Company_NN also_RB arranges_VBZ individual_JJ and_CC Senior_JJ non-executive_JJ director_NN group_NN meetings_NNS with_IN its_PRP$ institutional_JJ shareholders_NNS in_IN order_NN to_TO discuss_VB Dr_NNP Barry_NNP Price_NNP is_VBZ the_DT nominated_VBN senior_JJ independent_JJ non-executive_JJ relevant_JJ communications_NNS to_TO ensure_VB that_IN the_DT investing_VBG community_NN director_NN ._.
receives_VBZ a_DT balanced_JJ and_CC complete_JJ view_NN of_IN the_DT Companys_NNP performance_NN Supply_NN of_IN information_NN and_CC issues_NNS faced_VBN by_IN the_DT business_NN ._.
The_DT Company_NN holds_VBZ its_PRP$ Annual_JJ The_DT executive_NN directors_NNS and_CC the_DT Company_NNP Secretary_NNP are_VBP responsible_JJ for_IN General_NNP Meeting_VBG in_IN London_NNP and_CC all_DT shareholders_NNS are_VBP given_VBN the_DT ensuring_VBG that_IN detailed_VBN information_NN is_VBZ provided_VBN to_TO the_DT Board_NNP at_IN least_JJS one_CD opportunity_NN to_TO ask_VB questions_NNS of_IN the_DT Board_NNP ._.
week_NN before_IN any_DT scheduled_VBN meeting_NN of_IN the_DT Board_NNP ._.
Before_IN decisions_NNS are_VBP The_DT Companys_NNP website_NN at_IN www_NN ._.
com_NN provides_VBZ Company_NN made_VBN ,_, consideration_NN is_VBZ given_VBN to_TO the_DT adequacy_NN of_IN information_NN available_JJ to_TO information_NN and_CC is_VBZ regularly_RB updated_VBN ._.
the_DT Board_NNP and_CC ,_, if_IN necessary_JJ ,_, decisions_NNS are_VBP deferred_VBN if_IN further_JJ information_NN is_VBZ required_VBN ._.
Balanced_JJ and_CC understandable_JJ assessment_NN of_IN positions_NNS and_CC prospects_NNS Re-appointment_JJ The_DT Company_NN strives_VBZ to_TO give_VB full_JJ ,_, timely_JJ and_CC realistic_JJ assessments_NNS of_IN Non-executive_JJ directors_NNS are_VBP appointed_VBN for_IN a_DT term_NN of_IN two_CD years_NNS ._.
matters_NNS that_WDT impact_VBP on_IN its_PRP$ business_NN and_CC financial_JJ position_NN and_CC to_TO present_VB Re-appointment_NN of_IN non-executive_JJ directors_NNS following_VBG the_DT expiry_NN of_IN scientific_JJ and_CC other_JJ price-sensitive_JJ data_NNS in_IN a_DT balanced_JJ way_NN ._.
Before_IN it_PRP was_VBD such_JJ two-year_JJ period_NN is_VBZ subject_JJ to_TO Board_NNP approval_NN ._.
required_VBN under_IN SEC_NNP rules_NNS ,_, the_DT Company_NN voluntarily_RB adopted_VBD quarterly_JJ financial_JJ reporting_NN ,_, which_WDT is_VBZ not_RB obligatory_JJ in_IN the_DT UK_NNP ._.
48_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ governance_NN statement_NN Financial_NNP disclosure_NN ,_, internal_JJ control_NN and_CC the_DT role_NN of_IN the_DT auditors_NNS These_DT reviews_NNS ,_, together_RB with_IN regular_JJ reports_NNS on_IN financial_JJ performance_NN ,_, The_NNP Board_NNP has_VBZ ,_, through_IN the_DT Audit_NNP Committee_NNP ,_, established_VBD formal_JJ and_CC represent_VB the_DT main_JJ elements_NNS in_IN establishing_VBG the_DT effectiveness_NN of_IN the_DT transparent_JJ arrangements_NNS for_IN financial_JJ reporting_NN ,_, internal_JJ control_NN and_CC system_NN of_IN internal_JJ control_NN ._.
In_IN addition_NN ,_, the_DT Company_NN has_VBZ a_DT system_NN external_JJ auditing_NN ._.
The_DT Audit_NNP Committees_NNS terms_NNS of_IN reference_NN extend_VBP of_IN control_NN procedures_NNS and_CC compliance_NN with_IN these_DT procedures_NNS is_VBZ to_TO the_DT Groups_NNS risk_NN management_NN activities_NNS as_IN a_DT whole_JJ and_CC not_RB just_RB the_DT monitored_VBN through_IN a_DT system_NN of_IN internal_JJ review_NN ._.
Any_DT significant_JJ issues_NNS financial_JJ aspects_NNS of_IN internal_JJ control_NN ._.
arising_VBG are_VBP reported_VBN to_TO the_DT Audit_NNP Committee_NNP for_IN review_NN ._.
All_DT employees_NNS can_MD raise_VB any_DT concerns_NNS in_IN any_DT of_IN these_DT areas_NNS with_IN the_DT During_IN the_DT year_NN ,_, the_DT Audit_NNP Committee_NNP has_VBZ continued_VBN to_TO examine_VB Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP in_IN the_DT strictest_JJS confidence_NN ._.
The_DT how_WRB it_PRP obtains_VBZ assurance_NN that_IN risks_NNS are_VBP managed_VBN effectively_RB by_IN Company_NN has_VBZ introduced_VBN a_DT new_JJ whistle-blowing_JJ policy_NN ._.
This_DT provides_VBZ the_DT Company_NN and_CC the_DT necessary_JJ internal_JJ controls_NNS are_VBP in_IN place_NN ._.
a_DT confidential_JJ process_NN through_IN which_WDT all_DT employees_NNS are_VBP able_JJ to_TO report_VB During_IN 2002_CD ,_, the_DT internal_JJ audit_NN function_NN ,_, which_WDT is_VBZ outsourced_VBN ,_, has_VBZ concerns_NNS relating_VBG to_TO financial_JJ disclosure_NN ,_, internal_JJ control_NN and_CC other_JJ reviewed_VBN the_DT overall_JJ assurance_NN framework_NN and_CC has_VBZ reported_VBN to_TO the_DT compliance_NN issues_NNS in_IN good_JJ faith_NN without_IN fear_NN of_IN discrimination_NN or_CC reprisal_NN ._.
Executive_NNP Committee_NNP and_CC the_DT Audit_NNP Committee_NNP ._.
In_IN addition_NN ,_, the_DT Audit_NNP Committee_NNP has_VBZ introduced_VBN a_DT procedure_NN for_IN the_DT iii_FW External_NNP auditing_NN receipt_NN and_CC monitoring_NN of_IN complaints_NNS relating_VBG to_TO internal_JJ controls_NNS ._.
The_DT Audit_NNP Committee_NNP reviews_VBZ the_DT scope_NN and_CC results_NNS of_IN the_DT audit_NN i_FW Financial_NNP reporting_NN and_CC non-audit_JJ services_NNS provided_VBN by_IN the_DT auditors_NNS ,_, the_DT cost_NN The_DT Board_NNP has_VBZ ultimate_JJ responsibility_NN for_IN the_DT preparation_NN of_IN accounts_NNS effectiveness_NN and_CC the_DT independence_NN and_CC objectivity_NN of_IN the_DT auditors_NNS ._.
and_CC for_IN the_DT monitoring_NN of_IN systems_NNS of_IN internal_JJ financial_JJ control_NN ._.
The_DT In_IN recognition_NN of_IN the_DT importance_NN of_IN maintaining_VBG the_DT independence_NN of_IN Board_NNP strives_VBZ to_TO present_VB a_DT balanced_JJ and_CC understandable_JJ assessment_NN the_DT auditors_NNS ,_, the_DT Audit_NNP Committee_NNP has_VBZ put_VBN in_IN place_NN new_JJ procedures_NNS of_IN the_DT Companys_NNP position_NN and_CC its_PRP$ prospects_NNS and_CC endeavors_NNS to_TO for_IN the_DT pre-approval_JJ of_IN the_DT provision_NN of_IN non-audit_JJ services_NNS by_IN the_DT present_JJ scientific_JJ and_CC other_JJ price-sensitive_JJ information_NN in_IN a_DT balanced_JJ auditors_NNS ._.
The_DT Company_NN publishes_VBZ quarterly_JJ financial_JJ reports_NNS so_IN that_IN its_PRP$ Going_VBG concern_NN basis_NN shareholders_NNS can_MD monitor_VB the_DT Companys_NNPS financial_JJ position_NN regularly_RB ._.
After_IN making_VBG enquiries_NNS ,_, the_DT directors_NNS have_VBP formed_VBN a_DT judgement_NN ,_, at_IN the_DT On_NNP behalf_NN of_IN the_DT Board_NNP ,_, the_DT Audit_NNP Committee_NNP examines_VBZ the_DT time_NN of_IN approving_VBG the_DT financial_JJ statements_NNS ,_, that_IN there_EX is_VBZ a_DT reasonable_JJ effectiveness_NN of_IN systems_NNS of_IN internal_JJ financial_JJ control_NN on_IN a_DT regular_JJ expectation_NN that_IN the_DT Group_NNP has_VBZ adequate_JJ resources_NNS to_TO continue_VB in_IN basis_NN ._.
This_DT includes_VBZ having_VBG independent_JJ access_NN to_TO the_DT auditors_NNS operational_JJ existence_NN for_IN the_DT foreseeable_JJ future_NN ._.
For_IN this_DT reason_NN the_DT throughout_IN the_DT year_NN in_IN addition_NN to_TO presentations_NNS from_IN the_DT auditors_NNS on_IN directors_NNS continue_VBP to_TO adopt_VB the_DT going_VBG concern_NN basis_NN in_IN preparing_VBG the_DT a_DT quarterly_JJ basis_NN ._.
Any_DT significant_JJ findings_NNS or_CC identified_VBN risks_NNS are_VBP closely_RB financial_JJ statements_NNS ._.
examined_VBD and_CC are_VBP reported_VBN to_TO the_DT Board_NNP with_IN recommendations_NNS for_IN action_NN ._.
During_IN 2002_CD ,_, certain_JJ requirements_NNS of_IN the_DT Sarbanes-Oxley_NNP Act_NNP came_VBD into_IN force_NN in_IN the_DT US_NNP ._.
In_IN line_NN with_IN these_DT requirements_NNS ,_, the_DT Chief_NNP Executive_NNP and_CC the_DT Group_NNP Finance_NNP Director_NNP have_VBP formally_RB certified_VBN that_IN the_DT Annual_JJ Report_NNP has_VBZ been_VBN prepared_VBN in_IN accordance_NN with_IN US_NNP generally_RB accepted_VBD accounting_NN principles_NNS and_CC fairly_RB represents_VBZ the_DT financial_JJ condition_NN and_CC results_NNS of_IN the_DT Company_NN ._.
ii_FW Internal_NNP control_NN In_IN applying_VBG the_DT principle_NN that_IN the_DT Board_NNP should_MD maintain_VB a_DT sound_JJ system_NN of_IN internal_JJ control_NN to_TO safeguard_VB shareholders_NNS investment_NN and_CC the_DT Companys_NNPS assets_NNS and_CC in_IN accordance_NN with_IN the_DT Turnbull_NNP Committees_NNS guidance_NN on_IN internal_JJ control_NN ,_, the_DT directors_NNS recognize_VBP that_IN they_PRP have_VBP overall_JJ responsibility_NN for_IN the_DT Companys_NNP system_NN of_IN internal_JJ control_NN and_CC for_IN regularly_RB reviewing_VBG its_PRP$ effectiveness_NN ._.
The_DT directors_NNS believe_VBP that_IN the_DT Company_NN has_VBZ applied_VBN this_DT principle_NN during_IN the_DT year_NN under_IN review_NN and_CC up_RB to_TO the_DT date_NN of_IN signing_VBG these_DT accounts_NNS ._.
However_RB ,_, there_EX are_VBP limitations_NNS in_IN any_DT system_NN of_IN internal_JJ control_NN and_CC accordingly_RB even_RB the_DT most_RBS effective_JJ system_NN can_MD provide_VB only_JJ reasonable_JJ and_CC not_RB absolute_JJ assurance_NN ._.
Such_JJ a_DT system_NN is_VBZ designed_VBN to_TO manage_VB rather_RB than_IN eliminate_VB the_DT risk_NN of_IN failure_NN to_TO achieve_VB business_NN objectives_NNS and_CC can_MD only_RB provide_VB reasonable_JJ and_CC not_RB absolute_JJ assurance_NN against_IN material_NN misstatement_NN or_CC loss_NN ._.
The_DT Company_NN has_VBZ an_DT ongoing_JJ process_NN for_IN identifying_VBG ,_, evaluating_VBG and_CC managing_VBG the_DT significant_JJ risks_NNS that_IN it_PRP faces_VBZ ._.
This_DT process_NN has_VBZ been_VBN in_IN operation_NN throughout_IN the_DT period_NN under_IN review_NN and_CC up_RB to_TO the_DT date_NN of_IN the_DT signing_NN of_IN the_DT accounts_NNS ._.
In_IN particular_JJ ,_, the_DT Executive_NNP Committee_NNP ,_, the_DT Audit_NNP Committee_NNP and_CC the_DT Board_NNP have_VBP reviewed_VBN the_DT schedule_NN of_IN risks_NNS faced_VBN by_IN the_DT Company_NN ._.
This_DT includes_VBZ analysis_NN of_IN the_DT impact_NN of_IN the_DT operation_NN of_IN key_JJ risks_NNS and_CC the_DT action_NN being_VBG taken_VBN to_TO avoid_VB or_CC reduce_VB each_DT risk_NN ._.
In_IN particular_JJ ,_, the_DT schedule_NN of_IN risks_NNS allocates_VBZ responsibility_NN for_IN management_NN of_IN each_DT key_JJ risk_NN to_TO senior_JJ executives_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 49_CD Statement_NN of_IN directors_NNS responsibilities_NNS Report_NNP of_IN independent_JJ auditors_NNS English_JJ company_NN law_NN requires_VBZ the_DT directors_NNS to_TO prepare_VB financial_JJ To_TO the_DT shareholders_NNS of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN statements_NNS for_IN each_DT financial_JJ year_NN which_WDT give_VBP a_DT true_JJ and_CC fair_JJ view_NN of_IN We_PRP have_VBP audited_VBN the_DT accompanying_VBG consolidated_JJ balance_NN sheets_NNS of_IN the_DT state_NN of_IN affairs_NNS of_IN the_DT Company_NN and_CC the_DT Group_NNP as_IN at_IN the_DT end_NN of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN and_CC its_PRP$ subsidiaries_NNS as_IN of_IN December_NNP 31_CD ,_, the_DT financial_JJ year_NN and_CC of_IN the_DT profit_NN or_CC loss_NN of_IN the_DT Group_NNP for_IN that_DT period_NN ._.
2002_CD and_CC 2001_CD ,_, and_CC the_DT related_JJ consolidated_JJ statements_NNS of_IN operations_NNS ,_, In_IN preparing_VBG those_DT financial_JJ statements_NNS ,_, the_DT directors_NNS are_VBP required_VBN to_TO :_: comprehensive_JJ income_NN ,_, changes_NNS in_IN shareholders_NNS equity_NN ,_, and_CC cash_NN flows_NNS for_IN each_DT of_IN the_DT three_CD years_NNS in_IN the_DT period_NN ended_VBD December_NNP 31_CD ,_, select_JJ suitable_JJ accounting_NN policies_NNS and_CC then_RB apply_VB them_PRP consistently_RB :_: 2002_CD ._.
These_DT financial_JJ statements_NNS are_VBP the_DT responsibility_NN of_IN the_DT Companys_NNP management_NN ._.
Our_PRP$ responsibility_NN is_VBZ to_TO express_VB an_DT opinion_NN on_IN these_DT make_VBP judgements_NNS and_CC estimates_NNS that_WDT are_VBP reasonable_JJ and_CC prudent_JJ :_: financial_JJ statements_NNS based_VBN on_IN our_PRP$ audits_NN ._.
The_DT consolidated_JJ financial_JJ and_CC statements_NNS give_VBP retroactive_JJ effect_NN to_TO the_DT merger_NN of_IN Shire_NNP Pharmaceuticals_NNP state_NN whether_IN applicable_JJ accounting_NN standards_NNS have_VBP been_VBN followed_VBN ._.
Group_NNP plc_NN and_CC BioChem_NNP Pharma_NNP ,_, Inc._NNP which_WDT has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT pooling_VBG of_IN interests_NNS ,_, as_IN described_VBN in_IN Note_NN 3_CD to_TO the_DT consolidated_JJ The_DT directors_NNS are_VBP responsible_JJ for_IN keeping_VBG proper_JJ accounting_NN records_NNS financial_JJ statements_NNS ._.
which_WDT disclose_VBP with_IN reasonable_JJ accuracy_NN at_IN any_DT time_NN the_DT financial_JJ We_PRP did_VBD not_RB audit_VB the_DT balance_NN sheet_NN of_IN BioChem_NNP Pharma_NNP ,_, Inc._NNP a_DT position_NN of_IN the_DT Company_NN and_CC enable_VB them_PRP to_TO ensure_VB that_IN the_DT financial_JJ company_NN acquired_VBN in_IN 2001_CD in_IN a_DT transaction_NN accounted_VBD for_IN as_IN a_DT pooling_VBG statements_NNS comply_VB with_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
They_PRP are_VBP also_RB of_IN interests_NNS ,_, as_IN of_IN December_NNP 31_CD ,_, 2000_CD ,_, or_CC the_DT related_JJ statements_NNS of_IN responsible_JJ for_IN safeguarding_VBG the_DT assets_NNS of_IN the_DT Company_NN and_CC hence_RB income_NN ,_, shareholders_NNS equity_NN and_CC cash_NN flows_NNS of_IN BioChem_NNP Pharma_NNP ,_, Inc._NNP for_IN taking_VBG reasonable_JJ steps_NNS for_IN the_DT prevention_NN and_CC detection_NN of_IN fraud_NN for_IN the_DT year_NN then_RB ended_VBD ,_, which_WDT statements_NNS reflect_VBP total_JJ assets_NNS of_IN and_CC other_JJ irregularities_NNS ._.
$_$ 578.1_CD million_CD and_CC total_JJ revenues_NNS of_IN $_$ 517.6_CD million_CD ._.
Those_DT statements_NNS were_VBD audited_VBN by_IN other_JJ auditors_NNS whose_WP$ report_NN has_VBZ been_VBN furnished_VBN to_TO us_PRP ,_, and_CC our_PRP$ opinion_NN ,_, insofar_RB as_IN it_PRP relates_VBZ to_TO amounts_NNS included_VBN for_IN BioChem_NNP Pharma_NNP Inc._NNP for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2000_CD ,_, is_VBZ based_VBN solely_RB upon_IN the_DT report_NN of_IN such_JJ other_JJ auditors_NNS ._.
We_PRP also_RB audited_VBD the_DT accounting_NN policy_NN alignments_NNS described_VBN in_IN Note_NN 4_CD that_WDT were_VBD applied_VBN to_TO the_DT 2000_CD audited_VBD financial_JJ statements_NNS of_IN BioChem_NNP Pharma_NNP ,_, Inc._NNP ._.
In_IN our_PRP$ opinion_NN ,_, such_JJ adjustments_NNS are_VBP appropriate_JJ and_CC have_VBP been_VBN properly_RB applied_VBN ._.
We_PRP conducted_VBD our_PRP$ audits_NN in_IN accordance_NN with_IN auditing_NN standards_NNS generally_RB accepted_VBN in_IN the_DT United_NNP States_NNPS of_IN America_NNP ._.
Those_DT standards_NNS require_VBP that_IN we_PRP plan_VBP and_CC perform_VBP the_DT audit_NN to_TO obtain_VB reasonable_JJ assurance_NN about_IN whether_IN the_DT financial_JJ statements_NNS are_VBP free_JJ of_IN material_NN misstatement_NN ._.
An_DT audit_NN includes_VBZ examining_VBG ,_, on_IN a_DT test_NN basis_NN ,_, evidence_NN supporting_VBG the_DT amounts_NNS and_CC disclosures_NNS in_IN the_DT financial_JJ statements_NNS ._.
An_DT audit_NN also_RB includes_VBZ assessing_VBG the_DT accounting_NN principles_NNS used_VBN and_CC significant_JJ estimates_NNS made_VBN by_IN management_NN ,_, as_RB well_RB as_IN evaluating_VBG the_DT overall_JJ financial_JJ statement_NN presentation_NN ._.
We_PRP believe_VBP that_IN our_PRP$ audits_NN and_CC the_DT report_NN of_IN the_DT other_JJ auditors_NNS provide_VBP a_DT reasonable_JJ basis_NN for_IN our_PRP$ opinion_NN ._.
In_IN our_PRP$ opinion_NN ,_, based_VBN on_IN our_PRP$ audit_NN and_CC the_DT report_NN of_IN the_DT other_JJ auditors_NNS ,_, the_DT financial_JJ statements_NNS referred_VBD to_TO above_IN present_JJ fairly_RB ,_, in_IN all_DT material_NN respects_VBZ ,_, the_DT financial_JJ position_NN of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN and_CC subsidiaries_NNS as_IN of_IN December_NNP 31_CD ,_, 2002_CD and_CC 2001_CD ,_, and_CC the_DT results_NNS of_IN their_PRP$ operations_NNS and_CC their_PRP$ cash_NN flows_VBZ for_IN each_DT of_IN the_DT three_CD years_NNS in_IN the_DT period_NN ended_VBD December_NNP 31_CD ,_, 2002_CD ,_, in_IN conformity_NN with_IN accounting_NN principles_NNS generally_RB accepted_VBN in_IN the_DT United_NNP States_NNPS of_IN America_NNP ._.
As_IN explained_VBN in_IN note_NN 12_CD ,_, effective_JJ January_NNP 1_CD ,_, 2002_CD ,_, the_DT Company_NN adopted_VBN SFAS_NNP No._NN ._.
142_CD ,_, Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS ._.
Deloitte_NNP &_CC Touche_NNP Reading_VBG ,_, England_NNP February_NNP 26_CD ,_, 2003_CD 50_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP balance_NN sheets_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN share_NN data_NNS 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD Notes_NNS $_$ 000_CD $_$ 000_CD Assets_NNPS Current_JJ assets_NNS :_: Cash_NN and_CC cash_NN equivalents_NNS 897,718_CD 118,040_CD Marketable_JJ securities_NNS 6_CD 316,126_CD 723,911_CD Accounts_NNPS receivable_NN ,_, net_JJ 7_CD 138,397_CD 193,913_CD Inventories_NNS 8_CD 49,216_CD 44,911_CD Deferred_JJ tax_NN asset_NN 34,849_CD 19,430_CD Prepaid_NN expenses_NNS and_CC other_JJ current_JJ assets_NNS 9_CD 30,790_CD 38,571_CD Total_JJ current_JJ assets_NNS from_IN continuing_VBG operations_NNS 1,467,096_CD 1,138,776_CD Current_JJ assets_NNS from_IN discontinued_VBN operations_NNS 5_CD 1,779_CD Total_JJ current_JJ assets_NNS 1,467,096_CD 1,140,555_CD Investments_NNP 10_CD 71,962_CD 68,743_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ 11_CD 135,234_CD 113,347_CD Goodwill_NNP ,_, net_JJ 12_CD 203,767_CD 175,341_CD Other_JJ intangible_JJ assets_NNS ,_, net_JJ 12_CD 301,084_CD 308,355_CD Deferred_JJ tax_NN asset_NN 6,216_CD 20,274_CD Other_JJ non-current_JJ assets_NNS 13_CD 23,264_CD 26,168_CD Total_JJ long-term_JJ assets_NNS from_IN continuing_VBG operations_NNS 741,527_CD 712,228_CD Long-term_JJ assets_NNS from_IN discontinued_VBN operations_NNS 5_CD 57,948_CD Total_JJ assets_NNS 2,208,623_CD 1,910,731_CD Liabilities_NNS and_CC shareholders_NNS equity_NN Current_JJ liabilities_NNS :_: Current_JJ installments_NNS of_IN long-term_JJ debt_NN 16_CD 888_CD 4,325_CD Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS 14_CD 184,107_CD 167,152_CD Unearned_JJ income_NN 17,409_CD Other_JJ current_JJ liabilities_NNS 15_CD 15,492_CD 42,730_CD Total_JJ current_JJ liabilities_NNS from_IN continuing_VBG operations_NNS 200,487_CD 231,616_CD Current_JJ liabilities_NNS from_IN discontinued_VBN operations_NNS 5_CD 12,784_CD Total_JJ current_JJ liabilities_NNS 213,271_CD 231,616_CD Long-term_JJ debt_NN ,_, excluding_VBG current_JJ instalments_NNS 16_CD 407,302_CD 402,481_CD Other_JJ non-current_JJ liabilities_NNS 17_CD 14,884_CD 13,645_CD Total_JJ liabilities_NNS 635,457_CD 647,742_CD Shareholders_NNS equity_NN :_: Common_JJ stock_NN ,_, 5p_JJ par_NN value_NN :_: 800,000,000_CD shares_NNS authorised_VBN :_: and_CC 484,344,412_CD 2001_CD :_: 481,817,487_CD shares_NNS issued_VBN and_CC outstanding_JJ 40,051_CD 39,861_CD Exchangeable_JJ shares_NNS :_: 5,874,112_CD 2001_CD :_: 5,978,902_CD shares_NNS issued_VBN and_CC outstanding_JJ 272,523_CD 277,386_CD Additional_JJ paid-in_JJ capital_NN 1,027,499_CD 1,014,796_CD Accumulated_VBN other_JJ comprehensive_JJ losses_NNS 41,431_CD 93,009_CD Retained_VBN earnings_NNS 274,524_CD 23,955_CD Total_JJ shareholders_NNS equity_NN 1,573,166_CD 1,262,989_CD Total_JJ liabilities_NNS and_CC shareholders_NNS equity_NN 2,208,623_CD 1,910,731_CD The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 51_CD Consolidated_NNP statements_NNS of_IN operations_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN share_NN and_CC per_IN share_NN data_NNS 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP Notes_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Revenues_NNS :_: Product_NN sales_NNS 859,388_CD 699,351_CD 496,775_CD Licensing_NN and_CC development_NN 3,064_CD 5,498_CD 14,147_CD Royalties_NNS 174,812_CD 145,155_CD 135,470_CD Other_JJ revenues_NNS 34_CD 2,952_CD 1,262_CD Total_JJ revenues_NNS 22_CD 1,037,298_CD 852,956_CD 647,654_CD Costs_NNS and_CC expenses_NNS :_: Cost_NN of_IN product_NN sales_NNS 133,682_CD 112,006_CD 95,071_CD Research_NNP and_CC development_NN inclusive_NN of_IN stock_NN option_NN compensation_NN charge_NN on_IN warrants_NNS of_IN $_$ 4,502_CD for_IN 2001_CD 189,179_CD 171,029_CD 155,145_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ inclusive_NN of_IN stock_NN option_NN compensation_NN credit_NN charge_NN of_IN $_$ 166_CD ,_, $_$ 2,278_CD and_CC $_$ 21,914_CD for_IN 2002_CD ,_, 2001_CD and_CC 2000_CD respectively_RB 386,023_CD 303,480_CD 230,216_CD Other_JJ charges_NNS :_: 23_CD In_IN process_NN research_NN and_CC development_NN 26,947_CD Asset_NNP impairments_NNS and_CC restructuring_NN charges_NNS 29,699_CD Merger_NNP transaction_NN expenses_NNS 83,470_CD Loss_NN on_IN disposition_NN of_IN assets_NNS 1,376_CD 10,164_CD Total_JJ operating_NN expenses_NNS 710,260_CD 709,848_CD 507,379_CD Operating_NN income_NN 22_CD 327,038_CD 143,108_CD 140,275_CD Interest_NN income_NN 19,536_CD 19,667_CD 19,232_CD Interest_NN expense_NN 9,252_CD 8,315_CD 16,413_CD Other_JJ expense_NN income_NN ,_, net_JJ 24_CD 8,262_CD 52,933_CD 109,023_CD Total_JJ other_JJ income_NN expense_NN ,_, net_JJ 2,022_CD 41,581_CD 111,842_CD Income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS ,_, equity_NN in_IN earnings_NNS of_IN equity_NN method_NN investees_NNS and_CC extraordinary_JJ items_NNS 329,060_CD 101,527_CD 252,117_CD Income_NN taxes_NNS 26_CD 88,350_CD 68,897_CD 43,564_CD Equity_NN in_IN earnings_NNS of_IN equity_NN method_NN investees_VBZ 27_CD 1,668_CD 1,985_CD 3,809_CD Income_NN from_IN continuing_VBG operations_NNS before_IN extraordinary_JJ item_NN 242,378_CD 34,615_CD 204,744_CD Income_NN from_IN discontinued_VBN operations_NNS net_NN of_IN income_NN tax_NN expense_NN of_IN $_$ 3,588_CD ,_, $_$ 3,963_CD and_CC $_$ 4,100_CD respectively_RB 5_CD 6,108_CD 6,748_CD 6,983_CD Gain_NN on_IN disposition_NN of_IN discontinued_VBN operations_NNS net_NN of_IN income_NN tax_NN expense_NN of_IN $_$ 1,224_CD 5_CD 2,083_CD Extraordinary_JJ item_NN ,_, net_NN of_IN income_NN tax_NN 2,604_CD Net_JJ income_NN 250,569_CD 38,759_CD 211,727_CD Earnings_NNS per_IN share_NN basic_JJ 21_CD Income_NN from_IN continuing_VBG operations_NNS before_IN extraordinary_JJ item_NN 48.4_CD 7.0_CD 42.4_CD Income_NN from_IN discontinued_VBN operations_NNS 1.6_CD 1.4_CD 1.4_CD Extraordinary_JJ item_NN ,_, net_NN of_IN tax_NN 0.5_CD 50.0_CD 7.9_CD 43.8_CD Earnings_NNS per_IN share_NN diluted_VBN 21_CD Income_NN from_IN continuing_VBG operations_NNS before_IN extraordinary_JJ item_NN 47.4_CD 6.9_CD 41.4_CD Income_NN from_IN discontinued_VBN operations_NNS 1.6_CD 1.3_CD 1.4_CD Extraordinary_JJ item_NN ,_, net_NN of_IN tax_NN 0.5_CD 49.0_CD 7.7_CD 42.8_CD Weighted_VBN average_JJ number_NN of_IN shares_NNS :_: Basic_JJ 500,687,594_CD 492,594,226_CD 482,890,070_CD Diluted_NNP 522,418,246_CD 504,875,587_CD 494,691,805_CD The_DT results_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2000_CD have_VBP been_VBN restated_VBN to_TO include_VB the_DT results_NNS of_IN BioChem_NNP Pharma_NNP Inc._NNP the_DT merger_NN with_IN whom_WP was_VBD accounted_VBN for_IN as_IN a_DT pooling_VBG of_IN interests_NNS in_IN accordance_NN with_IN Accounting_NNP Principles_NNP Board_NNP Opinion_NNP No._NN ._.
16_CD Accounting_NN for_IN Business_NNP Combinations_NNPS APB_NNP 16_CD ._.
The_DT results_NNS for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2001_CD and_CC 2000_CD have_VBP been_VBN restated_VBN to_TO reflect_VB the_DT disposal_NN of_IN the_DT Over-The-Counter_NNP OTC_NNP business_NN which_WDT has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT discontinued_VBN operation_NN ._.
The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
52_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP statements_NNS of_IN changes_NNS in_IN shareholders_NNS equity_NN In_IN thousands_NNS of_IN US_NNP dollars_NNS except_IN share_NN data_NNS Common_JJ Exchangeable_NNP Common_NNP stock_NN Exchangeable_JJ shares_NNS Additional_JJ deficit_NN other_JJ Total_JJ stock_NN number_NN shares_NNS number_NN paid-in_NN retained_VBD comprehensive_JJ shareholders_NNS amount_NN of_IN shares_NNS amount_NN of_IN shares_NNS capital_NN earnings_NNS losses_NNS equity_NN $_$ 000_CD 000s_CD $_$ 000_CD 000s_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD At_IN 31_CD December_NNP 1999_CD 39,241_CD 474,400_CD 1,097,567_CD 226,531_CD 30,391_CD 879,886_CD Net_JJ income_NN 211,727_CD 211,727_CD Foreign_JJ currency_NN translation_NN 31,467_CD 31,467_CD Issue_NN of_IN common_JJ stock_NN 137_CD 1,843_CD 11,720_CD 11,857_CD Issue_NN costs_NNS 3,385_CD 3,385_CD Options_NNS exercised_VBN 914_CD 11,772_CD 50,850_CD 51,764_CD Stock_NN option_NN compensation_NN 21,914_CD 21,914_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 30,782_CD 30,782_CD Reclassification_NN of_IN realized_VBN loss_NN included_VBN in_IN net_JJ income_NN 1,356_CD 1,356_CD Unrealised_JJ holding_VBG loss_NN on_IN available_JJ for_IN sale_NN investments_NNS 48_CD 48_CD At_IN 31_CD December_NNP 2000_CD 40,292_CD 488,015_CD 1,209,448_CD 14,804_CD 60,550_CD 1,174,386_CD Net_JJ income_NN 38,759_CD 38,759_CD Foreign_JJ currency_NN translation_NN 32,507_CD 32,507_CD Issue_NN of_IN shares_NNS for_IN acquisitions_NNS 3,662_CD 51,876_CD 802,256_CD 17,292_CD 798,594_CD Issue_NN of_IN common_JJ stock_NN for_IN conversion_NN of_IN loan_NN 22_CD 295_CD 1,522_CD 1,544_CD Issue_NN costs_NNS 18_CD 18_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 2,414_CD 33,940_CD 524,870_CD 11,313_CD 522,456_CD Options_NNS exercised_VBN 795_CD 11,443_CD 69,397_CD 70,192_CD Stock_NN option_NN compensation_NN and_CC warrants_NNS 6,780_CD 6,780_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 3,805_CD 3,805_CD Unrealised_JJ holding_VBG loss_NN on_IN available_JJ for_IN sale_NN investments_NNS 48_CD 48_CD At_IN 31_CD December_NNP 2001_CD 39,861_CD 481,817_CD 277,386_CD 5,979_CD 1,014,796_CD 23,955_CD 93,009_CD 1,262,989_CD Net_JJ income_NN 250,569_CD 250,569_CD Foreign_JJ currency_NN translation_NN 50,314_CD 50,314_CD Issue_NN of_IN common_JJ stock_NN for_IN conversion_NN of_IN loan_NN note_NN 21_CD 268_CD 1,479_CD 1,500_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 22_CD 315_CD 4,863_CD 105_CD 4,841_CD Options_NNS exercised_VBN 147_CD 1,944_CD 5,861_CD 6,008_CD Stock_NN option_NN compensation_NN 166_CD 166_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 688_CD 688_CD Unrealised_JJ holding_VBG gain_NN on_IN available_JJ for_IN sale_NN investments_NNS 1,264_CD 1,264_CD At_IN 31_CD December_NNP 2002_CD 40,051_CD 484,344_CD 272,523_CD 5,874_CD 1,027,499_CD 274,524_CD 41,431_CD 1,573,166_CD The_DT results_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2000_CD have_VBP been_VBN restated_VBN to_TO include_VB the_DT results_NNS of_IN BioChem_NNP Pharma_NNP ,_, Inc._NNP the_DT merger_NN with_IN whom_WP was_VBD accounted_VBN for_IN as_IN a_DT pooling_VBG of_IN interests_NNS in_IN accordance_NN with_IN APB_NNP 16_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 53_CD Consolidated_NNP statements_NNS of_IN comprehensive_JJ income_NN losses_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Net_JJ income_NN 250,569_CD 38,759_CD 211,727_CD Other_JJ comprehensive_JJ income_NN loss_NN :_: Foreign_JJ currency_NN translation_NN adjustments_NNS 50,314_CD 32,507_CD 31,467_CD Reclassification_NN of_IN realized_VBN loss_NN included_VBN in_IN net_JJ income_NN 1,356_CD Unrealised_NNP holding_VBG gains_NNS losses_NNS on_IN available_JJ for_IN sale_NN securities_NNS 1,264_CD 48_CD 48_CD Comprehensive_JJ income_NN 302,147_CD 6,300_CD 181,568_CD The_DT components_NNS of_IN accumulated_VBN other_JJ comprehensive_JJ losses_NNS as_IN at_IN 31_CD December_NNP 2002_CD and_CC 2001_CD are_VBP as_IN follows_VBZ :_: 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Foreign_JJ currency_NN translation_NN adjustments_NNS 42,695_CD 93,009_CD Unrealised_JJ holding_NN gains_NNS on_IN non-current_JJ investments_NNS 1,264_CD Accumulated_VBN other_JJ comprehensive_JJ losses_NNS 41,431_CD 93,009_CD There_EX are_VBP no_DT material_NN tax_NN effects_NNS related_VBN to_TO the_DT items_NNS included_VBD above_RB ._.
The_DT results_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2000_CD have_VBP been_VBN restated_VBN to_TO include_VB the_DT results_NNS of_IN BioChem_NNP Pharma_NNP ,_, Inc._NNP the_DT merger_NN with_IN whom_WP was_VBD accounted_VBN for_IN as_IN a_DT pooling_VBG of_IN interests_NNS in_IN accordance_NN with_IN APB_NNP 16_CD ._.
Consolidated_NNP statements_NNS of_IN cash_NN flows_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Cash_NN flows_VBZ from_IN operating_VBG activities_NNS :_: Net_JJ income_NN 250,569_CD 38,759_CD 211,727_CD Adjustments_NNS to_TO reconcile_VB net_JJ income_NN to_TO net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS :_: Acquired_VBN in-process_JJ research_NN and_CC development_NN 26,947_CD Depreciation_NN and_CC amortisation_NN 36,434_CD 45,809_CD 37,987_NNP Stock_NNP option_NN compensation_NN options_NNS 166_CD 2,278_CD 21,914_CD Stock_NN option_NN compensation_NN warrants_NNS 4,502_CD Tax_NNP benefit_NN of_IN stock_NN option_NN compensation_NN ,_, credited_VBD directly_RB to_TO equity_NN 688_CD 3,805_CD 30,782_CD Increase_VBP decrease_NN in_IN deferred_JJ tax_NN asset_NN 8,761_CD 1,229_CD 3,782_CD Non-cash_JJ exchange_NN gains_NNS and_CC losses_NNS 12,495_CD 1,017_CD 1,676_CD Gain_NN on_IN sale_NN of_IN long-term_JJ investments_NNS 98,627_CD Loss_NN on_IN sale_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 1,376_CD 8,112_CD Loss_NN on_IN sale_NN of_IN intangible_JJ assets_NNS 2,052_CD 1,514_CD Gain_NN on_IN sale_NN of_IN a_DT business_NN 3,307_CD Write-down_NN of_IN long-term_JJ investments_NNS 8,732_CD 61,596_CD Write-down_NN of_IN intangible_JJ assets_NNS 18,777_CD 25,393_CD Equity_NN in_IN earnings_NNS losses_NNS of_IN equity_NN method_NN investees_VBZ 1,668_CD 1,985_CD 3,809_CD Other_JJ elements_NNS 1,788_CD 1,102_CD Changes_NNS in_IN operating_VBG assets_NNS and_CC liabilities_NNS ,_, net_NN of_IN acquisitions_NNS :_: Decrease_NN increase_NN in_IN accounts_NNS receivable_JJ 61,159_CD 52,033_CD 52,570_CD Increase_VBP decrease_NN in_IN inventory_NN 5,327_CD 2,922_CD 7,916_CD Decrease_NN increase_NN in_IN prepayments_NNS and_CC other_JJ current_JJ assets_NNS 8,662_CD 26,109_CD 1,215_CD Decrease_NN in_IN other_JJ assets_NNS 2,905_CD 823_CD Decrease_NN increase_NN in_IN accounts_NNS payable_JJ and_CC other_JJ liabilities_NNS 8,642_CD 61,504_CD 37,727_CD Decrease_NN increase_NN in_IN unearned_JJ income_NN 17,409_CD 17,409_CD Reserve_NNP for_IN restructuring_VBG charges_NNS 83,608_CD Net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS 356,517_CD 196,837_CD 134,109_CD 54_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP statements_NNS of_IN cash_NN flows_NNS continued_VBD In_IN thousands_NNS of_IN US_NNP dollars_NNS 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Cash_NN flows_VBZ from_IN investing_VBG activities_NNS :_: Redemption_NN of_IN investment_NN in_IN marketable_JJ securities_NNS 407,653_CD 367,206_CD 186,019_CD Purchase_NN of_IN subsidiary_NN undertakings_NNS 17,000_CD Expenses_NNS of_IN acquisition_NN 350_CD 1,461_CD Net_JJ cash_NN acquired_VBN with_IN subsidiary_NN undertakings_NNS 50_CD Additional_JJ investment_NN in_IN existing_VBG subsidiary_NN 32,302_CD Purchase_NN of_IN long-term_JJ investments_NNS 5,933_CD 20,351_CD 16,995_CD Purchase_NN of_IN intangible_JJ assets_NNS 24,032_CD 35,986_CD 38,379_CD Purchase_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 22,647_CD 13,604_CD 44,243_CD Purchase_NN of_IN other_JJ assets_NNS 6,658_CD Proceeds_NNS from_IN sale_NN of_IN long-term_JJ investments_NNS 4,108_CD 123,327_CD Proceeds_NNS from_IN sale_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 721_CD 7,081_CD 12,007_CD Proceeds_NNS from_IN sale_NN of_IN intangible_JJ assets_NNS 4,556_CD Proceeds_NNS from_IN sale_NN of_IN a_DT business_NN 71,000_CD Collection_NNP on_IN notes_NNS receivable_JJ 766_CD Other_JJ investing_NN activities_NNS 1,427_CD Net_JJ cash_NN provided_VBN by_IN used_VBN in_IN investing_VBG activities_NNS 413,570_CD 425,510_CD 191,384_CD Cash_NN flows_VBZ from_IN financing_VBG activities_NNS :_: Proceeds_NNS from_IN issue_NN of_IN long-term_JJ debt_NN 400,000_CD Payment_NN of_IN debt_NN issuance_NN costs_NNS 9,000_CD Changes_NNS in_IN long-term_JJ debt_NN ,_, capital_NN leases_NNS and_CC notes_NNS 3,381_CD 207,762_CD 8,514_CD Proceeds_NNS from_IN issue_NN of_IN common_JJ stock_NN ,_, net_JJ 1,526_CD 14,589_CD Proceeds_NNS from_IN exercise_NN of_IN options_NNS 6,008_CD 70,192_CD 45,647_CD Net_JJ cash_NN provided_VBN by_IN financing_VBG activities_NNS 2,627_CD 254,956_CD 51,722_CD Effect_NN of_IN foreign_JJ exchange_NN rate_NN changes_NNS on_IN cash_NN and_CC cash_NN equivalents_NNS 6,964_CD 1,509_CD 1,975_CD Net_JJ increase_NN decrease_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 779,678_CD 24,774_CD 7,528_CD Cash_NN flows_NNS used_VBN in_IN discontinued_VBN operations_NNS 1,708_CD Net_JJ increase_NN decrease_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 779,678_CD 24,774_CD 9,236_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN beginning_NN of_IN period_NN 118,040_CD 93,266_CD 102,502_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN end_NN of_IN period_NN 897,718_CD 118,040_CD 93,266_CD Supplemental_NNP information_NN associated_VBN with_IN continuing_VBG operations_NNS :_: Interest_NN paid_VBD 8,101_CD 11,122_CD 12,264_CD Income_NN taxes_NNS paid_VBD 101,779_CD 65,773_CD 14,095_CD Non_NNP cash_NN activities_NNS :_: Common_JJ stock_NN issued_VBN for_IN product_NN acquisitions_NNS 3,085_CD Common_JJ stock_NN issued_VBN on_IN conversion_NN of_IN zero-coupon_JJ note_NN 1,500_CD 1,544_CD 8,772_CD Capital_NNP leases_NNS assumed_VBD on_IN acquisition_NN of_IN subsidiaries_NNS 6,266_CD The_DT results_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2000_CD have_VBP been_VBN restated_VBN to_TO include_VB the_DT results_NNS of_IN BioChem_NNP Pharma_NNP ,_, Inc._NNP the_DT merger_NN with_IN whom_WP was_VBD accounted_VBN for_IN as_IN a_DT pooling_VBG of_IN interests_NNS in_IN accordance_NN with_IN APB_NNP 16_CD ._.
Supplemental_NNP disclosures_NNS for_IN non-cash_JJ transactions_NNS :_: see_VB note_NN 29_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 55_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 1_CD Description_NN of_IN operations_NNS Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP ,_, and_CC subsidiaries_NNS collectively_RB ,_, the_DT Company_NN is_VBZ an_DT emerging_VBG global_JJ international_JJ pharmaceutical_JJ company_NN with_IN a_DT strategic_JJ focus_NN on_IN four_CD therapeutic_JJ areas_NNS :_: central_JJ nervous_JJ system_NN disorders_NNS ,_, gastro_NN intestinal_NN ,_, oncology_NN and_CC anti-infectives_NNS ._.
The_DT Companys_NNP strategy_NN is_VBZ further_JJ supported_VBN by_IN three_CD technology_NN platforms_NNS :_: advanced_VBN drug_NN delivery_NN ,_, lead_NN optimisation_NN for_IN small_JJ molecules_NNS ,_, and_CC biologics_NNS ._.
Shire_NNP has_VBZ sales_NNS and_CC marketing_NN subsidiaries_NNS with_IN a_DT portfolio_NN of_IN products_NNS targeting_VBG the_DT US_NNP ,_, Canada_NNP ,_, the_DT UK_NNP ,_, the_DT Republic_NNP of_IN Ireland_NNP ,_, France_NNP ,_, Germany_NNP ,_, Italy_NNP and_CC Spain_NNP ._.
Shire_NNP also_RB covers_VBZ other_JJ significant_JJ pharmaceutical_JJ markets_NNS indirectly_RB through_IN distributors_NNS ._.
The_DT business_NN is_VBZ operated_VBN and_CC managed_VBN within_IN three_CD individual_JJ operating_NN segments_NNS :_: US_NNP ,_, International_NNP ,_, and_CC Global_NNP Research_NNP and_CC Development_NNP ._.
Within_IN these_DT segments_NNS ,_, revenues_NNS are_VBP derived_VBN primarily_RB from_IN three_CD sources_NNS :_: sales_NNS of_IN products_NNS by_IN Shires_NNP own_JJ sales_NNS and_CC marketing_NN operations_NNS ,_, royalties_NNS where_WRB Shire_NNP has_VBZ out-licensed_VBN to_TO third_JJ parties_NNS and_CC licensing_NN and_CC development_NN fees_NNS ._.
The_DT Company_NN has_VBZ a_DT particular_JJ interest_NN in_IN innovative_JJ therapies_NNS that_WDT are_VBP prescribed_VBN by_IN specialist_NN doctors_NNS as_IN opposed_VBN to_TO primary_JJ care_NN physicians_NNS ._.
The_DT Company_NN follows_VBZ two_CD main_JJ approaches_NNS :_: firstly_RB to_TO start_VB projects_NNS in-house_RB through_IN research_NN and_CC advanced_VBN drug_NN delivery_NN ,_, and_CC secondly_RB to_TO in-license_JJ projects_NNS and_CC products_NNS on_IN reasonable_JJ commercial_JJ terms_NNS ,_, and_CC then_RB to_TO develop_VB them_PRP and_CC launch_VB them_PRP ._.
To_TO complete_VB its_PRP$ geographic_JJ coverage_NN of_IN the_DT key_JJ world_NN pharmaceutical_JJ markets_NNS ,_, Shire_NNP intends_VBZ to_TO build_VB a_DT presence_NN in_IN Japan_NNP in_IN the_DT future_NN ._.
The_DT Companys_NNPS principal_JJ products_NNS include_VBP :_: in_IN the_DT US_NNP ,_, ADDERALL_NNP XR_NNP and_CC ADDERALL_NNP for_IN the_DT treatment_NN of_IN attention_NN deficit_NN hyperactivity_NN disorder_NN ADHD_NNP :_: AGRYLIN_NNP for_IN the_DT treatment_NN of_IN elevated_JJ blood_NN platelets_NNS :_: PENTASA_NNP for_IN the_DT treatment_NN of_IN ulcerative_JJ colitis_NNS :_: CARBATROL_NNP for_IN the_DT treatment_NN of_IN epilepsy_NN :_: and_CC PROAMATINE_NNP for_IN the_DT treatment_NN of_IN orthostatic_JJ hypotension_NN ._.
In_IN addition_NN ,_, the_DT Company_NN receives_VBZ royalties_NNS on_IN sales_NNS of_IN REMINYL_NNP for_IN the_DT treatment_NN of_IN Alzheimers_NNP disease_NN ,_, marketed_VBN by_IN Johnson_NNP &_CC Johnson_NNP ,_, and_CC on_IN EPIVIR_NNP ,_, COMBIVIR_NNP and_CC TRIZIVIR_NNP for_IN the_DT treatment_NN of_IN HIV_NNP AIDS_NNP and_CC EPIVIR-HBV_NNP for_IN the_DT treatment_NN of_IN hepatitis_NNP B_NNP ,_, each_DT marketed_VBN by_IN GlaxoSmithKline_NNP GSK_NNP :_: in_IN the_DT UK_NNP and_CC the_DT Republic_NNP of_IN Ireland_NNP ,_, the_DT CALCICHEW_NNP range_NN ,_, used_VBN primarily_RB as_IN adjuncts_NNS in_IN the_DT treatment_NN of_IN osteoporosis_NN ,_, and_CC REMINYL_NNP ,_, which_WDT was_VBD launched_VBN in_IN September_NNP 2000_CD and_CC is_VBZ co-promoted_VBN by_IN Janssen-Cilag_NNP :_: in_IN Canada_NNP ,_, 3TC_NNP for_IN the_DT treatment_NN of_IN HIV_NNP AIDS_NNP ,_, COMBIVIR_NNP and_CC HEPTOVIR_NNP all_DT marketed_VBN in_IN partnership_NN with_IN GSK_NNP :_: AMATINE_NNP :_: and_CC FLUVIRAL_NNP S_NNP F_NN ,_, a_DT vaccine_NN for_IN the_DT prevention_NN of_IN influenza_NN :_: and_CC in_IN the_DT Rest_VB of_IN the_DT World_NNP ,_, royalties_NNS on_IN the_DT sales_NNS of_IN ZEFFIX_NNP for_IN the_DT treatment_NN of_IN hepatitis_NNP B_NNP ,_, marketed_VBN by_IN GSK_NNP ,_, and_CC royalties_NNS on_IN sales_NNS of_IN REMINYL_NNP marketed_VBN by_IN Johnson_NNP &_CC Johnson_NNP ._.
In_IN addition_NN ,_, the_DT Company_NN has_VBZ a_DT number_NN of_IN products_NNS in_IN late_JJ stage_NN development_NN including_VBG FOSRENOL_NNP for_IN the_DT treatment_NN of_IN high_JJ blood_NN phosphate_NN levels_NNS associated_VBN with_IN kidney_NN failure_NN and_CC TROXATYL_NNP for_IN the_DT treatment_NN of_IN leukemia_NN and_CC pancreatic_JJ cancer_NN ._.
The_DT Company_NN submitted_VBD the_DT first_JJ regulatory_JJ submission_NN for_IN FOSRENOL_NNP under_IN the_DT European_JJ Mutual_JJ Recognition_NN procedure_NN on_IN 13_CD March_NNP 2001_CD and_CC a_DT New_NNP Drug_NNP Application_NNP with_IN the_DT US_NNP FDA_NNP on_IN 30_CD April_NNP 2002_CD ._.
Registered_NNP trademark_NN of_IN Johnson_NNP &_CC Johnson_NNP ._.
Registered_NNP trademark_NN of_IN GlaxoSmithKline_NNP Unless_IN otherwise_RB indicated_VBN ,_, all_DT product_NN names_NNS set_VBN out_RP in_IN this_DT document_NN are_VBP trademarks_NNS of_IN Shire_NNP or_CC companies_NNS within_IN the_DT Shire_NNP Group_NNP ,_, many_JJ of_IN which_WDT are_VBP the_DT subject_NN of_IN trade_NN mark_NN registrations_NNS in_IN certain_JJ territories_NNS ._.
2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS a_DT Basis_NN of_IN preparation_NN The_DT accompanying_VBG consolidated_JJ financial_JJ statements_NNS include_VBP the_DT accounts_NNS of_IN Shire_NNP and_CC all_DT of_IN its_PRP$ subsidiary_NN undertakings_NNS after_IN elimination_NN of_IN intercompany_NN accounts_NNS and_CC transactions_NNS ._.
b_NN Use_NN of_IN estimates_NNS in_IN financial_JJ statements_NNS The_DT preparation_NN of_IN financial_JJ statements_NNS ,_, in_IN conformity_NN with_IN US_NNP generally_RB accepted_VBD accounting_NN principles_NNS ,_, requires_VBZ management_NN to_TO make_VB estimates_NNS and_CC assumptions_NNS that_WDT affect_VBP the_DT reported_VBN amounts_NNS of_IN assets_NNS and_CC liabilities_NNS ,_, the_DT disclosure_NN of_IN contingent_JJ assets_NNS and_CC liabilities_NNS at_IN the_DT date_NN of_IN the_DT financial_JJ statements_NNS and_CC reported_VBD amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT reporting_NN period_NN ._.
Actual_JJ results_NNS could_MD differ_VB from_IN those_DT estimates_NNS ._.
Estimates_NNS and_CC assumptions_NNS are_VBP primarily_RB made_VBN in_IN relation_NN to_TO provisions_NNS for_IN product_NN returns_NNS ,_, litigation_NN and_CC sales_NNS deductions_NNS ._.
c_NN Revenue_NN recognition_NN The_DT Company_NN recognizes_VBZ revenue_NN when_WRB :_: there_EX is_VBZ persuasive_JJ evidence_NN of_IN an_DT arrangement_NN :_: delivery_NN of_IN products_NNS has_VBZ occurred_VBN or_CC services_NNS have_VBP been_VBN rendered_VBN :_: the_DT sellers_NNS price_NN to_TO the_DT buyer_NN is_VBZ fixed_VBN or_CC determinable_JJ :_: and_CC collectibility_NN is_VBZ reasonably_RB assured_VBN ._.
56_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD The_DT Companys_NNPS principal_JJ revenue_NN streams_NNS and_CC their_PRP$ respective_JJ accounting_NN treatments_NNS are_VBP discussed_VBN below_IN :_: i_FW Product_NNP sales_NNS Revenue_NN for_IN the_DT sales_NNS of_IN products_NNS is_VBZ recognized_VBN upon_IN shipment_NN to_TO customers_NNS ._.
Provisions_NNS for_IN certain_JJ rebates_NNS ,_, product_NN returns_NNS and_CC discounts_NNS to_TO customers_NNS are_VBP provided_VBN for_IN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
Approximately_RB $_$ 17.0_CD million_CD of_IN ADDERALL_NNP XR_NNP product_NN launch_NN shipments_NNS made_VBN in_IN the_DT last_JJ quarter_NN of_IN 2001_CD were_VBD not_RB recognized_VBN as_IN product_NN revenue_NN until_IN the_DT first_JJ quarter_NN of_IN 2002_CD ,_, in_IN accordance_NN with_IN Staff_NNP Accounting_NNP Bulletin_NNP 101_CD ,_, as_IN these_DT sales_NNS had_VBD not_RB been_VBN realized_VBN and_CC earned_VBN at_IN 31_CD December_NNP 2001_CD ._.
ii_FW Licensing_NN and_CC development_NN fees_NNS Licensing_VBG and_CC development_NN fees_NNS represent_VBP revenues_NNS derived_VBN from_IN licence_NN agreements_NNS and_CC from_IN collaborative_JJ research_NN and_CC development_NN arrangements_NNS ._.
Initial_JJ licence_NN fees_NNS are_VBP thus_RB deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN of_IN the_DT licence_NN term_NN ,_, or_CC the_DT period_NN of_IN the_DT associated_VBN research_NN and_CC development_NN agreement_NN ._.
During_IN the_DT term_NN of_IN certain_JJ research_NN and_CC development_NN agreements_NNS ,_, the_DT Company_NN receives_VBZ non-refundable_JJ milestones_NNS as_IN certain_JJ technical_JJ targets_NNS are_VBP achieved_VBN ._.
Revenues_NNS are_VBP recognized_VBN on_IN achievement_NN of_IN milestones_NNS ._.
The_DT Company_NN also_RB receives_VBZ non-refundable_JJ clinical_JJ milestones_NNS when_WRB certain_JJ targets_NNS are_VBP achieved_VBN during_IN the_DT clinical_JJ phases_NNS of_IN development_NN ,_, such_JJ as_IN the_DT submission_NN of_IN clinical_JJ data_NNS to_TO a_DT regulatory_JJ authority_NN ._.
These_DT clinical_JJ milestones_NNS are_VBP recognized_VBN when_WRB received_VBN ._.
iii_FW Royalty_NN income_NN Royalty_NN income_NN relating_VBG to_TO licensed_JJ technology_NN is_VBZ recognized_VBN when_WRB earned_VBN ._.
Where_WRB applicable_JJ ,_, all_DT revenues_NNS are_VBP stated_VBN net_NN of_IN value_NN added_VBD tax_NN and_CC similar_JJ taxes_NNS ,_, trade_NN discounts_NNS and_CC intercompany_NN transactions_NNS ._.
d_LS Research_NNP and_CC development_NN Research_NN and_CC development_NN expenditures_NNS include_VBP funded_VBN and_CC unfunded_JJ expenditures_NNS and_CC are_VBP charged_VBN to_TO operations_NNS in_IN the_DT period_NN in_IN which_WDT the_DT expense_NN is_VBZ incurred_VBN ._.
e_LS Leased_VBN assets_NNS The_DT costs_NNS of_IN operating_VBG leases_NNS are_VBP charged_VBN to_TO operations_NNS on_IN a_DT straight-line_JJ basis_NN over_IN the_DT lease_NN term_NN ,_, even_RB if_IN rental_JJ payments_NNS are_VBP not_RB made_VBN on_IN such_PDT a_DT basis_NN ._.
Assets_NNS acquired_VBN under_IN capital_NN leases_NNS are_VBP included_VBN in_IN the_DT balance_NN sheet_NN as_IN tangible_JJ fixed_JJ assets_NNS and_CC are_VBP depreciated_VBN over_IN the_DT shorter_JJR of_IN the_DT period_NN of_IN the_DT lease_NN or_CC their_PRP$ useful_JJ lives_NNS ._.
The_DT capital_NN elements_NNS of_IN future_JJ lease_NN payments_NNS are_VBP recorded_VBN as_IN liabilities_NNS ,_, while_IN the_DT interest_NN elements_NNS are_VBP charged_VBN to_TO operations_NNS over_IN the_DT period_NN of_IN the_DT leases_NNS to_TO produce_VB a_DT level_NN yield_NN on_IN the_DT balance_NN of_IN the_DT capital_NN lease_NN obligation_NN ._.
f_LS Pensions_NNPS The_NNP Group_NNP contributes_VBZ to_TO personal_JJ defined_VBN contribution_NN pension_NN plans_NNS of_IN employees_NNS ._.
Contributions_NNS are_VBP charged_VBN to_TO the_DT statement_NN of_IN operations_NNS as_IN they_PRP become_VBP payable_JJ ._.
Details_NNS relating_VBG to_TO these_DT contributions_NNS and_CC the_DT Supplemental_NNP Executive_NNP Retirement_NNP Plan_NNP SERP_NNP operated_VBN by_IN the_DT Group_NNP are_VBP given_VBN in_IN note_NN 25_CD ._.
g_NN Finance_NNP costs_NNS of_IN debt_NN Finance_NNP costs_NNS of_IN debt_NN are_VBP recorded_VBN as_IN a_DT deferred_JJ asset_NN and_CC then_RB amortised_VBD to_TO the_DT statement_NN of_IN operations_NNS over_IN the_DT term_NN of_IN the_DT debt_NN ,_, using_VBG the_DT effective_JJ interest_NN method_NN ._.
Deferred_JJ financing_NN costs_NNS relating_VBG to_TO debt_NN extinguishments_NNS are_VBP written_VBN off_RP to_TO the_DT statement_NN of_IN operations_NNS in_IN that_DT period_NN ._.
h_NN Income_NN taxes_NNS The_DT Company_NN provides_VBZ for_IN income_NN taxes_NNS in_IN accordance_NN with_IN Statement_NN of_IN Accounting_NNP Standards_NNPS SFAS_NNP No._NN ._.
109_CD ,_, Accounting_NNP for_IN Income_NNP Taxes_NNS SFAS_NNP No._NN ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP provided_VBN for_IN differences_NNS between_IN the_DT carrying_VBG amounts_NNS in_IN the_DT financial_JJ statements_NNS and_CC tax_NN bases_NNS of_IN assets_NNS and_CC liabilities_NNS that_WDT will_MD result_VB in_IN future_JJ taxable_JJ or_CC deductible_JJ amounts_NNS ._.
The_DT deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP measured_VBN using_VBG the_DT enacted_VBN tax_NN laws_NNS and_CC rates_NNS applicable_JJ to_TO the_DT periods_NNS in_IN which_WDT the_DT differences_NNS are_VBP expected_VBN to_TO affect_VB taxable_JJ income_NN ._.
Income_NNP tax_NN expense_NN is_VBZ computed_VBN as_IN the_DT tax_NN payable_JJ or_CC refundable_JJ for_IN the_DT period_NN ,_, plus_CC or_CC minus_CC the_DT change_NN during_IN the_DT period_NN in_IN deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS ._.
Deferred_JJ tax_NN assets_NNS are_VBP reduced_VBN by_IN a_DT valuation_NN allowance_NN when_WRB ,_, in_IN the_DT opinion_NN of_IN management_NN ,_, it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN some_DT portion_NN or_CC all_DT of_IN the_DT deferred_JJ tax_NN assets_NNS will_MD not_RB be_VB realized_VBN ._.
i_FW Earnings_NNS per_IN share_NN Earnings_NNS per_IN share_NN EPS_NNP is_VBZ computed_VBN in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
128_CD ,_, Earnings_NNS per_IN Share_NN SFAS_NNP No._NN ._.
Basic_JJ EPS_NNP is_VBZ computed_VBN by_IN dividing_VBG consolidated_JJ net_JJ income_NN available_JJ to_TO common_JJ shareholders_NNS by_IN the_DT weighted_JJ average_JJ number_NN of_IN common_JJ shares_NNS outstanding_JJ during_IN the_DT period_NN ._.
Diluted_JJ EPS_NNP is_VBZ computed_VBN by_IN dividing_VBG consolidated_JJ net_JJ income_NN available_JJ to_TO common_JJ shareholders_NNS by_IN the_DT sum_NN of_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS outstanding_JJ and_CC the_DT weighted_JJ average_JJ number_NN of_IN all_DT potentially_RB dilutive_JJ common_JJ shares_NNS ._.
Such_JJ potentially_RB dilutive_JJ common_JJ shares_NNS are_VBP excluded_VBN when_WRB the_DT effect_NN would_MD be_VB to_TO increase_VB earnings_NNS per_IN share_NN or_CC reduce_VB a_DT loss_NN per_IN share_NN ._.
j_NN Advertising_NN expense_NN The_DT Company_NN expenses_NNS the_DT cost_NN of_IN advertising_NN as_IN incurred_VBN ._.
Advertising_NN costs_NNS amounted_VBD to_TO $_$ 45.6_CD million_CD ,_, $_$ 21.8_CD million_CD and_CC $_$ 6.6_CD million_CD for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD respectively_RB ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 57_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD k_NN Foreign_JJ currency_NN The_DT functional_JJ currency_NN of_IN each_DT of_IN Shires_NNP subsidiaries_NNS is_VBZ the_DT local_JJ currency_NN ._.
Monetary_NNP assets_NNS and_CC liabilities_NNS in_IN foreign_JJ currencies_NNS are_VBP translated_VBN into_IN the_DT relevant_JJ functional_JJ currency_NN at_IN the_DT rate_NN of_IN exchange_NN ruling_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
Transactions_NNS in_IN foreign_JJ currencies_NNS are_VBP translated_VBN into_IN the_DT relevant_JJ functional_JJ currency_NN at_IN the_DT rate_NN of_IN exchange_NN ruling_NN at_IN the_DT date_NN of_IN the_DT transaction_NN ._.
Transaction_NN gains_NNS and_CC losses_NNS are_VBP recognized_VBN in_IN arriving_VBG at_IN operating_VBG income_NN ._.
The_DT results_NNS of_IN overseas_JJ operations_NNS ,_, whose_WP$ functional_JJ currencies_NNS are_VBP not_RB US_NNP dollars_NNS ,_, are_VBP translated_VBN at_IN the_DT average_JJ rates_NNS of_IN exchange_NN during_IN the_DT period_NN and_CC their_PRP$ balance_NN sheets_NNS at_IN the_DT rates_NNS ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT cumulative_JJ effect_NN of_IN exchange_NN rate_NN movements_NNS is_VBZ included_VBN in_IN a_DT separate_JJ component_NN of_IN other_JJ comprehensive_JJ income_NN ._.
Foreign_JJ currency_NN exchange_NN transaction_NN gains_NNS and_CC losses_NNS on_IN an_DT after-tax_JJ basis_NN included_VBD in_IN consolidated_JJ net_JJ income_NN in_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD ,_, pursuant_JJ to_TO SFAS_NNP No._NN ._.
52_CD ,_, Foreign_NNP Currency_NNP Translation_NN SFAS_NNP No._NN ._.
52_CD ,_, amounted_VBD to_TO a_DT $_$ 0.3_CD million_CD loss_NN ,_, $_$ 0.5_CD million_CD loss_NN and_CC $_$ 2.1_CD million_CD gain_NN ,_, respectively_RB ._.
l_NN Employee_NN stock_NN plans_NNS SFAS_NNP No._NN ._.
123_CD ,_, Accounting_NNP for_IN Stock_NNP Based_VBD Compensation_NNP SFAS_NNP No._NN ._.
123_CD ,_, prescribes_VBZ accounting_NN and_CC reporting_NN standards_NNS for_IN all_DT stock-based_JJ compensation_NN plans_NNS ,_, including_VBG employee_NN stock_NN options_NNS ._.
123_CD ,_, Shire_NNP has_VBZ chosen_VBN to_TO continue_VB to_TO account_VB for_IN stock-based_JJ compensation_NN using_VBG the_DT intrinsic-value_JJ method_NN prescribed_VBN in_IN Accounting_NNP Principles_NNP Board_NNP Opinion_NNP No._NN ._.
25_CD ,_, Accounting_NNP for_IN Stock_NNP Issued_NNP to_TO Employees_NNS APB_NNP No._NN ._.
Accordingly_RB ,_, compensation_NN cost_NN of_IN stock_NN options_NNS is_VBZ measured_VBN as_IN the_DT excess_NN ,_, if_IN any_DT ,_, of_IN the_DT quoted_VBN market_NN price_NN of_IN Shires_NNP stock_NN at_IN the_DT measurement_NN date_NN over_IN the_DT option_NN exercise_NN price_NN and_CC is_VBZ charged_VBN to_TO operations_NNS over_IN the_DT vesting_JJ period_NN ._.
For_IN fixed_VBN plans_NNS ,_, the_DT measurement_NN date_NN is_VBZ the_DT grant_NN date_NN ._.
For_IN plans_NNS where_WRB the_DT measurement_NN date_NN occurs_VBZ after_IN the_DT grant_NN date_NN ,_, referred_VBD to_TO as_IN variable_JJ plans_NNS ,_, the_DT compensation_NN cost_NN is_VBZ re-measured_JJ on_IN the_DT basis_NN of_IN the_DT current_JJ market_NN value_NN of_IN the_DT Companys_NNP stock_NN at_IN the_DT end_NN of_IN each_DT reporting_NN period_NN ._.
Shire_NNP recognizes_VBZ compensation_NN expense_NN for_IN variable_JJ plans_NNS with_IN performance_NN conditions_NNS if_IN achievement_NN of_IN those_DT conditions_NNS becomes_VBZ probable_JJ ._.
The_DT Companys_NNP basis_NN for_IN electing_VBG accounting_NN treatment_NN under_IN APB_NNP No._NN ._.
25_CD is_VBZ principally_RB due_JJ to_TO the_DT satisfactory_JJ incorporation_NN of_IN the_DT dilutive_JJ effect_NN of_IN these_DT shares_NNS in_IN the_DT reported_VBN earnings_NNS per_IN share_NN calculation_NN and_CC the_DT presence_NN of_IN pro_FW forma_FW supplemental_JJ disclosure_NN of_IN the_DT estimated_VBN fair_JJ value_NN methodology_NN prescribed_VBN by_IN SFAS_NNP No._NN ._.
148_CD ,_, Accounting_NNP for_IN Stock-Based_NNP Compensation_NNP Transition_NN and_CC Disclosure_NN ._.
At_IN 31_CD December_NNP 2002_CD ,_, the_DT Company_NN has_VBZ nine_CD stock-based_JJ employee_NN compensation_NN plans_NNS ,_, which_WDT are_VBP described_VBN more_RBR fully_RB in_IN note_NN 28_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
The_DT following_VBG table_NN illustrates_VBZ the_DT effect_NN on_IN net_JJ income_NN and_CC earnings_NNS per_IN share_NN if_IN the_DT Company_NN had_VBD applied_VBN the_DT fair_JJ value_NN recognition_NN provisions_NNS of_IN SFAS_NNP No._NN ._.
2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Net_JJ income_NN As_IN reported_VBN 250,569_CD 38,759_CD 211,727_CD Pro_FW forma_FW 226,319_CD 8,791_CD 227,018_CD Income_NN per_IN share_NN As_IN reported_VBN basic_JJ 50.0_CD 7.9_CD 43.8_CD As_IN reported_VBN diluted_VBN 49.0_CD 7.7_CD 42.8_CD Pro_FW forma_FW basic_JJ 45.2_CD 1.8_CD 47.0_CD Pro_FW forma_FW diluted_VBN 44.4_CD 1.7_CD 45.9_CD m_NN Cash_NN and_CC cash_NN equivalents_NNS Cash_NN and_CC cash_NN equivalents_NNS are_VBP defined_VBN as_IN short-term_JJ highly_RB liquid_JJ investments_NNS with_IN original_JJ maturities_NNS of_IN 90_CD days_NNS or_CC less_JJR ._.
n_JJ Marketable_JJ securities_NNS Marketable_JJ securities_NNS consist_VBP of_IN commercial_JJ paper_NN and_CC institutional_JJ and_CC managed_VBD cash_NN funds_NNS ._.
In_IN accordance_NN with_IN SFAS_NNP No._NN ._.
115_CD Accounting_NN for_IN Certain_NNP Investments_NNP in_IN Debt_NNP and_CC Equity_NNP Securities_NNPS SFAS_NNP No._NN ._.
115_CD ,_, and_CC based_VBN on_IN the_DT Companys_NNP intentions_NNS regarding_VBG these_DT instruments_NNS ,_, the_DT Company_NN has_VBZ classified_VBN all_DT marketable_JJ securities_NNS as_IN held-to-maturity_NN and_CC has_VBZ accounted_VBN for_IN these_DT investments_NNS at_IN amortised_JJ cost_NN ._.
Institutional_JJ and_CC managed_VBD cash_NN funds_NNS are_VBP short-term_JJ money_NN market_NN instruments_NNS ,_, including_VBG bank_NN and_CC building_NN society_NN term_NN deposits_NNS from_IN a_DT variety_NN of_IN companies_NNS with_IN strong_JJ credit_NN ratings_NNS ._.
o_NN Inventories_NNS Inventories_NNS ,_, consisting_VBG primarily_RB of_IN finished_VBN goods_NNS ,_, are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN or_CC net_JJ realisable_JJ value_NN ._.
p_NN Investments_NNP The_NNP Company_NNP has_VBZ certain_JJ investments_NNS in_IN equity_NN securities_NNS ._.
Investments_NNP are_VBP accounted_VBN for_IN using_VBG the_DT equity_NN method_NN of_IN accounting_NN if_IN the_DT investment_NN gives_VBZ the_DT Company_NN the_DT ability_NN to_TO exercise_VB significant_JJ influence_NN ,_, but_CC not_RB control_VB over_RP ,_, the_DT investee_NN ._.
Significant_JJ influence_NN is_VBZ generally_RB deemed_VBN to_TO exist_VB if_IN the_DT Company_NN has_VBZ an_DT ownership_NN interest_NN in_IN the_DT voting_NN stock_NN of_IN the_DT investee_NN between_IN 20_CD %_NN and_CC 50_CD %_NN ,_, although_IN other_JJ factors_NNS ,_, such_JJ as_IN representation_NN on_IN the_DT investees_NNS Board_NNP of_IN Directors_NNS and_CC the_DT impact_NN of_IN commercial_JJ arrangements_NNS ,_, are_VBP considered_VBN in_IN determining_VBG whether_IN the_DT equity_NN method_NN of_IN accounting_NN is_VBZ appropriate_JJ ._.
58_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD Under_IN the_DT equity_NN method_NN of_IN accounting_NN ,_, the_DT Company_NN records_NNS its_PRP$ investments_NNS in_IN equity-method_JJ investees_NNS on_IN the_DT consolidated_JJ balance_NN sheet_NN as_IN Investments_NNP and_CC its_PRP$ share_NN of_IN the_DT investees_NNS earnings_NNS or_CC losses_NNS together_RB with_IN other-than-temporary_JJ impairments_NNS in_IN value_NN as_IN Equity_NN in_IN earnings_NNS of_IN equity_NN method_NN investees_NNS on_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS ._.
All_DT other_JJ equity_NN investments_NNS ,_, which_WDT consist_VBP of_IN investments_NNS for_IN which_WDT the_DT Company_NN does_VBZ not_RB have_VB the_DT ability_NN to_TO exercise_VB significant_JJ influence_NN ,_, are_VBP accounted_VBN for_IN under_IN the_DT cost_NN method_NN or_CC at_IN fair_JJ value_NN ._.
Investments_NNP in_IN private_JJ companies_NNS are_VBP carried_VBN at_IN cost_NN ,_, less_JJR provisions_NNS for_IN other_JJ than_IN temporary_JJ impairment_NN in_IN value_NN ._.
For_IN public_JJ companies_NNS that_WDT have_VBP readily_RB determinable_JJ fair_JJ values_NNS ,_, the_DT Company_NN classifies_VBZ its_PRP$ equity_NN investments_NNS as_IN available-forsale_JJ and_CC ,_, accordingly_RB ,_, records_NNS these_DT investments_NNS at_IN their_PRP$ fair_JJ values_NNS with_IN unrealised_JJ gains_NNS and_CC losses_NNS included_VBD in_IN Accumulated_NNP other_JJ comprehensive_JJ loss_NN ,_, net_NN of_IN any_DT related_JJ tax_NN effect_NN ._.
Realised_VBN gains_NNS and_CC losses_NNS and_CC declines_NNS in_IN value_NN judged_VBN to_TO be_VB other-than-temporary_JJ on_IN available-for-sale_JJ securities_NNS are_VBP included_VBN in_IN other_JJ expense_NN income_NN ,_, net_JJ see_VBP note_NN 24_CD ._.
The_DT cost_NN of_IN securities_NNS sold_VBN is_VBZ based_VBN on_IN the_DT method_NN ._.
Interest_NN and_CC dividends_NNS on_IN securities_NNS classified_VBN as_IN available-for-sale_NN are_VBP included_VBN as_IN interest_NN income_NN ._.
q_NN Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS i_FW Goodwill_NNP Goodwill_NNP arising_VBG on_IN the_DT acquisition_NN of_IN subsidiary_NN undertakings_NNS and_CC businesses_NNS ,_, representing_VBG any_DT excess_NN of_IN the_DT fair_JJ value_NN of_IN the_DT consideration_NN given_VBN over_IN the_DT fair_JJ value_NN of_IN the_DT identifiable_JJ assets_NNS and_CC liabilities_NNS acquired_VBN ,_, is_VBZ capitalized_VBN ._.
Periods_NNS ending_VBG on_IN or_CC before_IN 31_CD December_NNP 2001_CD For_IN periods_NNS ending_VBG on_IN or_CC before_IN 31_CD December_NNP 2001_CD goodwill_NN recognized_VBN in_IN respect_NN of_IN each_DT significant_JJ business_NN combination_NN was_VBD amortised_VBN over_IN a_DT period_NN of_IN 5_CD to_TO 30_CD years_NNS weighted_VBN average_JJ 19_CD years_NNS on_IN a_DT straight-line_JJ basis_NN depending_VBG on_IN the_DT nature_NN of_IN the_DT goodwill_NN ,_, and_CC was_VBD evaluated_VBN for_IN impairment_NN when_WRB events_NNS or_CC changes_NNS in_IN circumstance_NN indicate_VBP ,_, in_IN managements_NNS judgement_NN ,_, that_IN the_DT carrying_VBG value_NN of_IN such_JJ assets_NNS may_MD not_RB be_VB recoverable_JJ ._.
Impairments_NNS of_IN goodwill_NN were_VBD recognized_VBN if_IN expected_VBN undiscounted_JJ cash_NN flows_NNS were_VBD not_RB sufficient_JJ to_TO recover_VB the_DT goodwill_NN ._.
If_IN a_DT material_NN impairment_NN was_VBD identified_VBN ,_, goodwill_NN was_VBD written_VBN down_RP to_TO its_PRP$ estimated_VBN fair_JJ value_NN ._.
Fair_NNP value_NN was_VBD determined_VBN based_VBN on_IN the_DT present_JJ value_NN of_IN expected_JJ net_JJ cash_NN flows_VBZ to_TO be_VB generated_VBN by_IN the_DT business_NN ,_, discounted_VBN using_VBG a_DT rate_NN commensurate_JJ with_IN the_DT risks_NNS involved_VBN ._.
Periods_NNS commencing_VBG 1_CD January_NNP 2002_CD Effective_NNP 1_CD January_NNP 2002_CD ,_, the_DT Company_NN adopted_VBN SFAS_NNP No._NN ._.
142_CD ,_, Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS SFAS_NNP No._NN ._.
The_DT statement_NN directs_VBZ that_IN goodwill_NN and_CC intangible_JJ assets_NNS that_WDT have_VBP indefinate_JJ lives_NNS will_MD not_RB be_VB amortised_VBN but_CC rather_RB will_MD be_VB tested_VBN at_IN least_JJS annually_RB for_IN impairment_NN ._.
Intangible_JJ assets_NNS that_WDT have_VBP finite_JJ lives_NNS will_MD continue_VB to_TO be_VB amortised_VBN over_IN their_PRP$ useful_JJ lives_NNS ,_, but_CC without_IN the_DT constraint_NN of_IN an_DT arbitrary_JJ ceiling_NN ._.
Going_VBG forward_RB ,_, the_DT Company_NN will_MD carry_VB out_RP an_DT annual_JJ impairment_NN review_NN of_IN goodwill_NN as_IN of_IN 30_CD September_NNP date_NN unless_IN any_DT events_NNS occur_VBP which_WDT trigger_VBP the_DT need_NN for_IN an_DT earlier_JJR impairment_NN review_NN ._.
ii_FW Other_JJ intangible_JJ assets_NNS Other_JJ intangible_JJ assets_NNS ,_, which_WDT comprise_VBP intellectual_JJ property_NN including_VBG trademarks_NNS for_IN products_NNS with_IN an_DT immediate_JJ defined_VBN revenue_NN stream_NN and_CC acquired_VBN for_IN valued_VBN consideration_NN ,_, are_VBP recorded_VBN at_IN cost_NN and_CC amortised_VBN in_IN equal_JJ annual_JJ installments_NNS over_IN the_DT estimated_VBN useful_JJ life_NN of_IN the_DT related_JJ product_NN which_WDT range_VBP from_IN 5_CD to_TO 40_CD years_NNS weighted_VBN average_JJ 23_CD years_NNS ._.
Intellectual_NNP property_NN with_IN no_DT defined_VBN revenue_NN stream_NN ,_, where_WRB the_DT related_JJ product_NN has_VBZ not_RB yet_RB completed_VBN the_DT necessary_JJ approval_NN process_NN ,_, is_VBZ written_VBN off_RP to_TO operations_NNS on_IN acquisition_NN ._.
The_DT following_VBG factors_NNS are_VBP considered_VBN in_IN estimating_VBG the_DT useful_JJ lives_NNS ._.
Where_WRB an_DT intangible_JJ asset_NN is_VBZ a_DT composite_NN of_IN a_DT number_NN of_IN factors_NNS ,_, the_DT period_NN of_IN amortisation_NN is_VBZ determined_VBN from_IN considering_VBG these_DT factors_NNS together_RB :_: regulatory_JJ and_CC legal_JJ provisions_NNS ,_, including_VBG the_DT regulatory_JJ approval_NN and_CC review_NN process_NN ,_, patent_NN issues_NNS and_CC actions_NNS by_IN government_NN agencies_NNS :_: the_DT effects_NNS of_IN obsolescence_NN ,_, changes_NNS in_IN demand_NN ,_, competing_VBG products_NNS and_CC other_JJ economic_JJ factors_NNS ,_, including_VBG the_DT development_NN of_IN competing_VBG drugs_NNS that_WDT are_VBP more_RBR effective_JJ clinically_RB or_CC economically_RB :_: and_CC actions_NNS of_IN competitors_NNS ,_, suppliers_NNS ,_, regulatory_JJ agencies_NNS or_CC others_NNS that_WDT may_MD eliminate_VB current_JJ competitive_JJ advantages_NNS ._.
r_NN Property_NN ,_, plant_NN and_CC equipment_NN Property_NN ,_, plant_NN and_CC equipment_NN is_VBZ shown_VBN at_IN cost_NN ,_, less_JJR accumulated_VBN depreciation_NN and_CC any_DT provision_NN for_IN impairment_NN ._.
Cost_NN of_IN significant_JJ assets_NNS includes_VBZ capitalized_JJ interest_NN incurred_VBN during_IN the_DT construction_NN period_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN a_DT straight-line_JJ basis_NN at_IN rates_NNS calculated_VBN to_TO write_VB off_RP the_DT cost_NN less_JJR estimated_VBN residual_JJ value_NN of_IN each_DT asset_NN over_IN its_PRP$ estimated_VBN useful_JJ life_NN as_IN follows_VBZ :_: Buildings_NNS 20_CD to_TO 50_CD years_NNS Office_NNP furniture_NN ,_, fittings_NNS and_CC equipment_NN 4_CD to_TO 10_CD years_NNS Warehouse_NNP ,_, laboratory_NN and_CC manufacturing_NN equipment_NN 4_CD to_TO 10_CD years_NNS The_DT cost_NN of_IN land_NN is_VBZ not_RB depreciated_VBN ._.
Expenditures_NNS for_IN maintenance_NN and_CC repairs_NNS are_VBP charged_VBN to_TO operations_NNS as_IN incurred_VBN ._.
The_DT costs_NNS of_IN major_JJ renewals_NNS and_CC improvements_NNS are_VBP capitalized_VBN ._.
At_IN the_DT time_NN property_NN ,_, plant_NN and_CC equipment_NN is_VBZ retired_VBN or_CC otherwise_RB disposed_JJ of_IN ,_, the_DT cost_NN and_CC accumulated_VBN depreciation_NN are_VBP eliminated_VBN from_IN the_DT asset_NN and_CC accumulated_VBN depreciation_NN accounts_NNS ._.
The_DT profit_NN or_CC loss_NN on_IN such_JJ disposition_NN is_VBZ reflected_VBN in_IN operating_VBG income_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 59_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD s_PRP Impairment_NN of_IN long-lived_JJ assets_NNS other_JJ than_IN goodwill_NN and_CC investments_NNS The_DT Company_NN periodically_RB evaluates_VBZ the_DT recoverability_NN of_IN long-lived_JJ assets_NNS other_JJ than_IN goodwill_NN and_CC investments_NNS in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
144_CD ,_, Accounting_NNP for_IN the_DT Impairment_NN or_CC Disposal_NN of_IN Long-Lived_NNP Assets_NNPS SFAS_NNP No._NN ._.
Whenever_NNP events_NNS or_CC changes_NNS in_IN circumstances_NNS indicate_VBP that_IN the_DT carrying_VBG amounts_NNS of_IN those_DT assets_NNS may_MD not_RB be_VB recoverable_JJ ,_, the_DT Company_NN compares_VBZ undiscounted_JJ net_JJ cash_NN estimated_VBN to_TO be_VB generated_VBN by_IN those_DT assets_NNS to_TO the_DT carrying_VBG amounts_NNS of_IN those_DT assets_NNS ._.
When_WRB these_DT undiscounted_JJ cash_NN flows_NNS are_VBP less_JJR than_IN the_DT carrying_VBG amount_NN of_IN the_DT assets_NNS ,_, the_DT Company_NN records_NNS impairment_NN losses_NNS to_TO write_VB the_DT asset_NN down_IN to_TO its_PRP$ estimated_VBN fair_JJ market_NN value_NN ._.
This_DT is_VBZ usually_RB calculated_VBN by_IN reference_NN to_TO discounted_VBN estimated_VBN cash_NN flows_NNS ._.
t_NN Concentration_NN of_IN credit_NN risk_NN Revenues_NNS are_VBP mainly_RB derived_VBN from_IN agreements_NNS with_IN major_JJ pharmaceutical_JJ companies_NNS and_CC relationships_NNS with_IN pharmaceutical_JJ wholesale_JJ distributors_NNS and_CC retail_JJ pharmacy_NN chains_NNS ._.
Significant_JJ customers_NNS are_VBP disclosed_VBN in_IN note_NN 22_CD ._.
Such_JJ clients_NNS have_VBP significant_JJ cash_NN resources_NNS and_CC therefore_RB any_DT credit_NN risk_NN associated_VBN with_IN these_DT transactions_NNS is_VBZ considered_VBN minimal_JJ ._.
Excess_JJ cash_NN is_VBZ invested_VBN in_IN bank_NN and_CC building_NN society_NN term_NN deposits_NNS and_CC commercial_JJ paper_NN from_IN a_DT variety_NN of_IN companies_NNS with_IN strong_JJ credit_NN ratings_NNS ._.
These_DT investments_NNS typically_RB bear_VBP minimal_JJ credit_NN risk_NN ._.
A_DT significant_JJ proportion_NN of_IN revenue_NN is_VBZ derived_VBN from_IN the_DT sale_NN of_IN ADDERALL_NNP XR_NNP and_CC ADDERALL_NNP ._.
During_IN 2002_CD and_CC 2001_CD sales_NNS of_IN these_DT products_NNS were_VBD $_$ 427.7_CD million_CD and_CC $_$ 350.3_CD million_CD respectively_RB ,_, representing_VBG 41_CD %_NN of_IN total_JJ revenues_NNS in_IN both_DT years_NNS ._.
As_IN a_DT result_NN ,_, factors_NNS affecting_VBG the_DT sale_NN or_CC production_NN of_IN ADDERALL_NNP XR_NNP and_CC ADDERALL_NNP would_MD have_VB a_DT material_NN adverse_JJ effect_NN on_IN our_PRP$ financial_JJ condition_NN and_CC results_NNS of_IN operation_NN ._.
u_NNP Reclassifications_NNP Certain_NNP amounts_VBZ reported_VBN in_IN previous_JJ years_NNS have_VBP been_VBN reclassified_VBN to_TO conform_VB to_TO the_DT 2002_CD presentation_NN ._.
v_FW New_NNP accounting_NN pronouncements_NNS In_IN June_NNP 2001_CD ,_, the_DT Financial_NNP Accounting_NNP Standards_NNP Board_NNP FASB_NNP issued_VBD SFAS_NNP No._NN ._.
143_CD ,_, Accounting_NNP for_IN Asset_NNP Retirement_NNP Obligations_NNS SFAS_NNP No._NN ._.
143_CD requires_VBZ that_IN the_DT fair_JJ value_NN of_IN a_DT liability_NN for_IN asset_NN retirement_NN obligations_NNS be_VB recognized_VBN in_IN the_DT period_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN if_IN a_DT reasonable_JJ estimate_NN of_IN the_DT fair_JJ value_NN can_MD be_VB made_VBN ._.
The_DT associated_VBN asset_NN retirement_NN costs_NNS are_VBP capitalized_VBN as_IN part_NN of_IN the_DT carrying_VBG amount_NN of_IN the_DT related_JJ long-lived_JJ asset_NN ._.
143_CD is_VBZ effective_JJ for_IN financial_JJ statements_NNS issued_VBN for_IN fiscal_JJ years_NNS beginning_VBG after_IN 15_CD June_NNP 2002_CD ._.
The_DT Company_NN has_VBZ assessed_VBN the_DT potential_JJ impact_NN of_IN the_DT adoption_NN of_IN SFAS_NNP No._NN ._.
143_CD and_CC concluded_VBD that_IN there_EX is_VBZ no_DT impact_NN ._.
In_IN April_NNP 2002_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP No._NN ._.
145_CD ,_, Rescission_NNP of_IN FASB_NNP Statements_NNP No._NN ._.
4_CD ,_, 44_CD and_CC 64_CD ,_, Amendment_NNP of_IN FASB_NNP Statement_NNP No._NN ._.
13_CD and_CC Technical_NNP Corrections_NNPS SFAS_NNP No._NN ._.
The_DT principal_JJ change_NN is_VBZ that_IN gains_NNS or_CC losses_NNS from_IN extinguishment_NN of_IN debt_NN which_WDT are_VBP classified_VBN as_IN extraordinary_JJ items_NNS by_IN SFAS_NNP No._NN ._.
4_CD will_MD no_RB longer_RB be_VB classified_VBN as_IN such_JJ ._.
The_DT provisions_NNS of_IN SFAS_NNP No._NN ._.
145_CD are_VBP effective_JJ for_IN fiscal_JJ years_NNS beginning_VBG after_IN 15_CD May_NNP 2002_CD although_IN early_JJ application_NN of_IN the_DT Statement_NNP related_VBN to_TO the_DT rescission_NN of_IN SFAS_NNP No._NN ._.
The_DT Company_NN plans_VBZ to_TO adopt_VB SFAS_NNP No._NN ._.
145_CD for_IN its_PRP$ fiscal_JJ year_NN ending_VBG 31_CD December_NNP 2003_CD ._.
When_WRB adopted_VBN ,_, prior_RB extraordinary_JJ items_NNS related_VBN to_TO the_DT extinguishment_NN of_IN debt_NN will_MD need_VB to_TO be_VB reclassified_VBN ._.
The_DT potential_JJ impact_NN of_IN the_DT adoption_NN of_IN SFAS_NNP No._NN ._.
145_CD will_MD be_VB to_TO reclassify_VB $_$ 2.6_CD million_CD from_IN extraordinary_JJ items_NNS to_TO income_NN expense_NN ._.
In_IN June_NNP 2002_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP No._NN ._.
146_CD ,_, Accounting_NNP for_IN Costs_NNS Associated_NNP with_IN Exit_NN or_CC Disposal_NNP Activities_NNPS SFAS_NNP No._NN ._.
146_CD ,_, which_WDT addresses_VBZ accounting_NN and_CC processing_NN for_IN costs_NNS associated_VBN with_IN exit_NN or_CC disposal_NN activities_NNS and_CC nullifies_NNS Emerging_VBG Issues_NNS Task_NNP Force_NNP EITF_NNP Issue_NNP 94-3_CD ,_, Liability_NN Recognition_NN for_IN Certain_NNP Employee_NNP Termination_NN Benefits_NNS and_CC Other_JJ Costs_NNS to_TO Exit_NN and_CC Activity_NN Including_VBG Certain_NNP Costs_NNS Incurred_VBN in_IN a_DT Restructuring_NNP Issue_NNP 94-3_CD ._.
146_CD requires_VBZ that_IN a_DT liability_NN for_IN a_DT cost_NN associated_VBN with_IN an_DT exit_NN or_CC disposal_NN liability_NN be_VB recognized_VBN when_WRB the_DT liability_NN is_VBZ incurred_VBN ._.
Under_IN Issue_NNP 94-3_CD ,_, a_DT liability_NN for_IN an_DT exit_NN cost_NN was_VBD recognized_VBN at_IN the_DT date_NN of_IN an_DT entitys_JJ commitment_NN to_TO an_DT exit_NN plan_NN ._.
146_CD ,_, fair_JJ value_NN is_VBZ the_DT objective_NN for_IN initial_JJ measurement_NN of_IN the_DT liability_NN ._.
146_CD is_VBZ effective_JJ for_IN exit_NN or_CC disposal_NN activities_NNS that_WDT are_VBP initiated_VBN after_IN 31_CD December_NNP 2002_CD ,_, with_IN early_JJ application_NN encouraged_VBD ._.
We_PRP do_VBP no_DT expect_VBP the_DT adoption_NN of_IN SFAS_NNP No._NN ._.
146_CD to_TO have_VB a_DT material_NN impact_NN on_IN our_PRP$ financial_JJ position_NN ,_, results_NNS of_IN operations_NNS or_CC cash_NN flows_NNS ._.
In_IN November_NNP 2002_CD ,_, the_DT FASB_NNP issued_VBD Interpretation_NNP FIN_NNP No._NN ._.
45_CD ,_, Guarantors_NNP Accounting_NNP and_CC Disclosure_NNP Requirements_NNP for_IN Guarantees_NNP ,_, Including_VBG Indirect_NNP Guarantees_NNP of_IN Indebtedness_NNP of_IN Others_NNS FIN_NNP 45_CD ._.
This_DT interpretation_NN elaborates_VBZ on_IN the_DT disclosures_NNS to_TO be_VB made_VBN by_IN a_DT guarantor_NN in_IN its_PRP$ interim_JJ and_CC annual_JJ financial_JJ statements_NNS about_IN its_PRP$ obligations_NNS under_IN certain_JJ guarantees_NNS that_IN it_PRP has_VBZ issued_VBN ._.
It_PRP also_RB clarifies_VBZ that_IN a_DT guarantor_NN is_VBZ required_VBN to_TO recognize_VB ,_, at_IN the_DT inception_NN of_IN a_DT guarantee_NN ,_, a_DT liability_NN for_IN the_DT fair_JJ value_NN of_IN the_DT obligation_NN undertaken_VBN in_IN issuing_VBG the_DT guarantee_NN ._.
The_DT disclosure_NN requirements_NNS of_IN FIN_NNP 45_CD are_VBP effective_JJ for_IN interim_JJ and_CC annual_JJ periods_NNS after_IN 15_CD December_NNP 2002_CD ._.
The_DT initial_JJ recognition_NN and_CC initial_JJ measurement_NN requirements_NNS of_IN FIN_NNP 45_CD are_VBP effective_JJ prospectively_RB for_IN guarantees_NNS issued_VBN or_CC modified_VBN after_IN 31_CD December_NNP 2002_CD ._.
We_PRP are_VBP assessing_VBG ,_, but_CC at_IN this_DT point_NN do_VBP not_RB believe_VB the_DT adoption_NN of_IN the_DT recognition_NN and_CC initial_JJ measurement_NN requirements_NNS of_IN FIN_NNP 45_CD will_MD have_VB a_DT material_NN impact_NN on_IN our_PRP$ financial_JJ position_NN ,_, cash_NN flows_NNS or_CC results_NNS of_IN operations_NNS ._.
In_IN January_NNP 2003_CD ,_, the_DT FASB_NNP issued_VBD FIN_NNP No._NN ._.
46_CD ,_, Consolidation_NN of_IN Variable_JJ Interest_NN Entities_NNS ,_, an_DT Interpretation_NN of_IN APB_NNP No._NN ._.
This_DT interpretation_NN requires_VBZ certain_JJ variable_JJ interest_NN entities_NNS to_TO be_VB consolidated_VBN by_IN the_DT primary_JJ beneficiary_NN of_IN the_DT entity_NN if_IN the_DT equity_NN investors_NNS in_IN the_DT entity_NN do_VBP not_RB have_VB the_DT characteristics_NNS of_IN a_DT controlling_VBG financial_JJ interest_NN or_CC do_VB not_RB have_VB sufficient_JJ equity_NN at_IN risk_NN for_IN the_DT entity_NN to_TO finance_VB its_PRP$ activities_NNS without_IN additional_JJ subordinated_JJ financial_JJ support_NN from_IN other_JJ parties_NNS ._.
FIN_NNP 46_CD is_VBZ effective_JJ for_IN all_DT new_JJ variable_JJ interest_NN entities_NNS created_VBN or_CC acquired_VBN after_IN 31_CD January_NNP 2003_CD ._.
For_IN variable_JJ interest_NN entities_NNS created_VBN or_CC acquired_VBN prior_RB to_TO 1_CD February_NNP 2003_CD ,_, the_DT provisions_NNS of_IN FIN_NNP 46_CD must_MD be_VB applied_VBN for_IN the_DT first_JJ interim_NN or_CC annual_JJ period_NN beginning_VBG after_IN 15_CD June_NNP 2003_CD ._.
The_DT Company_NN is_VBZ currently_RB evaluating_VBG the_DT effect_NN that_IN the_DT adoption_NN of_IN FIN_NNP 46_CD will_MD have_VB on_IN its_PRP$ results_NNS of_IN operations_NNS and_CC financial_JJ condition_NN ._.
w_VB Statutory_JJ accounts_NNS The_DT consolidated_JJ financial_JJ statements_NNS as_IN of_IN 31_CD December_NNP 2002_CD and_CC 2001_CD and_CC for_IN each_DT of_IN the_DT three_CD years_NNS in_IN the_DT period_NN ended_VBD 31_CD December_NNP 2002_CD do_VBP not_RB comprise_VB statutory_JJ accounts_NNS within_IN the_DT meaning_NN of_IN Section_NN 240_CD of_IN the_DT UK_NNP Companies_NNP Act_NNP 1985_CD ._.
Statutory_JJ accounts_NNS prepared_VBN in_IN accordance_NN with_IN generally_RB accepted_VBN accounting_NN principles_NNS in_IN the_DT United_NNP Kingdom_NNP for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2001_CD and_CC 2000_CD have_VBP been_VBN delivered_VBN to_TO the_DT Registrar_NNP of_IN Companies_NNS for_IN England_NNP and_CC Wales_NNP ._.
The_DT auditors_NNS report_VBP on_IN those_DT accounts_NNS was_VBD unqualified_JJ ._.
60_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 3_CD Business_NN combinations_NNS and_CC reorganisations_NNS Year_NN ended_VBD 31_CD December_NNP 2002_CD a_DT Atlantic_NNP Pharmaceutical_NNP Services_NNPS Inc._NNP acquisition_NN On_IN 27_CD September_NNP 2002_CD ,_, the_DT Company_NN completed_VBD its_PRP$ acquisition_NN of_IN Atlantic_NNP Pharmaceutical_NNP Services_NNPS Inc._NNP ._.
APS_NNP from_IN Niro_NNP Inc._NNP for_IN cash_NN consideration_NN of_IN $_$ 17.3_CD million_CD ,_, including_VBG $_$ 0.3_CD million_CD costs_NNS of_IN acquisition_NN ._.
This_DT transaction_NN provided_VBD the_DT Company_NN with_IN an_DT in-house_JJ facility_NN in_IN which_WDT to_TO manufacture_VB several_JJ key_JJ US_NNP products_NNS ._.
The_DT acquisition_NN was_VBD accounted_VBN for_IN using_VBG the_DT purchase_NN method_NN and_CC goodwill_NN of_IN $_$ 10.2_CD million_CD was_VBD recorded_VBN ._.
The_DT results_NNS of_IN operations_NNS of_IN APS_NNP have_VBP been_VBN included_VBN in_IN the_DT consolidated_JJ results_NNS of_IN the_DT Company_NN since_IN the_DT date_NN of_IN acquisition_NN ._.
The_DT purchase_NN price_NN of_IN $_$ 17.3_CD million_CD was_VBD allocated_VBN as_IN follows_VBZ :_: Fair_NNP value_NN $_$ 000_CD Total_JJ current_JJ assets_NNS 3,188_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ 11,620_CD Current_JJ installments_NNS of_IN long-term_JJ debt_NN 216_CD Accounts_NNPS payable_JJ 1,367_CD Long-term_JJ debt_NN ,_, excluding_VBG current_JJ instalments_NNS 6,050_CD Net_JJ assets_NNS acquired_VBN 7,175_CD Goodwill_NNP 10,175_CD 17,350_CD Represented_VBN by_IN :_: Purchase_NN consideration_NN 17,000_CD Acquisition_NNP fees_NNS 350_CD 17,350_CD The_DT pro_FW forma_FW effect_NN in_IN 2002_CD and_CC 2001_CD of_IN the_DT APS_NNP acquisition_NN if_IN acquired_VBN on_IN 1_CD January_NNP 2002_CD and_CC 1_CD January_NNP 2001_CD respectively_RB would_MD have_VB resulted_VBN in_IN revenues_NNS ,_, income_NN before_IN extraordinary_JJ items_NNS ,_, net_JJ income_NN and_CC earnings_NNS per_IN share_NN data_NNS as_IN follows_VBZ :_: 2002_CD 2001_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD Revenues_NNS 1,042,748_CD 861,660_CD Income_NN before_IN extraordinary_JJ items_NNS 248,983_CD 41,428_CD Net_JJ income_NN 248,983_CD 38,824_CD Earnings_NNS per_IN share_NN basic_JJ 49.7_CD 7.9_CD Earnings_NNS per_IN share_NN diluted_VBN 48.7_CD 7.7_CD b_NN Divestment_NNP of_IN OTC_NNP products_NNS division_NN On_IN 27_CD December_NNP 2002_CD ,_, the_DT Company_NN completed_VBD its_PRP$ divestment_NN of_IN a_DT group_NN of_IN non-strategic_JJ US_NNP products_NNS ,_, known_VBN collectively_RB as_IN the_DT Over-TheCounter_NNP OTC_NNP products_NNS ._.
The_DT Company_NN received_VBD sale_NN proceeds_NNS of_IN $_$ 71.0_CD million_CD and_CC recorded_VBD a_DT gain_NN on_IN disposal_NN of_IN $_$ 2.1_CD million_CD ._.
In_IN addition_NN ,_, there_EX are_VBP potential_JJ warranties_NNS of_IN up_RB to_TO $_$ 7.0_CD million_CD in_IN respect_NN of_IN the_DT divestment_NN ,_, of_IN which_WDT the_DT Company_NN has_VBZ provided_VBN what_WP it_PRP deems_VBZ necessary_JJ at_IN this_DT stage_NN ._.
Further_JJ details_NNS of_IN this_DT discontinued_VBN operation_NN are_VBP provided_VBN in_IN note_NN 5_CD below_IN ._.
Year_NN ended_VBD 31_CD December_NNP 2001_CD a_DT BioChem_NNP merger_NN On_IN 11_CD May_NNP 2001_CD ,_, the_DT Company_NN acquired_VBD 100_CD %_NN of_IN the_DT outstanding_JJ stock_NN of_IN BioChem_NNP Pharma_NNP ,_, Inc._NNP ._.
BioChem_NNP ,_, an_DT international_JJ specialty_NN pharmaceutical_JJ company_NN based_VBN in_IN Laval_NNP ,_, Canada_NNP ._.
The_DT merger_NN was_VBD achieved_VBN through_IN an_DT exchange_NN of_IN shares_NNS ._.
Shire_NNP issued_VBD 179,447,629_CD common_JJ shares_NNS and_CC 17,292,149_CD exchangeable_JJ shares_NNS in_IN order_NN to_TO effect_VB the_DT business_NN combination_NN ._.
Each_DT exchangeable_JJ share_NN is_VBZ equivalent_JJ to_TO three_CD common_JJ shares_NNS and_CC is_VBZ exchangeable_JJ into_IN common_JJ shares_NNS or_CC ADSs_NNS at_IN a_DT rate_NN of_IN one_CD exchangeable_JJ share_NN for_IN three_CD common_JJ shares_NNS or_CC one_CD exchangeable_JJ share_NN for_IN one_CD ADS_NNPS ,_, at_IN any_DT time_NN at_IN the_DT request_NN of_IN the_DT holder_NN ._.
Holders_NNS of_IN exchangeable_JJ shares_NNS are_VBP entitled_VBN to_TO the_DT dividend_NN and_CC other_JJ rights_NNS that_WDT are_VBP economically_RB equivalent_JJ to_TO those_DT of_IN common_JJ shares_NNS ._.
Exchangeable_JJ shares_NNS are_VBP included_VBN in_IN deriving_VBG the_DT Companys_NNP weighted_JJ average_JJ number_NN of_IN shares_NNS for_IN both_DT basic_JJ and_CC diluted_JJ earnings_NNS per_IN share_NN see_VBP note_NN 20_CD because_IN they_PRP will_MD become_VB and_CC are_VBP equivalent_JJ to_TO common_JJ shares_NNS ._.
This_DT transaction_NN was_VBD accounted_VBN for_IN by_IN the_DT pooling-of-interests_NNS method_NN in_IN accordance_NN with_IN APB_NNP No._NN ._.
Consequently_RB ,_, the_DT consolidated_JJ financial_JJ statements_NNS give_VBP retroactive_JJ effect_NN to_TO the_DT merger_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 61_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 3_CD Business_NN combinations_NNS and_CC reorganisations_NNS continued_VBD Details_NNS of_IN the_DT results_NNS of_IN operations_NNS of_IN BioChem_NNP for_IN the_DT period_NN before_IN the_DT merger_NN was_VBD consummated_VBN ,_, which_WDT is_VBZ the_DT period_NN from_IN 1_CD January_NNP 2001_CD to_TO 11_CD May_NNP 2001_CD ,_, that_WDT are_VBP included_VBN in_IN the_DT combined_JJ net_JJ income_NN of_IN the_DT Company_NN are_VBP as_IN follows_VBZ :_: $_$ 000_CD Revenue_NN 51,592_CD Net_JJ income_NN 23,003_CD Other_JJ changes_NNS in_IN shareholders_NNS equity_NN :_: Issue_NN of_IN common_JJ shares_NNS on_IN exercise_NN of_IN stock_NN options_NNS 2,170_CD The_DT revenues_NNS and_CC earnings_NNS previously_RB reported_VBN by_IN the_DT Company_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2000_CD can_MD be_VB reconciled_VBN to_TO the_DT combined_VBN amounts_NNS presented_VBD herein_NN as_IN follows_VBZ :_: Revenue_NN Net_JJ income_NN $_$ 000_CD $_$ 000_CD As_IN previously_RB reported_VBN 517,608_CD 76,171_CD BioChem_NNP pooled_VBD results_NNS 198,478_CD 174,346_CD Accounting_NN policy_NN alignment_NN see_VBP note_NN 4_CD 44,976_CD 38,790_CD As_IN restated_VBN for_IN BioChem_NNP 671,110_CD 211,727_CD Discontinued_VBN operations_NNS see_VBP note_NN 5_CD 23,456_CD As_IN reported_VBN 647,654_CD 211,727_CD b_NN Dispositions_NNS During_IN 2001_CD ,_, the_DT Company_NN recorded_VBD a_DT $_$ 8.1_CD million_CD loss_NN on_IN the_DT sale_NN of_IN its_PRP$ manufacturing_NN facility_NN in_IN Toronto_NNP ,_, Canada_NNP ._.
As_IN a_DT result_NN of_IN the_DT merger_NN with_IN BioChem_NNP ,_, the_DT decision_NN was_VBD made_VBN to_TO close_VB the_DT Toronto_NNP facility_NN and_CC to_TO eliminate_VB duplicate_VB positions_NNS across_IN the_DT combined_VBN organization_NN ._.
The_DT Companys_NNP existing_VBG Canadian_JJ sales_NNS and_CC marketing_NN operations_NNS in_IN Toronto_NNP were_VBD combined_VBN with_IN those_DT of_IN BioChem_NNP in_IN Laval_NNP ._.
During_IN the_DT third_JJ quarter_NN of_IN 2001_CD ,_, the_DT Company_NN disposed_VBD of_IN certain_JJ non-strategic_JJ products_NNS for_IN net_JJ proceeds_NNS of_IN approximately_RB $_$ 4.5_CD million_CD ._.
A_DT loss_NN on_IN disposition_NN of_IN $_$ 2.1_CD million_CD was_VBD recorded_VBN in_IN operations_NNS ._.
4_CD Accounting_NN policy_NN alignment_NN In_IN 1998_CD ,_, BioChem_NNP spun_VBD off_RP its_PRP$ investments_NNS in_IN CliniChem_NNP to_TO its_PRP$ shareholders_NNS ._.
In_IN connection_NN with_IN this_DT spin-off_NN ,_, BioChem_NNP retained_VBD rights_NNS in_IN CliniChem_NNP ,_, including_VBG the_DT option_NN to_TO reacquire_VB all_DT shares_NNS in_IN CliniChem_NNP at_IN any_DT time_NN ._.
Under_IN EITF_NNP 99-16_CD ,_, this_DT transaction_NN would_MD result_VB in_IN CliniChem_NNP continuing_VBG to_TO be_VB consolidated_VBN by_IN BioChem_NNP ,_, as_IN BioChem_NNP would_MD have_VB significant_JJ continuing_VBG involvement_NN in_IN the_DT operation_NN of_IN CliniChem_NNP ._.
However_RB ,_, at_IN the_DT time_NN that_WDT CliniChem_NNP was_VBD spun_VBN off_RP ,_, EITF_NNP 99-16_CD had_VBD not_RB been_VBN issued_VBN and_CC BioChem_NNP elected_VBD to_TO fide-consolidate_VB CliniChem_NNP ,_, an_DT acceptable_JJ accounting_NN principle_NN at_IN that_DT time_NN ._.
The_DT management_NN of_IN Shire_NNP believes_VBZ that_IN its_PRP$ accounting_NN policies_NNS would_MD have_VB required_VBN Shire_NNP to_TO continue_VB to_TO consolidate_VB CliniChem_NNP ,_, also_RB an_DT acceptable_JJ accounting_NN alternative_NN at_IN the_DT date_NN of_IN the_DT spin-off_NN and_CC a_DT policy_NN that_WDT conforms_VBZ with_IN the_DT later_JJ guidance_NN issued_VBN under_IN EITF_NNP 99-16_CD ._.
The_DT effect_NN of_IN this_DT accounting_NN policy_NN alignment_NN is_VBZ to_TO reduce_VB the_DT net_JJ income_NN from_IN continuing_VBG operations_NNS previously_RB reported_VBN by_IN BioChem_NNP now_RB included_VBD in_IN the_DT pooled_VBN financial_JJ statements_NNS for_IN 2000_CD by_IN $_$ 38.8_CD million_CD ._.
On_IN 15_CD December_NNP 2000_CD BioChem_NNP reacquired_VBD CliniChem_NNP ._.
This_DT acquisition_NN has_VBZ been_VBN reflected_VBN in_IN the_DT accompanying_VBG financial_JJ statements_NNS using_VBG purchase_NN accounting_NN ._.
5_CD Discontinued_VBN operations_NNS In_IN December_NNP 1999_CD the_DT Company_NN acquired_VBD a_DT group_NN of_IN products_NNS ,_, collectively_RB referred_VBD to_TO as_IN the_DT OTC_NNP portfolio_NN ,_, through_IN its_PRP$ merger_NN with_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP Roberts_NNP ._.
The_DT OTC_NNP portfolio_NN consisted_VBD of_IN non-prescription_JJ laxatives_NNS and_CC dietary_JJ supplements_NNS sold_VBN by_IN the_DT Companys_NNPS US_NNP operating_VBG segment_NN ._.
As_IN a_DT specialty_NN pharmaceuticals_NNS company_NN that_WDT focuses_VBZ on_IN prescription_NN only_RB products_NNS ,_, this_DT part_NN of_IN the_DT business_NN was_VBD not_RB considered_VBN to_TO be_VB a_DT core_NN part_NN of_IN Shires_NNP long-term_JJ strategy_NN and_CC hence_RB the_DT decision_NN was_VBD made_VBN to_TO divest_VB the_DT OTC_NNP portfolio_NN in_IN December_NNP 2002_CD ._.
On_IN 27_CD December_NNP 2002_CD ,_, the_DT Company_NN completed_VBD its_PRP$ divestment_NN of_IN the_DT OTC_NNP business_NN ._.
The_DT historical_JJ consolidated_JJ financial_JJ statements_NNS have_VBP been_VBN restated_VBN to_TO reflect_VB the_DT OTC_NNP business_NN as_IN a_DT discontinued_VBN operation_NN for_IN all_DT periods_NNS presented_VBN ._.
Operating_VBG results_NNS of_IN the_DT discontinued_VBN operations_NNS are_VBP summarised_VBN below_IN ._.
The_DT amounts_NNS include_VBP income_NN tax_NN provisions_NNS based_VBN on_IN the_DT stand-alone_JJ results_NNS of_IN the_DT OTC_NNP business_NN ._.
There_EX have_VBP been_VBN no_DT allocations_NNS of_IN general_JJ and_CC administrative_JJ corporate_JJ costs_NNS or_CC interest_NN expense_NN related_VBN to_TO corporate_JJ credit_NN facilities_NNS to_TO the_DT discontinued_VBN operation_NN ._.
As_IN the_DT OTC_NNP business_NN functioned_VBD within_IN Shire_NNP US_NNP ,_, which_WDT itself_PRP essentially_RB functions_NNS as_IN an_DT independent_JJ entity_NN ,_, no_DT corporate_JJ costs_NNS were_VBD eliminated_VBN upon_IN discontinuance_NN of_IN the_DT operation_NN ._.
Within_IN Shire_NNP US_NNP ,_, the_DT OTC_NNP business_NN had_VBD few_JJ dedicated_VBN resources_NNS ._.
All_DT of_IN the_DT products_NNS were_VBD manufactured_VBN and_CC packaged_VBN by_IN third-party_JJ contract_NN manufacturers_NNS ._.
The_DT products_NNS were_VBD distributed_VBN through_IN a_DT shared_VBN warehouse_NN facility_NN and_CC sold_VBN through_IN a_DT small_JJ sales_NNS team_NN ._.
62_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 5_CD Discontinued_VBN operations_NNS continued_VBD 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Product_NN sales_NNS 24,010_CD 24,613_CD 23,456_CD Cost_NN of_IN product_NN sales_NNS 5,764_CD 6,279_CD 6,300_CD Gross_NNP profit_NN 18,246_CD 18,334_CD 17,156_CD Operating_NN expenses_NNS :_: Selling_VBG ,_, general_JJ and_CC administrative_JJ 8,550_CD 7,623_CD 6,073_CD Operating_NN income_NN 9,696_CD 10,711_CD 11,083_CD Income_NN taxes_NNS 3,588_CD 3,963_CD 4,100_CD Income_NN from_IN discontinued_VBN operations_NNS 6,108_CD 6,748_CD 6,983_CD Gain_NN on_IN sale_NN net_NN of_IN tax_NN 2,083_CD 8,191_CD 6,748_CD 6,983_CD The_DT assets_NNS and_CC liabilities_NNS of_IN the_DT discontinued_VBN operation_NN are_VBP summarised_VBN below_IN ._.
31_CD December_NNP 31_CD December_NNP 31_CD December_NNP 2002 2001 2000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Current_JJ assets_NNS :_: Inventories_NNS 1,779_CD 4,135_CD Long-term_JJ assets_NNS :_: Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS ,_, net_JJ 65,348_CD 67,340_CD Deferred_JJ tax_NN liability_NN 7,400_CD 6,354_CD Total_JJ long-term_JJ assets_NNS 57,948_CD 60,986_CD Current_JJ liabilities_NNS :_: Other_JJ current_JJ liabilities_NNS 12,784_CD Total_JJ current_JJ liabilities_NNS 12,784_CD Net_JJ liabilities_NNS assets_NNS 12,784_CD 59,727_CD 65,121_CD Included_VBN in_IN the_DT 2002_CD other_JJ current_JJ liabilities_NNS are_VBP amounts_NNS for_IN ongoing_JJ liabilities_NNS that_WDT were_VBD not_RB transferred_VBN to_TO the_DT purchaser_NN ._.
6_CD Marketable_JJ securities_NNS 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Commercial_JJ paper_NN 87,843_CD 246,174_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 228,283_CD 477,737_CD 316,126_CD 723,911_CD 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD Maturity_NN profile_NN of_IN commercial_JJ paper_NN $_$ 000_CD $_$ 000_CD Less_RBR than_IN one_CD month_NN 7,297_CD 168,678_CD 1-3_JJ months_NNS 12,981_CD 3-6_CD months_NNS 67,565_CD 77,496_CD 87,843_CD 246,174_CD 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD Maturity_NN profile_NN of_IN institutional_JJ and_CC managed_VBD cash_NN funds_NNS $_$ 000_CD $_$ 000_CD Less_RBR than_IN one_CD month_NN 63,600_CD 477,737_CD 1-3_JJ months_NNS 20,373_CD 3-6_CD months_NNS 45,090_CD 6-12_CD months_NNS 25,192_CD More_JJR than_IN one_CD year_NN 74,028_CD 228,283_CD 477,737_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 63_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 7_CD Accounts_NNPS receivable_NN ,_, net_JJ 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Trade_NNP receivables_NN 130,210_CD 187,694_CD Research_NNP and_CC development_NN contracts_NNS 5,184_CD 3,998_CD Other_JJ receivables_NN 3,003_CD 2,221_CD 138,397_CD 193,913_CD Trade_NNP receivables_NN included_VBD above_RB are_VBP stated_VBN net_NN of_IN a_DT provision_NN for_IN doubtful_JJ debts_NNS of_IN $_$ 0.8_CD million_CD 31_CD December_NNP 2001_CD :_: $_$ 1.1_CD million_CD ._.
Included_VBN within_IN trade_NN receivables_NN as_IN at_IN 31_CD December_NNP 2002_CD is_VBZ $_$ nil_CD in_IN respect_NN of_IN unearned_JJ income_NN relating_VBG to_TO ADDERALL_NNP XR_NNP product_NN sales_NNS 31_CD December_NNP 2001_CD :_: $_$ 17.0_CD million_CD ._.
Included_VBN within_IN research_NN and_CC development_NN contracts_NNS receivable_NN are_VBP amounts_NNS due_JJ in_IN respect_NN of_IN an_DT agreement_NN with_IN the_DT Canadian_JJ government_NN ,_, Technology_NNP Partnerships_NNS Canada_NNP TPC_NNP ,_, under_IN which_WDT a_DT contribution_NN is_VBZ made_VBN towards_IN certain_JJ eligible_JJ research_NN and_CC development_NN costs_NNS incurred_VBN by_IN Shires_NNP Canadian_NNP subsidiary_NN ,_, Shire_NNP BioChem_NNP Inc._NNP ._.
This_DT was_VBD $_$ 1.0_CD million_CD at_IN 31_CD December_NNP 2002_CD ._.
8_CD Inventories_NNS 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Finished_VBN goods_NNS 27,672_CD 18,101_CD Work-in-process_JJ 13,716_CD 18,262_CD Raw_NNP materials_NNS 7,828_CD 8,548_CD 49,216_CD 44,911_CD 9_CD Prepaid_NN expenses_NNS and_CC other_JJ current_JJ assets_NNS 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Prepaid_NN expenses_NNS 14,558_CD 18,780_CD Deferred_VBN financing_NN costs_NNS 1,208_CD 1,077_CD Income_NNP tax_NN receivable_NN 12_CD 7,712_CD Valued_VBN added_VBD taxes_NNS receivable_JJ 2,730_CD 5,407_CD Other_JJ current_JJ assets_NNS 12,282_CD 5,595_CD 30,790_CD 38,571_CD The_DT deferred_VBN financing_NN costs_NNS relate_VBP to_TO the_DT $_$ 400_CD million_CD convertible_JJ loan_NN note_NN see_VBP note_NN 16_CD ._.
These_DT costs_NNS are_VBP being_VBG amortised_VBN over_IN ten_CD years_NNS using_VBG the_DT effective_JJ interest_NN rate_NN method_NN ._.
10_CD Investments_NNP 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Investments_NNPS in_IN private_JJ companies_NNS 47,255_CD 51,549_CD Investments_NNP in_IN public_JJ companies_NNS 14,129_CD 13,855_CD Equity_NN method_NN investments_NNS 10,578_CD 3,339_CD 71,962_CD 68,743_CD 64_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBD 10_CD Investments_NNP continued_VBD a_DT Investments_NNP in_IN private_JJ companies_NNS i_FW GeneChem_NNP funds_NNS We_PRP have_VBP made_VBN investments_NNS in_IN two_CD venture_NN capital_NN funds_NNS ._.
In_IN March_NNP 1997_CD ,_, we_PRP entered_VBD into_IN an_DT agreement_NN to_TO make_VB an_DT investment_NN of_IN CAN$_NNP 30.0_CD million_CD in_IN the_DT GeneChem_NNP Technologies_NNPS Venture_NNP Fund_NNP L._NNP P._NNP a_DT venture_NN capital_NN fund_NN sponsored_VBN by_IN our_PRP$ subsidiary_NN ,_, GeneChem_NNP Financial_NNP Corporation_NNP ._.
This_DT CAN$_NNP 100.0_CD million_CD fund_NN invests_VBZ in_IN advanced_JJ academic_JJ research_NN projects_NNS and_CC early-stage_JJ private_JJ or_CC public_JJ companies_NNS in_IN the_DT area_NN of_IN genomics_NNS and_CC related_VBN technologies_NNS for_IN human_JJ application_NN ._.
As_IN of_IN 31_CD December_NNP 2002_CD ,_, we_PRP have_VBP invested_VBN CAN$_NNP 27.0_CD million_CD in_IN the_DT GeneChem_NNP Technologies_NNPS Venture_NNP Fund_NNP L._NNP P._NNP and_CC we_PRP are_VBP ,_, therefore_RB ,_, committed_VBN to_TO investing_VBG a_DT further_JJ $_$ 1.9_CD million_CD CAN$_NNP 3.0_CD million_CD into_IN this_DT fund_NN ._.
In_IN September_NNP 2000_CD ,_, we_PRP entered_VBD into_IN an_DT agreement_NN to_TO invest_VB CAN$_NNP 15.0_CD million_CD in_IN the_DT GeneChem_NNP Therapeutics_NNPS Venture_NNP Fund_NNP L._NNP P._NNP which_WDT invests_VBZ in_IN genomics_NNS companies_NNS focusing_VBG on_IN cancer_NN and_CC infectious_JJ diseases_NNS ._.
As_IN of_IN 31_CD December_NNP 2002_CD ,_, we_PRP have_VBP committed_VBN to_TO invest_VB a_DT further_JJ $_$ 4.3_CD million_CD CAN$_NNP 6.8_CD million_CD in_IN the_DT GeneChem_NNP Therapeutics_NNPS Venture_NNP Fund_NNP L._NNP P._NNP The_NNP manager_NN and_CC general_JJ partners_NNS of_IN these_DT funds_NNS are_VBP fully-owned_JJ subsidiaries_NNS of_IN the_DT Company_NN ._.
These_DT funds_NNS have_VBP not_RB been_VBN consolidated_JJ because_IN the_DT operational_JJ substance_NN of_IN the_DT funds_NNS is_VBZ such_JJ that_IN the_DT other_JJ partners_NNS have_VBP the_DT ability_NN to_TO veto_VB investment_NN decisions_NNS ._.
ii_FW EGS_FW healthcare_NN funds_NNS In_IN November_NNP 2000_CD ,_, we_PRP entered_VBD into_IN an_DT agreement_NN to_TO invest_VB up_RP to_TO $_$ 10.0_CD million_CD in_IN various_JJ EGS_NNP healthcare_NN funds_NNS ._.
As_IN of_IN 31_CD December_NNP 2002_CD ,_, we_PRP have_VBP invested_VBN $_$ 5.1_CD million_CD in_IN EGS_NNP healthcare_NN funds_NNS and_CC we_PRP are_VBP ,_, therefore_RB ,_, committed_VBN to_TO invest_VB a_DT further_JJ $_$ 4.9_CD million_CD into_IN these_DT funds_NNS ._.
b_NN Investments_NNP in_IN public_JJ companies_NNS During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, there_EX were_VBD no_DT new_JJ investments_NNS in_IN public_JJ companies_NNS ._.
In_IN July_NNP 2002_CD ,_, the_DT Companys_NNPS $_$ 11.1_CD million_CD preference_NN share_NN investment_NN in_IN Immunogen_NNP Inc._NNP was_VBD converted_VBN into_IN a_DT common_JJ stock_NN holding_NN ._.
During_IN the_DT year_NN ,_, the_DT Company_NN wrote_VBD down_RP the_DT cost_NN of_IN investments_NNS in_IN public_JJ companies_NNS by_IN $_$ 1.4_CD million_CD due_JJ to_TO other-than-temporary_JJ impairments_NNS ._.
This_DT expense_NN is_VBZ included_VBN within_IN non-operating_JJ other_JJ expense_NN income_NN ,_, net_JJ see_VBP note_NN 24_CD ._.
c_NN Equity_NN method_NN investments_NNS The_DT Company_NN has_VBZ accounted_VBN for_IN its_PRP$ commercialisation_NN partnership_NN with_IN GSK_NNP through_IN which_WDT the_DT products_NNS 3TC_NNP and_CC ZEFFIX_NNP are_VBP marketed_VBN in_IN Canada_NNP using_VBG the_DT equity_NN method_NN of_IN accounting_NN ._.
The_DT Companys_NNP share_NN of_IN the_DT partnership_NN is_VBZ included_VBN within_IN Equity_NN in_IN earnings_NNS of_IN equity_NN method_NN investees_NNS and_CC the_DT related_JJ equity_NN investment_NN of_IN $_$ 2.9_CD million_CD is_VBZ included_VBN above_IN ._.
In_IN September_NNP 2002_CD ,_, the_DT Company_NN sold_VBD the_DT net_JJ assets_NNS of_IN its_PRP$ CADx_NNP group_NN of_IN companies_NNS ,_, to_TO Qualia_NNP Computing_NNP Inc._NNP in_IN exchange_NN for_IN shares_NNS in_IN a_DT newly_RB formed_VBN joint_JJ venture_NN ._.
The_DT common_JJ stock_NN of_IN the_DT joint_JJ venture_NN ,_, Qualia_NNP Computing_NNP Inc._NNP is_VBZ 50_CD %_NN owned_VBN by_IN Shire_NNP ._.
The_DT initial_JJ value_NN of_IN the_DT investment_NN was_VBD equal_JJ to_TO the_DT book_NN value_NN of_IN assets_NNS sold_VBN ,_, therefore_RB ,_, no_DT gain_NN or_CC loss_NN was_VBD recognized_VBN ._.
The_DT Company_NN has_VBZ applied_VBN the_DT equity_NN method_NN of_IN accounting_NN as_IN the_DT Company_NN owns_VBZ but_CC does_VBZ not_RB exercise_VB control_NN over_IN its_PRP$ 50_CD %_NN share_NN of_IN the_DT joint_JJ venture_NN ._.
As_IN a_DT result_NN ,_, the_DT Companys_NNP investment_NN is_VBZ valued_VBN at_IN cost_NN ,_, adjusted_VBN for_IN its_PRP$ share_NN of_IN the_DT earnings_NNS or_CC losses_NNS of_IN the_DT joint_JJ venture_NN ._.
The_DT Companys_NNP share_NN of_IN the_DT partnership_NN is_VBZ included_VBN within_IN Equity_NN in_IN earnings_NNS of_IN equity_NN method_NN investees_NNS and_CC the_DT related_JJ equity_NN investment_NN of_IN $_$ 7.7_CD million_CD is_VBZ included_VBN above_IN ._.
There_EX is_VBZ no_DT significant_JJ difference_NN between_IN the_DT amount_NN at_IN which_WDT the_DT investment_NN is_VBZ carried_VBN and_CC the_DT amount_NN of_IN the_DT underlying_VBG equity_NN in_IN net_JJ assets_NNS of_IN the_DT joint_JJ venture_NN ._.
11_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Land_NNP and_CC buildings_NNS 111,164_CD 95,921_CD Office_NNP furniture_NN ,_, fittings_NNS and_CC equipment_NN 31,210_CD 12,659_CD Warehouse_NNP ,_, laboratory_NN and_CC manufacturing_NN equipment_NN 46,706_CD 46,613_CD 189,080_CD 155,193_CD Less_RBR :_: Accumulated_VBN depreciation_NN 53,846_CD 41,846_CD 135,234_CD 113,347_CD Depreciation_NN expense_NN for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD was_VBD $_$ 12.9_CD million_CD ,_, $_$ 14.4_CD million_CD and_CC $_$ 10.7_CD million_CD respectively_RB ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 65_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 12_CD Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS ,_, net_JJ 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Goodwill_NNP arising_VBG on_IN businesses_NNS acquired_VBN 254,207_CD 220,890_CD Less_RBR :_: accumulated_VBN amortisation_NN 50,440_CD 45,549_CD 203,767_CD 175,341_CD Other_JJ intangible_JJ assets_NNS acquired_VBN 397,807_CD 379,986_CD Less_RBR :_: accumulated_VBN amortisation_NN 96,723_CD 71,631_CD 301,084_CD 308,355_CD Total_JJ 504,851_CD 483,696_CD The_DT increase_NN decrease_NN in_IN the_DT net_JJ book_NN value_NN of_IN goodwill_NN and_CC other_JJ intangible_JJ assets_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP ,_, 2002_CD is_VBZ shown_VBN in_IN the_DT table_NN below_IN :_: Other_JJ intangible_JJ Goodwill_NNP assets_NNS $_$ 000_CD $_$ 000_CD Year_NN ended_VBD 31_CD December_NNP 2002_CD As_IN at_IN 1_CD January_NNP 2002_CD 175,341_CD 308,355_CD Acquisitions_NNPS 10,175_CD 23,467_CD Amortisation_NNP charged_VBD 23,493_CD Asset_NNP impairments_NNS 18,777_CD Foreign_JJ currency_NN translation_NN 18,251_CD 11,532_CD As_IN at_IN 31_CD December_NNP 2002_CD 203,767_CD 301,084_CD The_DT acquisition_NN of_IN goodwill_NN is_VBZ in_IN respect_NN of_IN APS_NNP see_VBP note_NN 3_CD ._.
Acquisitions_NNS of_IN other_JJ intangible_JJ assets_NNS primarily_RB related_VBN to_TO SOLARAZE_NNP ._.
The_DT Company_NN acquired_VBD the_DT exclusive_JJ rights_NNS to_TO manufacture_VB ,_, distribute_VB and_CC sell_VB SOLARAZE_NNP for_IN the_DT treatment_NN of_IN actinic_JJ keratosis_NN from_IN SkyePharma_NNP PLC._NNP ._.
In_IN May_NNP 2002_CD ,_, the_DT Company_NN paid_VBD $_$ 18.9_CD million_CD 12.9_CD million_CD in_IN respect_NN of_IN certain_JJ European_JJ territories_NNS ,_, followed_VBD in_IN December_NNP 2002_CD by_IN a_DT further_JJ $_$ 1.2_CD million_CD 0.7_CD million_CD in_IN respect_NN of_IN the_DT rights_NNS for_IN Australia_NNP ,_, New_NNP Zealand_NNP ,_, South_NNP Africa_NNP and_CC certain_JJ other_JJ countries_NNS in_IN the_DT Pacific_NNP Rim_NNP ._.
Amortisation_NNP charged_VBD for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD was_VBD $_$ 23.5_CD million_CD ,_, $_$ 31.4_CD million_CD and_CC $_$ 27.3_CD million_CD respectively_RB ._.
Goodwill_NN was_VBD no_RB longer_RB amortised_VBN with_IN effect_NN from_IN 1_CD January_NNP 2002_CD following_VBG the_DT implementation_NN of_IN SFAS_NNP No._NN ._.
142_CD As_IN described_VBN in_IN note_NN 2_CD ,_, the_DT Company_NN adopted_VBN SFAS_NNP No._NN ._.
A_DT transitional_JJ assessment_NN of_IN goodwill_NN impairment_NN as_IN of_IN 1_CD January_NNP 2002_CD was_VBD completed_VBN by_IN 30_CD June_NNP 2002_CD ._.
Management_NN concluded_VBD that_IN the_DT fair_JJ value_NN of_IN the_DT Companys_NNP individual_JJ reporting_VBG units_NNS exceeded_VBD the_DT carrying_VBG value_NN of_IN the_DT net_JJ assets_NNS including_VBG goodwill_NN ,_, and_CC hence_RB this_DT process_NN did_VBD not_RB result_VB in_IN any_DT impairment_NN to_TO be_VB recorded_VBN on_IN adoption_NN of_IN SFAS_NNP No._NN ._.
The_DT Company_NN completed_VBD a_DT second_JJ goodwill_NN impairment_NN review_NN as_IN of_IN 30_CD September_NNP 2002_CD and_CC found_VBD that_IN no_DT adjusting_VBG entries_NNS were_VBD necessary_JJ ._.
A_DT reconciliation_NN table_NN is_VBZ provided_VBN below_IN to_TO exclude_VB the_DT effect_NN of_IN goodwill_NN amortisation_NN in_IN accordance_NN with_IN the_DT transitional_JJ disclosures_NNS relating_VBG to_TO SFAS_NNP No._NN ._.
Results_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
66_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 12_CD Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS ,_, net_JJ continued_VBD 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Income_NN from_IN continuing_VBG operations_NNS before_IN extraordinary_JJ items_NNS as_IN reported_VBN 242,378_CD 34,615_CD 204,744_CD Add-back_NN of_IN goodwill_NN amortisation_NN charge_NN 10,763_CD 11,324_CD Adjusted_JJ income_NN from_IN continuing_VBG operations_NNS before_IN extraordinary_JJ items_NNS 242,378_CD 45,378_CD 216,068_CD Net_JJ income_NN as_IN reported_VBN 250,569_CD 38,759_CD 211,727_CD Add-back_NN of_IN goodwill_NN amortisation_NN charge_NN 10,763_CD 11,324_CD Adjusted_VBN net_JJ income_NN for_IN basic_JJ earnings_NNS per_IN share_NN 250,569_CD 49,522_CD 223,051_CD Interest_NN charged_VBN on_IN convertible_JJ debt_NN ,_, net_NN of_IN tax_NN 5,585_CD Adjusted_VBN net_JJ income_NN for_IN diluted_JJ earnings_NNS per_IN share_NN 256,154_CD 49,522_CD 223,051_CD Basic_JJ earnings_NNS per_IN share_NN in_IN $_$ :_: Net_JJ income_NN as_IN reported_VBN 50.0_CD 7.9_CD 43.8_CD Add-back_JJ goodwill_NN amortisation_NN charge_NN 2.2_CD 2.3_CD Adjusted_VBN net_JJ income_NN 50.0_CD 10.1_CD 46.1_CD Diluted_VBN earnings_NNS per_IN share_NN in_IN $_$ :_: Net_JJ income_NN as_IN reported_VBN 49.0_CD 7.7_CD 42.8_CD Add-back_JJ goodwill_NN amortisation_NN charge_NN 2.1_CD 2.3_CD Interest_NN charged_VBN on_IN convertible_JJ debt_NN ,_, net_NN of_IN tax_NN 0.1_CD Adjusted_VBN net_JJ income_NN 49.1_CD 9.8_CD 45.1_CD Number_NNP Number_NNP Number_NNP of_IN shares_NNS of_IN shares_NNS of_IN shares_NNS Weighted_VBN average_JJ number_NN of_IN shares_NNS :_: Basic_JJ 500,687,594_CD 492,594,226_CD 482,890,070_CD Diluted_NNP 522,418,246_CD 504,875,587_CD 494,691,805_CD There_EX is_VBZ no_DT tax_NN effect_NN related_VBN to_TO the_DT goodwill_NN amortisation_NN disclosed_VBN above_IN ._.
The_DT useful_JJ economic_JJ lives_NNS of_IN all_DT intangible_JJ assets_NNS that_WDT continue_VBP to_TO be_VB amortised_VBN under_IN SFAS_NNP No._NN ._.
Management_NNP estimates_VBZ that_IN the_DT annual_JJ amortisation_NN charges_NNS in_IN respect_NN of_IN intangible_JJ fixed_JJ assets_NNS held_VBN at_IN 31_CD December_NNP 2002_CD will_MD be_VB approximately_RB $_$ 13.2_CD million_CD for_IN each_DT of_IN the_DT five_CD years_NNS to_TO 31_CD December_NNP 2007_CD ._.
Estimated_VBN amortisation_NN expense_NN can_MD be_VB affected_VBN by_IN various_JJ factors_NNS including_VBG future_JJ acquisitions_NNS and_CC disposals_NNS of_IN product_NN rights_NNS ._.
The_DT net_JJ book_NN value_NN of_IN goodwill_NN by_IN operating_VBG segment_NN is_VBZ as_IN follows_VBZ :_: US_NNP International_NNP R&D_NNP Total_NNP 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000 2002 174_CD ,617_CD 29,150_CD 203,767_CD 2001_CD 148,660_CD 26,681_CD 175,341_CD During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, the_DT Company_NN acquired_VBD exclusive_JJ rights_NNS to_TO manufacture_VB ,_, distribute_VB and_CC sell_VB SOLARAZE_NNP in_IN certain_JJ countries_NNS ._.
The_DT purchase_NN cost_NN was_VBD $_$ 20.1_CD million_CD ._.
The_DT amortisation_NN period_NN in_IN respect_NN of_IN this_DT product_NN is_VBZ ten_CD years_NNS ._.
13_CD Other_JJ non-current_JJ assets_NNS 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Deferred_VBN financing_NN costs_NNS 7,915_CD 8,617_CD SERP_NNP investment_NN 12,070_CD 14,367_CD Other_JJ assets_NNS 3,279_CD 3,184_CD 23,264_CD 26,168_CD The_DT deferred_VBN financing_NN costs_NNS at_IN 31_CD December_NNP 2002_CD and_CC 2001_CD were_VBD in_IN respect_NN of_IN the_DT $_$ 400_CD million_CD convertible_JJ loan_NN note_NN ._.
These_DT costs_NNS are_VBP being_VBG amortised_VBN over_IN ten_CD years_NNS ._.
The_DT current_JJ element_NN of_IN these_DT costs_NNS is_VBZ included_VBN within_IN prepaid_JJ expenses_NNS and_CC other_JJ current_JJ assets_NNS note_VBP 9_CD ._.
Further_JJ details_NNS of_IN the_DT Supplemental_NNP Executive_NNP Retirement_NNP Plan_NNP SERP_NNP investment_NN are_VBP provided_VBN in_IN note_NN 25_CD ._.
The_DT amount_NN shown_VBN above_IN is_VBZ the_DT cash_NN surrender_NN value_NN of_IN life_NN insurance_NN policies_NNS which_WDT is_VBZ backed_VBN by_IN marketable_JJ securities_NNS ._.
A_DT liability_NN of_IN $_$ 8.4_CD million_CD is_VBZ included_VBN within_IN note_NN 17_CD 2001_CD :_: $_$ 11.3_CD million_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 67_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 14_CD Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Trade_NNP accounts_NNS payable_JJ 46,912_CD 51,952_CD Accrued_VBN rebates_NNS and_CC charge-backs_NNS 45,919_CD 41,086_CD Accrued_VBN expenses_NNS 91,276_CD 74,114_CD 184,107_CD 167,152_CD 15_CD Other_JJ current_JJ liabilities_NNS 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Income_NN taxes_NNS payable_JJ 5,440_CD 25,604_CD Payable_JJ for_IN termination_NN of_IN licence_NN agreement_NN 738_CD Interest_NN on_IN long-term_JJ debt_NN 2,893_CD 2,928_CD Social_NNP security_NN liabilities_NNS 1,934_CD 7,237_CD Value_NNP added_VBD taxes_NNS 1,957_CD 1,148_CD Other_JJ accrued_VBN liabilities_NNS 3,268_CD 5,075_CD 15,492_CD 42,730_CD 16_CD Long-term_JJ debt_NN 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Total_JJ obligations_NNS 408,190_CD 406,806_CD Current_JJ maturities_NNS of_IN long-term_JJ obligations_NNS 888_CD 4,325_CD Total_JJ long-term_JJ debt_NN 407,302_CD 402,481_CD An_DT analysis_NN of_IN total_JJ obligations_NNS by_IN loan_NN type_NN is_VBZ presented_VBN below_IN :_: 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Convertible_JJ notes_NNS due_JJ 2011_CD 400,000_CD 400,000_CD Unsecured_JJ convertible_JJ zero_CD coupon_NN loan_NN notes_NNS 1,450_CD Canadian_JJ provincial_JJ and_CC federal_JJ government_NN loan_NN 1,880_CD 3,100_CD Bank_NNP term_NN loans_NNS 2,256_CD Capital_NN leases_NNS 6,310_CD 408,190_CD 406,806_CD Principal_NN payments_NNS in_IN each_DT of_IN the_DT next_JJ five_CD years_NNS and_CC thereafter_RB on_IN total_JJ obligations_NNS outstanding_JJ at_IN 31_CD December_NNP 2002_CD amount_NN to_TO :_: 31_CD December_NNP 2002_CD $_$ 000 2003 888 2004_CD 400,897_CD 2005 863 2006 254_CD 2007_CD 272_CD Thereafter_RB 5,016_CD 408,190_CD The_DT principal_NN payments_NNS presented_VBN above_IN have_VBP been_VBN calculated_VBN on_IN the_DT basis_NN that_IN the_DT $_$ 400_CD million_CD convertible_JJ notes_NNS due_JJ 2011_CD convert_VBP to_TO common_JJ shares_NNS or_CC will_MD be_VB paid_VBN as_IN cash_NN at_IN the_DT earliest_JJS opportunity_NN ,_, which_WDT is_VBZ 21_CD August_NNP 2004_CD ._.
Further_JJ details_NNS in_IN respect_NN of_IN the_DT convertible_JJ notes_NNS are_VBP presented_VBN below_IN ._.
68_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBD 16_CD Long-term_JJ debt_NN continued_VBD i_FW Convertible_JJ notes_NNS due_JJ 2011_CD The_DT $_$ 400.0_CD million_CD of_IN guaranteed_VBN convertible_JJ notes_NNS due_JJ 2011_CD were_VBD issued_VBN in_IN August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP the_DT Issuer_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ._.
On_IN or_CC after_IN 21_CD August_NNP 2004_CD ,_, the_DT Company_NN may_MD redeem_VB ,_, for_IN cash_NN ,_, all_DT or_CC part_NN of_IN the_DT notes_NNS providing_VBG the_DT ordinary_JJ share_NN price_NN has_VBZ exceeded_VBN $_$ 26.20_CD sterling_NN equivalent_NN at_IN the_DT time_NN for_IN 20_CD of_IN the_DT 30_CD consecutive_JJ dealing_VBG days_NNS in_IN the_DT period_NN prior_RB to_TO redemption_NN ._.
The_DT decision_NN as_IN to_TO whether_IN a_DT note_NN holder_NN should_MD exercise_VB a_DT put_NN option_NN will_MD depend_VB on_IN a_DT number_NN of_IN factors_NNS particularly_RB the_DT price_NN of_IN Shire_NNP stock_NN at_IN the_DT put_JJ date_NN and_CC the_DT likelihood_NN of_IN the_DT Companys_NNP stock_NN price_NN exceeding_VBG the_DT conversion_NN threshold_NN price_NN ._.
The_DT conversion_NN threshold_NN price_NN is_VBZ equivalent_JJ to_TO $_$ 20.15_CD or_CC 12.52_CD at_IN the_DT closing_NN exchange_NN rate_NN for_IN 2002_CD for_IN Shire_NNP common_JJ shares_NNS and_CC $_$ 60.46_CD for_IN Shire_NNP ADSs_NNP ._.
If_IN the_DT price_NN of_IN Shire_NNP common_JJ shares_NNS at_IN the_DT first_JJ put_JJ date_NN of_IN 21_CD August_NNP 2004_CD remains_VBZ at_IN a_DT level_NN similar_JJ to_TO the_DT year-end_JJ price_NN of_IN 3.97_CD $_$ 18.89_CD for_IN Shire_NNP ADSs_NNPS it_PRP is_VBZ quite_RB possible_JJ that_IN note_NN holders_NNS will_MD choose_VB to_TO exercise_VB their_PRP$ put_JJ options_NNS ._.
The_DT Company_NN currently_RB has_VBZ adequate_JJ resources_NNS from_IN which_WDT it_PRP could_MD satisfy_VB repayment_NN of_IN the_DT entire_JJ convertible_JJ debt_NN principal_NN of_IN $_$ 400.0_CD million_CD ._.
The_DT interest_NN expense_NN recorded_VBN in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD was_VBD $_$ 8.0_CD million_CD 2001_CD :_: $_$ 2.9_CD million_CD ._.
ii_FW Unsecured_JJ convertible_JJ zero_CD coupon_NN loan_NN notes_VBZ The_DT Company_NN financed_VBN the_DT purchase_NN of_IN intellectual_JJ property_NN relating_VBG to_TO the_DT manufacture_NN of_IN ADDERALL_NNP from_IN Arenol_NNP Corporation_NNP by_IN a_DT total_NN of_IN $_$ 11.8_CD million_CD in_IN loan_NN notes_NNS ._.
On_IN 5_CD March_NNP 1999_CD the_DT Company_NN issued_VBD a_DT $_$ 5.8_CD million_CD principal_JJ amount_NN unsecured_JJ convertible_JJ zero_CD coupon_NN loan_NN note_NN due_JJ 30_CD July_NNP 2001_CD the_DT First_NNP Loan_NNP Note_NN and_CC a_DT $_$ 6.0_CD million_CD principal_JJ amount_NN unsecured_JJ convertible_JJ zero_CD coupon_NN loan_NN note_NN due_JJ 30_CD July_NNP 2004_CD the_DT Second_JJ Loan_NN Note_NN ._.
Both_DT loan_NN notes_NNS were_VBD in_IN the_DT name_NN of_IN the_DT parent_NN company_NN ,_, Shire_NNP ._.
The_DT agreement_NN provided_VBN for_IN the_DT cancellation_NN of_IN certain_JJ specified_VBN amounts_NNS of_IN the_DT aggregate_NN principal_NN amount_NN of_IN the_DT First_NNP Loan_NNP Note_NN and_CC of_IN such_JJ amounts_NNS of_IN the_DT Second_JJ Loan_NN Note_NN on_IN certain_JJ dates_NNS to_TO the_DT extent_NN of_IN certain_JJ indemnified_JJ losses_NNS or_CC ,_, to_TO the_DT extent_NN that_IN such_JJ amounts_NNS of_IN the_DT First_NNP Loan_NNP Note_NN or_CC the_DT Second_JJ Loan_NN Note_NN together_RB the_DT Loan_NN Notes_NNS were_VBD not_RB so_RB canceled_VBN ,_, for_IN their_PRP$ conversion_NN into_IN common_JJ shares_NNS ._.
The_DT number_NN of_IN common_JJ shares_NNS was_VBD calculated_VBN by_IN dividing_VBG the_DT amount_NN not_RB canceled_VBN by_IN the_DT lower_JJR of_IN 3.565_CD approximately_RB $_$ 5.75_CD and_CC the_DT midweek_JJ closing_NN price_NN of_IN the_DT common_JJ shares_NNS on_IN the_DT London_NNP Stock_NNP Exchange_NNP on_IN the_DT relevant_JJ date_NN ._.
Translation_NN from_IN pounds_NNS sterling_NN to_TO US_NNP dollars_NNS was_VBD made_VBN using_VBG the_DT exchange_NN rate_NN on_IN the_DT relevant_JJ date_NN ._.
The_DT Company_NN has_VBZ issued_VBN common_JJ shares_NNS to_TO Arenol_NNP Corporation_NNP or_CC its_PRP$ nominee_NN broker_NN ,_, as_IN set_VBN out_RP in_IN the_DT table_NN below_IN ,_, in_IN consideration_NN of_IN the_DT conversion_NN of_IN each_DT of_IN the_DT Loan_NN Notes_NNS ._.
As_IN at_IN 31_CD December_NNP 2002_CD there_EX is_VBZ no_DT liability_NN remaining_VBG ._.
Number_NN of_IN common_JJ Date_NN of_IN conversion_NN shares_NNS issued_VBD $_$ 000_CD 13_CD March_NNP 2000_CD 533,279_CD 3,000_CD 3_CD August_NNP 2000_CD 560,076_CD 2,800_CD 6_CD November_NNP 2000_CD 541,478_CD 3,000_CD 30_CD July_NNP 2001_CD 295,061_CD 1,500_CD 6_CD August_NNP 2002_CD 267,572_CD 1,500_CD 2,197,466_CD 11,800_CD iii_FW Canadian_JJ federal_JJ and_CC provincial_JJ government_NN loan_NN The_DT Company_NN has_VBZ a_DT Canadian_JJ federal_JJ and_CC provincial_JJ government_NN loan_NN outstanding_JJ of_IN $_$ 1.9_CD million_CD CAN$_NNP 3.0_CD million_CD ._.
This_DT facility_NN is_VBZ non-interestbearing_JJ and_CC is_VBZ repayable_JJ in_IN annual_JJ instalments_NNS of_IN $_$ 0.6_CD million_CD CAN$_NNP 1.0_CD million_CD ._.
iv_NNP Bank_NNP term_NN loans_NNS The_DT Company_NN had_VBD a_DT bank_NN term_NN loan_NN at_IN 31_CD December_NNP 2001_CD bearing_NN interest_NN at_IN the_DT lenders_NNS prime_JJ rate_NN ,_, which_WDT was_VBD secured_VBN by_IN a_DT charge_NN on_IN land_NN and_CC buildings_NNS ._.
The_DT final_JJ payment_NN in_IN respect_NN of_IN this_DT loan_NN was_VBD made_VBN in_IN May_NNP 2002_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 69_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBD 16_CD Long-term_JJ debt_NN continued_VBD v_NNP Capital_NNP leases_VBZ 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD Obligations_NNS under_IN capital_NN leases_NNS $_$ 000_CD $_$ 000_CD Current_JJ 261_CD Non-current_JJ 6,049_CD 6,310_CD The_DT following_NN is_VBZ an_DT analysis_NN of_IN the_DT leased_VBN property_NN under_IN capital_NN leases_NNS by_IN major_JJ asset_NN classes_NNS :_: 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD Classes_NNS of_IN property_NN $_$ 000_CD $_$ 000_CD Land_NNP and_CC buildings_NNS 6,259_CD Office_NNP furniture_NN ,_, fittings_NNS and_CC equipment_NN 160_CD 6,419_CD Less_RBR :_: accumulated_VBN depreciation_NN 126_CD 6,293_CD The_DT following_NN is_VBZ a_DT schedule_NN by_IN years_NNS of_IN future_JJ minimum_NN lease_NN payments_NNS under_IN capital_NN leases_NNS together_RB with_IN the_DT present_JJ value_NN of_IN the_DT net_JJ minimum_NN lease_NN payments_NNS as_IN of_IN 31_CD December_NNP 2002_CD ._.
31_CD December_NNP 2002_CD $_$ 000 2003 261 2004_CD 270 2005 237 2006_CD 254 2007 272_CD Thereafter_RB 5,016_CD 6,310_CD 17_CD Other_JJ non-current_JJ liabilities_NNS 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD SERP_NNP note_NN 25_CD 8,364_CD 11,348_CD Other_JJ accrued_VBN liabilities_NNS 6,520_CD 2,297_CD 14,884_CD 13,645_CD 18_CD Financial_NNP instruments_NNS The_DT estimated_VBN fair_JJ value_NN of_IN the_DT Companys_NNPS financial_JJ instruments_NNS at_IN 31_CD December_NNP is_VBZ summarised_VBN below_IN ._.
Certain_JJ estimates_NNS and_CC judgements_NNS were_VBD required_VBN to_TO develop_VB the_DT fair_JJ value_NN amounts_NNS ._.
The_DT fair_JJ value_NN amounts_NNS shown_VBN below_IN are_VBP not_RB necessarily_RB indicative_JJ of_IN the_DT amounts_NNS that_IN the_DT Company_NN would_MD realize_VB upon_IN disposition_NN nor_CC do_VBP they_PRP indicate_VBP the_DT Companys_NNPS intent_NN or_CC ability_NN to_TO dispose_VB of_IN the_DT financial_JJ instrument_NN ._.
The_DT following_VBG methods_NNS and_CC assumptions_NNS were_VBD used_VBN to_TO estimate_VB the_DT fair_JJ value_NN of_IN each_DT material_NN class_NN of_IN financial_JJ instrument_NN :_: Marketable_JJ securities_NNS the_DT carrying_NN value_NN of_IN marketable_JJ securities_NNS approximates_VBZ fair_JJ value_NN because_IN of_IN the_DT short-term_JJ nature_NN of_IN these_DT investments_NNS ._.
Investments_NNP non-current_JJ investments_NNS with_IN readily_RB determinable_JJ market_NN values_NNS are_VBP marked_VBN to_TO market_NN ._.
Long-term_JJ debt_NN the_DT fair_JJ value_NN of_IN long-term_JJ debt_NN is_VBZ estimated_VBN based_VBN on_IN the_DT discounted_JJ future_JJ cash_NN flows_VBZ using_VBG currently_RB available_JJ interest_NN rates_NNS or_CC ,_, where_WRB the_DT debt_NN instrument_NN is_VBZ traded_VBN ,_, by_IN reference_NN to_TO the_DT market_NN price_NN ._.
70_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 18_CD Financial_NNP instruments_NNS continued_VBD The_DT carrying_VBG amounts_NNS and_CC corresponding_JJ fair_JJ values_NNS of_IN financial_JJ instruments_NNS at_IN 31_CD December_NNP 2002_CD and_CC 2001_CD were_VBD as_IN follows_VBZ :_: Carrying_VBG amount_NN Fair_NN value_NN $_$ 000_CD $_$ 000_CD 31_CD December_NNP 2002_CD Financial_NNP assets_NNS :_: Commercial_JJ paper_NN 87,843_CD 87,843_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 228,283_CD 228,283_CD Investments_NNP 14,129_CD 14,129_CD Financial_NNP liabilities_NNS :_: Long-term_JJ debt_NN 408,190_CD 376,883_CD 31_CD December_NNP 2001_CD Financial_NNP assets_NNS :_: Commercial_JJ paper_NN 246,174_CD 246,174_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 477,737_CD 477,737_CD Investments_NNP 13,855_CD 13,855_CD Financial_NNP liabilities_NNS :_: Long-term_JJ debt_NN 406,806_CD 394,206_CD 19_CD Leases_NNS and_CC other_JJ commitments_NNS a_DT Leases_NNP The_NNP Company_NNP leases_VBZ facilities_NNS ,_, motor_NN vehicles_NNS and_CC certain_JJ office_NN equipment_NN under_IN operating_VBG leases_NNS ._.
The_DT Companys_NNP commitments_NNS under_IN the_DT noncancellable_JJ portion_NN of_IN all_DT operating_VBG leases_NNS for_IN the_DT next_JJ five_CD years_NNS and_CC thereafter_RB as_IN of_IN 31_CD December_NNP 2002_CD are_VBP as_IN follows_VBZ :_: 31_CD December_NNP 2002_CD $_$ 000_CD 2003_CD 7,215_CD 2004_CD 7,887_CD 2005_CD 5,855_CD 2006_CD 4,085_CD 2007_CD 3,038_CD Thereafter_RB 12,805_CD 40,885_CD Lease_NNP and_CC rental_JJ expense_NN included_VBD in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS in_IN the_DT accompanying_VBG statements_NNS of_IN operations_NNS amounted_VBD to_TO $_$ 6.7_CD million_CD ,_, $_$ 6.1_CD million_CD and_CC $_$ 4.3_CD million_CD for_IN the_DT fiscal_JJ years_NNS ended_VBN 31_CD December_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD respectively_RB ._.
b_NN Contingent_JJ liabilities_NNS i_FW Commitments_NNP The_NNP Company_NNP has_VBZ undertaken_VBN to_TO subscribe_VB to_TO interests_NNS in_IN companies_NNS and_CC partnerships_NNS for_IN amounts_NNS totalling_VBG $_$ 38.1_CD million_CD 31_CD December_NNP 2001_CD :_: $_$ 37.7_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2002_CD an_DT amount_NN of_IN $_$ 20.3_CD million_CD 31_CD December_NNP 2001_CD :_: $_$ 20.1_CD million_CD has_VBZ been_VBN subscribed_VBN ._.
ii_FW FLUVIRAL_NNP The_NNP Company_NNP signed_VBD a_DT ten-year_JJ contract_NN with_IN the_DT Government_NN of_IN Canada_NNP in_IN 2001_CD to_TO assure_VB a_DT state_NN of_IN readiness_NN in_IN the_DT case_NN of_IN an_DT influenza_NN pandemic_JJ worldwide_NN epidemic_NN and_CC to_TO provide_VB influenza_NN vaccine_NN for_IN all_DT Canadian_JJ citizens_NNS in_IN such_JJ an_DT event_NN ._.
Canada_NNP would_MD require_VB 32_CD million_CD doses_NNS of_IN single-strain_JJ monovalent_JJ flu_NN vaccine_NN within_IN a_DT production_NN period_NN of_IN 16_CD weeks_NNS ._.
Shire_NNP Biologics_NNPS has_VBZ therefore_RB begun_VBN to_TO expand_VB its_PRP$ production_NN capacity_NN in_IN order_NN to_TO meet_VB this_DT objective_NN within_IN a_DT five-year_JJ period_NN ._.
Shire_NNP Biologics_NNPS is_VBZ committed_VBN to_TO CAN$_NNP 18_CD million_CD approximately_RB $_$ 11.3_CD million_CD of_IN capital_NN expenditure_NN on_IN immoveables_NNS for_IN the_DT purpose_NN of_IN achieving_VBG the_DT level_NN of_IN pandemic_JJ readiness_NN required_VBN ._.
In_IN addition_NN ,_, a_DT performance_NN bond_NN equal_JJ to_TO 10_CD %_NN of_IN the_DT minimum_NN estimated_VBN contract_NN value_NN in_IN any_DT year_NN ,_, which_WDT for_IN 2002_CD 2003_CD will_MD be_VB CAN$_NNP 19.2_CD million_CD approximately_RB $_$ 12_CD million_CD ,_, would_MD become_VB payable_JJ to_TO the_DT Government_NN of_IN Canada_NNP if_IN contracted_VBN penalty_NN clauses_NNS were_VBD triggered_VBN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 71_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 19_CD Leases_NNPS and_CC other_JJ commitments_NNS continued_VBD c_NN Legal_JJ proceedings_NNS i_FW General_NNP Shire_NNP accounts_VBZ for_IN litigation_NN losses_NNS in_IN accordance_NN with_IN Statement_NN of_IN Financial_NNP Accounting_NNP Standards_NNPS SFAS_NNP No._NN ._.
5_CD ,_, Accounting_NNP for_IN Contingencies_NNPS SFAS_NNP No._NN ._.
5_CD ,_, loss_NN contingency_NN provisions_NNS are_VBP recorded_VBN for_IN probable_JJ losses_NNS when_WRB management_NN is_VBZ able_JJ reasonably_RB to_TO estimate_VB the_DT loss_NN ._.
Where_WRB the_DT estimated_JJ loss_NN lies_VBZ within_IN a_DT range_NN and_CC no_DT particular_JJ amount_NN within_IN that_DT range_NN is_VBZ a_DT better_JJR estimate_NN than_IN any_DT other_JJ amount_NN the_DT minimum_NN amount_NN is_VBZ recorded_VBN ._.
In_IN other_JJ cases_NNS managements_NNS best_JJS estimate_NN of_IN the_DT loss_NN is_VBZ recorded_VBN ._.
These_DT estimates_NNS are_VBP developed_VBN substantially_RB earlier_JJR than_IN the_DT ultimate_JJ loss_NN is_VBZ known_VBN ,_, and_CC the_DT estimates_NNS are_VBP refined_VBN each_DT accounting_NN period_NN ,_, in_IN light_NN of_IN additional_JJ information_NN being_VBG known_VBN ._.
In_IN instances_NNS where_WRB Shire_NNP is_VBZ unable_JJ to_TO develop_VB a_DT best_JJS estimate_NN of_IN loss_NN ,_, no_DT litigation_NN loss_NN is_VBZ recorded_VBN at_IN that_DT time_NN ._.
As_IN information_NN becomes_VBZ known_VBN a_DT loss_NN provision_NN is_VBZ set_VBN up_RP when_WRB a_DT best_JJS estimate_NN can_MD be_VB made_VBN ._.
The_DT best_JJS estimates_NNS are_VBP reviewed_VBN quarterly_JJ and_CC the_DT estimates_NNS are_VBP changed_VBN when_WRB expectations_NNS are_VBP revised_VBN ._.
ii_FW Phentermine_NNP Shire_NNP US_NNP Inc._NNP ._.
SUS_NNP is_VBZ a_DT defendant_NN in_IN 11_CD lawsuits_NNS still_RB pending_VBG in_IN both_DT US_NNP federal_JJ and_CC state_NN courts_NNS which_WDT seek_VBP damages_NNS for_IN ,_, among_IN other_JJ things_NNS ,_, personal_JJ injury_NN arising_VBG from_IN phentermine_NN products_NNS supplied_VBD for_IN the_DT treatment_NN of_IN obesity_NN by_IN SUS_NNP and_CC several_JJ other_JJ pharmaceutical_JJ companies_NNS ._.
SUS_NNP ,_, formerly_RB known_VBN as_IN Shire_NNP Richwood_NNP Inc._NNP has_VBZ been_VBN sued_VBN as_IN a_DT manufacturer_NN and_CC distributor_NN of_IN phentermine_NN ,_, an_DT anorectic_NN used_VBN in_IN the_DT short-term_JJ treatment_NN of_IN obesity_NN and_CC one_CD of_IN the_DT products_NNS addressed_VBN by_IN the_DT lawsuits_NNS ._.
The_DT lawsuits_NNS generally_RB allege_VBP the_DT following_VBG claims_NNS :_: the_DT defendants_NNS marketed_VBN phentermine_NN and_CC other_JJ products_NNS for_IN the_DT treatment_NN of_IN obesity_NN and_CC misled_VBD users_NNS about_IN the_DT products_NNS and_CC dangers_NNS associated_VBN with_IN them_PRP :_: the_DT defendants_NNS failed_VBD adequately_RB to_TO test_NN phentermine_NN individually_RB and_CC when_WRB taken_VBN in_IN combination_NN with_IN the_DT other_JJ drugs_NNS :_: and_CC the_DT defendants_NNS knew_VBD or_CC should_MD have_VB known_VBN about_IN the_DT negative_JJ effects_NNS of_IN the_DT drugs_NNS and_CC should_MD have_VB informed_VBN the_DT public_JJ about_IN such_JJ risks_NNS and_CC or_CC failed_VBD to_TO provide_VB appropriate_JJ warning_NN labels_NNS ._.
SUS_NNP has_VBZ been_VBN named_VBN as_IN a_DT defendant_NN in_IN a_DT total_NN of_IN 3,804_CD such_JJ phentermine_NN lawsuits_NNS ,_, in_IN respect_NN of_IN which_WDT SUS_NNP has_VBZ been_VBN dismissed_VBN as_IN a_DT defendant_NN in_IN 3,756_CD cases_NNS ._.
Shire_NNP is_VBZ awaiting_VBG the_DT furtherance_NN of_IN proceedings_NNS in_IN the_DT remaining_VBG 37_CD law_NN suits_NNS ._.
SUS_NNP became_VBD involved_VBN with_IN phentermine_NN through_IN its_PRP$ acquisition_NN of_IN certain_JJ assets_NNS of_IN Rexar_NNP Pharmacal_NNP Corporation_NNP Rexar_NNP in_IN January_NNP 1994_CD ._.
In_IN addition_NN to_TO SUS_NNP potentially_RB incurring_VBG liability_NN as_IN a_DT result_NN of_IN its_PRP$ own_JJ production_NN of_IN Oby-Cap_NNP ,_, a_DT phentermine_JJ product_NN ,_, the_DT plaintiffs_NNS may_MD additionally_RB seek_VB to_TO impose_VB liability_NN on_IN SUS_NNP as_IN successor_NN to_TO Rexar_NNP ._.
SUS_NNP intends_VBZ vigorously_RB to_TO defend_VB all_PDT the_DT lawsuits_NNS and_CC pursue_VB all_DT available_JJ reasonable_JJ defences_NNS ._.
SUS_NNP denies_VBZ liability_NN on_IN a_DT number_NN of_IN grounds_NNS including_VBG lack_NN of_IN scientific_JJ evidence_NN that_IN phentermine_NN ,_, properly_RB prescribed_VBN ,_, causes_VBZ the_DT alleged_JJ side_NN effects_NNS and_CC that_IN SUS_NNP did_VBD not_RB promote_VB phentermine_NN for_IN long-term_JJ combined_VBN use_NN as_IN part_NN of_IN the_DT fen_NN phen_NN diet_NN ._.
Accordingly_RB ,_, SUS_NNP intends_VBZ to_TO defend_VB vigorously_RB any_DT and_CC all_DT claims_NNS made_VBN against_IN the_DT Group_NNP in_IN respect_NN of_IN phentermine_NN and_CC believes_VBZ that_IN liability_NN is_VBZ neither_DT probable_JJ nor_CC quantifiable_JJ at_IN this_DT stage_NN of_IN litigation_NN ._.
Legal_JJ expenses_NNS have_VBP been_VBN paid_VBN by_IN Eon_NNP Labs_NNPS Manufacturing_NNP Inc._NNP ._.
Eon_NNP ,_, the_DT supplier_NN to_TO SUS_NNP ,_, or_CC Eons_NNS insurance_NN carriers_NNS but_CC such_JJ insurance_NN is_VBZ now_RB exhausted_VBN ._.
Eon_NNP has_VBZ agreed_VBN to_TO defend_VB and_CC indemnify_VB SUS_NNP in_IN this_DT litigation_NN pursuant_JJ to_TO an_DT agreement_NN dated_VBN 30_CD November_NNP 2000_CD between_IN Eon_NNP and_CC SUS_NNP ._.
iii_FW ADDERALL_NNP Shires_NNPS extended-release_NN once-daily_RB version_NN of_IN ADDERALL_NNP ,_, ADDERALL_NNP XR_NNP ,_, is_VBZ covered_VBN by_IN US_NNP patent_NN No._NN ._.
However_RB ,_, there_EX can_MD be_VB no_DT assurance_NN that_IN the_DT Company_NN will_MD be_VB successful_JJ in_IN the_DT suit_NN ._.
In_IN the_DT event_NN that_IN the_DT Company_NN does_VBZ not_RB prevail_VB ,_, then_RB Barr_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ extended-release_NN mixed_JJ amphetamine_NN salt_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP application_NN ._.
This_DT may_MD have_VB a_DT material_NN adverse_JJ impact_NN on_IN the_DT Companys_NNPS results_NNS and_CC financial_JJ position_NN ._.
In_IN the_DT event_NN that_IN the_DT Company_NN does_VBZ not_RB prevail_VB in_IN the_DT suit_NN ,_, a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP could_MD not_RB be_VB launched_VBN before_IN October_NNP 2004_CD ,_, the_DT current_JJ expiry_NN of_IN the_DT existing_VBG Hatch-Waxman_NNP exclusivity_NN ._.
In_IN November_NNP 2002_CD Shire_NNP received_VBD approval_NN from_IN the_DT FDA_NNP for_IN a_DT new_JJ formulation_NN of_IN ADDERALL_NNP which_WDT is_VBZ patent_NN protected_VBN ._.
In_IN January_NNP 2003_CD Shire_NNP received_VBD a_DT Paragraph_NNP IV_NNP notice_NN from_IN Barr_NNP alleging_VBG that_IN this_DT patent_NN is_VBZ invalid_JJ and_CC not_RB infringed_VBN by_IN Barrs_NNP 7.5_CD mg_NN and_CC 15mg_JJ mixed_JJ amphetamine_NN salt_NN products_NNS ._.
72_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 19_CD Leases_NNPS and_CC other_JJ commitments_NNS continued_VBD iv_JJ Emory_NNP Shire_NNP BioChem_NNP was_VBD involved_VBN in_IN worldwide_JJ patent_NN disputes_NNS with_IN Emory_NNP University_NNP Emory_NNP relating_VBG to_TO lamivudine_JJ wherein_NN Shire_NNP BioChem_NNP opposed_VBD certain_JJ patents_NNS and_CC patent_NN applications_NNS of_IN Emory_NNP and_CC wherein_JJ Emory_NNP opposed_VBD certain_JJ patents_NNS and_CC patent_NN applications_NNS of_IN Shire_NNP BioChem_NNP ._.
Shire_NNP BioChem_NNP was_VBD also_RB involved_VBN in_IN worldwide_JJ patent_NN disputes_NNS with_IN Emory_NNP and_CC the_DT University_NNP of_IN Georgia_NNP Research_NNP Foundation_NNP Georgia_NNP relating_VBG to_TO certain_JJ dioxolane_NN nucleoside_NN analogs_NNS wherein_VBP Shire_NNP BioChem_NNP opposed_VBD certain_JJ patents_NNS and_CC patent_NN applications_NNS of_IN Emory_NNP and_CC Georgia_NNP and_CC wherein_JJ Emory_NNP opposed_VBD a_DT European_JJ patent_NN of_IN Shire_NNP BioChem_NNP ._.
Pursuant_JJ to_TO global_JJ Settlement_NNP and_CC Licence_NNP Agreements_NNP finalized_VBD in_IN August_NNP 2002_CD by_IN Shire_NNP BioChem_NNP ,_, Shire_NNP ,_, Georgia_NNP and_CC Triangle_NNP Pharmaceuticals_NNP Inc._NNP ._.
Triangle_NNP ,_, Shire_NNP will_MD grant_VB an_DT exclusive_JJ royalty-bearing_NN licence_NN to_TO Emory_NNP ,_, sub_NN licensable_JJ to_TO Triangle_NNP ,_, for_IN certain_JJ dioxolane_NN nucleoside_NN analogs_NNS ,_, including_VBG diamino_NN purine_NN dioxolane_NN DAPD_NNP ._.
Emory_NNP ,_, Georgia_NNP and_CC Triangle_NNP will_MD grant_VB an_DT exclusive_JJ royalty-bearing_NN licence_NN to_TO Shire_NNP for_IN certain_JJ dioxolane_NN nucleosides_NNS ,_, including_VBG SPD_NNP 756_CD ._.
The_DT compounds_NNS the_DT subject_NN of_IN these_DT licences_NNS are_VBP in_IN development_NN ._.
A_DT low_JJ royalty_NN will_MD be_VB payable_JJ by_IN Shire_NNP upon_IN commercialisation_NN of_IN SPD_NNP 756_CD ._.
The_DT Settlement_NNP and_CC Licence_NNP Agreements_NNP provide_VB for_IN the_DT resolution_NN of_IN all_DT worldwide_JJ patent_NN disputes_NNS relating_VBG to_TO the_DT licensed_JJ patents_NNS ._.
v_FW Other_JJ matters_NNS In_IN addition_NN ,_, the_DT Company_NN is_VBZ involved_VBN in_IN claims_NNS and_CC lawsuits_NNS in_IN the_DT normal_JJ course_NN of_IN business_NN ._.
It_PRP is_VBZ not_RB possible_JJ at_IN this_DT time_NN to_TO determine_VB the_DT ultimate_JJ outcome_NN of_IN any_DT of_IN these_DT claims_NNS ._.
20_CD Related_VBN parties_NNS a_DT Mr_NNP Spitznagel_NNP Mr_NNP Spitznagel_NNP ,_, a_DT former_JJ director_NN of_IN the_DT Company_NN ,_, who_WP resigned_VBD during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2001_CD ,_, entered_VBD into_IN a_DT consultancy_NN agreement_NN with_IN the_DT Company_NN in_IN December_NNP 1999_CD ,_, which_WDT provided_VBD that_DT :_: if_IN he_PRP had_VBD good_JJ reason_NN ,_, as_IN defined_VBN in_IN his_PRP$ service_NN agreement_NN with_IN Roberts_NNP ,_, to_TO terminate_VB his_PRP$ employment_NN with_IN Roberts_NNP under_IN his_PRP$ service_NN agreement_NN ,_, the_DT Company_NN would_MD cause_VB Roberts_NNP to_TO provide_VB him_PRP with_IN the_DT payments_NNS and_CC benefits_NNS he_PRP would_MD be_VB entitled_VBN to_TO upon_IN a_DT good_JJ reason_NN termination_NN :_: Mr_NNP Spitznagel_NNP would_MD provide_VB consulting_VBG services_NNS to_TO the_DT Company_NN for_IN at_IN least_JJS 42_CD months_NNS following_VBG the_DT acquisition_NN of_IN Roberts_NNP ,_, unless_IN Mr_NNP Spitznagel_NNP terminated_VBD the_DT consultancy_NN agreement_NN prior_RB to_TO the_DT end_NN of_IN the_DT 42nd_NNP month_NN upon_IN 30_CD days_NNS notice_NN :_: and_CC the_DT Company_NN would_MD pay_VB Mr_NNP Spitznagel_NNP at_IN a_DT rate_NN of_IN $_$ 400,000_CD per_IN annum_NN for_IN his_PRP$ consulting_NN services_NNS ,_, $_$ 150,000_CD per_IN annum_NN as_IN an_DT office_NN allowance_NN ,_, $_$ 250,000_CD per_IN annum_NN to_TO comply_VB with_IN certain_JJ restrictive_JJ covenants_NNS contained_VBD therein_RB and_CC $_$ 150,000_CD per_IN annum_NN for_IN tax_NN ,_, financial_JJ and_CC estate_NN planning_NN advice_NN ,_, life_NN insurance_NN and_CC health_NN insurance_NN ._.
The_DT amount_NN owed_VBN to_TO Mr_NNP Spitznagel_NNP at_IN 31_CD December_NNP 2002_CD was_VBD $_$ 0.5_CD million_CD at_IN 31_CD December_NNP 2001_CD it_PRP was_VBD $_$ 1.4_CD million_CD ._.
b_NN Professional_NNP fees_NNS The_DT Company_NN incurred_VBN professional_JJ fees_NNS with_IN law_NN firms_NNS ,_, in_IN which_WDT The_DT Hon_NNP James_NNP Grant_NNP ,_, a_DT director_NN of_IN the_DT Company_NN ,_, is_VBZ a_DT partner_NN ,_, totalling_VBG $_$ 1,239_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD $_$ 1.9_CD million_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2001_CD and_CC $_$ 0.4_CD million_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2000_CD ._.
No_DT amounts_NNS were_VBD due_JJ to_TO from_IN the_DT law_NN firms_NNS in_IN which_WDT The_DT Hon_NNP James_NNP Grant_NNP is_VBZ a_DT partner_NN at_IN 31_CD December_NNP 2002_CD ,_, or_CC at_IN 31_CD December_NNP 2001_CD ._.
c_NN Immunosystems_NNPS BioChem_NNP Immunosystems_NNPS Inc._NNP ._.
Immunosystems_NNS ,_, formally_RB a_DT wholly_RB owned_VBN subsidiary_NN of_IN BioChem_NNP ,_, was_VBD sold_VBN in_IN February_NNP 2000_CD to_TO a_DT third_JJ party_NN ._.
Dr_NNP Bellini_NNP ,_, the_DT former_JJ Chief_NNP Executive_NNP Officer_NNP of_IN BioChem_NNP ,_, continued_VBD as_IN a_DT director_NN of_IN Immunosystems_NNPS ._.
In_IN December_NNP 2001_CD ,_, the_DT Company_NN acquired_VBD a_DT 19.9_CD %_NN equity_NN interest_NN in_IN Immunosystems_NNPS in_IN consideration_NN for_IN the_DT release_NN of_IN a_DT debt_NN owing_NN to_TO the_DT Company_NN from_IN Immunosystems_NNPS ._.
This_DT debt_NN existed_VBD prior_RB to_TO the_DT Companys_NNPS merger_NN with_IN BioChem_NNP ._.
As_IN part_NN of_IN the_DT same_JJ transaction_NN ,_, the_DT Company_NN was_VBD released_VBN from_IN a_DT pre-existing_JJ BioChem_NNP guarantee_NN over_IN other_JJ Immunosystems_NNPS liabilities_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 73_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 21_CD Earnings_NNS per_IN share_NN The_DT following_VBG table_NN reconciles_NNS income_NN from_IN continuing_VBG operations_NNS before_IN extraordinary_JJ items_NNS and_CC the_DT weighted_JJ average_JJ common_JJ shares_NNS outstanding_JJ for_IN basic_JJ and_CC diluted_JJ EPS_NNP for_IN the_DT periods_NNS presented_VBN :_: 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Income_NN from_IN continuing_VBG operations_NNS before_IN extraordinary_JJ items_NNS 242,378_CD 34,615_CD 204,744_CD Income_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 8,191_CD 6,748_CD 6,983_CD Extraordinary_JJ item_NN ,_, net_NN of_IN tax_NN 2,604_CD Net_JJ income_NN 250,569_CD 38,759_CD 211,727_CD Effect_NN of_IN dilutive_JJ securities_NNS :_: Interest_NN charged_VBN on_IN convertible_JJ debt_NN ,_, net_NN of_IN tax_NN 5,585_CD Number_NNP Number_NNP Number_NNP of_IN shares_NNS of_IN shares_NNS of_IN shares_NNS Weighted_VBN average_JJ number_NN of_IN shares_NNS outstanding_JJ Earnings_NNS per_IN share_NN basic_JJ 500,687,594_CD 492,594,226_CD 482,890,070_CD Effect_NN of_IN dilutive_JJ securities_NNS :_: Share_NN options_NNS 1,883,475_CD 11,362,332_CD 11,801,735_CD Convertible_JJ debt_NN 19,847,177_CD Warrants_NNS 919,029_CD 21,730,652_CD 12,281,361_CD 11,801,735_CD Earnings_NNS per_IN share_NN diluted_VBN 522,418,246_CD 504,875,587_CD 494,691,805_CD Earnings_NNS per_IN share_NN basic_JJ Income_NN from_IN continuing_VBG operations_NNS before_IN extraordinary_JJ items_NNS 48.4_CD 7.0_CD 42.4_CD Income_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 1.6_CD 1.4_CD 1.4_CD Extraordinary_JJ item_NN ,_, net_NN of_IN tax_NN 0.5_CD Earnings_NNS per_IN share_NN basic_JJ 50.0_CD 7.9_CD 43.8_CD Earnings_NNS per_IN share_NN diluted_VBN Income_NN from_IN continuing_VBG operations_NNS before_IN extraordinary_JJ items_NNS 47.4_CD 6.9_CD 41.4_CD Income_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 1.6_CD 1.3_CD 1.4_CD Extraordinary_JJ item_NN ,_, net_NN of_IN tax_NN 0.5_CD Earnings_NNS per_IN share_NN diluted_VBN 49.0_CD 7.7_CD 42.8_CD The_DT computation_NN of_IN weighted_JJ average_JJ number_NN of_IN shares_NNS for_IN diluted_VBN EPS_NNP for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2001_CD and_CC 2000_CD does_VBZ not_RB include_VB convertible_JJ debt_NN because_IN ,_, after_IN eliminating_VBG interest_NN charged_VBN to_TO operations_NNS from_IN the_DT numerator_NN ,_, the_DT inclusion_NN would_MD be_VB anti-dilutive_JJ ._.
The_DT warrants_NNS are_VBP issuable_JJ in_IN respect_NN of_IN a_DT research_NN and_CC development_NN agreement_NN ._.
A_DT charge_NN of_IN $_$ 4.5_CD million_CD has_VBZ been_VBN made_VBN in_IN the_DT results_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2001_CD ._.
The_DT warrants_NNS and_CC share_NN options_NNS not_RB included_VBD within_IN the_DT calculation_NN of_IN the_DT diluted_VBN weighted_JJ average_JJ number_NN of_IN shares_NNS ,_, because_IN the_DT exercise_NN prices_NNS exceeded_VBD the_DT Companys_NNPS average_JJ share_NN price_NN during_IN the_DT calculation_NN period_NN ,_, are_VBP shown_VBN below_IN ._.
2002 2001 2000_CD Number_NNP Number_NNP Number_NNP Year_NN ended_VBD 31_CD December_NNP of_IN shares_NNS of_IN shares_NNS of_IN shares_NNS Share_NN options_NNS 17,492,575_CD 10,384,600_CD Warrants_NNS 1,346,407_CD 18,838,982_CD 10,384,600_CD 74_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 22_CD Analysis_NN of_IN revenues_NNS ,_, operating_VBG income_NN loss_NN and_CC assets_NNS by_IN reportable_JJ segments_NNS The_DT Company_NN has_VBZ disclosed_VBN segment_NN information_NN for_IN the_DT individual_JJ operating_NN areas_NNS of_IN the_DT business_NN ,_, based_VBN on_IN the_DT way_NN in_IN which_WDT the_DT business_NN is_VBZ managed_VBN and_CC controlled_VBN ._.
Shires_NNS principal_JJ reporting_VBG segments_NNS are_VBP geographic_JJ ,_, each_DT being_VBG managed_VBN and_CC monitored_VBN separately_RB and_CC serving_VBG different_JJ markets_NNS ._.
The_DT Company_NN evaluates_VBZ performance_NN based_VBN on_IN operating_VBG income_NN or_CC loss_NN before_IN interest_NN and_CC income_NN taxes_NNS ._.
The_DT accounting_NN policies_NNS of_IN each_DT reportable_JJ segment_NN are_VBP consistent_JJ with_IN those_DT of_IN the_DT Company_NN ._.
Operating_VBG income_NN loss_NN US_NNP International_NNP R&D_NNP Total_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Year_NN ended_VBD 31_CD December_NNP 2002_CD External_NNP revenues_NNS :_: Product_NN sales_NNS 714,655_CD 144,733_CD 859,388_CD Licensing_NN and_CC development_NN 2,661_CD 403_CD 3,064_CD Royalties_NNS 215_CD 174,597_CD 174,812_CD Other_JJ revenues_NNS 34_CD 34_CD Intersegment_NNP revenues_NNS 21,169_CD 127,823_CD 148,992_CD 738,700_CD 319,767_CD 127,823_CD 1,186,290_CD Elimination_NN of_IN intersegment_NN sales_NNS 21,169_CD 127,823_CD 148,992_CD Total_JJ revenues_NNS 717,531_CD 319,767_CD 1,037,298_CD Cost_NN of_IN revenues_NNS 63,356_CD 70,326_CD 133,682_CD Research_NNP and_CC development_NN 189,179_CD 189,179_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 238,810_CD 147,213_CD 386,023_CD Loss_NN on_IN disposition_NN of_IN assets_NNS 1,221_CD 155_CD 1,376_CD Total_JJ operating_NN expenses_NNS 303,387_CD 217,694_CD 189,179_CD 710,260_CD Operating_NN income_NN loss_NN 414,144_CD 102,073_CD 189,179_CD 327,038_CD 31_CD December_NNP 2002_CD Total_JJ assets_NNS 818,383_CD 1,340,116_CD 50,124_CD 2,208,623_CD Long-lived_JJ assets_NNS 260,751_CD 451,435_CD 29,341_CD 741,527_NNP Capital_NNP expenditure_NN on_IN long-lived_JJ assets_NNS 8,188_CD 38,940_CD 7,152_CD 54,280_CD Year_NN ended_VBD 31_CD December_NNP 2001_CD Product_NNP sales_NNS 587,449_CD 111,902_CD 699,351_CD Licensing_NN and_CC development_NN 4,507_CD 991_CD 5,498_CD Royalties_NNS 264_CD 144,891_CD 145,155_CD Other_JJ revenues_NNS 2,952_CD 2,952_CD Intersegment_NNP revenues_NNS 19,319_CD 36,705_CD 56,024_CD 611,539_CD 260,736_CD 36,705_CD 908,980_CD Elimination_NN of_IN intersegment_NN sales_NNS 19,319_CD 36,705_CD 56,024_CD Total_JJ revenues_NNS 592,220_CD 260,736_CD 852,956_CD Cost_NN of_IN revenues_NNS 58,655_CD 53,351_CD 112,006_CD Research_NNP and_CC development_NN 171,029_CD 171,029_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 195,438_CD 108,042_CD 303,480_CD Asset_NNP impairments_NNS and_CC restructuring_NN charges_NNS 29,699_CD 29,699_CD Merger_NNP transaction_NN expenses_NNS 83,470_CD 83,470_CD Loss_NN on_IN disposition_NN of_IN assets_NNS 2,052_CD 8,112_CD 10,164_CD Total_JJ operating_NN expenses_NNS 256,145_CD 282,674_CD 171,029_CD 709,848_CD Operating_NN income_NN loss_NN 336,075_CD 21,938_CD 171,029_CD 143,108_CD 31_CD December_NNP 2001_CD Total_JJ assets_NNS 658,031_CD 1,223,604_CD 29,096_CD 1,910,731_CD Long-lived_JJ assets_NNS 327,289_CD 419,601_CD 23,286_CD 770,176_CD Capital_NN expenditure_NN on_IN long-lived_JJ assets_NNS 3,880_CD 65,558_CD 2,488_CD 71,926_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 75_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 22_CD Analysis_NN of_IN revenues_NNS ,_, operating_VBG income_NN loss_NN and_CC assets_NNS by_IN reportable_JJ segments_NNS continued_VBD US_NNP International_NNP R&D_NNP Total_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Year_NN ended_VBD 31_CD December_NNP 2000_CD Product_NNP sales_NNS 391,168_CD 105,607_CD 496,775_CD Licensing_NN and_CC development_NN 1,326_CD 12,821_CD 14,147_CD Royalties_NNS 266_CD 135,204_CD 135,470_CD Other_JJ revenues_NNS 20_CD 1,242_CD 1,262_CD Intersegment_NNP revenues_NNS 18,408_CD 51,666_CD 70,074_CD 411,188_CD 254,874_CD 51,666_CD 717,728_CD Elimination_NN of_IN intersegment_NN sales_NNS 18,408_CD 51,666_CD 70,074_CD Total_JJ revenues_NNS 392,780_CD 254,874_CD 647,654_CD Cost_NN of_IN revenues_NNS 47,093_CD 47,978_CD 95,071_CD Research_NNP and_CC development_NN 155,145_CD 155,145_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 116,761_CD 113,455_CD 230,216_CD Asset_NNP impairments_NNS and_CC restructuring_NN charges_NNS 26,947_CD 26,947_CD Total_JJ operating_NN expenses_NNS 163,854_CD 188,380_CD 155,145_CD 507,379_CD Operating_NN income_NN loss_NN 228,926_CD 66,494_CD 155,145_CD 140,275_CD 31_CD December_NNP 2000_CD Total_JJ assets_NNS 560,864_CD 943,687_CD 43,944_CD 1,548,495_CD Long-lived_JJ assets_NNS 353,656_CD 475,361_CD 23,625_CD 852,642_CD Capital_NN expenditure_NN on_IN long_JJ lived_VBD assets_NNS 27,945_CD 50,435_CD 21,237_CD 99,617_CD Material_NNP customers_NNS In_IN the_DT periods_NNS set_VBN out_RP below_IN ,_, certain_JJ customers_NNS accounted_VBD for_IN greater_JJR than_IN 10_CD %_NN of_IN Shires_NNP total_JJ revenues_NNS :_: 2002 2002 2001 2001_CD 2000_CD 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD %_NN revenue_NN $_$ 000_CD %_NN revenue_NN $_$ 000_CD %_NN revenue_NN Customer_NN A_DT 231,270_CD 22_CD 176,941_CD 21_CD 132,913_CD 21_CD Customer_NN B_NNP 197,184_CD 19_CD 123,350_CD 14_CD 80,293_CD 12_CD Customer_NN C_NNP 149,613_CD 14_CD Amounts_NNS outstanding_JJ at_IN 31_CD December_NNP in_IN respect_NN of_IN these_DT material_NN customers_NNS were_VBD as_IN follows_VBZ :_: 2002_CD 2001_CD At_IN 31_CD December_NNP $_$ 000_CD $_$ 000_CD Customer_NN A_DT 4,354_CD 34,882_CD Customer_NN B_NNP 9,189_CD 39,094_CD Customer_NN C_NNP 9,738_CD 20,937_CD 76_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 23_CD Other_JJ charges_NNS 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD In-process_JJ research_NN and_CC development_NN 26,947_CD Asset_NNP impairments_NNS and_CC restructuring_NN charges_NNS 29,699_CD Merger_NNP transaction_NN expenses_NNS 83,470_CD Losses_NNS on_IN disposition_NN of_IN assets_NNS 1,376_CD 10,164_CD Year_NN ended_VBD 31_CD December_NNP 2001_CD a_DT BioChem_NNP merger_NN The_DT asset_NN impairments_NNS and_CC restructuring_NN charges_NNS ,_, merger_NN transaction_NN expenses_NNS and_CC most_JJS of_IN the_DT losses_NNS on_IN disposal_NN of_IN assets_NNS in_IN 2001_CD related_VBN to_TO the_DT BioChem_NNP merger_NN on_IN 11_CD May_NNP 2001_CD ._.
The_DT asset_NN impairments_NNS and_CC restructuring_NN charges_NNS included_VBD an_DT impairment_NN charge_NN of_IN $_$ 20.9_CD million_CD to_TO adjust_VB intangible_JJ asset_NN values_NNS ,_, primarily_RB trademark_NN and_CC patent_NN costs_NNS but_CC also_RB an_DT element_NN of_IN product_NN rights_NNS ,_, to_TO their_PRP$ estimated_VBN fair_JJ value_NN ._.
These_DT charges_NNS are_VBP consistent_JJ with_IN the_DT Companys_NNP accounting_NN policy_NN to_TO review_VB periodically_RB the_DT carrying_VBG value_NN of_IN the_DT intangibles_NNS and_CC evaluate_VB whether_IN there_EX has_VBZ been_VBN any_DT impairment_NN in_IN the_DT value_NN of_IN those_DT intangibles_NNS as_IN compared_VBN with_IN estimated_VBN undiscounted_JJ future_JJ cash_NN flows_VBZ relating_VBG to_TO those_DT intangibles_NNS ._.
There_EX was_VBD also_RB a_DT total_NN of_IN $_$ 8.8_CD million_CD recorded_VBN in_IN respect_NN of_IN employee-related_JJ costs_NNS ,_, as_IN a_DT result_NN of_IN employee_NN terminations_NNS related_VBN to_TO the_DT closure_NN of_IN the_DT Toronto_NNP facility_NN and_CC the_DT elimination_NN of_IN duplicate_VB positions_NNS across_IN the_DT combined_VBN organization_NN ._.
Shires_NNP existing_VBG Canadian_JJ sales_NNS and_CC marketing_NN operations_NNS in_IN Toronto_NNP have_VBP been_VBN combined_VBN with_IN those_DT of_IN BioChem_NNP in_IN Laval_NNP ._.
A_DT total_NN of_IN 57_CD employees_NNS were_VBD identified_VBN to_TO be_VB terminated_VBN ._.
As_IN of_IN 31_CD December_NNP 2001_CD all_DT of_IN the_DT planned_VBN terminations_NNS were_VBD completed_VBN ._.
The_DT Company_NN incurred_VBD a_DT loss_NN on_IN the_DT sale_NN of_IN a_DT duplicated_VBN facility_NN in_IN Toronto_NNP ,_, Canada_NNP ,_, of_IN $_$ 8.1_CD million_CD ._.
b_NN Product_NNP disposals_NNS During_IN the_DT third_JJ quarter_NN of_IN 2001_CD ,_, Shire_NNP disposed_VBD of_IN certain_JJ non-strategic_JJ products_NNS for_IN net_JJ proceeds_NNS of_IN approximately_RB $_$ 4.5_CD million_CD ,_, recording_VBG a_DT loss_NN on_IN disposition_NN of_IN $_$ 2.1_CD million_CD ._.
Year_NN ended_VBD 31_CD December_NNP 2000_CD As_IN a_DT result_NN of_IN the_DT merger_NN with_IN BioChem_NNP ,_, the_DT Company_NN incurred_VBD a_DT charge_NN of_IN $_$ 26.9_CD million_CD relating_VBG to_TO the_DT acquisition_NN of_IN in-process_JJ research_NN and_CC development_NN in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
24_CD Other_JJ expense_NN income_NN ,_, net_JJ 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD SERP_NNP valuation_NN adjustment_NN 2,301_CD 2,018_CD 607_CD Gain_NN on_IN sale_NN of_IN long-term_JJ investments_NNS 104,000_CD Write-down_NN of_IN long-term_JJ investments_NNS due_JJ to_TO impairment_NN 8,680_CD 55,748_CD GeneChem_NNP funds_NNS income_NN 3,333_CD 3,995_CD 6,773_CD Other_JJ 614_CD 838_CD 1,143_CD 8,262_CD 52,933_CD 109,023_CD In_IN 2001_CD ,_, the_DT $_$ 55.7_CD million_CD write-down_NN of_IN investments_NNS related_VBN to_TO the_DT BioChem_NNP merger_NN and_CC comprised_VBD the_DT write-down_NN of_IN long-term_JJ unquoted_JJ investments_NNS $_$ 24.9_CD million_CD and_CC a_DT write-down_NN of_IN $_$ 30.8_CD million_CD to_TO a_DT debenture_NN held_VBN by_IN BioChem_NNP ,_, which_WDT was_VBD received_VBN on_IN divestiture_NN of_IN its_PRP$ diagnostics_NNS subsidiary_NN ._.
These_DT charges_NNS are_VBP consistent_JJ with_IN the_DT Companys_NNPS policy_NN to_TO provide_VB for_IN other-than-temporary_JJ impairments_NNS in_IN investment_NN by_IN reference_NN to_TO the_DT fair_JJ value_NN of_IN the_DT investment_NN using_VBG established_VBN financial_JJ methodologies_NNS ._.
The_DT main_JJ components_NNS of_IN other_JJ income_NN in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2000_CD was_VBD a_DT $_$ 104.0_CD million_CD gain_NN resulting_VBG from_IN the_DT sale_NN of_IN long-term_JJ investments_NNS ,_, primarily_RB in_IN respect_NN of_IN North_JJ American_JJ Vaccine_NNP ,_, Inc._NNP a_DT publicly_RB traded_VBN biotechnology_NN company_NN listed_VBN on_IN the_DT American_NNP Stock_NNP Exchange_NNP ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 77_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 25_CD Retirement_NNP benefits_NNS a_DT Personal_JJ defined_VBN contribution_NN pension_NN plans_VBZ The_DT Company_NN makes_VBZ contributions_NNS to_TO defined_VBN contribution_NN retirement_NN plans_NNS that_WDT together_RB cover_VBP substantially_RB all_DT employees_NNS within_IN the_DT Group_NNP ._.
For_IN the_DT defined_VBN contribution_NN retirement_NN plans_NNS ,_, the_DT level_NN of_IN Company_NN contribution_NN is_VBZ fixed_VBN at_IN a_DT set_VBN percentage_NN of_IN employees_NNS pay_VBP ._.
Company_NN contributions_NNS to_TO personal_JJ defined_VBN contribution_NN pension_NN plans_NNS totalled_VBD $_$ 6.8_CD million_CD ,_, $_$ 4.9_CD million_CD and_CC $_$ 2.6_CD million_CD for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD respectively_RB ,_, and_CC were_VBD charged_VBN to_TO operations_NNS as_IN they_PRP became_VBD payable_JJ ._.
b_NN Defined_VBN benefit_NN pension_NN plan_NN Roberts_NNP ,_, a_DT company_NN with_IN whom_WP the_DT Company_NN merged_VBD in_IN December_NNP 1999_CD ,_, operated_VBD a_DT defined_VBN SERP_NNP for_IN certain_JJ US_NNP employees_NNS ,_, which_WDT was_VBD established_VBN in_IN 1998_CD ._.
This_DT plan_NN was_VBD available_JJ to_TO former_JJ employees_NNS of_IN Roberts_NNP who_WP met_VBD certain_JJ age_NN and_CC service_NN requirements_NNS ._.
As_IN part_NN of_IN the_DT restructuring_NN of_IN the_DT Group_NNP following_VBG the_DT Roberts_NNP merger_NN ,_, the_DT SERP_NNP was_VBD closed_VBN to_TO new_JJ members_NNS and_CC contributions_NNS ceased_VBD being_VBG paid_VBN into_IN the_DT plan_NN for_IN existing_VBG members_NNS ._.
As_IN part_NN of_IN this_DT arrangement_NN ,_, the_DT Company_NN paid_VBD a_DT lump_NN sum_NN contribution_NN into_IN the_DT plan_NN of_IN $_$ 18.0_CD million_CD ,_, the_DT result_NN of_IN which_WDT is_VBZ that_IN the_DT Company_NN has_VBZ no_DT future_JJ contributions_NNS under_IN the_DT plan_NN ._.
In_IN accordance_NN with_IN EITF_NNP 97-14_CD ,_, the_DT asset_NN and_CC liability_NN of_IN $_$ 12.1_CD million_CD and_CC $_$ 8.4_CD million_CD respectively_RB are_VBP shown_VBN on_IN the_DT balance_NN sheet_NN within_IN the_DT categories_NNS Other_JJ non-current_JJ assets_NNS and_CC Other_JJ non-current_JJ liabilities_NNS ._.
26_CD Income_NN taxes_NNS The_DT components_NNS of_IN income_NN before_IN income_NN taxes_NNS and_CC equity_NN in_IN net_JJ income_NN of_IN associates_NNS for_IN the_DT years_NNS ended_VBN 31_CD December_NNP are_VBP as_IN follows_VBZ :_: 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD UK_NNP 50,520_CD 101,756_CD 37,577_CD US_NNP 218,139_CD 190,068_CD 70,700_CD Other_JJ jurisdictions_NNS 161,441_CD 13,215_CD 218,994_CD Income_NN before_IN income_NN taxes_NNS ,_, equity_NN in_IN net_JJ income_NN of_IN associates_NNS and_CC extraordinary_JJ items_NNS attributable_JJ to_TO continuing_VBG operations_NNS 329,060_CD 101,527_CD 252,117_CD Income_NN before_IN income_NN taxes_NNS attributable_JJ to_TO discontinued_VBN operations_NNS 9,696_CD 10,711_CD 11,083_CD Total_JJ income_NN before_IN income_NN taxes_NNS and_CC equity_NN in_IN net_JJ income_NN of_IN associates_NNS and_CC extraordinary_JJ items_NNS 338,756_CD 112,238_CD 263,200_CD The_DT provision_NN for_IN income_NN taxes_NNS by_IN location_NN of_IN the_DT taxing_VBG jurisdiction_NN for_IN the_DT years_NNS ended_VBN 31_CD December_NNP consisted_VBD of_IN the_DT following_NN :_: 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Current_JJ income_NN taxes_NNS :_: UK_NNP corporation_NN tax_NN US_NNP federal_JJ tax_NN 67,686_CD 40,818_CD 22,434_CD US_NNP state_NN and_CC local_JJ taxes_NNS 9,561_CD 8,988_CD 2,744_CD Other_JJ jurisdictions_NNS 19,864_CD 17,862_CD 14,604_CD Total_JJ current_JJ taxes_NNS 97,111_CD 67,668_CD 39,782_CD Deferred_JJ taxes_NNS UK_NNP corporation_NN tax_NN US_NNP federal_JJ tax_NN 1,136_CD 20,586_CD 4,268_CD US_NNP state_NN and_CC local_JJ taxes_NNS 34 618 128_CD Other_JJ jurisdictions_NNS 9,931_CD 19,975_CD 614_CD Total_JJ deferred_JJ taxes_NNS 8,761_CD 1,229_CD 3,782_CD Total_JJ income_NN taxes_NNS attributable_JJ to_TO continuing_VBG operations_NNS 88,350_CD 68,897_CD 43,564_CD Total_JJ incomes_NNS taxes_NNS attributable_JJ to_TO discontinued_VBN operations_NNS 4,812_CD 3,963_CD 4,100_CD Total_JJ income_NN taxes_NNS 93,162_CD 72,860_CD 47,664_CD The_DT reconciliation_NN of_IN income_NN before_IN income_NN taxes_NNS ,_, equity_NN in_IN net_JJ income_NN of_IN associates_NNS and_CC extraordinary_JJ items_NNS attributing_VBG to_TO continuing_VBG operations_NNS to_TO provision_NN for_IN income_NN taxes_NNS is_VBZ shown_VBN in_IN the_DT following_VBG table_NN ._.
78_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 26_CD Income_NN taxes_NNS continued_VBD 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Income_NN before_IN income_NN taxes_NNS ,_, equity_NN in_IN net_JJ income_NN of_IN associates_NNS and_CC extraordinary_JJ items_NNS attributing_VBG to_TO continuing_VBG operations_NNS 329,060_CD 101,527_CD 252,117_CD Corporation_NNP tax_NN rate_NN 30_CD %_NN 30_CD %_NN 30_CD %_NN Income_NN tax_NN expense_NN at_IN corporation_NN tax_NN rate_NN 98,718_CD 30,458_CD 75,635_CD Adjustments_NNS to_TO derive_VB effective_JJ rate_NN :_: Non-deductible_JJ items_NNS :_: Goodwill_NNP amortisation_NN 3,309_CD 3,783_CD Permanent_JJ differences_NNS 4,280_CD 32,268_CD 963_CD Other_JJ items_NNS :_: Change_NNP in_IN valuation_NN allowance_NN 13,948_CD 27,395_CD 8,238_CD Difference_NN in_IN taxation_NN rates_NNS 36,450_CD 27,662_CD 33,181_CD Prior_RB year_NN adjustment_NN 2,317_CD 2,958_CD 1,950_CD Other_JJ 5,537_CD 6,087_CD 2,652_CD Provision_NNP for_IN income_NN taxes_NNS on_IN continuing_VBG operations_NNS 88,350_CD 68,897_CD 43,564_CD Provision_NNP for_IN income_NN taxes_NNS on_IN discontinued_VBN operations_NNS 4,812_CD 3,963_CD 4,100_CD Provision_NNP for_IN income_NN taxes_NNS 93,162_CD 72,860_CD 47,664_CD The_DT corporation_NN tax_NN rate_NN of_IN 30_CD %_NN is_VBZ the_DT tax_NN rate_NN of_IN the_DT parent_NN company_NN ._.
The_DT significant_JJ components_NNS of_IN deferred_JJ income_NN tax_NN assets_NNS and_CC liabilities_NNS and_CC their_PRP$ balance_NN sheet_NN classifications_NNS ,_, as_IN of_IN 31_CD December_NNP ,_, are_VBP as_IN follows_VBZ :_: 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Deferred_VBN tax_NN assets_NNS :_: Accrued_VBN expenses_NNS not_RB currently_RB deductible_JJ 7,847_CD 6,238_CD Losses_NNS carried_VBD forward_RB 188,937_CD 170,512_CD Provisions_NNS 5,347_CD 7,874_CD Other_JJ 6,517_CD 6,267_CD Gross_NNP deferred_VBN tax_NN assets_NNS 208,648_CD 190,891_CD Less_RBR :_: valuation_NN allowance_NN 139,513_CD 125,565_CD 69,135_CD 65,326_CD Excess_NNPS of_IN tax_NN value_NN over_IN book_NN value_NN of_IN assets_NNS 28,070_CD 33,022_CD Net_JJ deferred_JJ tax_NN assets_NNS 41,065_CD 32,304_CD Balance_NN sheet_NN classifications_NNS :_: Continuing_VBG operations_NNS Deferred_VBN tax_NN assets_NNS current_JJ 34,849_CD 19,430_CD Deferred_JJ tax_NN assets_NNS non-current_JJ 6,216_CD 20,274_CD 41,065_CD 39,704_CD Discontinued_VBN operations_NNS Deferred_JJ tax_NN liability_NN non-current_JJ 7,400_CD Net_JJ deferred_JJ tax_NN assets_NNS 41,065_CD 32,304_CD The_DT approximate_JJ net_JJ operating_NN loss_NN carry-forwards_NNS as_IN at_IN 31_CD December_NNP ,_, are_VBP as_IN follows_VBZ :_: 31_CD December_NNP 31_CD December_NNP 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Approximate_JJ net_JJ operating_NN loss_NN carry-forwards_NNS against_IN future_JJ US_NNP federal_JJ tax_NN liabilities_NNS 33,386_CD 55,803_CD Approximate_JJ net_JJ operating_NN loss_NN carry-forwards_NNS against_IN future_JJ US_NNP state_NN and_CC foreign_JJ tax_NN liabilities_NNS 639,756_CD 470,177_CD Total_JJ 673,142_CD 525,980_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 79_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 26_CD Income_NN taxes_NNS continued_VBD The_DT tax_NN losses_NNS shown_VBN above_IN have_VBP the_DT following_VBG expiration_NN dates_NNS :_: 31_CD December_NNP 2002_CD $_$ 000 2003 2004_CD 2,527_CD 2005_CD 30,362_CD 2006_CD 38,001_CD 2007_CD 20,731_CD 2008_CD 34,411_CD 2009_CD 27,245_CD Available_JJ indefinitely_RB 519,865_CD 673,142_CD As_IN of_IN 31_CD December_NNP 2002_CD ,_, the_DT Company_NN had_VBD a_DT valuation_NN allowance_NN of_IN $_$ 139.5_CD million_CD to_TO reduce_VB its_PRP$ deferred_JJ tax_NN assets_NNS to_TO estimated_VBN realisable_JJ value_NN ._.
The_DT valuation_NN allowance_NN relates_VBZ to_TO the_DT deferred_VBN tax_NN assets_NNS arising_VBG from_IN overseas_JJ tax_NN operating_NN loss_NN carryforwards_NNS and_CC capital_NN loss_NN carryforwards_NNS ,_, which_WDT have_VBP no_DT expiration_NN date_NN ._.
In_IN addition_NN ,_, capital_NN loss_NN carryforwards_NNS can_MD only_RB be_VB offset_VBN against_IN capital_NN gains_NNS ._.
As_IN of_IN 31_CD December_NNP 2002_CD ,_, based_VBN upon_IN the_DT level_NN of_IN historical_JJ taxable_JJ income_NN and_CC projections_NNS for_IN future_JJ taxable_JJ income_NN over_IN the_DT periods_NNS in_IN which_WDT the_DT temporary_JJ differences_NNS are_VBP anticipated_VBN to_TO reverse_VB ,_, and_CC prudent_JJ and_CC feasible_JJ tax-planning_JJ strategies_NNS ,_, management_NN believes_VBZ it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN the_DT Company_NN will_MD realize_VB the_DT benefits_NNS of_IN these_DT deductible_JJ differences_NNS ,_, net_NN of_IN the_DT valuation_NN allowances_NNS ._.
The_DT Company_NN recognizes_VBZ a_DT deferred_JJ tax_NN liability_NN related_VBN to_TO the_DT undistributed_JJ earnings_NNS of_IN subsidiaries_NNS when_WRB the_DT Company_NN expects_VBZ that_IN it_PRP will_MD recover_VB those_DT undistributed_JJ earnings_NNS in_IN a_DT taxable_JJ manner_NN ,_, such_JJ as_IN through_IN receipt_NN of_IN dividends_NNS or_CC sale_NN of_IN the_DT investments_NNS ._.
The_DT Company_NN does_VBZ not_RB ,_, however_RB ,_, provide_VB for_IN income_NN taxes_NNS on_IN the_DT unremitted_JJ earnings_NNS of_IN certain_JJ other_JJ subsidiaries_NNS located_VBN outside_IN the_DT UK_NNP where_WRB ,_, in_IN managements_NNS opinion_NN ,_, such_JJ earnings_NNS have_VBP been_VBN indefinitely_RB reinvested_VBN in_IN these_DT operations_NNS ,_, will_MD be_VB remitted_VBN in_IN a_DT tax-free_JJ liquidation_NN ,_, or_CC will_MD be_VB remitted_VBN as_IN dividends_NNS with_IN taxes_NNS substantially_RB offset_VBN by_IN foreign_JJ tax_NN credits_NNS ._.
27_CD Equity_NNP method_NN investees_VBZ 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD GSK_NNP 2,592_CD 1,985_CD CADx_NNP Qualia_NNP 924_CD North_JJ American_JJ Vaccine_NNP ,_, Inc._NNP 3,809_CD 1,668_CD 1,985_CD 3,809_CD The_DT Company_NN has_VBZ accounted_VBN for_IN its_PRP$ commercialisation_NN partnership_NN with_IN GSK_NNP through_IN which_WDT the_DT products_NNS 3TC_NNP and_CC ZEFFIX_NNP are_VBP marketed_VBN in_IN Canada_NNP using_VBG the_DT equity_NN method_NN of_IN accounting_NN ._.
The_DT Company_NN owns_VBZ ,_, but_CC does_VBZ not_RB exercise_VB control_NN over_IN ,_, a_DT 50_CD %_NN share_NN of_IN the_DT partnership_NN ._.
The_DT Company_NN has_VBZ applied_VBN the_DT equity_NN method_NN of_IN accounting_NN as_IN the_DT Company_NN owns_VBZ ,_, but_CC does_VBZ not_RB exercise_VB control_NN over_IN ,_, a_DT 50_CD %_NN share_NN of_IN the_DT new_JJ joint_JJ venture_NN ._.
80_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 28_CD Stock_NNP incentive_NN plans_VBZ The_DT Company_NN has_VBZ adopted_VBN the_DT disclosure-only_JJ provisions_NNS of_IN SFAS_NNP No._NN ._.
25_CD and_CC related_VBN interpretations_NNS in_IN accounting_NN for_IN its_PRP$ plans_NNS ._.
In_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD the_DT Company_NN recognized_VBD a_DT credit_NN charge_NN under_IN APB_NNP No._NN ._.
25_CD of_IN $_$ 0.2_CD million_CD ,_, $_$ 2.3_CD million_CD and_CC $_$ 21.9_CD million_CD respectively_RB ._.
Had_VBD compensation_NN for_IN stock_NN options_NNS awarded_VBN under_IN the_DT plans_NNS been_VBN determined_VBN in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
123_CD ,_, the_DT Companys_NNPS net_JJ income_NN and_CC per_IN share_NN data_NNS would_MD have_VB been_VBN changed_VBN to_TO the_DT pro_FW forma_FW amounts_VBZ indicated_VBN below_IN :_: 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Net_JJ income_NN As_IN reported_VBN 250,569_CD 38,759_CD 211,727_CD Pro_FW forma_FW 226,319_CD 8,791_CD 227,018_CD Income_NN per_IN share_NN As_IN reported_VBN basic_JJ 50.0_CD 7.9_CD 43.8_CD As_IN reported_VBN diluted_VBN 49.0_CD 7.7_CD 42.8_CD Pro_FW forma_FW basic_JJ 45.2_CD 1.8_CD 47.0_CD Pro_FW forma_FW diluted_VBN 44.4_CD 1.7_CD 45.9_CD The_DT fair_JJ value_NN of_IN stock_NN options_NNS used_VBN to_TO compute_VB pro_FW forma_FW net_JJ income_NN and_CC per_IN share_NN disclosures_NNS is_VBZ the_DT estimated_VBN present_JJ value_NN at_IN grant_NN date_NN using_VBG the_DT Black-Scholes_NNP option-pricing_NN model_NN with_IN the_DT following_VBG weighted_JJ average_JJ assumptions_NNS :_: 2002 2001 2000_CD Year_NN ended_VBD 31_CD December_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Risk-free_JJ interest_NN rate_NN 1.90_CD 5.33_CD %_NN 3.43_CD 5.22_CD %_NN 5.68_CD 6.58_CD %_NN Expected_VBN dividend_NN yield_NN 0_CD %_NN 0_CD %_NN 0_CD %_NN Expected_VBN life_NN 5_CD years_NNS 5_CD years_NNS 5_CD years_NNS Expected_VBN volatility_NN 55.2_CD %_NN 59.5_CD %_NN 64.2_CD %_NN Directors_NNS and_CC employees_NNS have_VBP been_VBN granted_VBN options_NNS over_IN common_JJ shares_NNS under_IN the_DT following_VBG nine_CD stock_NN option_NN plans_NNS :_: i_FW Shire_NNP Holdings_NNP Limited_NNP Share_NNP Options_NNPS Scheme_NNP SHL_NNP Scheme_NNP Options_NNPS issued_VBN under_IN the_DT SHL_NNP Scheme_NN were_VBD originally_RB granted_VBN over_IN shares_NNS in_IN Shire_NNP Holdings_NNP Limited_NNP ,_, a_DT previous_JJ holding_VBG company_NN of_IN the_DT Group_NNP ._.
Exercise_NN of_IN these_DT options_NNS results_NNS in_IN the_DT option_NN holder_NN receiving_VBG common_JJ shares_NNS in_IN Shire_NNP ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT SHL_NNP Plan_NNP ._.
ii_FW Shire_FW Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP Executive_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ ,_, unless_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ._.
On_IN 28_CD February_NNP 2000_CD ,_, the_DT Remuneration_NNP Committee_NNP of_IN the_DT Board_NNP exercised_VBD its_PRP$ powers_NNS to_TO amend_VB the_DT terms_NNS of_IN the_DT Executive_NNP Share_NNP Option_NN Scheme_NN so_RB as_IN to_TO include_VB a_DT cliff_NN vesting_VBG provision_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT Executive_NNP Scheme_NNP ._.
iii_FW Shire_FW Pharmaceuticals_NNPS Group_NNP plc_NN 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP 2000_CD Executive_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ unless_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ period_NN ._.
During_IN 2002_CD ,_, the_DT performance_NN criteria_NNS was_VBD again_RB reviewed_VBN to_TO ensure_VB the_DT criteria_NNS reflected_VBD the_DT market_NN in_IN which_WDT the_DT Company_NN operates_VBZ ._.
Therefore_RB the_DT performance_NN criteria_NNS was_VBD amended_VBN so_RB that_IN options_NNS will_MD only_RB become_VB exercisable_JJ in_IN full_JJ if_IN the_DT Companys_NNPS EPS_NNP growth_NN exceeds_VBZ the_DT UK_NNP Retail_NNP Prices_NNS Index_NNP RPI_NNP over_IN at_IN least_JJS a_DT three-year_JJ period_NN for_IN the_DT following_VBG tranches_NNS of_IN grants_NNS :_: Options_NNS with_IN a_DT grant_NN value_NN of_IN up_RB to_TO 100_CD %_NN of_IN salary_NN RPI_NNP plus_CC 3_CD %_NN RPI_NNP plus_CC 5_CD %_NN for_IN Executive_NNP Directors_NNS per_IN annum_NN Between_IN 101_CD %_NN and_CC 200_CD %_NN of_IN salary_NN RPI_NNP plus_CC 5_CD %_NN per_IN annum_NN Between_IN 201_CD %_NN and_CC 300_CD %_NN of_IN salary_NN RPI_NNP plus_CC 7_CD %_NN per_IN annum_NN Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 9_CD %_NN per_IN annum_NN The_DT adoption_NN of_IN the_DT new_JJ criteria_NNS applies_VBZ to_TO all_DT options_NNS granted_VBN from_IN August_NNP 2002_CD onwards_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 81_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 28_CD Stock_NNP incentive_NN plans_NNS continued_VBD iv_JJ Shire_NNP Pharmaceuticals_NNP Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS ._.
v_NN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP Under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP ,_, options_NNS are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, whichever_WDT is_VBZ the_DT lower_JJR ._.
vi_FW Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP Options_NNPS issued_VBN under_IN the_DT SLI_NNP Plan_NNP were_VBD originally_RB granted_VBN over_IN shares_NNS in_IN SLI_NNP ,_, formerly_RB Pharmavene_NNP Inc._NNP a_DT company_NN acquired_VBN by_IN the_DT Company_NN on_IN 23_CD March_NNP 1997_CD ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN SLI_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ share_NN option_NN plan_NN ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT SLI_NNP Plan_NNP ._.
vii_FW Roberts_NNP Stock_NNP Option_NN Plan_NNP Roberts_NNP Plan_NNP Options_NNPS issued_VBN under_IN the_DT Roberts_NNP Plan_NNP were_VBD originally_RB granted_VBN over_IN shares_NNS in_IN Roberts_NNP ,_, a_DT company_NN acquired_VBN by_IN the_DT Company_NN on_IN 23_CD December_NNP 1999_CD ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN Roberts_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ Roberts_NNP share_NN option_NN plan_NN ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT Roberts_NNP Plan_NNP ._.
viii_FW BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP Following_VBG the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP ,_, Inc._NNP on_IN 11_CD May_NNP 2001_CD ,_, the_DT BioChem_NNP Plan_NNP was_VBD amended_VBN such_JJ that_IN options_NNS over_IN BioChems_NNPS common_JJ stock_NN became_VBD options_NNS over_IN ordinary_JJ shares_NNS of_IN Shire_NNP ._.
All_DT BioChem_NNP options_NNS ,_, which_WDT were_VBD not_RB already_RB exercisable_JJ ,_, vested_JJ and_CC became_VBD exercisable_JJ as_IN a_DT result_NN of_IN the_DT acquisition_NN ._.
ix_FW Richwood_NNP SRI_NNP Plan_NNP All_NNP options_NNS granted_VBN over_IN shares_NNS in_IN SRI_NNP ,_, formerly_RB Richwood_NNP Pharmaceutical_NNP Company_NNP Inc._NNP a_DT company_NN acquired_VBN by_IN the_DT Group_NNP on_IN 22_CD August_NNP 1997_CD ,_, have_VBP been_VBN exercised_VBN ._.
Exercise_NN of_IN these_DT options_NNS resulted_VBD in_IN the_DT option_NN holder_NN receiving_VBG ordinary_JJ shares_NNS in_IN the_DT Company_NN ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN SRI_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ share_NN option_NN plan_NN ,_, all_DT options_NNS granted_VBN under_IN the_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT SRI_NNP Plan_NNP ._.
In_IN a_DT period_NN of_IN ten_CD years_NNS ,_, not_RB more_JJR than_IN 10_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN of_IN Shire_NNP may_MD be_VB placed_VBN under_IN option_NN under_IN any_DT employee_NN share_NN scheme_NN ._.
In_IN addition_NN ,_, the_DT following_VBG terms_NNS apply_VB to_TO options_NNS that_WDT may_MD be_VB granted_VBN under_IN the_DT various_JJ plans_NNS :_: 2000_CD Executive_NNP Scheme_NNP :_: the_DT maximum_JJ number_NN of_IN shares_NNS over_IN which_WDT incentive_NN options_NNS may_MD be_VB granted_VBN under_IN Part_NN 3_CD of_IN the_DT scheme_NN is_VBZ 25,000,000_CD ._.
Stock_NNP Purchase_NNP Plan_NNP :_: up_RP to_TO 2,000,000_CD common_JJ shares_NNS ._.
Options_NNS outstanding_JJ at_IN 31_CD December_NNP 2002_CD under_IN the_DT various_JJ plans_NNS are_VBP as_IN follows_VBZ :_: Expiry_JJ period_NN from_IN Scheme_NNP Number_NNP of_IN options_NNS date_NN of_IN issue_NN Vesting_JJ period_NN Executive_NNP Scheme_NNP 4,432,303_CD 10_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS 2000_CD Executive_NNP Scheme_NNP 8,104,356_CD 10_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS Sharesave_NNP Scheme_NNP 253,862_CD 6_CD months_NNS after_IN vesting_VBG 3_CD or_CC 5_CD years_NNS Stock_NNP Purchase_NNP Plan_NNP 1,553,302_CD 27_CD months_NNS SLI_NNP Plan_NNP 40,084_CD 10_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN Shire_NNP Roberts_NNP Plan_NNP 567,399_CD 6_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN Shire_NNP BioChem_NNP Plan_NNP 5,099,991_CD 10_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN Shire_NNP Total_NNP 20,051,297_CD Options_NNPS expire_VBP on_IN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ._.
82_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT financial_JJ consolidated_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 28_CD Stock_NNP incentive_NN plans_NNS continued_VBD A_DT summary_NN of_IN the_DT status_NN of_IN the_DT Companys_NNP stock_NN option_NN plans_NNS as_IN of_IN 31_CD December_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD ,_, and_CC the_DT related_JJ transactions_NNS during_IN the_DT periods_NNS then_RB ended_VBD is_VBZ presented_VBN below_IN :_: Weighted_JJ average_JJ exercise_NN price_NN Number_NN of_IN $_$ shares_NNS Year_NN ended_VBD 31_CD December_NNP 2002_CD Outstanding_JJ at_IN beginning_VBG of_IN period_NN 10.80_CD 16,249,844_CD Granted_VBN 8.49_CD 6,179,894_CD Exercised_VBN 3.52_CD 1,940,546_CD Forfeited_NNP 11.07_CD 437,895_CD Outstanding_JJ at_IN end_NN of_IN period_NN 11.55_CD 20,051,297_CD Exercisable_JJ at_IN end_NN of_IN period_NN 9.24_CD 8,491,051_CD 4,539,529_CD options_NNS were_VBD granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP ._.
These_DT options_NNS were_VBD issued_VBN with_IN exercise_NN prices_NNS equivalent_JJ to_TO the_DT fair_JJ market_NN value_NN of_IN the_DT Companys_NNP common_JJ stock_NN on_IN the_DT date_NN of_IN grant_NN as_IN these_DT options_NNS were_VBD granted_VBN at_IN market_NN prices_NNS ._.
186,052_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 5.02_CD approximately_RB $_$ 8.08_CD ._.
These_DT options_NNS were_VBD granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS were_VBD issued_VBN to_TO employees_NNS ._.
18,342_CD and_CC 1,435,971_CD options_NNS were_VBD granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 3.19_CD and_CC 5.44_CD approximately_RB $_$ 5.14_CD and_CC $_$ 8.76_CD respectively_RB ._.
These_DT options_NNS were_VBD granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS were_VBD issued_VBN to_TO employees_NNS ._.
The_DT average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD is_VBZ $_$ 8.91_CD ._.
Weighted_JJ average_JJ exercise_NN price_NN Number_NN of_IN $_$ shares_NNS Year_NN ended_VBD 31_CD December_NNP 2001_CD Outstanding_JJ at_IN beginning_VBG of_IN period_NN 7.83_CD 24,790,322_CD Granted_VBN 17.24_CD 4,405,089_CD Exercised_VBN 6.29_CD 11,443,831_CD Forfeited_NNP 13.86_CD 1,501,736_CD Outstanding_JJ at_IN end_NN of_IN period_NN 10.80_CD 16,249,844_CD Exercisable_JJ at_IN end_NN of_IN period_NN 7.50_CD 9,054,150_CD All_DT options_NNS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP ,_, 2000_CD Executive_NNP Scheme_NNP and_CC BioChem_NNP Plan_NNP were_VBD issued_VBN with_IN exercise_NN prices_NNS equivalent_JJ to_TO the_DT fair_JJ market_NN value_NN of_IN the_DT Companys_NNP common_JJ stock_NN on_IN the_DT date_NN of_IN grant_NN as_IN these_DT options_NNS were_VBD granted_VBN at_IN market_NN prices_NNS ._.
81,888_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 8.41_CD approximately_RB $_$ 12.24_CD ._.
301,656_CD ,_, 120,819_CD and_CC 6,551_CD options_NNS were_VBD granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 8.06_CD ,_, 9.10_CD and_CC 9.74_CD approximately_RB $_$ 11.73_CD ,_, $_$ 13.24_CD and_CC $_$ 14.18_CD respectively_RB ._.
The_DT average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2001_CD is_VBZ $_$ 17.51_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 83_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 28_CD Stock_NNP incentive_NN plans_NNS continued_VBD Weighted_JJ average_JJ exercise_NN price_NN Number_NN of_IN $_$ shares_NNS Year_NN ended_VBD 31_CD December_NNP 2000_CD Outstanding_JJ at_IN beginning_VBG of_IN period_NN 5.99_CD 32,540,132_CD Granted_VBN 14.53_CD 4,386,258_CD Exercised_VBN 4.30_CD 11,491,088_CD Forfeited_NNP 10.95_CD 644,980_CD Outstanding_JJ at_IN end_NN of_IN period_NN 7.83_CD 24,790,322_CD Exercisable_JJ at_IN end_NN of_IN period_NN 6.84_CD 13,385,095_CD All_DT options_NNS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP ,_, 2000_CD Executive_NNP Scheme_NNP and_CC BioChem_NNP Plan_NNP were_VBD issued_VBN with_IN exercise_NN prices_NNS equivalent_JJ to_TO the_DT fair_JJ market_NN value_NN of_IN Shires_NNP common_JJ stock_NN on_IN the_DT date_NN of_IN grant_NN as_IN these_DT options_NNS were_VBD granted_VBN at_IN market_NN prices_NNS ._.
79,424_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 8.56_CD approximately_RB $_$ 12.79_CD ._.
The_DT average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2000_CD is_VBZ $_$ 8.80_CD ._.
This_DT continues_VBZ to_TO be_VB included_VBN within_IN investments_NNS note_VBP 10_CD ._.
Arenol_NNP loan_NN note_NN conversion_NN In_IN 1999_CD the_DT Company_NN financed_VBN the_DT purchase_NN of_IN intellectual_JJ property_NN relating_VBG to_TO the_DT manufacture_NN of_IN ADDERALL_NNP from_IN Arenol_NNP Corporation_NNP by_IN a_DT total_NN of_IN $_$ 11.8_CD million_CD in_IN unsecured_JJ convertible_JJ zero_CD coupon_NN loan_NN notes_NNS ._.
On_IN 6_CD August_NNP 2002_CD ,_, the_DT Company_NN issued_VBD the_DT final_JJ instalment_NN of_IN 267,572_CD ordinary_JJ shares_NNS to_TO Arenol_NNP Corporation_NNP in_IN consideration_NN of_IN the_DT conversion_NN of_IN the_DT loan_NN notes_NNS in_IN the_DT Company_NN ._.
Qualia_NNP Computing_NNP Inc._NNP joint_JJ venture_NN In_IN September_NNP 2002_CD ,_, the_DT Company_NN sold_VBD the_DT net_JJ assets_NNS of_IN its_PRP$ CADx_NNP group_NN of_IN companies_NNS ,_, to_TO Qualia_NNP Computing_NNP Inc._NNP in_IN exchange_NN for_IN 50_CD %_NN of_IN the_DT common_JJ stock_NN in_IN the_DT joint_JJ venture_NN ._.
The_DT value_NN of_IN the_DT assets_NNS in_IN the_DT CADx_NNP group_NN of_IN companies_NNS at_IN the_DT time_NN of_IN transfer_NN was_VBD $_$ 9.3_CD million_CD ._.
Quarterly_JJ results_NNS of_IN operations_NNS unaudited_JJ The_DT following_VBG table_NN presents_NNS summarised_VBN unaudited_JJ quarterly_JJ results_NNS for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2002_CD and_CC 2001_CD ._.
The_DT unaudited_JJ quarterly_JJ results_NNS for_IN 2001_CD have_VBP been_VBN restated_VBN to_TO reflect_VB the_DT merger_NN with_IN BioChem_NNP ._.
The_DT results_NNS for_IN all_DT quarterly_JJ periods_NNS presented_VBN have_VBP been_VBN restated_VBN to_TO reflect_VB the_DT OTC_NNP divestment_NN which_WDT has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT discontinued_VBN operation_NN ._.
142_CD with_IN effect_NN from_IN 1_CD January_NNP 2002_CD ,_, the_DT amortisation_NN expense_NN shown_VBN for_IN 2002_CD in_IN the_DT selected_VBN consolidated_JJ financial_JJ data_NNS presented_VBN below_IN is_VBZ not_RB on_IN a_DT consistent_JJ basis_NN of_IN accounting_NN with_IN earlier_JJR periods_NNS ._.
the_DT impact_NN of_IN this_DT is_VBZ shown_VBN in_IN note_NN 12_CD of_IN our_PRP$ consolidated_JJ financial_JJ statements_NNS included_VBD herein_NN ._.
Balance_NN sheet_NN data_NNS Total_JJ current_JJ assets_NNS 1,467,096_CD 1,140,555_CD 695,853_CD 520,023_CD 445,972_CD Total_JJ assets_NNS 2,208,623_CD 1,910,731_CD 1,548,495_CD 1,351,791_CD 1,210,153_CD Total_JJ current_JJ liabilities_NNS 213,271_CD 231,616_CD 227,850_CD 233,818_CD 99,770_CD Total_JJ liabilities_NNS 635,457_CD 647,742_CD 374,109_CD 471,905_CD 236,921_CD Total_JJ shareholders_NNS equity_NN 1,573,166_CD 1,262,989_CD 1,174,386_CD 879,886_CD 973,232_CD 86_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD General_NNP This_DT summary_NN financial_JJ statement_NN does_VBZ not_RB contain_VB sufficient_JJ information_NN to_TO allow_VB for_IN a_DT full_JJ understanding_NN of_IN the_DT results_NNS and_CC state_NN of_IN affairs_NNS of_IN the_DT Company_NN or_CC Group_NNP ._.
The_DT summary_NN financial_JJ statement_NN is_VBZ prepared_VBN under_IN UK_NNP GAAP_NNP ._.
For_IN further_JJ information_NN ,_, the_DT full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS ,_, the_DT auditors_NNS report_VBP on_IN those_DT accounts_NNS and_CC the_DT directors_NNS report_NN should_MD be_VB consulted_VBN ._.
In_IN accordance_NN with_IN Section_NN 239_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD shareholders_NNS have_VBP a_DT right_NN and_CC can_MD elect_VB to_TO obtain_VB the_DT full_JJ reports_NNS and_CC accounts_NNS free_JJ of_IN charge_NN by_IN writing_VBG to_TO :_: The_DT Company_NNP Secretary_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Hampshire_NNP International_NNP Business_NNP Park_NNP Chineham_NNP Basingstoke_NNP Hampshire_NNP RG24_NNP 8EP_NNP The_NNP full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS are_VBP signed_VBN on_IN behalf_NN of_IN the_DT Board_NNP by_IN A_DT C_NNP Russell_NNP ,_, Group_NNP Finance_NNP Director_NNP ._.
The_DT Companys_NNP auditors_NNS have_VBP given_VBN an_DT unqualified_JJ report_NN on_IN the_DT statutory_JJ accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ._.
The_DT report_NN did_VBD not_RB contain_VB a_DT statement_NN under_IN Section_NN 237_CD 2_CD or_CC 3_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 87_CD Summary_NNP financial_JJ statement_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD Independent_NNP auditors_NNS statement_NN to_TO the_DT members_NNS of_IN Summary_NNP directors_NNS report_VBP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN :_: Results_NNS and_CC dividends_NNS We_PRP have_VBP examined_VBN the_DT summary_NN financial_JJ statement_NN which_WDT comprises_VBZ Loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN of_IN the_DT Group_NNP was_VBD the_DT summary_NN directors_NNS report_NN ,_, consolidated_JJ profit_NN and_CC loss_NN account_NN ,_, 526.8_CD million_CD 2001_CD :_: profit_NN 81.4_CD million_CD ._.
The_DT net_JJ assets_NNS of_IN the_DT Group_NNP consolidated_JJ balance_NN sheet_NN ,_, consolidated_JJ cash_NN flow_NN statement_NN and_CC as_RB at_IN 31_CD December_NNP 2002_CD were_VBD 2,747.7_CD million_CD 2001_CD :_: 3,393.9_CD million_CD ._.
notes_NNS 1_CD to_TO 3_CD of_IN the_DT summary_NN financial_JJ statement_NN ._.
The_DT directors_NNS do_VBP not_RB recommend_VB the_DT payment_NN of_IN a_DT dividend_NN ._.
This_DT statement_NN is_VBZ made_VBN solely_RB to_TO the_DT Company_NN 's_POS members_NNS ,_, as_IN a_DT body_NN ,_, in_IN accordance_NN with_IN section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Our_PRP$ work_NN Business_NN review_NN has_VBZ been_VBN undertaken_VBN so_RB that_IN we_PRP might_MD state_VB to_TO the_DT companys_NNS members_NNS A_DT review_NN of_IN the_DT Groups_NNS business_NN and_CC important_JJ events_NNS during_IN the_DT year_NN those_DT matters_NNS we_PRP are_VBP required_VBN to_TO state_NN to_TO them_PRP in_IN an_DT auditors_NNS report_NN and_CC and_CC likely_JJ future_NN developments_NNS is_VBZ set_VBN out_RP in_IN the_DT Chairmans_NNPS review_NN ,_, for_IN no_DT other_JJ purpose_NN ._.
To_TO the_DT fullest_JJS extent_NN permitted_VBN by_IN law_NN ,_, we_PRP do_VBP not_RB the_DT Chief_NNP Executives_NNS review_NN ,_, the_DT financial_JJ review_NN and_CC the_DT directors_NNS accept_VBP or_CC assume_VBP responsibility_NN to_TO anyone_NN other_JJ than_IN the_DT Company_NN and_CC remuneration_NN report_NN in_IN the_DT full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS ,_, which_WDT the_DT Companys_NNPS members_NNS as_IN a_DT body_NN ,_, for_IN our_PRP$ audit_NN work_NN ,_, for_IN this_DT report_NN ,_, are_VBP similar_JJ to_TO the_DT statements_NNS contained_VBN in_IN the_DT annual_JJ review_NN at_IN the_DT front_NN for_IN our_PRP$ audit_NN report_NN ,_, or_CC for_IN the_DT opinions_NNS we_PRP have_VBP formed_VBN ._.
of_IN this_DT document_NN which_WDT form_VBP part_NN of_IN this_DT summary_NN financial_JJ statement_NN ._.
Respective_JJ responsibilities_NNS of_IN directors_NNS and_CC auditors_NNS Directors_NNS The_DT directors_NNS are_VBP responsible_JJ for_IN preparing_VBG the_DT summarised_JJ annual_JJ The_DT directors_NNS who_WP served_VBD during_IN the_DT year_NN were_VBD as_IN follows_VBZ :_: report_NN in_IN accordance_NN with_IN applicable_JJ United_NNP Kingdom_NNP law_NN ._.
Our_PRP$ responsibility_NN is_VBZ to_TO report_VB to_TO you_PRP our_PRP$ opinion_NN on_IN the_DT consistency_NN of_IN the_DT Dr_NNP James_NNP Cavanaugh_NNP Chairman_NNP and_CC Non-executive_JJ Director_NNP summary_NN financial_JJ statement_NN with_IN the_DT full_JJ annual_JJ accounts_NNS the_DT directors_NNS Chairman_NNP Nomination_NNP Committee_NNP report_NN and_CC the_DT directors_NNS remuneration_JJ report_NN ,_, and_CC its_PRP$ compliance_NN with_IN Mr_NNP Matthew_NNP Emmens_NNP Chief_NNP Executive_NNP the_DT relevant_JJ requirements_NNS of_IN section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD Appointed_VBN 12_CD March_NNP 2003_CD and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
We_PRP also_RB read_VBD the_DT other_JJ information_NN contained_VBN in_IN the_DT summarised_JJ annual_JJ report_NN as_IN described_VBN Mr_NNP Rolf_NNP Stahel_NNP Former_NNP Chief_NNP Executive_NNP in_IN the_DT contents_NNS section_NN ,_, and_CC consider_VB the_DT implications_NNS for_IN our_PRP$ report_NN Stepped_VBD down_RP 19_CD March_NNP 2003_CD if_IN we_PRP become_VBP aware_JJ of_IN any_DT apparent_JJ misstatements_NNS or_CC material_NN Mr_NNP Angus_NNP Russell_NNP Group_NNP Finance_NNP Director_NNP inconsistencies_NNS with_IN the_DT summary_NN financial_JJ statement_NN ._.
Dr_NNP Wilson_NNP Totten_NNP Group_NNP R&D_NNP Director_NNP Basis_NNP of_IN opinion_NN We_PRP conducted_VBD our_PRP$ work_NN in_IN accordance_NN with_IN bulletin_NN 1999_CD 6_CD The_DT Auditors_NNS Dr_NNP Barry_NNP Price_NNP Senior_NNP Non-executive_JJ Director_NNP Statement_NNP on_IN the_DT Summary_NNP Financial_NNP Statement_NNP issued_VBN by_IN the_DT United_NNP Chairman_NNP Remuneration_NNP Committee_NNP Kingdom_NNP Auditing_NNP Practices_NNPS Board_NNP ._.
Dr_NNP Francesco_NNP Bellini_NNP Non-executive_JJ Director_NNP Opinion_NNP Dr_NNP Bernard_NNP Canavan_NNP Non-executive_JJ Director_NNP In_IN our_PRP$ opinion_NN ,_, the_DT summary_NN financial_JJ statement_NN is_VBZ consistent_JJ with_IN Deceased_JJ 8_CD August_NNP 2002_CD the_DT full_JJ annual_JJ accounts_NNS ,_, the_DT directors_NNS report_NN and_CC the_DT directors_NNS remuneration_JJ report_NN of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN for_IN the_DT year_NN The_DT Hon_NNP James_NNP Grant_NNP Non-executive_JJ Director_NNP ended_VBD 31_CD December_NNP 2002_CD and_CC Companies_NNP Act_NNP 1985_CD ,_, and_CC the_DT Mr_NNP Ronald_NNP Nordmann_NNP Non-executive_JJ Director_NNP regulations_NNS made_VBD thereunder_RB ._.
Chairman_NNP Audit_NNP Committee_NNP Deloitte_NNP &_CC Touche_NNP Mr_NNP Grard_NNP Veilleux_NNP Non-executive_JJ Director_NNP Chartered_NNP Accountants_NNPS and_CC Registered_NNP Auditors_NNS Reading_VBG 1_CD May_NNP 2003_CD 88_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD Consolidated_NNP profit_NN and_CC loss_NN account_NN Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 31_CD December_NNP 2002 2001 000 000_CD Turnover_NN :_: group_NN and_CC share_NN of_IN joint_JJ venture_NN 696,661_CD 563,249_CD Less_RBR :_: share_NN of_IN joint_JJ ventures_NNS turnover_NN 762_CD Group_NNP turnover_NN on_IN continuing_VBG operations_NNS 695,899_CD 563,249_CD Acquisitions_NNPS 653_CD Continuing_VBG operations_NNS 696,552_CD 563,249_CD Discontinued_VBN operations_NNS 15,975_CD 17,120_CD Group_NNP turnover_NN 712,527_CD 580,369_CD Cost_NN of_IN sales_NNS 95,042_CD 83,149_CD Gross_NNP profit_NN 617,485_CD 497,220_CD Net_JJ operating_NN expenses_NNS including_VBG 613,983,000_CD exceptional_JJ goodwill_NN impairment_NN 1,150,630_CD 420,798_CD Operating_NN loss_NN profit_NN 533,145_CD 76,422_CD Continuing_VBG operations_NNS Group_NNP 539,772_CD 68,972_CD Acquisitions_NNPS 1,831_CD 541,603_CD 68,972_CD Discontinued_VBN operations_NNS 8,458_CD 7,450_CD 533,145_CD 76,422_CD Share_NN of_IN joint_JJ ventures_NNS operating_VBG loss_NN 559_CD Finance_NNP charges_NNS ,_, net_JJ 6,931_CD 4,955_CD Loss_NN profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 526,773_CD 81,377_CD Tax_NNP on_IN loss_NN profit_NN on_IN ordinary_JJ activities_NNS 61,626_CD 45,668_CD Retained_VBN loss_NN profit_NN for_IN the_DT year_NN transferred_VBN from_IN to_TO reserves_NNS 588,399_CD 35,709_CD Loss_NN earnings_NNS per_IN share_NN basic_JJ 117.5_CD p_NN 8.7_CD p_NN diluted_VBN 117.5_CD p_NN 8.5_CD p_NN Consolidated_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 2002 2001 000 000_CD Loss_NN profit_NN for_IN the_DT year_NN 588,399_CD 35,709_CD Translation_NN of_IN the_DT financial_JJ statements_NNS of_IN overseas_JJ subsidiaries_NNS 62,739_CD 6,640_CD Total_JJ recognized_VBN gains_NNS and_CC losses_NNS relating_VBG to_TO the_DT year_NN 651,138_CD 29,069_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 89_CD Summary_NNP financial_JJ statement_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD Consolidated_NNP balance_NN sheet_NN 31_CD December_NNP 31_CD December_NNP 2002 2001 000 000_CD Fixed_JJ assets_NNS Intangible_JJ assets_NNS intellectual_JJ property_NN 183,404_CD 259,850_CD Intangible_JJ assets_NNS goodwill_NN 1,900,896_CD 2,643,578_CD Tangible_JJ assets_NNS 84,001_CD 77,880_CD Fixed_VBN asset_NN investments_NNS 37,345_CD 45,045_CD Investment_NN in_IN joint_JJ ventures_NNS share_NN of_IN gross_JJ assets_NNS 5,082_CD share_NN of_IN gross_JJ liabilities_NNS 342_CD 2,210,386_CD 3,026,353_CD Current_JJ assets_NNS Stocks_NNS 30,571_CD 32,080_CD Debtors_NNS due_JJ within_IN one_CD year_NN excluding_VBG deferred_JJ tax_NN 106,125_CD 159,586_CD due_JJ after_IN one_CD year_NN deferred_VBN tax_NN 21,646_CD 13,351_CD due_JJ after_IN more_JJR than_IN one_CD year_NN excluding_VBG deferred_JJ tax_NN 9,535_CD 11,953_CD due_JJ after_IN more_JJR than_IN one_CD year_NN deferred_VBN tax_NN 3,861_CD 8,845_CD Current_JJ asset_NN investments_NNS 196,364_CD 497,397_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 558,432_CD 81,434_CD 926,534_CD 804,646_CD Creditors_NNPS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Convertible_JJ debt_NN 1,032_CD Other_JJ creditors_NNS 131,885_CD 158,229_CD 131,885_CD 159,261_CD Net_JJ current_JJ assets_NNS 794,649_CD 645,385_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 3,005,035_CD 3,671,738_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Convertible_JJ debt_NN 243,547_CD 268,178_CD Other_JJ creditors_NNS 13,782_CD 9,654_CD 257,329_CD 277,832_CD Net_JJ assets_NNS 2,747,706_CD 3,393,906_CD Capital_NN and_CC reserves_NNS Called-up_JJ share_NN capital_NN 24,217_CD 24,091_CD Share_NN premium_NN 3,214,512_CD 3,206,280_CD Exchangeable_JJ shares_NNS 191,552_CD 194,972_CD Capital_NN reserve_NN 2,755_CD 2,755_CD Other_JJ reserves_NNS 24,247_CD 24,247_CD Profit_NN and_CC loss_NN account_NN 709,577_CD 58,439_CD Equity_NNP shareholders_NNS funds_NNS 2,747,706_CD 3,393,906_CD 90_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD Consolidated_NNP cash_NN flow_NN statement_NN Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 31_CD December_NNP 2002 2001 000 000_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 302,321_CD 202,876_CD Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN :_: Interest_NN and_CC other_JJ income_NN received_VBD 15,434_CD 13,077_CD Interest_NN paid_VBN 8,458_CD 8,122_CD Interest_NN element_NN of_IN finance_NN lease_NN rentals_NNS 45_CD Net_JJ cash_NN inflow_NN from_IN returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN 6,931_CD 4,955_CD Taxation_NNP :_: Corporation_NNP tax_NN paid_VBN 73,145_CD 44,982_CD Capital_NN expenditure_NN and_CC financial_JJ investments_NNS :_: Purchase_NN of_IN long-term_JJ investment_NN 2,957_CD Purchase_NN of_IN intangible_JJ fixed_JJ assets_NNS 15,470_CD 20,159_CD Purchase_NN of_IN tangible_JJ fixed_JJ assets_NNS 15,014_CD 9,593_CD Proceeds_NNS from_IN sale_NN of_IN a_DT business_NN 44,103_CD Proceeds_NNS from_IN sale_NN of_IN intangible_JJ fixed_JJ assets_NNS 3,200_CD Proceeds_NNS from_IN sale_NN of_IN tangible_JJ fixed_JJ assets_NNS 542_CD 4,974_CD Net_JJ cash_NN inflow_NN outflow_NN for_IN capital_NN expenditure_NN and_CC financial_JJ investments_NNS 11,204_CD 21,578_CD Acquisitions_NNPS and_CC disposals_NNS :_: Purchase_NN of_IN subsidiary_NN undertaking_NN 11,647_CD Expenses_NNS of_IN acquisitions_NNS 235_CD 16,450_CD Net_JJ cash_NN acquired_VBN with_IN subsidiary_NN undertakings_NNS 33_CD 44,452_CD Net_JJ cash_NN outflow_NN inflow_NN from_IN acquisitions_NNS 11,849_CD 28,002_CD Cash_NN inflow_NN before_IN management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN 235,462_CD 169,273_CD Management_NN of_IN liquid_JJ resources_NNS :_: Decrease_NN increase_NN in_IN cash_NN placed_VBN on_IN short-term_JJ deposit_NN 254,561_CD 325,479_CD Financing_NN :_: Issue_NN of_IN ordinary_JJ share_NN capital_NN 1,050_CD Exercise_NN of_IN share_NN options_NNS 3,985_CD 46,961_CD Expenses_NNS of_IN share_NN issues_NNS 23,584_CD Capital_NNP element_NN of_IN finance_NN leases_VBZ 74_CD Net_JJ decrease_NN increase_NN in_IN debt_NN during_IN the_DT year_NN 832_CD 182,808_CD Net_JJ cash_NN inflow_NN from_IN financing_VBG 3,079_CD 207,235_CD Increase_VBP in_IN cash_NN in_IN the_DT year_NN 493,102_CD 51,029_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 91_CD Notes_NNS to_TO the_DT summary_NN financial_JJ statement_NN Notes_NNS to_TO the_DT summary_NN financial_JJ statement_NN For_IN the_DT year_NN to_TO 31_CD December_NNP 2002_CD For_IN the_DT year_NN to_TO 31_CD December_NNP 2002_CD 1_CD Basis_NN of_IN preparation_NN The_DT summary_NN financial_JJ statement_NN has_VBZ been_VBN prepared_VBN in_IN accordance_NN with_IN the_DT accounting_NN policies_NNS set_VBN out_RP in_IN the_DT full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ._.
2_CD Directors_NNS remuneration_NN ,_, interests_NNS and_CC transactions_NNS Aggregate_JJ directors_NNS remuneration_VBP The_DT total_JJ amounts_NNS for_IN directors_NNS remuneration_NN and_CC other_JJ benefits_NNS were_VBD as_IN follows_VBZ :_: 2002_CD 2001_CD Years_NNS ended_VBD 31_CD December_NNP 000_CD 000_CD Emoluments_NNS 2,300_CD 2,019_CD Compensation_NNP for_IN loss_NN of_IN office_NN 2,754_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 2,962_CD 22,005_CD Money_NN purchase_NN pension_NN contributions_NNS 383_CD 103_CD Total_JJ 5,645_CD 26,881_CD Directors_NNS emoluments_NNS and_CC compensation_NN for_IN loss_NN of_IN office_NN Fees_NNS basic_JJ Taxable_NNP Annual_JJ salary_NN benefits_NNS bonus_NN 2002_CD 2001_CD Director_NNP 000 000 000 000_CD 000_CD Executive_NNP directors_NNS Mr_NNP Rolf_NNP Stahel_NNP 559_CD 26_CD 559_CD 1,144_CD 726_CD Mr_NNP Angus_NNP Russell_NNP 290 26 128 444_CD 393_CD Dr_NNP Wilson_NNP Totten_NNP 310 30 141 481_CD 419_CD Non-executive_JJ directors_NNS Dr_NNP James_NNP Cavanaugh_NNP 45_CD 45_CD 42_CD Dr_NNP Barry_NNP Price_NNP 37_CD 37_CD 31_CD Dr_NNP Francesco_NNP Bellini_NNP 30_CD 30_CD 3,012_CD The_DT late_JJ Dr_NNP Bernard_NNP Canavan_NNP 23_CD 23_CD 60_CD The_DT Hon_NNP James_NNP Grant_NNP 30_CD 30_CD 19_CD Dr_NNP Zola_NNP Horovitz_NNP 7_CD Mr_NNP Ronald_NNP Nordmann_NNP 34_CD 34_CD 29_CD Mr_NNP Joseph_NNP Smith_NNP 7_CD Mr_NNP John_NNP Spitznagel_NNP 7_CD Mr_NNP Grard_NNP Veilleux_NNP 32_CD 32_CD 21_CD Total_JJ 1,390_CD 82_CD 828_CD 2,300_CD 4,773_CD 92_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT summary_NN financial_JJ statement_NN For_IN the_DT year_NN to_TO 31_CD December_NNP 2002_CD 3_CD Loss_NN earnings_NNS per_IN share_NN Loss_NN earnings_NNS per_IN share_NN EPS_NNP has_VBZ been_VBN calculated_VBN by_IN dividing_VBG the_DT loss_NN profit_NN on_IN ordinary_JJ activities_NNS after_IN taxation_NN for_IN each_DT period_NN by_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN during_IN those_DT periods_NNS ._.
The_DT weighted_JJ average_JJ number_NN of_IN shares_NNS used_VBN in_IN calculating_VBG fully_RB diluted_VBN earnings_NNS per_IN share_NN has_VBZ been_VBN adjusted_VBN for_IN the_DT effects_NNS of_IN all_DT dilutive_JJ potential_JJ ordinary_JJ shares_NNS ._.
The_DT $_$ 400_CD million_CD convertible_JJ loan_NN note_NN is_VBZ excluded_VBN from_IN the_DT calculation_NN of_IN weighted_JJ average_JJ number_NN of_IN shares_NNS for_IN fully_RB diluted_VBN earnings_NNS per_IN share_NN in_IN 2002_CD and_CC 2001_CD as_IN it_PRP was_VBD not_RB dilutive_JJ ._.
The_DT zero_CD coupon_NN convertible_JJ loan_NN note_NN included_VBD in_IN 2001_CD has_VBZ no_DT impact_NN on_IN the_DT numerator_NN for_IN fully_RB diluted_VBN earnings_NNS per_IN share_NN ._.
Years_NNS ended_VBD 31_CD December_NNP 2002_CD 2001_CD Basic_JJ earnings_NNS per_IN share_NN 117.5_CD p_VBP 8.7_CD p_JJ Diluted_JJ earnings_NNS per_IN share_NN 117.5_CD p_NN 8.5_CD p_NN Basic_JJ earnings_NNS per_IN share_NN weighted_VBN average_JJ shares_NNS 500,687,594_CD 412,183,058_CD Conversion_NNP of_IN convertible_JJ debt_NN 289,101_CD Exercise_NN of_IN share_NN options_NNS 6,270,923_CD Exercise_NN of_IN warrants_NNS 919,029_CD Fully_RB diluted_VBN earnings_NNS per_IN share_NN weighted_VBN average_JJ shares_NNS 500,687,594_CD 419,662,111_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 93_CD Shire_NNP head_NN office_NN and_CC main_JJ operating_NN locations_NNS Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP Italia_NNP S._NNP p._NNP A_NNP Shire_NNP Biologics_NNPS Inc._NNP ._.
Chief_NNP Executive_NNP :_: Matthew_NNP Emmens_NNP General_NNP Manager_NNP :_: Riccardo_NNP Palmisano_NNP Canada_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP Via_NNP Lucchese_NNP 70_CD President_NNP :_: Randal_NNP Chase_NNP Chineham_NNP ,_, Basingstoke_NNP Sesto_NNP Fiorentino_NNP 50019_CD Firenze_NNP ,_, Italy_NNP 275_CD ,_, Armand-Frappier_NNP Blvd_NNP Hampshire_NNP RG24_NNP 8EP_NNP ,_, UK_NNP Laval_NNP ,_, Quebec_NNP ,_, Canada_NNP H7V_NNP 4A7_NNP Tel_NNP 39_CD 0_CD 5530_CD 250_CD 50_CD Tel_NNP 44_CD 0_CD 1256 894 000_CD Fax_NNP 39_CD 0_CD 5530_CD 250_CD 51_CD Tel_NNP 1_CD 450 978 7800_CD Fax_NNP 44_CD 0_CD 1256 894 708_CD Fax_NN 1_CD 450 978 7755_CD Shire_NNP Pharmaceuticals_NNP Iberica_NNP SL_NNP Shire_NNP Pharmaceuticals_NNP Limited_NNP Managing_VBG Director_NNP :_: 2323_CD du_NNP Parc_NNP Technologique_NNP Blvd_NNP Managing_VBG Director_NNP :_: John_NNP Freeman_NNP Jos_NNP Antonio_NNP Senz_NNP fide_NNP Broto_NNP Sainte-Foy_NNP ,_, Quebec_NNP ,_, Canada_NNP G1P_NNP 4RB_NNP Tel_NNP 1_CD 418 650 0010_CD Hampshire_NNP International_NNP Business_NNP Park_NNP C_NNP Benito_NNP Gutierrez_NNP Fax_NNP 1_CD 418 650 0080_CD Chineham_NNP ,_, Basingstoke_NNP 261B_NNP ,_, 28008_CD Madrid_NNP ,_, Spain_NNP Hampshire_NNP RG24_NNP 8EP_NNP ,_, UK_NNP Tel_NNP 34_CD 9_CD 1550_CD 0691_CD US_NNP Tel_NNP 44_CD 0_CD 1256 894 000_CD Shire_NNP US_NNP ,_, Inc._NNP ._.
Senior_JJ Vice_NNP President_NNP R&D_NNP :_: Ronald_NNP Ellis_NNP Fax_NNP 44_CD 0_CD 1256 894 708_CD President_NNP and_CC Chief_NNP Executive_NNP Officer_NNP :_: 30_CD Bearfoot_NNP Rd_NNP William_NNP Nuerge_NNP Northborough_NNP Shire_NNP Pharmaceuticals_NNP Ireland_NNP Limited_NNP Director_NNP and_CC General_NNP Manager_NNP :_: Brian_NNP Martin_NNP One_CD Riverfront_NNP Place_NNP MA_NNP 01532_CD ,_, USA_NNP Newport_NNP ,_, KY_NNP 41071_CD ,_, USA_NNP Tel_NNP 1_CD 508 351-9944_CD Pharmapark_NNP ,_, Chapelizod_NNP Tel_NNP 1_CD 800 828 2088_CD Fax_NN 1_CD 508 351-9675_CD Dublin_NNP 20_CD ,_, Ireland_NNP Tel_NNP 1_CD 859 669 8000_CD Tel_NNP 00_CD 353_CD 1_CD 630_CD 5411_CD Fax_NN 1_CD 859 669 8414_CD Shire_NNP BioChem_NNP Inc._NNP ._.
Fax_NN 00_CD 353_CD 1_CD 623_CD 7469_CD President_NNP and_CC Chief_NNP Executive_NNP Officer_NNP :_: Shire_NNP US_NNP Manufacturing_NNP ,_, Inc._NNP ._.
Joseph_NNP Rus_NNP Shire_NNP Pharmaceutical_NNP Contracts_NNPS Limited_NNP Senior_NNP Vice_NNP President_NNP of_IN Operations_NNPS :_: Singapore_NNP representative_JJ office_NN 275_CD ,_, Armand-Frappier_NNP Blvd_NNP John_NNP Lee_NNP Managing_VBG Director_NNP :_: Tony_NNP Ooi_NNP Laval_NNP ,_, Quebec_NNP ,_, Canada_NNP H7V_NNP 4A7_NNP 11200_CD Gundry_NNP Lane_NNP Tel_NNP 1_CD 450 978-7800_CD LiFung_NNP Centre_NNP Owings_NNP Mills_NNP ,_, MD_NNP 21117_CD ,_, USA_NNP Fax_NNP 1_CD 450 978-7755_CD 58_CD Toh_NNP Guan_NNP Road_NNP #_# 03-03_CD Tel_NNP 1_CD 410 413 1000_CD Singapore_NNP 608829_CD Fax_NNP 1_CD 410 413 2000_CD Tel_NNP 65 568 0114_CD Fax_NNP 65 425 6330_CD Shire_NNP Laboratories_NNPS ,_, Inc._NNP ._.
President_NNP and_CC Chief_NNP Executive_NNP Officer_NNP :_: Shire_NNP Deutschland_NNP GmbH_NNP &_CC Co_NNP KG_NNP Jack_NNP Khattar_NNP General_NNP Manager_NNP :_: Leonhard_NNP Terp_NNP 1550_CD East_NNP Gude_NNP Drive_NNP Siegburger_NNP Strasse_NNP 126_CD Rockville_NNP ,_, MD_NNP 20850_CD ,_, USA_NNP D-50679_NNP Kln_NNP ,_, Germany_NNP Tel_NNP 1_CD 301 838 2500_CD Tel_NNP 49 221 88047_CD 30_CD Fax_NN 1_CD 301 838 2501_CD Fax_NNP 49 221 88047_CD 41_CD Shire_NNP Pharmaceutical_NNP Development_NNP ,_, Inc._NNP ._.
Shire_NNP France_NNP S._NNP A._NNP Senior_NNP Vice_NNP President_NNP :_: Simon_NNP Tulloch_NNP General_NNP Manager_NNP :_: Vincent_NNP Lucet_NNP 1901_CD Research_NNP Boulevard_NNP 160_CD rue_NN fide_NN Paris_NNP Rockville_NNP ,_, MD_NNP 20850_CD ,_, USA_NNP 92771_CD Boulogne_NNP Cedex_NNP ,_, France_NNP Tel_NNP 1_CD 240 453 6400_CD Tel_NNP 33_CD 1_CD 41_CD 10_CD 25_CD 25_CD Fax_NN 1_CD 240 453 6404_CD Fax_NNP 33_CD 1_CD 41_CD 10_CD 92_CD 02_CD 94_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shareholder_NN information_NN Registered_NNP office_NN address_NN US_NNP shareholders_NNS Hampshire_NNP International_NNP Business_NNP Park_NNP i_FW ADSs_NNP Chineham_NNP ,_, Basingstoke_NNP The_NNP Companys_NNP American_NNP Depository_NNP Shares_NNP Hampshire_NNP RG24_NNP 8EP_NNP ,_, UK_NNP ADSs_NNP ,_, each_DT representing_VBG three_CD ordinary_JJ Registered_NNP in_IN England_NNP shares_NNS are_VBP listed_VBN on_IN the_DT Nasdaq_NNP national_JJ No._NN ._.
2883758_CD market_NN under_IN the_DT symbol_NN SHPGY_NNP ._.
The_DT Company_NN files_VBZ reports_NNS and_CC other_JJ documents_NNS Investor_NNP relations_NNS with_IN the_DT Securities_NNPS and_CC Exchange_NNP Commission_NNP Global_NNP outside_IN US_NNP and_CC Canada_NNP SEC_NNP which_WDT are_VBP available_JJ for_IN inspection_NN and_CC Cla_NNP Rosenfeld_NNP copying_NN at_IN the_DT SECs_NNS public_JJ reference_NN facilities_NNS Tel_NNP 44_CD 0_CD 1256 894 000_CD or_CC can_MD be_VB obtained_VBN by_IN writing_VBG to_TO the_DT Company_NN Fax_NNP 44_CD 0_CD 1256 894 716_CD Secretary_NNP ._.
com_NN ii_FW ADR_NNP Depositary_NNP www_NN ._.
com_NN Morgan_NNP Guaranty_NNP Trust_NNP Company_NN of_IN New_NNP York_NNP is_VBZ the_DT depositary_NN for_IN Shire_NNP Pharmaceuticals_NNP Canada_NNP and_CC US_NNP Group_NNP plc._NN ._.
All_DT enquiries_NNS concerning_VBG American_JJ Gordon_NNP Ngan_NNP Depositary_NNP Receipts_NNPS records_NNS ,_, certificates_NNS or_CC Tel_NNP 1_CD 450 978 7938_CD transfer_NN of_IN ordinary_JJ shares_NNS into_IN ADSs_NNS should_MD Fax_NNP 1_CD 450 975 7755_CD be_VB addressed_VBN to_TO :_: Email_NNP ir@ca_NNP ._.
com_NN Morgan_NNP Guaranty_NNP Trust_NNP Company_NN of_IN New_NNP York_NNP PO_NNP Box_NNP 8205_CD ,_, Boston_NNP Registrars_NNPS and_CC transfer_VB office_NN MA_NNP 02266-8205_CD ,_, USA_NNP All_NNP administrative_JJ enquiries_NNS relating_VBG to_TO shareholdings_NNS should_MD be_VB addressed_VBN to_TO Lloyds_NNP Tel_NNP 1_CD 781 575 4328_CD TSB_NNP Registrars_NNPS ,_, clearly_RB stating_VBG the_DT registered_VBN Fax_NN 1_CD 781 575 4088_CD shareholders_NNS name_NN and_CC address_NN ._.
Lloyds_NNP TSB_NNP Registrars_NNPS The_DT Causeway_NNP ,_, Worthing_NNP West_NNP Sussex_NNP BN99_NNP 6DA_NNP ,_, UK_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 95_CD Glossary_NNP 5-hydroxytryptamine_JJ 5HT_NNP ,_, also_RB known_VBN as_IN Dopamine_NNP A_NNP neurotransmitter_NN that_WDT can_MD affect_VB Pivotal_JJ study_NN A_DT major_JJ clinical_JJ trial_NN that_WDT has_VBZ a_DT enteramine_NN or_CC serotonin_NN A_DT neurotransmitter_NN brain_NN processes_VBZ that_IN control_NN movement_NN ,_, significant_JJ impact_NN on_IN the_DT labeling_VBG approved_VBN that_IN can_MD affect_VB mood_NN ,_, aggression_NN and_CC other_JJ emotional_JJ response_NN and_CC ability_NN to_TO experience_VB usage_NN of_IN a_DT drug_NN CNS_NNP functions_NNS pleasure_NN and_CC pain_NN Platelet_NNP A_NNP constituent_NN of_IN blood_NN that_IN helps_VBZ form_VB ADHD_NNP See_VB attention_NN deficit_NN and_CC hyperactivity_NN Guanosine_NNP A_NNP nucleoside_NN consisting_VBG of_IN clots_NNS to_TO control_VB bleeding_VBG disorder_NN guanine_NN a_DT component_NN of_IN DNA_NNP and_CC RNA_NNP Preclinical_NNP Studies_NNP of_IN compounds_NNS conducted_VBN Adverse_JJ effects_NNS An_DT undesirable_JJ medical_JJ linked_VBN to_TO ribose_VB in_IN the_DT laboratory_NN ,_, in_IN isolated_JJ tissues_NNS ,_, or_CC in_IN living_VBG occurrance_NN in_IN a_DT patient_NN or_CC clinical_JJ trial_NN subject_JJ Meningitis_NNP An_DT infection_NN of_IN the_DT fluid_NN of_IN animals_NNS Alzheimers_NNP disease_NN A_DT degenerative_JJ brain_NN a_DT persons_NNS spinal_JJ cord_NN and_CC the_DT fluid_NN that_WDT Proof-of-concept_JJ study_NN A_DT study_NN intended_VBN to_TO disease_NN that_IN usually_RB begins_VBZ gradually_RB ,_, causing_VBG surrounds_NNS the_DT brain_NN show_NN that_IN a_DT hypothesis_NN or_CC concept_NN is_VBZ valid_JJ a_DT person_NN to_TO forget_VB recent_JJ events_NNS or_CC familiar_JJ Noradrenaline_NNP A_NNP neurotransmitter_NN involved_VBD Renal_JJ osteodystrophy_NN A_DT bone_NN disease_NN that_WDT tasks_NNS in_IN temperature_NN regulation_NN ,_, appetite_NN and_CC occurs_VBZ when_WRB the_DT kidneys_NNS fail_VBP to_TO maintain_VB the_DT Anemia_NNP A_NNP condition_NN in_IN which_WDT the_DT number_NN of_IN aggression_NN proper_JJ levels_NNS of_IN calcium_NN and_CC phosphorus_NN in_IN red_JJ blood_NN cells_NNS or_CC the_DT amount_NN of_IN hemoglobin_NN Nosocomial_NNP infection_NN An_DT infection_NN originating_VBG the_DT blood_NN in_IN a_DT given_VBN volume_NN of_IN blood_NN is_VBZ less_JJR than_IN normal_JJ from_IN a_DT hospital_NN environment_NN that_WDT was_VBD not_RB Retrovirus_NNP A_NNP type_NN of_IN virus_NN containing_VBG RNA_NNP Analgesic_NNP A_NNP pain-relieving_JJ agent_NN that_WDT does_VBZ not_RB present_JJ when_WRB the_DT patient_NN was_VBD admitted_VBN instead_RB of_IN DNA_NNP cause_NN loss_NN of_IN consciousness_NN Nucleoside_NNP reverse_VB transcriptase_NN Ribonucleic_NNP acid_NN RNA_NNP A_NNP nucleic_JJ acid_NN found_VBD Attention_NN deficit_NN and_CC hyperactivity_NN disorder_NN inhibitors_NNS A_DT family_NN of_IN antiviral_JJ compounds_NNS in_IN all_DT living_VBG cells_NNS that_WDT plays_VBZ a_DT role_NN in_IN the_DT flow_NN of_IN ADHD_NNP A_NNP CNS_NNP disorder_NN characterised_VBN by_IN which_WDT interfere_VBP with_IN the_DT activity_NN of_IN the_DT viral_JJ genetic_JJ information_NN inattention_NN ,_, impulsiveness_NN and_CC hyperactivity_NN enzyme_NN reverse_VB transcriptase_NN Septicemia_NNP A_NNP life-threatening_JJ condition_NN in_IN CNS_NNP Central_NNP nervous_JJ system_NN Pharmacokinetics_NNP The_NNP movements_NNS of_IN which_WDT the_DT blood_NN is_VBZ infected_VBN by_IN bacteria_NNS Cytidine_NNP A_NNP nucleoside_NN consisting_VBG of_IN cytosine_NN drugs_NNS within_IN biological_JJ systems_NNS ,_, as_IN affected_JJ Serogroup_NNP A_NNP group_NN of_IN bacteria_NNS ,_, all_DT of_IN which_WDT a_DT component_NN of_IN DNA_NNP and_CC RNA_NNP linked_VBD to_TO by_IN uptake_NN ,_, distribution_NN ,_, elimination_NN and_CC contain_VB a_DT common_JJ element_NN antigen_NN that_WDT can_MD ribose_VB biotransformation_NN elicit_VB an_DT immune_JJ response_NN Deoxyribonucleic_JJ acid_NN DNA_NN The_DT chemical_NN Phase_NN I_PRP Clinical_JJ trials_NNS usually_RB conducted_VBN in_IN Stimulant_NNP A_NNP compound_NN which_WDT increases_VBZ the_DT basis_NN of_IN heredity_NN and_CC the_DT carrier_NN of_IN genetic_JJ healthy_JJ human_JJ volunteers_NNS to_TO determine_VB if_IN a_DT level_NN of_IN neurotransmitters_NNS in_IN the_DT brain_NN information_NN drug_NN candidate_NN is_VBZ safe_JJ for_IN more_JJR extensive_JJ Trigeminal_NNP neuralgia_NN A_DT painful_JJ condition_NN DNA_NN chain_NN terminator_NN A_DT compound_NN which_WDT testing_NN involving_VBG the_DT trigeminal_JJ nerve_NN ,_, one_CD of_IN the_DT blocks_NNS the_DT continuation_NN of_IN a_DT DNA_NN chain_NN Phase_NN II_NNP Clinical_NNP trials_NNS conducted_VBN in_IN patients_NNS largest_JJS nerves_NNS in_IN the_DT head_NN ,_, characterised_VBN by_IN DNA_NNP polymerase_NN An_DT enzyme_NN that_WDT catalyses_VBZ with_IN relevant_JJ disease_NN to_TO assess_VB the_DT safety_NN and_CC sudden_JJ ,_, severe_JJ pain_NN in_IN areas_NNS surrounding_VBG the_DT elongation_NN of_IN DNA_NNP chains_NNS efficacy_NN of_IN the_DT drug_NN candidate_NN this_DT nerve_NN Phase_NN III_NNP Clinical_JJ trials_NNS conducted_VBN in_IN the_DT target_NN patient_NN population_NN to_TO assess_VB comprehensively_RB the_DT safety_NN and_CC efficacy_NN of_IN the_DT drug_NN candidate_NN Designed_VBN and_CC produced_VBN by_IN C&FD_NNP ._.
Printed_NNP in_IN England_NNP by_IN St_NNP Ives_NNP Westerham_NNP Press_NNP ,_, environmentally_RB accredited_VBN printers_NNS ISO_NNP 14001_CD ._.
This_DT report_NN is_VBZ printed_VBN on_IN paper_NN which_WDT is_VBZ made_VBN from_IN 50_CD %_NN totally_RB chlorine-free_JJ pulp_NN from_IN plantation_NN forests_NNS ,_, and_CC from_IN 50_CD %_NN recycled_JJ and_CC fide-inked_JJ fibers_NNS ._.
It_PRP is_VBZ recyclable_JJ and_CC bio-degradable_JJ ._.
96_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Glossary_NNP Shire_NNP trade_NN marks_NNS Third-party_JJ trade_NN marks_NNS ADDERALL_NNP XR_NNP mixed_JJ amphetamine_NN salts_VBZ MICROTROL_NNP 3TC_NNP lamivudine_NN trade_NN mark_NN of_IN GSK_NNP ADDERALL_NNP mixed_JJ amphetamine_NN salts_NNS MICROTROL_NNP DR_NNP ADEPT_NNP 4_CD %_NN icodextrin_NN solution_NN trade_NN mark_NN of_IN AGRYLIN_NNP anagrelide_NN hydrochloride_NN MICROTROL_NNP PR_NNP ML_NNP Laboratories_NNP plc_NN AMATINE_NNP midodrine_NN hydrochloride_NN MICROTROL_NNP XR_NNP AZT_NNP trade_NN mark_NN of_IN GSK_NNP CALCICHEW_NNP calcium_NN carbonate_NN OPTISCREEN_NNP BIO-HEP_NNP B_NNP trade_NN mark_NN of_IN Berna_NNP Biotech_NNP AG_NNP CARBATROL_NNP carbamazepine_NN PENTASA_NNP mesalamine_NN COMBIVIR_NNP trade_NN mark_NN of_IN GSK_NNP COLAZIDE_NNP balsalazide_NN PROAMATINE_NNP midodrine_NN hydrochloride_NN EPIVIR_NNP trade_NN mark_NN of_IN GSK_NNP DEXTROSTAT_NNP dextroamphetamine_NN salt_NN PROSCREEN_NNP HEPAVAX_NNP GENE_NNP trade_NN mark_NN of_IN Berna_NNP Biotech_NNP AG_NNP DIRAME_NNP RAPITROL_NNP NEISVAC-C_NNP trade_NN mark_NN of_IN Baxter_NNP International_NNP Inc._NNP ._.
EMUTROL_NNP SOLARAZE_NNP diclofenac_NN sodium_NN 3_CD %_NN REMINYL_NNP galantamine_NN hydrobromide_NN trade_NN ENSOTROL_NNP SOLUTROL_NNP mark_NN of_IN Johnson_NNP &_CC Johnson_NNP FARESTON_NNP toremifene_NN TROXATYL_NNP troxacitabine_NN TRIZIVIR_NNP trade_NN mark_NN of_IN GSK_NNP FLUVIRAL_NNP S_NNP F_NN split-virion_NN influenza_NN vaccine_NN XAGRID_NNP anagrelide_NN hydrochloride_NN ZEFFIX_NNP lamivudine_NN trade_NN mark_NN of_IN GSK_NNP FOSRENOL_NNP lanthanum_NN carbonate_NN METHYPATCH_NNP methylphenidate_NN Cautionary_JJ statement_NN Statements_NNS included_VBD herein_NN which_WDT are_VBP not_RB historical_JJ facts_NNS are_VBP forward-looking_JJ statements_NNS ._.
Such_JJ forward-looking_JJ statements_NNS involve_VBP a_DT number_NN of_IN risks_NNS and_CC uncertainties_NNS and_CC are_VBP subject_JJ to_TO change_VB at_IN any_DT time_NN ._.
In_IN the_DT event_NN that_IN such_JJ risks_NNS or_CC uncertainties_NNS materialise_NN ,_, Shires_NNP results_NNS could_MD be_VB materially_RB affected_VBN ._.
The_DT risks_NNS and_CC uncertainties_NNS include_VBP ,_, but_CC are_VBP not_RB limited_VBN to_TO ,_, risks_NNS associated_VBN with_IN the_DT inherent_JJ uncertainty_NN of_IN pharmaceutical_JJ research_NN ,_, product_NN development_NN ,_, manufacturing_NN and_CC commercialisation_NN ,_, the_DT impact_NN of_IN competitive_JJ products_NNS ,_, including_VBG ,_, but_CC not_RB limited_VBN to_TO ,_, the_DT impact_NN on_IN Shires_NNP attention_NN deficit_NN hyperactivity_NN disorder_NN ADHD_NNP franchise_NN ,_, patents_NNS including_VBG ,_, but_CC not_RB limited_VBN to_TO ,_, legal_JJ challenges_NNS relating_VBG to_TO Shires_NNP ADHD_NNP franchise_NN ,_, government_NN regulation_NN and_CC approval_NN ,_, including_VBG ,_, but_CC not_RB limited_VBN to_TO ,_, the_DT expected_VBN approval_NN date_NN of_IN lanthanum_NN carbonate_NN FOSRENOL_NNP and_CC METHYPATCH_NNP ,_, product_NN liability_NN claims_NNS ,_, insurance_NN and_CC other_JJ risks_NNS and_CC uncertainties_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2002_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Hampshire_NNP International_NNP Business_NNP Park_NNP Chineham_NNP Basingstoke_NNP Hampshire_NNP RG24_NNP 8EP_NNP Tel_NNP 44_CD 0_CD 1256 894 000_CD Fax_NNP 44_CD 0_CD 1256 894 708_CD www_NN ._.
